<?xml version="1.0" encoding="utf-8" standalone="no"?>
<business:PatentDocumentAndRelated xmlns:base="http://www.sipo.gov.cn/XMLSchema/base" xmlns:business="http://www.sipo.gov.cn/XMLSchema/business" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:tbl="http://oasis-open.org/specs/soextblx" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sipo.gov.cn/XMLSchema/business /DTDS/PatentDocument/Elements/OtherElements.xsd" xsdVersion="V2.2.1" file="CN112021000002433CN00001137847210AFULZH20211210CN002.XML" dateProduced="20211205" status="C" lang="zh" country="CN" docNumber="113784721" kind="A" datePublication="20211210">
  <business:BibliographicData>
    <business:PublicationReference dataFormat="original" sequence="1" sourceDB="national office">
      <base:DocumentID>
        <base:WIPOST3Code>CN</base:WIPOST3Code>
        <base:DocNumber>113784721</base:DocNumber>
        <base:Kind>A</base:Kind>
        <base:Date>20211210</base:Date>
      </base:DocumentID>
    </business:PublicationReference>
    <business:PublicationReference dataFormat="standard" sequence="1">
      <base:DocumentID>
        <base:WIPOST3Code>CN</base:WIPOST3Code>
        <base:DocNumber>113784721</base:DocNumber>
        <base:Kind>A</base:Kind>
        <base:Date>20211210</base:Date>
      </base:DocumentID>
    </business:PublicationReference>
    <business:PublicAvailabilityDate>
      <business:GazetteReference>
        <business:GazetteNumber>37-5002</business:GazetteNumber>
        <base:Date>20211210</base:Date>
      </business:GazetteReference>
    </business:PublicAvailabilityDate>
    <business:ApplicationReference applType="11" dataFormat="original" sequence="1" sourceDB="national office">
      <base:DocumentID>
        <base:WIPOST3Code>CN</base:WIPOST3Code>
        <base:DocNumber>202180002433.9</base:DocNumber>
        <base:Date>20210224</base:Date>
      </base:DocumentID>
    </business:ApplicationReference>
    <business:ApplicationReference applType="11" dataFormat="standard" sequence="1">
      <base:DocumentID>
        <base:WIPOST3Code>CN</base:WIPOST3Code>
        <base:DocNumber>112021000002433</base:DocNumber>
        <base:Date>20210224</base:Date>
      </base:DocumentID>
    </business:ApplicationReference>
    <business:PriorityDetails>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="1">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>62/982,670</base:DocNumber>i
        <base:Date>20200227</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="2">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>62/994,206</base:DocNumber>
        <base:Date>20200324</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="3">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>63/032,247</base:DocNumber>
        <base:Date>20200529</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="4">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>63/039,352</base:DocNumber>
        <base:Date>20200615</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="5">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>63/040,985</base:DocNumber>
        <base:Date>20200618</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="6">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>63/054,680</base:DocNumber>
        <base:Date>20200721</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="7">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>63/073,328</base:DocNumber>
        <base:Date>20200901</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="original" sourceDB="national office" sequence="8">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>63/146,456</base:DocNumber>
        <base:Date>20210205</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="1">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000982670</base:DocNumber>
        <base:Date>20200227</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="2">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000994206</base:DocNumber>
        <base:Date>20200324</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="3">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000032247</base:DocNumber>
        <base:Date>20200529</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="4">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000039352</base:DocNumber>
        <base:Date>20200615</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="5">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000040985</base:DocNumber>
        <base:Date>20200618</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="6">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000054680</base:DocNumber>
        <base:Date>20200721</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="7">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002020000073328</base:DocNumber>
        <base:Date>20200901</base:Date>
      </business:Priority>
      <business:Priority kind="international" dataFormat="standard" sequence="8">
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>002021000146456</base:DocNumber>
        <base:Date>20210205</base:Date>
      </business:Priority>
    </business:PriorityDetails>
    <business:ClassificationIPCRDetails creator="03" processingType="original">
      <business:ClassificationIPCR sequence="1">
        <business:IPCVersionDate>20060101</business:IPCVersionDate>
        <business:Section>A</business:Section>
        <business:MainClass>61</business:MainClass>
        <business:Subclass>K</business:Subclass>
        <business:MainGroup>31</business:MainGroup>
        <business:Subgroup>7076</business:Subgroup>
        <business:GeneratingOffice>
          <base:WIPOST3Code>CN</base:WIPOST3Code>
        </business:GeneratingOffice>
        <business:ClassificationDataSource>H</business:ClassificationDataSource>
        <base:Text>A61K   31/7076  (2006.01)</base:Text>
      </business:ClassificationIPCR>
      <business:ClassificationIPCR sequence="2">
        <business:IPCVersionDate>20060101</business:IPCVersionDate>
        <business:Section>A</business:Section>
        <business:MainClass>61</business:MainClass>
        <business:Subclass>P</business:Subclass>
        <business:MainGroup>31</business:MainGroup>
        <business:Subgroup>14</business:Subgroup>
        <business:GeneratingOffice>
          <base:WIPOST3Code>CN</base:WIPOST3Code>
        </business:GeneratingOffice>
        <business:ClassificationDataSource>H</business:ClassificationDataSource>
        <base:Text>A61P   31/14    (2006.01)</base:Text>
      </business:ClassificationIPCR>
      <business:ClassificationIPCR sequence="3">
        <business:IPCVersionDate>20060101</business:IPCVersionDate>
        <business:Section>C</business:Section>
        <business:MainClass>07</business:MainClass>
        <business:Subclass>H</business:Subclass>
        <business:MainGroup>19</business:MainGroup>
        <business:Subgroup>207</business:Subgroup>
        <business:GeneratingOffice>
          <base:WIPOST3Code>CN</base:WIPOST3Code>
        </business:GeneratingOffice>
        <business:ClassificationDataSource>H</business:ClassificationDataSource>
        <base:Text>C07H   19/207   (2006.01)</base:Text>
      </business:ClassificationIPCR>
    </business:ClassificationIPCRDetails>
    <business:InventionTitle lang="zh" dataFormat="original" sourceDB="national office" processingType="original" creator="03">抗COVID-19的高活性化合物</business:InventionTitle>
    <business:Parties>
      <business:ApplicantDetails representative="1">
        <business:Applicant sequence="1" appType="applicant" dataFormat="original" sourceDB="national office" lang="zh" creator="03" processingType="original">
          <base:AddressBook lang="zh">
            <base:Name>阿堤亚制药公司</base:Name>
            <base:Address>
              <base:AddressLine>0</base:AddressLine>
              <base:AddressMailCode>0</base:AddressMailCode>
              <base:PostBox>0</base:PostBox>
              <base:AddressRoom>0</base:AddressRoom>
              <base:AddressFloor>0</base:AddressFloor>
              <base:AddressBuilding>0</base:AddressBuilding>
              <base:Street>0</base:Street>
              <base:AddressCity>0</base:AddressCity>
              <base:County>0</base:County>
              <base:City>0</base:City>
              <base:Province>0</base:Province>
              <base:PostCode>0</base:PostCode>
              <base:WIPOST3Code>US</base:WIPOST3Code>
              <base:Text>美国马萨诸塞州</base:Text>
            </base:Address>
          </base:AddressBook>
          <business:OrganizationCode createDate="00000000" creator="00">0000000000</business:OrganizationCode>
        </business:Applicant>
      </business:ApplicantDetails>
      <business:InventorDetails>
        <business:Inventor sequence="1" dataFormat="original" sourceDB="national office" lang="zh" publicationMark="0" creator="03" processingType="original">
          <base:AddressBook lang="zh">
            <base:Name>J-P·索玛迪西</base:Name>
          </base:AddressBook>
        </business:Inventor>
        <business:Inventor sequence="2" dataFormat="original" sourceDB="national office" lang="zh" publicationMark="0" creator="03" processingType="original">
          <base:AddressBook lang="zh">
            <base:Name>A·莫萨</base:Name>
          </base:AddressBook>
        </business:Inventor>
      </business:InventorDetails>
      <business:AgentDetails>
        <business:CustomerNumber>11256</business:CustomerNumber>
        <business:Agent sequence="1" lang="zh" dataFormat="original" sourceDB="national office" repType="agent" processingType="original" creator="03">
          <business:Agency>
            <base:AddressBook lang="zh">
              <base:OrganizationName>北京市金杜律师事务所 11256</base:OrganizationName>
            </base:AddressBook>
          </business:Agency>
          <base:AddressBook lang="zh">
            <base:Name>吴亦华</base:Name>
          </base:AddressBook>
        </business:Agent>
        <business:Agent sequence="2" lang="zh" dataFormat="original" sourceDB="national office" repType="agent" processingType="original" creator="03">
          <business:Agency>
            <base:AddressBook lang="zh">
              <base:OrganizationName>北京市金杜律师事务所 11256</base:OrganizationName>
            </base:AddressBook>
          </business:Agency>
          <base:AddressBook lang="zh">
            <base:Name>吴斌</base:Name>
          </base:AddressBook>
        </business:Agent>
      </business:AgentDetails>
    </business:Parties>
    <business:NationalStageEntryDate>
      <base:Date>20210903</base:Date>
    </business:NationalStageEntryDate>
    <business:PCTPublicationLanguage>en</business:PCTPublicationLanguage>
    <business:PCTOrRegionalApplicationData>
      <base:DocumentID>
        <base:WIPOST3Code>US</base:WIPOST3Code>
        <base:DocNumber>PCT/US2021/019468</base:DocNumber>
        <base:Date>20210224</base:Date>
      </base:DocumentID>
    </business:PCTOrRegionalApplicationData>
    <business:PCTOrRegionalPublishingData>
      <base:DocumentID lang="en">
        <base:WIPOST3Code>WO</base:WIPOST3Code>
        <base:DocNumber>2021/173713</base:DocNumber>
        <base:Date>20210902</base:Date>
      </base:DocumentID>
    </business:PCTOrRegionalPublishingData>
  </business:BibliographicData>
  <business:Abstract dataFormat="original" lang="zh" sourceDB="national office" processingType="original" creator="03">
    <base:Paragraphs num="0001">本发明是以有效量施用的嘌呤核苷酸氨基磷酸酯或其药学上可接受的盐用于在需要的宿主(例如人类)中治疗或预防COVID‑19，由SARS CoV‑2病毒引起的感染的用途。</base:Paragraphs>
    <business:AbstractFigure>
      <base:Figure num="0001">
        <base:Image he="526" wi="1000" file="202180002433.JPG" imgContent="undefined" imgFormat="JPEG" />
      </base:Figure>
    </business:AbstractFigure>
  </business:Abstract>
  <business:Description lang="zh" dataFormat="original" sourceDB="national office" creator="03">
    <business:InventionTitle id="title1">抗COVID-19的高活性化合物</business:InventionTitle>
    <base:Paragraphs id="p0001" num="n0001">
      <base:Underline>相关申请的交叉引用</base:Underline>
    </base:Paragraphs>
    <base:Paragraphs id="p0002" num="n0002">本申请要求于2020年2月27日提交的美国临时申请号62/982,670，于2020年3月24日提交美国临时申请号62/994,206，于2020年5月29日提交的美国临时申请号63/032,247，于2020年6月15日提交的美国临时申请号63/039,352，于2020年6月18日提交的美国临时申请号63/040,985，于2020年7月21日提交的美国临时申请号63/054,680，于2020年9月1日提交的美国临时63/073,328，以及于2021年2月5日提交的美国临时申请号63/146,456的权益。这些申请通过引用将其整体并入以用于所有目的。</base:Paragraphs>
    <business:TechnicalField id="technical-field001">
      <base:Paragraphs id="p0003">技术领域</base:Paragraphs>
      <base:Paragraphs id="p0004" num="n0003">本发明涉及具有优越的活性和剂量便利性的选择性嘌呤核苷酸及其药学上可接受的盐用于在有需要的宿主(通常是人类)中治疗或预防引起COVID-19的SARS-CoV-2病毒的用途。</base:Paragraphs>
    </business:TechnicalField>
    <business:BackgroundArt id="background-art001">
      <base:Paragraphs id="p0005">背景技术</base:Paragraphs>
      <base:Paragraphs id="p0006" num="n0004">2019年12月，有多名患者被确诊为肺炎。这些患者表现出类似于2002-2003年SARS(严重急性呼吸系统综合症)爆发的症状。2020年1月，该传染源被确定为一种新型冠状病毒，命名为严重急性呼吸系统综合症冠状病毒-2(SARS-CoV-2)，由此产生的疾病称为2019冠状病毒病(COVID-19)。这种潜在的严重且有时是致命的疾病迅速蔓延到世界各地。2020年3月11日，世界卫生组织宣布COVID-19为全球大流行病。</base:Paragraphs>
      <base:Paragraphs id="p0007" num="n0005">大多数感染SARS-CoV-2病毒的患者表现出轻微的类似感冒的症状，包括发烧、咳嗽、疲劳、呼吸急促、肌肉酸痛以及味觉和/或嗅觉丧失。这些症状通常会在几周内通过最少的医疗护理来解决。然而，偶尔，症状会持续数月。该病毒可能对肺、心脏和大脑造成长期损害。此外，在某些患者中，尤其是老年人、免疫功能低下者或有基础疾病的患者，该病毒可引起严重症状，导致住院、人工呼吸和/或死亡。</base:Paragraphs>
      <base:Paragraphs id="p0008" num="n0006">SARS-CoV-2是一种冠状病毒(CoV)，其为巢病毒目(Nidovirales)、冠状病毒科、冠状病毒亚科，它们是具有单链正链RNA基因组的包膜病毒。SARS-CoV-2的大小约为30千碱基，是已知最大的RNA基因组之一。相关冠状病毒包括严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)。然而，SARS-CoV-2仅与SARS-CoV共享其基因组的79.5％，因此被认为是一种新的人类感染β冠状病毒(Zhou et al.Nature 2020,579,270)。与SARS-CoV和MERS-CoV相比,SARS-CoV-2表现出更快的人际传播速度(Huang etal.,Lancet 2000,395,497)，使其控制特别具有挑战性和危险。冠状病毒通常起源于跨越动物-人类物种屏障的地方性动物感染，并逐渐在人类中建立人畜共患病(Lau et al.,PNAS 2005,102,14040-5；Rest et al.,Infect Genet Evol.2003,3,219-25)。跨物种屏障跳跃使如SARS CoV和中东呼吸综合征CoV(MERS)的CoV表现为致病性强的人类病毒(Schoeman and Fielding,Virology 2019,16,69)。同样，基因组测序显示SARS-CoV-2在全基因组水平上与蝙蝠冠状病毒有96％的同一性(Zhou等人，Nature 2020,579,270)，因此最可能起源于蝙蝠。</base:Paragraphs>
      <base:Paragraphs id="p0009" num="n0007">SARS-CoV-2通过与血管紧张素转化酶2(hACE2)受体结合进入人体细胞。病毒包膜表面的刺突糖蛋白与ACE2受体结合，然后人跨膜蛋白酶丝氨酸2切割并激活刺突蛋白，使SARS-CoV-2通过内吞作用或与宿主膜直接融合进入细胞(Luan et al.Biochem.Biophys.Res.Commun.2020:527,165；Hoffman,M.et al.Cell,2020,181,271；Yang etal.Int.J.Biol.Sci.2020,16,1724)。</base:Paragraphs>
      <base:Paragraphs id="p0010" num="n0008">一旦进入细胞，SARS-CoV-2的转录和复制由多亚基聚合酶复合物介导。该复合物的催化亚基是RNA依赖性RNA聚合酶(RdRp)，称为nsp12。虽然分离的nsp12亚基自身能够进行聚合酶反应，但辅酶因子nsp7和nsp8的存在显著提高了聚合酶反应的效率(Ahn etal.Arch Virol.2012,157,2095；Subissi et al.Proc.Natl.Acad.Sci.,2014,111,E3900)。</base:Paragraphs>
      <base:Paragraphs id="p0011" num="n0009">2020年4月，与nsp-7和nsp-8复合的SARS-CoV-2nsp-12的晶体结构得到解析(Gaoet al.Science 2020,368:779-782)。nsp12的结构包含聚合酶C端RdRp域，该域连接到N端扩展域，称为套状病毒RdRp相关核苷酸转移酶(NiRAN)域。该NiRAN结构域，在所有套病毒中都是保守的，能够执行核苷酸化活性，其特征在于由8个α螺旋和一个5链β折叠组成的α和β折叠(Gao et al.Science 2020,368:779-782)。C末端域已被表征为具有手指，拇指和手掌子域的“杯状右手”域。</base:Paragraphs>
      <base:Paragraphs id="p0012" num="n0010">随着SARS-CoV-2病毒在世界范围内传播，它表现出很高的突变率，并且该病毒的多种突变形式正在全球传播。这些突变有可能影响病毒引起感染的能力和传播速度。例如，英国鉴定出B.1.1.7变种，2020年秋季被英国公共卫生署命名为关注变种202012/01，该变种在刺突区域有8个突变。有证据表明，这种变体传播更快、更容易，并且可能与死亡风险增加有关。在南非，已经确定了其他变体B.1.351和501Y.V2。两种变体都与B.11.7变体共有一些突变，包括N501Y突变。巴西还确定了一种称为P.1的变体，其中包含可能影响病毒被抗体识别能力的突变。出于这个原因，开发能够治疗病毒突变形式的疗法非常重要，尤其是那些刺突蛋白发生突变的病毒。</base:Paragraphs>
      <base:Paragraphs id="p0013" num="n0011">创造人类冠状病毒疾病治疗剂的历史说明了该问题的复杂性和挑战。尽管MERS-CoV和SARS-CoV分别于2012年和2003年被发现，但仍没有商业疫苗或药物获得批准。</base:Paragraphs>
      <base:Paragraphs id="p0014" num="n0012">缺乏批准的治疗方法，再加上其高死亡率及其传播的容易和速度，凸显了开发有效的COVID-19抗病毒药物的必要性。</base:Paragraphs>
      <base:Paragraphs id="p0015" num="n0013">因此，本发明的一个目的是提供用于治疗和预防引起COVID-19的SARS-CoV-2病毒的化合物、组合物和方法。</base:Paragraphs>
    </business:BackgroundArt>
    <business:Disclosure id="disclosure001">
      <base:Paragraphs id="p0016">发明内容</base:Paragraphs>
      <base:Paragraphs id="p0017" num="n0014">本发明提供了在有需要的宿主中治疗SARS-CoV-2病毒的方法，包括施用有效量的本文进一步描述的选择性嘌呤核苷酸化合物，用于有利地治疗、预防或防止导致COVID-19的SARS-CoV-2病毒。这些嘌呤核苷酸表现出对抗病毒的集中活性。</base:Paragraphs>
      <base:Paragraphs id="p0018" num="n0015">此外，且重要的是，这些化合物可以使用简单的固体口服剂型施予有需要的宿主，例如人类，该剂型可以方便地在家中或通常在医疗机构外服用而无需肠胃外给药或住院治疗。如果需要或合适，本文所述的活性化合物也可以在医疗机构中肠胃外或口服给药。该疗法可用于治疗轻度、中度或重度疾病。</base:Paragraphs>
      <base:Paragraphs id="p0019" num="n0016">本发明的一个实施方案中，式I化合物</base:Paragraphs>
      <base:Paragraphs id="p0020" num="n0017">
        <base:Image he="567" wi="897" file="GDA0003327089700000041.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0021" num="n0018">或其药学上可接受的盐，任选地在药学上可接受的载体中，以有效量施用给患有COVID-19的有需要的宿主，通常是人，或具有感染或再感染SARS-CoV-2病毒风险的宿主。例如，作为预防剂(并且其中术语预防是指，相对于没有这种预防性治疗的疾病，完全预防或最小化获得性感染)，其中：</base:Paragraphs>
      <base:Paragraphs id="p0022" num="n0019">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基，和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0023" num="n0020">R<base:Sup>2</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>3-7</base:Sub>环烷基或芳基(包括苯基和萘基)，和在一个替代实施方案中，R<base:Sup>2</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，杂芳基或杂烷基；</base:Paragraphs>
      <base:Paragraphs id="p0024" num="n0021">R<base:Sup>3</base:Sup>是氢或C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)；</base:Paragraphs>
      <base:Paragraphs id="p0025" num="n0022">R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)和C<base:Sub>3-7</base:Sub>环烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0026" num="n0023">R<base:Sup>5</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>1-6</base:Sub>卤代烷基或C<base:Sub>3-7</base:Sub>环烷基，和在一个替代实施方案中，R<base:Sup>5</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，芳基，杂芳基或杂烷基。</base:Paragraphs>
      <base:Paragraphs id="p0027" num="n0024">C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基的非限制性实例包括甲基，乙基，丙基，异丙基，丁基，叔丁基，仲丁基，异丁基，-CH<base:Sub>2</base:Sub>C(CH<base:Sub>3</base:Sub>)<base:Sub>3</base:Sub>，-CH(CH<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>)<base:Sub>2</base:Sub>和-CH<base:Sub>2</base:Sub>CH(CH<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>)<base:Sub>2</base:Sub>。C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基的非限制性实例包括环丙基，CH<base:Sub>2</base:Sub>-环丙基，环丁基和CH<base:Sub>2</base:Sub>-环丁基。</base:Paragraphs>
      <base:Paragraphs id="p0028" num="n0025">芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-的非限制性实例是苄基。芳基的非限制性实例是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0029" num="n0026">在一个实施方案中，SARS-CoV-2病毒是野生型的。在另一个实施例中，SARS-CoV-2病毒经历了自然或药物诱导的突变，例如但不限于选自包膜(E)蛋白、膜(M)蛋白、刺突(S)蛋白、nsp1、nsp2、nsp3、nsp4、nsp5、nsp 6、nsp7、nsp8、nsp9、nsp10、nsp12、nsp13、nsp14、nsp15、nsp16、ORF1ab、ORF<base:Sub>3</base:Sub>a、ORF6、ORF7a、ORF7b、ORF10的病毒蛋白中的突变。</base:Paragraphs>
      <base:Paragraphs id="p0030" num="n0027">式I化合物的非限制性实例是化合物1或其药学上可接受的盐。在一个实施方案中，化合物1或其药学上可接受的盐，任选地在药学上可接受的载体中，施用于有需要的感染了SARS-CoV-2的宿主，例如人，或有感染SARS-CoV-2病毒风险的宿主，即作为预防剂。</base:Paragraphs>
      <base:Paragraphs id="p0031" num="n0028">
        <base:Image he="572" wi="957" file="GDA0003327089700000051.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0032" num="n0029">上面描述的化合物1不涉及磷原子(它是手性的)处的立体化学。化合物1的使用可以不考虑磷的立体化学，也可以以磷-外消旋形式使用，或者可以使用化合物的磷R-和S-对映体的任何所需比例，包括对映体富集的(例如，高达至少90％、95％、98％、99％或甚至100％不含相反的对映异构体，它们实际上是非对映异构体，因为分子中有多个手性碳)。化合物1A是S-对映体，化合物1B是R-对映体。</base:Paragraphs>
      <base:Paragraphs id="p0033" num="n0030">
        <base:Image he="1000" wi="655" file="GDA0003327089700000061.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0034" num="n0031">化合物1，包括化合物1A和化合物1B，是对抗由SARS-CoV-2病毒引起的COVID-19的强效抑制剂。如实施例5和实施例6所述，化合物1A在HAE细胞(人气道上皮细胞)中对SARS-Cov-2表现出0.64μM的EC<base:Sub>90</base:Sub>值。使用HAE细胞的测定是肺的体外模型，并且是SARS-CoV-2复制的代表性系统。还令人惊讶地发现，化合物1A的活性三磷酸酯代谢物在暴露于正常的原代支气管和鼻上皮细胞时会稳健地形成。如实施例7中所述，当化合物1A在人鼻和支气管上皮细胞中孵育时，活性三磷酸酯物质在支气管和鼻上皮细胞中的半衰期均大于1.5天。这是无法提前预测的，这对于治疗病毒大量集中在鼻腔和支气管细胞中时的早期感染的患者尤其重要。</base:Paragraphs>
      <base:Paragraphs id="p0035" num="n0032">本文提供的数据显示化合物相对于肝脏在肺部集中，并且先前报道的数据证实化合物相对于心脏优先地在肝脏集中(参见例如PCT申请PCT/US2018/016301的实施例19)。综上所述，该数据证实该化合物集中在靶器官，肺，肝脏或心脏，从而降低毒性。</base:Paragraphs>
      <base:Paragraphs id="p0036" num="n0033">在一个实施方案中，化合物1，例如化合物1A或化合物1B或其药学上可接受的盐，任选地在药学上可接受的载体中，以有效量施用于有需要的感染了SARS-CoV-2病毒的宿主，例如人，或有感染SARS-CoV-2病毒风险的宿主，即作为预防剂。在一个实施方案中，药学上可接受的盐是半硫酸盐，如下所示为化合物2、化合物2A和化合物2B：</base:Paragraphs>
      <base:Paragraphs id="p0037" num="n0034">
        <base:Image he="1000" wi="538" file="GDA0003327089700000071.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0038" num="n0035">
        <base:Image he="60" wi="250" file="GDA0003327089700000081.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />
      </base:Paragraphs>
      <base:Paragraphs id="p0039" num="n0036">如实施例8中所述，将化合物2A施用于非人灵长类动物，并在肺、肾和肝细胞中测量活性三磷酸酯物质的细胞内浓度。令人惊讶的是，活性三磷酸酯代谢物集中在肺中超过肝脏(表8)，并且活性代谢物在肺中的半衰期为9.4小时(图7A)。这很重要，因为COVID-19通常表现为呼吸系统疾病。事实上，在每天两次口服给药30mg/kg的化合物2A后，肺中的活性三磷酸酯物质浓度是肝脏的1.6倍。</base:Paragraphs>
      <base:Paragraphs id="p0040" num="n0037">此外，本发明的化合物可以通过具有高选择性的独特作用机制抑制SARS-CoV-2感染。CoV病毒复制是在RNA依赖性RNA聚合酶(RdRp)nsp12亚基上实现的，该亚基由辅因子nsp7和nsp8激活。如实施例6所述，化合物1A对SARS-CoV-2和MERS-CoV的活性存在30倍的差异，即使MERS-CoV和其他CoV，例如SARS-CoV-1和SARS-CoV-2,在RdRp活性位点没有表现出显著的结构差异。这表明聚合酶抑制不是对抗这些病毒的不同活性的唯一基础。</base:Paragraphs>
      <base:Paragraphs id="p0041" num="n0038">COVID-19是一种急性病毒感染，在感染的第一阶段，当病毒载量达到最大值并且最初在鼻腔、喉咙和肺细胞中进行快速病毒复制时，抗病毒治疗可能有效。在疾病的早期阶段向感染SARS-CoV-2的个体施用有效、安全的口服抗病毒药物有可能避免临床疾病，最大限度地减少长期损害，并缓解COVID-19大流行。如上所述，已经表明本发明的选定化合物能够相对于肝脏在肺部集中。当需要预防或减轻晚期病毒损伤时，在治疗SARS-CoV-2病原体感染的第一阶段患者时，这在治疗上是有益的。在肺部相对于心脏和肝脏的高集中也有利于治疗感染后期的患者。</base:Paragraphs>
      <base:Paragraphs id="p0042" num="n0039">本发明还包括有效量的式II化合物或其药学上可接受的盐在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0043" num="n0040">
        <base:Image he="581" wi="839" file="GDA0003327089700000091.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0044" num="n0041">其中：</base:Paragraphs>
      <base:Paragraphs id="p0045" num="n0042">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基，和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0046" num="n0043">R<base:Sup>2</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>3-7</base:Sub>环烷基或芳基(包括苯基和萘基)，和在一个替代实施方案中，R<base:Sup>2</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，杂芳基或杂烷基；</base:Paragraphs>
      <base:Paragraphs id="p0047" num="n0044">R<base:Sup>3</base:Sup>是氢或C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)；</base:Paragraphs>
      <base:Paragraphs id="p0048" num="n0045">R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)和C<base:Sub>3-7</base:Sub>环烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0049" num="n0046">R<base:Sup>5</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>1-6</base:Sub>卤代烷基或C<base:Sub>3-7</base:Sub>环烷基，和在一个替代实施方案中，R<base:Sup>5</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，芳基，杂芳基或杂烷基。</base:Paragraphs>
      <base:Paragraphs id="p0050" num="n0047">在一个实施方案中，式II的化合物或其药学上可接受的盐，任选地在药学上可接受的载体中，以有效量施用于感染SARS-CoV-2病毒的有需要的宿主，或施用于存在感染或再次感染SARS-CoV-2病毒风险的宿主，即作为预防剂。</base:Paragraphs>
      <base:Paragraphs id="p0051" num="n0048">式II化合物的非限制性实例是化合物3或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0052" num="n0049">
        <base:Image he="550" wi="860" file="GDA0003327089700000092.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0053" num="n0050">在一个实施方案中，化合物3或其药学上可接受的盐，任选地在药学上可接受的载体中，以有效量施用地感染SARS-CoV-2病毒的有需要的宿主，或施用于存在感染感染SARS-CoV-2病毒风险的宿主，即作为预防剂。化合物3可以以磷-外消旋形式使用，或以化合物的磷R-和S-对映体的任何所需比率，包括对映体富集材料直至纯对映体。化合物3A是S-对映体，化合物3B是R-对映体。</base:Paragraphs>
      <base:Paragraphs id="p0054" num="n0051">
        <base:Image he="1000" wi="607" file="GDA0003327089700000101.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0055" num="n0052">式II的另一个非限制性实例包括化合物4。化合物4的可选构型包括化合物4A和化合物4B。在一个实施方案中，任选地在药学上可接受的载体中的化合物4以有效量施用给感染SARS-CoV-2病毒的有需要的宿主或有感染风险的宿主，即作为预防剂。</base:Paragraphs>
      <base:Paragraphs id="p0056" num="n0053">
        <base:Image he="457" wi="991" file="GDA0003327089700000102.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0057" num="n0054">
        <base:Image he="1000" wi="679" file="GDA0003327089700000111.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0058" num="n0055">本发明还包括式III化合物或其药学上可接受的盐在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0059" num="n0056">
        <base:Image he="576" wi="898" file="GDA0003327089700000112.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0060" num="n0057">其中：</base:Paragraphs>
      <base:Paragraphs id="p0061" num="n0058">X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0062" num="n0059">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0063" num="n0060">在一个实施方案中，用于治疗或预防COVID-19疾病的式III化合物是式IIIa、式IIIb、式IIIc、式IIId、式IIIe或式IIIf的化合物或其药学上可接受的盐：</base:Paragraphs>
      <base:Paragraphs id="p0064" num="n0061">
        <base:Image he="1000" wi="362" file="GDA0003327089700000121.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0065" num="n0062">
        <base:Image he="1000" wi="720" file="GDA0003327089700000131.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0066" num="n0063">本发明还包括有效量的式IV化合物在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0067" num="n0064">
        <base:Image he="576" wi="900" file="GDA0003327089700000132.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0068" num="n0065">或其药学上可接受的盐，其中：</base:Paragraphs>
      <base:Paragraphs id="p0069" num="n0066">X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0070" num="n0067">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0071" num="n0068">在一个实施方案中，用于治疗或预防COVID-19疾病的式IV化合物是式IVa、式IVb、式IVc、式IVd、式IVe或式IVf的化合物或其药学上可接受的盐：</base:Paragraphs>
      <base:Paragraphs id="p0072" num="n0069">
        <base:Image he="1000" wi="362" file="GDA0003327089700000141.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0073" num="n0070">
        <base:Image he="1000" wi="731" file="GDA0003327089700000151.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0074" num="n0071">本发明还包括有效量的式V化合物在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0075" num="n0072">
        <base:Image he="568" wi="900" file="GDA0003327089700000152.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0076" num="n0073">或其药学上可接受的盐，其中：</base:Paragraphs>
      <base:Paragraphs id="p0077" num="n0074">Y和Y’独立地选自Cl和F；和</base:Paragraphs>
      <base:Paragraphs id="p0078" num="n0075">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0079" num="n0076">式V化合物的非限制性实例包括</base:Paragraphs>
      <base:Paragraphs id="p0080" num="n0077">
        <base:Image he="240" wi="1000" file="GDA0003327089700000153.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0081">
        <base:Image he="252" wi="1000" file="GDA0003327089700000161.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0082" num="n0078">本发明还包括式VI化合物在有需要的宿主中治疗或预防COVID-19的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0083" num="n0079">
        <base:Image he="585" wi="879" file="GDA0003327089700000162.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0084" num="n0080">其中</base:Paragraphs>
      <base:Paragraphs id="p0085" num="n0081">R<base:Sup>6</base:Sup>选自氢，-C(O)R<base:Sup>6A</base:Sup>，-C(O)OR<base:Sup>6A</base:Sup>，C<base:Sub>1-6</base:Sub>烷基和-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>，在一个替代实施方案中，-C(O)NR<base:Sup>6B</base:Sup>R<base:Sup>6C</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0086" num="n0082">R<base:Sup>6A</base:Sup>选自氢，C<base:Sub>1-6</base:Sub>烷基，C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基(例如-CHCl<base:Sub>2</base:Sub>,-CCl<base:Sub>3</base:Sub>,-CH<base:Sub>2</base:Sub>Cl,-CF<base:Sub>3</base:Sub>,-CHF<base:Sub>2</base:Sub>,-CH<base:Sub>2</base:Sub>F)，芳基和芳基(C<base:Sub>1-6</base:Sub>烷基)-，其中芳基任选地被选自烷氧基，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的取代基取代，在一个可选的实施方案中，R<base:Sup>6A</base:Sup>选自C<base:Sub>1-20</base:Sub>烷基和C<base:Sub>2-20</base:Sub>烯基；</base:Paragraphs>
      <base:Paragraphs id="p0087" num="n0083">R<base:Sup>6B</base:Sup>和R<base:Sup>6C</base:Sup>独立地选自氢，C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基，其中C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基可以任选地被选自烷氧基(包括但不限于甲氧基和乙氧基)，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的至少一个取代基取代；</base:Paragraphs>
      <base:Paragraphs id="p0088" num="n0084">R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>，H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0089" num="n0085">R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基，-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0090" num="n0086">Y选自F和Cl；</base:Paragraphs>
      <base:Paragraphs id="p0091" num="n0087">Z选自甲基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素(包括Cl和F)，在一个替代实施方案中，Z是C<base:Sub>1-4</base:Sub>烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0092" num="n0088">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0093" num="n0089">R<base:Sup>6</base:Sup>的非限制性例子包括</base:Paragraphs>
      <base:Paragraphs id="p0094" num="n0090">
        <base:Image he="890" wi="1000" file="GDA0003327089700000171.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0095" num="n0091">R<base:Sup>6</base:Sup>的其他非限制性示例包括：</base:Paragraphs>
      <base:Paragraphs id="p0096" num="n0092">
        <base:Image he="371" wi="1000" file="GDA0003327089700000181.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0097" num="n0093">R<base:Sup>6</base:Sup>的其他非限制性示例包括：</base:Paragraphs>
      <base:Paragraphs id="p0098" num="n0094">
        <base:Image he="366" wi="1000" file="GDA0003327089700000182.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0099" num="n0095">R<base:Sup>6</base:Sup>的其他非限制性示例包括：</base:Paragraphs>
      <base:Paragraphs id="p0100" num="n0096">
        <base:Image he="610" wi="1000" file="GDA0003327089700000183.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0101">
        <base:Image he="334" wi="1000" file="GDA0003327089700000191.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0102" num="n0097">式VI化合物的非限制性实例包括</base:Paragraphs>
      <base:Paragraphs id="p0103" num="n0098">
        <base:Image he="987" wi="1000" file="GDA0003327089700000192.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0104" num="n0099">
        <base:Image he="1000" wi="654" file="GDA0003327089700000201.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0105" num="n0100">
        <base:Image he="1000" wi="350" file="GDA0003327089700000211.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0106" num="n0101">
        <base:Image he="1000" wi="397" file="GDA0003327089700000221.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0107">
        <base:Image he="470" wi="1000" file="GDA0003327089700000231.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0108" num="n0102">本发明还包括式VII化合物在有需要的宿主中治疗或预防COVID-19的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0109" num="n0103">
        <base:Image he="390" wi="691" file="GDA0003327089700000232.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0110" num="n0104">其中</base:Paragraphs>
      <base:Paragraphs id="p0111" num="n0105">B选自</base:Paragraphs>
      <base:Paragraphs id="p0112" num="n0106">
        <base:Image he="194" wi="1000" file="GDA0003327089700000233.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0113" num="n0107">R<base:Sup>6</base:Sup>选自氢，-C(O)R<base:Sup>6A</base:Sup>，-C(O)OR<base:Sup>6A</base:Sup>，C<base:Sub>1-6</base:Sub>烷基和-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>，在一个替代实施方案中，-C(O)NR<base:Sup>6B</base:Sup>R<base:Sup>6C</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0114" num="n0108">R<base:Sup>6A</base:Sup>选自氢，C<base:Sub>1-6</base:Sub>烷基，C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基(例如-CHCl<base:Sub>2</base:Sub>,-CCl<base:Sub>3</base:Sub>,-CH<base:Sub>2</base:Sub>Cl,-CF<base:Sub>3</base:Sub>,-CHF<base:Sub>2</base:Sub>,-CH<base:Sub>2</base:Sub>F)，芳基和芳基(C<base:Sub>1-6</base:Sub>烷基)-，其中芳基任选地被选自烷氧基，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的取代基取代，在一个可选的实施方案中，R<base:Sup>6A</base:Sup>选自C<base:Sub>1-20</base:Sub>烷基和C<base:Sub>2-20</base:Sub>烯基；</base:Paragraphs>
      <base:Paragraphs id="p0115" num="n0109">R<base:Sup>6B</base:Sup>和R<base:Sup>6C</base:Sup>独立地选自氢，C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基，其中C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基可以任选地被选自烷氧基(包括但不限于甲氧基和乙氧基)，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的至少一个取代基取代；</base:Paragraphs>
      <base:Paragraphs id="p0116" num="n0110">R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>，H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0117" num="n0111">R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基，-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0118" num="n0112">Y选自F和Cl；</base:Paragraphs>
      <base:Paragraphs id="p0119" num="n0113">Z选自甲基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F,CHF<base:Sub>2</base:Sub>,CF<base:Sub>3</base:Sub>,CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>,CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>,CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F,CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>,CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>,和CH<base:Sub>2</base:Sub>Cl)，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素(包括Cl和F)，在一个替代实施方案中，Z是C<base:Sub>1-4</base:Sub>烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0120" num="n0114">R<base:Sup>40</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷氧基、C<base:Sub>1-3</base:Sub>烷基、N<base:Sub>3</base:Sub>、CN和卤素(包括Cl和F)；</base:Paragraphs>
      <base:Paragraphs id="p0121" num="n0115">R<base:Sup>41</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷基(包括甲基)和卤素(包括Cl、F和Br)；</base:Paragraphs>
      <base:Paragraphs id="p0122" num="n0116">R<base:Sup>42a</base:Sup>和R<base:Sup>42b</base:Sup>独立地选自C<base:Sub>1-3</base:Sub>烷基(包括甲基)、NH<base:Sub>2</base:Sub>、H、-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>和-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；和</base:Paragraphs>
      <base:Paragraphs id="p0123" num="n0117">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0124" num="n0118">在一个实施方案中，本发明还包括式VIIa、式VIIb、式VIIc和式VIId的化合物：</base:Paragraphs>
      <base:Paragraphs id="p0125" num="n0119">
        <base:Image he="1000" wi="788" file="GDA0003327089700000241.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0126" num="n0120">
        <base:Image he="1000" wi="695" file="GDA0003327089700000251.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0127" num="n0121">B的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0128" num="n0122">
        <base:Image he="582" wi="1000" file="GDA0003327089700000252.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0129" num="n0123">式VII化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0130" num="n0124">
        <base:Image he="1000" wi="701" file="GDA0003327089700000261.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0131">
        <base:Image he="535" wi="1000" file="GDA0003327089700000271.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0132" num="n0125">本发明还包括式VIII、式IX或式X的化合物的用途，其中R<base:Sup>10</base:Sup>是单磷酸酯、二磷酸酯、三磷酸酯或R<base:Sup>10A</base:Sup>，其中R<base:Sup>10A</base:Sup>是稳定的磷酸酯前药，其在体内代谢成单磷酸酯、二磷酸酯或三磷酸酯，以治疗或预防有需要的宿主的COVID-19疾病，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0133" num="n0126">
        <base:Image he="752" wi="1000" file="GDA0003327089700000272.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0134" num="n0127">其中</base:Paragraphs>
      <base:Paragraphs id="p0135" num="n0128">R<base:Sup>10</base:Sup>选自<base:Image he="188" wi="1000" file="GDA0003327089700000281.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />和R<base:Sup>10A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0136" num="n0129">R<base:Sup>10A</base:Sup>是稳定的磷酸酯前药，可在体内代谢为单磷酸酯、二磷酸酯或三磷酸酯；</base:Paragraphs>
      <base:Paragraphs id="p0137" num="n0130">R<base:Sup>11</base:Sup>选自氢和R<base:Sup>1</base:Sup>；和</base:Paragraphs>
      <base:Paragraphs id="p0138" num="n0131">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0139" num="n0132">式VIII、式IX或式X化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0140" num="n0133">
        <base:Image he="1000" wi="852" file="GDA0003327089700000282.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0141">
        <base:Image he="675" wi="1000" file="GDA0003327089700000291.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0142" num="n0134">式VIII、式IX或式X化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0143" num="n0135">
        <base:Image he="734" wi="1000" file="GDA0003327089700000292.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0144" num="n0136">
        <base:Image he="878" wi="1000" file="GDA0003327089700000301.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0145" num="n0137">本文所述的任何式中的磷可以是手性的，因此可以作为R或S对映异构体或其混合物提供，包括外消旋混合物。该化合物通常至少90％不含相反的对映异构体，并且可以至少95％、96％、97％、98％、99％或甚至100％不含相反的对映异构体。除非另有说明，否则该化合物至少90％不含相反的对映异构体。例如，化合物1的描述不考虑磷原子(它是手性的)处的立体化学。化合物1可以以外消旋形式使用，或以化合物的磷Rp-和Sp-对映体的任何所需比例使用，包括对映异构富集的材料直至纯对映体。化合物1A在磷处具有S-立体化学，化合物1B在磷处具有R-立体化学。在一些实施方案中，化合物1以至少90％不含相反对映体的形式使用，并且可以至少98％、99％或甚至100％不含相反对映体。例如，化合物1A可以至少90％、95％、98％、99％或甚至100％不含相反的Rp-对映异构体。或者，化合物1B可至少90％、95％、98％、99％或甚至100％不含相反的Sp-对映异构体。</base:Paragraphs>
      <base:Paragraphs id="p0146" num="n0138">类似地，化合物2的描述不考虑磷原子(它是手性的)处的立体化学。化合物2可以以外消旋形式使用，或以化合物的磷R-和S-对映体的任何所需比例使用，包括对映体富集的材料直至纯对映体。化合物2A在磷处具有S-立体化学，化合物2B在磷处具有R-立体化学。在一些实施方案中，化合物2以至少90％不含相反对映体的形式使用，并且可以至少98％、99％或甚至100％不含相反对映体。在一个实施方案中，化合物2A可以至少90％、95％、98％、99％或甚至100％不含相反的Rp-对映异构体。在一个实施方案中，化合物2B可以至少90％、95％、98％、99％或甚至100％不含相反的Sp-对映异构体。</base:Paragraphs>
      <base:Paragraphs id="p0147" num="n0139">除非另有说明，关于磷原子的立体化学式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物是至少90％不含相反的对映异构体。</base:Paragraphs>
      <base:Paragraphs id="p0148" num="n0140">提供了用于通过施用有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐在有需要的宿主中治疗由SARS-CoV-2病毒引起的COVID-19的化合物、组合物、剂型和方法。在一个实施方案中，还可以使用所述式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以有效预防或限制COVID-19在有需要的宿主中的进展，这些宿主已暴露于病毒或有感染或再感染的风险。</base:Paragraphs>
      <base:Paragraphs id="p0149" num="n0141">除非另外特别指明，本文所述剂型中活性化合物的重量是关于化合物的游离形式或盐形式。例如，约600mg化合物2相当于约550mg化合物1。在一个非限制性实施方案中，负荷剂量为1100mg/天(游离碱)(即，1200mg/天化合物1的半硫酸盐)，维持剂量为550毫克/天(游离碱)(即600毫克/天的半硫酸盐)。在一个实施方案中，负荷剂量施用一次并且维持剂量每天施用两次，持续至少3、4、5、6、7、8、9、10、11或12天。</base:Paragraphs>
      <base:Paragraphs id="p0150" num="n0142">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以至少约100、200、250、300、350、400、450、500、550、600、650、700、750、800、850、900、950、1000、1050、1100、1150、1200、1250、1300、1350、1400、1450、1500、1550、1600、1650、或1700mg的剂型施用。在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以至少250mg、500mg、至少600mg、至少700mg、至少800mg、至少900mg、至少1000mg、至少1100mg、至少1200mg、至少1300mg的剂量，至少1400mg或至少1500毫克的剂量施用。</base:Paragraphs>
      <base:Paragraphs id="p0151" num="n0143">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，包括化合物1或其药学上可接受的盐，例如化合物2，以约550mg的剂型每天一次施用。</base:Paragraphs>
      <base:Paragraphs id="p0152" num="n0144">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，包括化合物1或其药学上可接受的盐，例如化合物2，以约600mg的剂型每天一次施用。</base:Paragraphs>
      <base:Paragraphs id="p0153" num="n0145">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以约550毫克的剂型一天两次施用。</base:Paragraphs>
      <base:Paragraphs id="p0154" num="n0146">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以约600毫克的剂型一天两次施用。</base:Paragraphs>
      <base:Paragraphs id="p0155" num="n0147">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以约550mg的剂型每天两次施用至少五天，任选地与标准护理一起。在一个实施方案中，化合物1或其药学上可接受的盐以约550mg的剂型每天两次施用至少五天，任选地与标准护理一起。在一个实施例中，化合物1是化合物1A。在一个实施例中，化合物1是化合物1B。</base:Paragraphs>
      <base:Paragraphs id="p0156" num="n0148">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以约600mg的剂型每天两次施用，持续至少数天，任选地与标准护理一起。在一个实施方案中，化合物2或其药学上可接受的盐以约600mg的剂型每天两次给药至少五天，任选地与标准护理一起。在一个实施例中，化合物2是化合物2A。在一个实施例中，化合物2是化合物2B。</base:Paragraphs>
      <base:Paragraphs id="p0157" num="n0149">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以约550mg的剂型每天两次施用至少约5、6、7、8、9、10、11、12、13、14、15、16、17、18或更多天，任选地与标准护理一起。在一个实施方案中，化合物1或其药学上可接受的盐以约550mg的剂型每天两次施用至少约5、6、7、8、9、10、11、12、13、14、15、16、17、18天或更多天，任选地与标准护理一起。</base:Paragraphs>
      <base:Paragraphs id="p0158" num="n0150">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以约600mg的剂型每天两次施用至少约5、6、7、8、9、10、11、12、13、14、15、16、17、18或更多天，任选地与标准护理一起。在一个实施方案中，化合物2或其药学上可接受的盐约600mg的剂型每天两次施用至少约5、6、7、8、9、10、11、12、13、14、15、16、17、18天或更多天，任选地与标准护理一起。</base:Paragraphs>
      <base:Paragraphs id="p0159" num="n0151">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，例如化合物1或化合物3或其药学上可接受的盐，包括化合物2或化合物4，以初始剂量(或负荷剂量)随后维持剂量施用，其中负荷剂量由医生根据疾病呈现的严重程度和患者的大小酌情决定。在某些实施方案中，负荷剂量比维持剂量在约或至少1.5倍、约或至少2倍、约或至少2.5倍、或约或至少3倍。在一个实施方案中，负荷剂量在第一次维持剂量之前施用一次、两次、三次、四次或更多次，并且可以按照医师的指示每天施用一次、两次、三次或四次。</base:Paragraphs>
      <base:Paragraphs id="p0160" num="n0152">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，例如化合物1或化合物3或其药学上可接受的盐，包括化合物2或化合物4，以至少约800mg、至少约900mg毫克、至少约1000毫克、至少约1100毫克、至少约1200毫克、至少约1300毫克或至少约1400毫克的日负荷剂量(其可以全天以一个或多个剂量提供)施用，然后施用至少约300毫克、至少约350毫克、至少约400mg、至少约450mg、至少约500mg、至少约550mg、至少约600mg、至少约650mg、至少约700mg或至少约750mg的维持剂量，维持剂量每天服用一次、两次或三次。在一个实施方案中，维持剂量每天服用两次，并且任选地超过1、2、3或4天。在一个实施方案中，此后维持剂量每天施用1、2或3次，至少约4天、至少约5天、至少约6天、至少约7天、至少约8天、至少约9天、至少约10天、至少约15天、至少约20天、至少约25天或更多。</base:Paragraphs>
      <base:Paragraphs id="p0161" num="n0153">在某些实施方案中，化合物1或化合物3或其药学上可接受的盐，包括化合物2或化合物4，以至少约300mg、至少约350mg、至少约400mg、至少约450mg、至少约500mg、至少约550mg、至少约650或至少约750mg的剂量施用，该剂量每天服用一次、两次或三次。</base:Paragraphs>
      <base:Paragraphs id="p0162" num="n0154">在一个实施方案中，化合物1或其药学上可接受的盐，例如化合物2，以至少约500mg、至少约550mg或至少600mg的剂量给药并且该剂量每天服用两次。在一个实施方案中，化合物1或其药学上可接受的盐，例如化合物2，以至少约1000mg、至少约1100mg、或至少约1200mg的负荷剂量给药，随后是至少约500毫克、至少约550毫克或至少600毫克的维持剂量每天两次。在一个实施方案中，维持剂量施用至少约4、5、6、7、8、9、10或更多天。在一个实施方案中，化合物1是化合物1A。在一个实施方案中，化合物1是化合物1B。在一个实施例中，化合物2是化合物2A。在一个实施方案中，化合物2是化合物2B。</base:Paragraphs>
      <base:Paragraphs id="p0163" num="n0155">在一个实施方案中，化合物1以约550mg的剂量给药并且该剂量每天服用两次。在一个实施例中，化合物1是化合物1A。在一个实施例中，化合物1是化合物1B。</base:Paragraphs>
      <base:Paragraphs id="p0164" num="n0156">在一个实施方案中，化合物2以约600mg的剂量给药并且该剂量每天服用两次。在一个实施例中，化合物2是化合物2A。在一个实施例中，化合物2是化合物2B。</base:Paragraphs>
      <base:Paragraphs id="p0165" num="n0157">在某些实施方案中，根据治疗感染的需要，本发明的方法包括施用如本文所述的化合物，例如式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X、或式XIII，或其药学上可接受的盐，例如化合物1或化合物2，每天一次、两次、三次或四次或更多次。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，例如化合物1或化合物2，施用至少约4、5、6、7、8、9、10、15、20、25或更多天，或根据医疗保健提供者确定的一段时间。或者，可以将化合物施用适合于避免感染或降低有感染病毒风险的人或其他动物的感染严重程度的一段时间。</base:Paragraphs>
      <base:Paragraphs id="p0166" num="n0158">在一个实施方案中，本发明的化合物被无限期地给药直到感染或再感染的风险不再存在。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐施用至少1个月、至少2个月、至少3个月、至少4个月、至少5个月或至少6个月或更长时间。在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐被施用一天一次，两次、三次、四次或更多次。</base:Paragraphs>
      <base:Paragraphs id="p0167" num="n0159">在另一个替代实施方案中，提供了一种防止传播的方法，其包括在暴露于高风险情况之前向有需要的人施用有效量的本文所述的一种化合物达足够长的时间，包括在旅行或公共活动或会议期间，或者如果宿主属于高风险群体，包括例如，在可传染情况之前，然后在潜在暴露期间和任选在这之后最多3、5、7、10、12、14天或更多天。或者，可以无限期地以维持剂量施用如本文所述的选定化合物以保护处于高风险环境中的人。</base:Paragraphs>
      <base:Paragraphs id="p0168" num="n0160">本发明还包括式XI和式XII的化合物：</base:Paragraphs>
      <base:Paragraphs id="p0169" num="n0161">
        <base:Image he="264" wi="1000" file="GDA0003327089700000361.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0170" num="n0162">或其药学上可接受的盐</base:Paragraphs>
      <base:Paragraphs id="p0171" num="n0163">其中</base:Paragraphs>
      <base:Paragraphs id="p0172" num="n0164">R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>是氧保护基团并且R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>中的至少一个是-C(O)OC<base:Sub>1-6</base:Sub>烷基，例如-C(O)OtBu，或-C(O)O-苄基，其中烷基和苄基可以任选地被选自烷氧基、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代。</base:Paragraphs>
      <base:Paragraphs id="p0173" num="n0165">在一个实施方案中，R<base:Sup>12a</base:Sup>是-C(O)OC<base:Sub>1-6</base:Sub>烷基或-C(O)O-苄基并且R<base:Sup>12b</base:Sup>是氧保护基团，其当连接到氧时是酯、醚或甲硅烷基醚部分。在另一个实施方案中，R<base:Sup>12b</base:Sup>是-C(O)OC<base:Sub>1-6</base:Sub>烷基或-C(O)O-苄基并且R<base:Sup>12a</base:Sup>是氧保护基团，其当连接到氧时是酯、醚或甲硅烷基醚部分。在一个实施方案中，R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>都是-C(O)OC<base:Sub>1-6</base:Sub>烷基，例如-C(O)OtBu。在一个实施例中，R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>都是-C(O)O-苄基。</base:Paragraphs>
      <base:Paragraphs id="p0174" num="n0166">在一个实施例中，式XII的化合物是式XIIA：</base:Paragraphs>
      <base:Paragraphs id="p0175" num="n0167">
        <base:Image he="282" wi="424" file="GDA0003327089700000362.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0176" num="n0168">在一个实施例中，式XII的化合物是式XIIB：</base:Paragraphs>
      <base:Paragraphs id="p0177" num="n0169">
        <base:Image he="282" wi="422" file="GDA0003327089700000363.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0178" num="n0170">因此，本发明包括以下特征：</base:Paragraphs>
      <base:Paragraphs id="p0179" num="n0171">(a)一种在有需要的宿主中治疗由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，任选地在药学上可接受的载体中；</base:Paragraphs>
      <base:Paragraphs id="p0180" num="n0172">(b)一种在有需要的宿主中预防或最小化COVID-19的方法，包括施用有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，任选地在药学上可接受的载体中；</base:Paragraphs>
      <base:Paragraphs id="p0181" num="n0173">(c)(b)的方法，用于在有需要的宿主中预防或最小化SARS-CoV-2病毒的再感染或感染COVID-19；</base:Paragraphs>
      <base:Paragraphs id="p0182" num="n0174">(d)(a)-(c)的方法，其中化合物是化合物1；</base:Paragraphs>
      <base:Paragraphs id="p0183" num="n0175">(e)(a)-(c)的方法，其中化合物是化合物1A；</base:Paragraphs>
      <base:Paragraphs id="p0184" num="n0176">(f)(a)-(c)的方法，其中化合物是化合物1B；</base:Paragraphs>
      <base:Paragraphs id="p0185" num="n0177">(g)(a)-(c)的方法，其中化合物是化合物2；</base:Paragraphs>
      <base:Paragraphs id="p0186" num="n0178">(h)(a)-(c)的方法，其中化合物是化合物2A；</base:Paragraphs>
      <base:Paragraphs id="p0187" num="n0179">(i)(a)-(c)的方法，其中化合物是化合物2B；</base:Paragraphs>
      <base:Paragraphs id="p0188" num="n0180">(j)(a)-(c)的方法，其中化合物是化合物3；</base:Paragraphs>
      <base:Paragraphs id="p0189" num="n0181">(k)(a)-(c)的方法，其中化合物是化合物3A；</base:Paragraphs>
      <base:Paragraphs id="p0190" num="n0182">(l)(a)-(c)的方法，其中化合物是化合物3B；</base:Paragraphs>
      <base:Paragraphs id="p0191" num="n0183">(m)(a)-(c)的方法，其中化合物是化合物4；</base:Paragraphs>
      <base:Paragraphs id="p0192" num="n0184">(n)(a)-(c)的方法，其中化合物是化合物4A；</base:Paragraphs>
      <base:Paragraphs id="p0193" num="n0185">(o)(a)-(c)的方法，其中化合物是化合物4B；</base:Paragraphs>
      <base:Paragraphs id="p0194" num="n0186">(p)(a)-(c)的方法，其中化合物为式IIIa；</base:Paragraphs>
      <base:Paragraphs id="p0195" num="n0187">(q)(a)-(c)的方法，其中化合物为式IIIb；</base:Paragraphs>
      <base:Paragraphs id="p0196" num="n0188">(r)(a)-(c)的方法，其中化合物为式IIIc；</base:Paragraphs>
      <base:Paragraphs id="p0197" num="n0189">(s)(a)-(c)的方法，其中化合物为式IIId；</base:Paragraphs>
      <base:Paragraphs id="p0198" num="n0190">(t)(a)-(c)的方法，其中化合物为式IIIe；</base:Paragraphs>
      <base:Paragraphs id="p0199" num="n0191">(u)(a)-(c)的方法，其中化合物为式IIIf；</base:Paragraphs>
      <base:Paragraphs id="p0200" num="n0192">(v)(a)-(c)的方法，其中化合物为式IVa；</base:Paragraphs>
      <base:Paragraphs id="p0201" num="n0193">(w)(a)-(c)的方法，其中化合物为式IVb；</base:Paragraphs>
      <base:Paragraphs id="p0202" num="n0194">(x)(a)-(c)的方法，其中化合物为式IVc；</base:Paragraphs>
      <base:Paragraphs id="p0203" num="n0195">(y)(a)-(c)的方法，其中化合物为式IVd；</base:Paragraphs>
      <base:Paragraphs id="p0204" num="n0196">(z)(a)-(c)的方法，其中化合物为式IVe；</base:Paragraphs>
      <base:Paragraphs id="p0205" num="n0197">(aa)(a)-(c)的方法，其中化合物为式IVf；</base:Paragraphs>
      <base:Paragraphs id="p0206" num="n0198">(bb)(a)-(c)的方法，其中化合物为式V；</base:Paragraphs>
      <base:Paragraphs id="p0207" num="n0199">(cc)(a)-(c)的方法，其中化合物为式VI；</base:Paragraphs>
      <base:Paragraphs id="p0208" num="n0200">(dd)(a)-(c)的方法，其中化合物为式VII；</base:Paragraphs>
      <base:Paragraphs id="p0209" num="n0201">(ee)(a)-(c)的方法，其中化合物为式VIII、式IX或式X；</base:Paragraphs>
      <base:Paragraphs id="p0210" num="n0202">(ff)式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，用于在有需要的宿主中治疗由SARS-CoV-2病毒引起的COVID-19感染，任选地在药学上可接受的载体中；</base:Paragraphs>
      <base:Paragraphs id="p0211" num="n0203">(gg)式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐用于在有需要的宿主中预防或最小化(相对于未治疗)由SARS-CoV-2病毒引起的感染，可选地在药学上可接受的载体中；</base:Paragraphs>
      <base:Paragraphs id="p0212" num="n0204">(hh)(gg)的化合物，用于在有需要的宿主中预防由SARS-CoV-2病毒引起的再感染；</base:Paragraphs>
      <base:Paragraphs id="p0213" num="n0205">(ii)式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，任选地在药学上可接受的载体中，制造用于治疗由SARS-CoV-2病毒引起的2019冠状病毒病(COVID-19)的药物的用途；</base:Paragraphs>
      <base:Paragraphs id="p0214" num="n0206">(jj)式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，任选地在药学上可接受的载体中，制造用于在有需要的宿主中预防由SARS-CoV-2病毒引起的COVID-19的药物的用途；</base:Paragraphs>
      <base:Paragraphs id="p0215" num="n0207">(kk)(jj)的用途，用于在有需要的宿主中预防由SARS-CoV-2病毒引起的再感染；</base:Paragraphs>
      <base:Paragraphs id="p0216" num="n0208">(ll)任何上述实施方案，其中药学上可接受的载体是适合口服给药的剂型；</base:Paragraphs>
      <base:Paragraphs id="p0217" num="n0209">(mm)(ll)的剂型，其中该剂型是固体剂型；</base:Paragraphs>
      <base:Paragraphs id="p0218" num="n0210">(nn)(mm)的剂型，其为片剂形式；</base:Paragraphs>
      <base:Paragraphs id="p0219" num="n0211">(oo)(mm)的剂型，其为胶囊形式；</base:Paragraphs>
      <base:Paragraphs id="p0220" num="n0212">(pp)(ll)的剂型，其中该剂型是液体剂型；</base:Paragraphs>
      <base:Paragraphs id="p0221" num="n0213">(qq)(pp)的剂型，其为溶液或悬浮液的形式；</base:Paragraphs>
      <base:Paragraphs id="p0222" num="n0214">(rr)实施方案(a)-(kk)中的任一项，其中药学上可接受的载体是适合静脉内给药的剂型；</base:Paragraphs>
      <base:Paragraphs id="p0223" num="n0215">(ss)实施方案(a)-(kk)中的任一项，其中药学上可接受的载体是适合肠胃外给药的剂型；</base:Paragraphs>
      <base:Paragraphs id="p0224" num="n0216">(tt)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐每天给药一次；</base:Paragraphs>
      <base:Paragraphs id="p0225" num="n0217">(uu)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐每天给药两次；</base:Paragraphs>
      <base:Paragraphs id="p0226" num="n0218">(vv)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐一日给药3次。</base:Paragraphs>
      <base:Paragraphs id="p0227" num="n0219">(ww)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐给药至少一周、十天、两周、三周、一个月、至少两个月、至少三个月、至少四个月、至少五个月或至少六个月或更长时间。</base:Paragraphs>
      <base:Paragraphs id="p0228" num="n0220">(xx)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐无限期地每天给药至少一次、至少两次或至少三次，直至感染的风险不再存在；</base:Paragraphs>
      <base:Paragraphs id="p0229" num="n0221">(yy)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以至少约400mg的剂量给药；</base:Paragraphs>
      <base:Paragraphs id="p0230" num="n0222">(zz)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以至少约500mg的剂量给药；</base:Paragraphs>
      <base:Paragraphs id="p0231" num="n0223">(aaa)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以至少约550mg的剂量给药；</base:Paragraphs>
      <base:Paragraphs id="p0232" num="n0224">(bbb)任何上述实施方案，其中式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以至少约600mg的剂量给药；</base:Paragraphs>
      <base:Paragraphs id="p0233" num="n0225">(ccc)一种用于在有需要的宿主中治疗COVID-19的方法，包括施用化合物1，其中化合物1以至少约550mg的剂量施用并且该剂量每天施用两次；</base:Paragraphs>
      <base:Paragraphs id="p0234" num="n0226">(ddd)一种用于在有需要的宿主中治疗COVID-19病毒的方法，包括施用化合物1，其中化合物1以至少约1100mg的负荷剂量施用，然后以至少约550mg的维持剂量施用一天两次；</base:Paragraphs>
      <base:Paragraphs id="p0235" num="n0227">(eee)实施方案(ccc或ddd)，其中化合物1是化合物1A；</base:Paragraphs>
      <base:Paragraphs id="p0236" num="n0228">(fff)实施方案(ccc或ddd)，其中化合物1是化合物1B；</base:Paragraphs>
      <base:Paragraphs id="p0237" num="n0229">(ggg)一种在有需要的宿主中治疗COVID-19的方法，包括施用化合物2，其中化合物2以至少约600mg的剂量施用并且该剂量每天施用两次；</base:Paragraphs>
      <base:Paragraphs id="p0238" num="n0230">(hhh)一种在有需要的宿主中治疗COVID-19的方法，包括施用化合物2，其中化合物2以至少约1200mg的负荷剂量施用，然后以至少约600mg的维持剂量施用一天两次；</base:Paragraphs>
      <base:Paragraphs id="p0239" num="n0231">(iii)实施方案(ggg或hhh)，其中化合物2是化合物2A；</base:Paragraphs>
      <base:Paragraphs id="p0240" num="n0232">(jjj)实施方案(ggg或hhh)，其中化合物2是化合物2B；</base:Paragraphs>
      <base:Paragraphs id="p0241" num="n0233">(kkk)式II化合物或其药学上可接受的盐；</base:Paragraphs>
      <base:Paragraphs id="p0242" num="n0234">(lll)如本文所述的化合物4或药学上可接受的盐；</base:Paragraphs>
      <base:Paragraphs id="p0243" num="n0235">(mmm)如本文所述的化合物4A和化合物4B；</base:Paragraphs>
      <base:Paragraphs id="p0244" num="n0236">(nnn)一种药物制剂，其包含有效量的式II化合物，任选地在药学上可接受的载体中。</base:Paragraphs>
      <base:Paragraphs id="p0245" num="n0237">(ooo)式XI或式XII的化合物；</base:Paragraphs>
      <base:Paragraphs id="p0246" num="n0238">(ppp)式XIIA化合物；</base:Paragraphs>
      <base:Paragraphs id="p0247" num="n0239">(qqq)式XIIB的化合物；</base:Paragraphs>
      <base:Paragraphs id="p0248" num="n0240">(rrr)式VII化合物；</base:Paragraphs>
      <base:Paragraphs id="p0249" num="n0241">(sss)式VIIa化合物；</base:Paragraphs>
      <base:Paragraphs id="p0250" num="n0242">(ttt)式VIIb的化合物；</base:Paragraphs>
      <base:Paragraphs id="p0251" num="n0243">(uuu)式VIIc化合物；</base:Paragraphs>
      <base:Paragraphs id="p0252" num="n0244">(vvv)式VIId的化合物；和</base:Paragraphs>
      <base:Paragraphs id="p0253" num="n0245">(www)包含有效量的式VIIa、式VIIb、式VIIc或式VIId的化合物的药物组合物。</base:Paragraphs>
    </business:Disclosure>
    <business:DrawingsDescription id="description-of-drawings001">
      <base:Paragraphs id="p0254">附图说明</base:Paragraphs>
      <base:Paragraphs id="p0255" num="n0246">图1是在暴露于10μM的化合物1A后人支气管和鼻上皮细胞中三磷酸酯化合物1-6浓度的图，如实施例7中所描述。化合物1-6在支气管细胞和鼻细胞中的半衰期分别为39小时和38小时。x轴是以小时为单位测量的冲洗后时间，y轴是以pmol/百万细胞为单位的化合物1-6浓度。</base:Paragraphs>
      <base:Paragraphs id="p0256" num="n0247">图2是比较暴露于化合物1A(1A)、ALS-8112(ALS)和4'-Me取代的前药((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-2,4-二甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(4’-Me)后人支气管上皮细胞中三磷酸酯化合物1-6水平的图，如实施例7中所述。x轴是以小时为单位测量的冲洗后时间，y轴是以pmol/百万细胞为单位的化合物1-6的浓度。</base:Paragraphs>
      <base:Paragraphs id="p0257" num="n0248">图3是比较暴露于化合物1A(1A)、ALS-8112(ALS)和4'-Me取代的前药((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-2,4-二甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(4’-Me)的人鼻上皮细胞中三磷酸酯化合物1-6水平的图，如实施例7中所述。x轴是以小时为单位测量的冲洗后时间，y轴是以pmol/百万细胞为单位的化合物1-6的浓度。</base:Paragraphs>
      <base:Paragraphs id="p0258" num="n0249">图4是每天两次(BID)以30mg/kg口服剂量给药化合物2A 3天的猴中化合物1A的平均血浆分布图，如实施例8所描述。x轴是以小时为单位测量的冲洗后时间，y轴是以ng/mL为单位的化合物1A的血浆浓度。</base:Paragraphs>
      <base:Paragraphs id="p0259" num="n0250">图5是每天两次(BID)以30mg/kg口服剂量给药化合物2A 3天的猴中代谢物化合物1-2的平均血浆分布图，如实施例8所描述。x轴是以小时为单位测量的冲洗后时间，y轴是以ng/mL为单位的化合物1-2的血浆浓度。</base:Paragraphs>
      <base:Paragraphs id="p0260" num="n0251">图6是每天两次(BID)以30mg/kg口服剂量给药化合物2A 3天的猴中三磷酸酯代理代谢物化合物1-7的平均血浆分布图，如实施例8所描述。x轴是以小时为单位测量的冲洗后时间，y轴是以ng/mL为单位的化合物1-7的血浆浓度。</base:Paragraphs>
      <base:Paragraphs id="p0261" num="n0252">图7A是每天两次(BID)以30mg/kg口服剂量给药化合物2A 3天的猴子的肺、肾和肝组织中三磷酸酯化合物1-6浓度的图，如实施例8所描述。在肺、肾和肝中的半衰期分别为9.4小时、8.0小时和4.3小时。x轴是以小时为单位测量的给药后时间，y轴是以ng/g为单位测量的化合物1-6的组织浓度。</base:Paragraphs>
      <base:Paragraphs id="p0262" num="n0253">图7B是每天两次(BID)以30mg/kg口服剂量给药化合物2A 3天的猴子的肺、肾和肝组织中三磷酸酯化合物1-6浓度的图，如实施例8所描述。化合物1-6的组织浓度显示最后一次给药后2小时、12小时、24小时和48小时。x轴是以小时为单位测量的最后一次给药后的时间，y轴是以μM为单位测量的组织浓度。</base:Paragraphs>
      <base:Paragraphs id="p0263" num="n0254">图8是与化合物2A一起孵育的肝细胞中三磷酸酯化合物1-6水平的图，如实施例9中所描述以及先前由Good,S.S.et al.2020PLoS ONE 15(1):e0227104)所述的。人肝细胞中的浓度比猴中高7倍。x轴是以小时为单位测量的孵育时间，y轴是以pmol/10<base:Sup>6</base:Sup>细胞为单位测量的化合物1-6的浓度。</base:Paragraphs>
      <base:Paragraphs id="p0264" num="n0255">图9是人肺组织中化合物1-6的细胞内浓度的模拟，如实施例10中所描述。预测的肺浓度基于预测的谷(C<base:Sub>12h</base:Sub>)稳态血浆化合物1-7，人中细胞内三磷酸酯化合物1-6的血浆替代物,(Berliba,e.et al.2019Antimicrob.Agents Chemother.63(12):e01201-19)乘以1.6的比率(肺中三磷酸酯浓度是肝脏中稳态谷水平的1.6倍，如实施例8所述)。x轴是以天为单位测量的时间并且y轴是以μM为单位测量的模拟肺化合物1-6浓度。</base:Paragraphs>
      <base:Paragraphs id="p0265" num="n0256">图10是使用两种方法对人肺组织中化合物1-6的细胞内浓度的模拟，如实施例10中所描述。实线代表在针对化合物1-6肺-肝浓度比率1.6校正后，活性三磷酸酯化合物1-6代谢物的预测肺浓度。虚线代表在针对化合物1-6肺与化合物1-7血浆比率1.2校正之后，活性三磷酸酯化合物1-6代谢物的预测肺浓度。水平线代表化合物1A在体外HAE细胞中对抗SARS-CoV-2的EC<base:Sub>90</base:Sub>(0.47μM)。x轴是以天为单位测量的时间并且y轴是以μM为单位测量的模拟肺化合物1-6浓度。</base:Paragraphs>
      <base:Paragraphs id="p0266" num="n0257">图11是式I化合物的说明，其也可以作为药学上可接受的盐给药。</base:Paragraphs>
    </business:DrawingsDescription>
    <business:InventionMode id="mode-for-invention001">
      <base:Paragraphs id="p0267" num="n0258">
        <base:Underline>发明详述</base:Underline>
      </base:Paragraphs>
      <base:Paragraphs id="p0268" num="n0259">本文公开了一种在有需要的宿主(例如人)中治疗或预防由SARS-CoV-2病毒引起的2019冠状病毒疾病(COVID-19)的方法，包括施用有效量的式I化合物或其药学上可接受的盐：</base:Paragraphs>
      <base:Paragraphs id="p0269" num="n0260">
        <base:Image he="469" wi="898" file="GDA0003327089700000431.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0270" num="n0261">
        <base:Image he="77" wi="130" file="GDA0003327089700000441.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />
      </base:Paragraphs>
      <base:Paragraphs id="p0271" num="n0262">其中</base:Paragraphs>
      <base:Paragraphs id="p0272" num="n0263">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基，和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0273" num="n0264">R<base:Sup>2</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>3-7</base:Sub>环烷基或芳基(包括苯基和萘基)，和在一个替代实施方案中，R<base:Sup>2</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，杂芳基或杂烷基；</base:Paragraphs>
      <base:Paragraphs id="p0274" num="n0265">R<base:Sup>3</base:Sup>是氢或C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)；</base:Paragraphs>
      <base:Paragraphs id="p0275" num="n0266">R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)和C<base:Sub>3-7</base:Sub>环烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0276" num="n0267">R<base:Sup>5</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>1-6</base:Sub>卤代烷基或C<base:Sub>3-7</base:Sub>环烷基，和在一个替代实施方案中，R<base:Sup>5</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，芳基，杂芳基或杂烷基。</base:Paragraphs>
      <base:Paragraphs id="p0277" num="n0268">式I化合物的非限制性实例包括化合物1和化合物2。在一个实施方案中，化合物作为S-对映异构体施予，例如化合物1A。在一个实施方案中，化合物作为R-对映异构体施予，例如化合物1B。在一个实施方案中，式I化合物是化合物2、化合物2A或化合物2B。</base:Paragraphs>
      <base:Paragraphs id="p0278" num="n0269">
        <base:Image he="1000" wi="785" file="GDA0003327089700000442.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0279" num="n0270">
        <base:Image he="1000" wi="341" file="GDA0003327089700000451.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0280" num="n0271">
        <base:Image he="77" wi="302" file="GDA0003327089700000461.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />
      </base:Paragraphs>
      <base:Paragraphs id="p0281" num="n0272">可以使用的化合物1或其药学上可接受的盐的替代构型包括：</base:Paragraphs>
      <base:Paragraphs id="p0282">
        <base:Image he="540" wi="1000" file="GDA0003327089700000462.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0283" num="n0273">可以使用的化合物2的替代构型包括：</base:Paragraphs>
      <base:Paragraphs id="p0284" num="n0274">
        <base:Image he="542" wi="1000" file="GDA0003327089700000463.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0285" num="n0275">可以使用的化合物1或其药学上可接受的盐，例如，化合物2的其他替代构型包括：</base:Paragraphs>
      <base:Paragraphs id="p0286" num="n0276">
        <base:Image he="500" wi="1000" file="GDA0003327089700000471.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0287" num="n0277">式I化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0288" num="n0278">
        <base:Image he="892" wi="1000" file="GDA0003327089700000472.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0289" num="n0279">
        <base:Image he="1000" wi="646" file="GDA0003327089700000481.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0290" num="n0280">
        <base:Image he="900" wi="1000" file="GDA0003327089700000491.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0291" num="n0281">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0292" num="n0282">式I化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0293" num="n0283">
        <base:Image he="287" wi="1000" file="GDA0003327089700000492.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0294" num="n0284">
        <base:Image he="1000" wi="738" file="GDA0003327089700000501.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0295" num="n0285">
        <base:Image he="1000" wi="742" file="GDA0003327089700000511.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0296">
        <base:Image he="265" wi="1000" file="GDA0003327089700000521.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0297" num="n0286">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0298" num="n0287">式I化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0299" num="n0288">
        <base:Image he="887" wi="1000" file="GDA0003327089700000522.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0300" num="n0289">
        <base:Image he="1000" wi="707" file="GDA0003327089700000531.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0301" num="n0290">
        <base:Image he="1000" wi="826" file="GDA0003327089700000541.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0302" num="n0291">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0303" num="n0292">本发明还包括有效量的式II化合物在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途：</base:Paragraphs>
      <base:Paragraphs id="p0304" num="n0293">
        <base:Image he="570" wi="839" file="GDA0003327089700000551.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0305" num="n0294">或其药学上可接受的盐，其中：</base:Paragraphs>
      <base:Paragraphs id="p0306" num="n0295">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基，和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0307" num="n0296">R<base:Sup>2</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>3-7</base:Sub>环烷基或芳基(包括苯基和萘基)，和在一个替代实施方案中，R<base:Sup>2</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，杂芳基或杂烷基；</base:Paragraphs>
      <base:Paragraphs id="p0308" num="n0297">R<base:Sup>3</base:Sup>是氢或C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)；</base:Paragraphs>
      <base:Paragraphs id="p0309" num="n0298">R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)和C<base:Sub>3-7</base:Sub>环烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0310" num="n0299">R<base:Sup>5</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>1-6</base:Sub>卤代烷基或C<base:Sub>3-7</base:Sub>环烷基，和在一个替代实施方案中，R<base:Sup>5</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，芳基，杂芳基或杂烷基。</base:Paragraphs>
      <base:Paragraphs id="p0311" num="n0300">在一个实施方案中，式II化合物或其药学上可接受的盐，任选地在药学上可接受的载体中，以有效量施用有需要的宿主，其患有COVID-19，或有感染SARS-CoV-2病毒的风险，即，作为预防剂。</base:Paragraphs>
      <base:Paragraphs id="p0312" num="n0301">式II化合物的非限制性实例包括化合物3和化合物4。在一个实施方案中，化合物作为S-对映异构体施予，例如化合物3A和4A。在一个实施方案中，化合物作为R-对映异构体施予，例如化合物3B和4B。</base:Paragraphs>
      <base:Paragraphs id="p0313" num="n0302">
        <base:Image he="577" wi="899" file="GDA0003327089700000552.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0314" num="n0303">
        <base:Image he="1000" wi="378" file="GDA0003327089700000561.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0315" num="n0304">
        <base:Image he="680" wi="992" file="GDA0003327089700000571.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0316" num="n0305">化合物3或其药学上可接受的盐的替代构型包括：</base:Paragraphs>
      <base:Paragraphs id="p0317" num="n0306">
        <base:Image he="580" wi="1000" file="GDA0003327089700000572.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0318" num="n0307">化合物4的其他替代构型包括：</base:Paragraphs>
      <base:Paragraphs id="p0319" num="n0308">
        <base:Image he="279" wi="1000" file="GDA0003327089700000573.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0320">
        <base:Image he="267" wi="1000" file="GDA0003327089700000581.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0321" num="n0309">可以使用的化合物3或其药学上可接受的盐，例如化合物4，的其他替代构型包括：</base:Paragraphs>
      <base:Paragraphs id="p0322" num="n0310">
        <base:Image he="524" wi="1000" file="GDA0003327089700000582.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0323" num="n0311">式II化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0324" num="n0312">
        <base:Image he="295" wi="1000" file="GDA0003327089700000583.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0325" num="n0313">
        <base:Image he="1000" wi="658" file="GDA0003327089700000591.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0326" num="n0314">
        <base:Image he="1000" wi="658" file="GDA0003327089700000601.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0327" num="n0315">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0328" num="n0316">式II化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0329" num="n0317">
        <base:Image he="1000" wi="730" file="GDA0003327089700000611.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0330" num="n0318">
        <base:Image he="1000" wi="745" file="GDA0003327089700000621.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0331" num="n0319">
        <base:Image he="546" wi="1000" file="GDA0003327089700000631.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0332" num="n0320">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0333" num="n0321">式II化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0334" num="n0322">
        <base:Image he="570" wi="1000" file="GDA0003327089700000632.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0335" num="n0323">
        <base:Image he="1000" wi="690" file="GDA0003327089700000641.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0336" num="n0324">
        <base:Image he="1000" wi="788" file="GDA0003327089700000651.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0337">
        <base:Image he="1000" wi="896" file="GDA0003327089700000661.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0338" num="n0325">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0339" num="n0326">本发明还包括有效量的式III化合物在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途：</base:Paragraphs>
      <base:Paragraphs id="p0340" num="n0327">
        <base:Image he="567" wi="899" file="GDA0003327089700000662.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0341" num="n0328">或其药学上可接受的盐，其中：</base:Paragraphs>
      <base:Paragraphs id="p0342" num="n0329">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基，和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0343" num="n0330">R<base:Sup>2</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>3-7</base:Sub>环烷基或芳基(包括苯基和萘基)，和在一个替代实施方案中，R<base:Sup>2</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，杂芳基或杂烷基；</base:Paragraphs>
      <base:Paragraphs id="p0344" num="n0331">R<base:Sup>3</base:Sup>是氢或C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)；</base:Paragraphs>
      <base:Paragraphs id="p0345" num="n0332">R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)和C<base:Sub>3-7</base:Sub>环烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0346" num="n0333">R<base:Sup>5</base:Sup>是氢，C<base:Sub>1-6</base:Sub>烷基(包括甲基，乙基，丙基和异丙基)，C<base:Sub>1-6</base:Sub>卤代烷基或C<base:Sub>3-7</base:Sub>环烷基，和在一个替代实施方案中，R<base:Sup>5</base:Sup>是芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-，芳基，杂芳基或杂烷基；</base:Paragraphs>
      <base:Paragraphs id="p0347" num="n0334">X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基。</base:Paragraphs>
      <base:Paragraphs id="p0348" num="n0335">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式III化合物是式IIIa化合物：</base:Paragraphs>
      <base:Paragraphs id="p0349" num="n0336">
        <base:Image he="579" wi="901" file="GDA0003327089700000671.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0350" num="n0337">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0351" num="n0338">在式IIIa的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0352" num="n0339">在式IIIa的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0353" num="n0340">在式IIIa的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0354" num="n0341">在式IIIa的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0355" num="n0342">在式IIIa的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0356" num="n0343">在式IIIa的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0357" num="n0344">在式IIIa的一个实施方案中，化合物是S<base:Sub>p</base:Sub>-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0358" num="n0345">在式IIIa的一个实施方案中，化合物是R<base:Sub>p</base:Sub>-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0359" num="n0346">在式IIIa的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0360" num="n0347">式IIIa化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0361" num="n0348">
        <base:Image he="1000" wi="756" file="GDA0003327089700000681.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0362" num="n0349">
        <base:Image he="1000" wi="705" file="GDA0003327089700000691.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0363" num="n0350">
        <base:Image he="1000" wi="691" file="GDA0003327089700000701.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0364" num="n0351">
        <base:Image he="1000" wi="698" file="GDA0003327089700000711.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0365" num="n0352">
        <base:Image he="1000" wi="700" file="GDA0003327089700000721.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0366" num="n0353">
        <base:Image he="1000" wi="771" file="GDA0003327089700000731.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0367" num="n0354">式IIIa化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0368" num="n0355">
        <base:Image he="795" wi="1000" file="GDA0003327089700000741.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0369" num="n0356">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式III化合物是式IIIb化合物：</base:Paragraphs>
      <base:Paragraphs id="p0370" num="n0357">
        <base:Image he="571" wi="898" file="GDA0003327089700000742.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0371" num="n0358">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0372" num="n0359">在式IIIb的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0373" num="n0360">在式IIIb的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0374" num="n0361">在式IIIb的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0375" num="n0362">在式IIIb的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0376" num="n0363">在式IIIb的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0377" num="n0364">在式IIIb的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0378" num="n0365">在式IIIb的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0379" num="n0366">在式IIIb的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0380" num="n0367">在式IIIb的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0381" num="n0368">式IIIb化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0382" num="n0369">
        <base:Image he="1000" wi="899" file="GDA0003327089700000751.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0383" num="n0370">
        <base:Image he="1000" wi="716" file="GDA0003327089700000761.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0384" num="n0371">
        <base:Image he="1000" wi="690" file="GDA0003327089700000771.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0385" num="n0372">
        <base:Image he="1000" wi="636" file="GDA0003327089700000781.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0386" num="n0373">
        <base:Image he="1000" wi="669" file="GDA0003327089700000791.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0387" num="n0374">
        <base:Image he="1000" wi="695" file="GDA0003327089700000801.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0388">
        <base:Image he="510" wi="960" file="GDA0003327089700000811.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0389" num="n0375">式IIIb化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0390" num="n0376">
        <base:Image he="794" wi="1000" file="GDA0003327089700000812.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0391" num="n0377">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式III化合物是式IIIc化合物：</base:Paragraphs>
      <base:Paragraphs id="p0392" num="n0378">
        <base:Image he="597" wi="868" file="GDA0003327089700000821.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0393" num="n0379">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0394" num="n0380">在式IIIc的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0395" num="n0381">在式IIIc的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0396" num="n0382">在式IIIc的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0397" num="n0383">在式IIIc的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0398" num="n0384">在式IIIc的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0399" num="n0385">在式IIIc的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0400" num="n0386">在式IIIc的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0401" num="n0387">在式IIIc的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0402" num="n0388">在式IIIc的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0403" num="n0389">式IIIc化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0404" num="n0390">
        <base:Image he="287" wi="1000" file="GDA0003327089700000822.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0405" num="n0391">
        <base:Image he="1000" wi="693" file="GDA0003327089700000831.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0406" num="n0392">
        <base:Image he="1000" wi="679" file="GDA0003327089700000841.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0407" num="n0393">
        <base:Image he="1000" wi="653" file="GDA0003327089700000851.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0408" num="n0394">
        <base:Image he="1000" wi="660" file="GDA0003327089700000861.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0409" num="n0395">
        <base:Image he="1000" wi="660" file="GDA0003327089700000871.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0410" num="n0396">
        <base:Image he="1000" wi="946" file="GDA0003327089700000881.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0411" num="n0397">式IIIc化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0412" num="n0398">
        <base:Image he="267" wi="1000" file="GDA0003327089700000882.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0413">
        <base:Image he="530" wi="1000" file="GDA0003327089700000891.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0414" num="n0399">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式III化合物是式IIId化合物：</base:Paragraphs>
      <base:Paragraphs id="p0415" num="n0400">
        <base:Image he="581" wi="899" file="GDA0003327089700000892.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0416" num="n0401">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0417" num="n0402">在式IIId的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0418" num="n0403">在式IIId的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0419" num="n0404">在式IIId的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0420" num="n0405">在式IIId的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0421" num="n0406">在式IIId的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0422" num="n0407">在式IIId的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0423" num="n0408">在式IIId的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0424" num="n0409">在式IIId的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0425" num="n0410">在式IIId的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0426" num="n0411">式IIId化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0427" num="n0412">
        <base:Image he="1000" wi="886" file="GDA0003327089700000901.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0428" num="n0413">
        <base:Image he="1000" wi="706" file="GDA0003327089700000911.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0429" num="n0414">
        <base:Image he="1000" wi="680" file="GDA0003327089700000921.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0430" num="n0415">
        <base:Image he="1000" wi="636" file="GDA0003327089700000931.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0431" num="n0416">
        <base:Image he="1000" wi="660" file="GDA0003327089700000941.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0432" num="n0417">
        <base:Image he="1000" wi="720" file="GDA0003327089700000951.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0433" num="n0418">
        <base:Image he="590" wi="1000" file="GDA0003327089700000961.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0434" num="n0419">式IIId化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0435" num="n0420">
        <base:Image he="795" wi="1000" file="GDA0003327089700000962.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0436" num="n0421">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式III化合物是式IIIe化合物：</base:Paragraphs>
      <base:Paragraphs id="p0437" num="n0422">
        <base:Image he="575" wi="899" file="GDA0003327089700000971.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0438" num="n0423">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0439" num="n0424">在式IIIe的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0440" num="n0425">在式IIIe的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0441" num="n0426">在式IIIe的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0442" num="n0427">在式IIIe的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0443" num="n0428">在式IIIe的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0444" num="n0429">在式IIIe的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0445" num="n0430">在式IIIe的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0446" num="n0431">在式IIIe的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0447" num="n0432">在式IIIe的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0448" num="n0433">式IIIe化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0449" num="n0434">
        <base:Image he="284" wi="1000" file="GDA0003327089700000972.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0450" num="n0435">
        <base:Image he="1000" wi="720" file="GDA0003327089700000981.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0451" num="n0436">
        <base:Image he="1000" wi="679" file="GDA0003327089700000991.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0452" num="n0437">
        <base:Image he="1000" wi="653" file="GDA0003327089700001001.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0453" num="n0438">
        <base:Image he="1000" wi="660" file="GDA0003327089700001011.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0454" num="n0439">
        <base:Image he="1000" wi="660" file="GDA0003327089700001021.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0455" num="n0440">
        <base:Image he="761" wi="1000" file="GDA0003327089700001031.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0456" num="n0441">式IIIe化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0457" num="n0442">
        <base:Image he="529" wi="1000" file="GDA0003327089700001032.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0458">
        <base:Image he="510" wi="923" file="GDA0003327089700001041.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0459" num="n0443">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式III化合物是式IIIf化合物：</base:Paragraphs>
      <base:Paragraphs id="p0460" num="n0444">
        <base:Image he="550" wi="900" file="GDA0003327089700001042.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0461" num="n0445">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0462" num="n0446">在式IIIf的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0463" num="n0447">在式IIIf的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0464" num="n0448">在式IIIf的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0465" num="n0449">在式IIIf的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0466" num="n0450">在式IIIf的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0467" num="n0451">在式IIIf的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0468" num="n0452">在式IIIf的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0469" num="n0453">在式IIIf的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0470" num="n0454">在式IIIf的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0471" num="n0455">式IIIf化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0472" num="n0456">
        <base:Image he="1000" wi="708" file="GDA0003327089700001051.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0473" num="n0457">
        <base:Image he="1000" wi="679" file="GDA0003327089700001061.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0474" num="n0458">
        <base:Image he="1000" wi="666" file="GDA0003327089700001071.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0475" num="n0459">
        <base:Image he="1000" wi="660" file="GDA0003327089700001081.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0476" num="n0460">
        <base:Image he="1000" wi="660" file="GDA0003327089700001091.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0477" num="n0461">
        <base:Image he="1000" wi="698" file="GDA0003327089700001101.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0478">
        <base:Image he="566" wi="960" file="GDA0003327089700001111.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0479" num="n0462">式IIIe化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0480" num="n0463">
        <base:Image he="1000" wi="915" file="GDA0003327089700001112.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0481">
        <base:Image he="592" wi="1000" file="GDA0003327089700001121.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0482" num="n0464">式III化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0483" num="n0465">
        <base:Image he="645" wi="1000" file="GDA0003327089700001122.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0484">
        <base:Image he="607" wi="1000" file="GDA0003327089700001131.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0485" num="n0466">本发明还包括式IV化合物在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0486" num="n0467">
        <base:Image he="573" wi="901" file="GDA0003327089700001132.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0487" num="n0468">或其药学上可接受的盐，其中：</base:Paragraphs>
      <base:Paragraphs id="p0488" num="n0469">X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0489" num="n0470">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0490" num="n0471">在一个实施方案中，用于治疗或预防COVID-19疾病的式IV化合物是式IVa、式IVb、式IVc、式IVd、式IVe或式IVf的化合物或其药学上可接受的盐：</base:Paragraphs>
      <base:Paragraphs id="p0491" num="n0472">
        <base:Image he="1000" wi="358" file="GDA0003327089700001141.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0492" num="n0473">
        <base:Image he="1000" wi="748" file="GDA0003327089700001151.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0493" num="n0474">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式IV化合物是式IVa化合物：</base:Paragraphs>
      <base:Paragraphs id="p0494" num="n0475">
        <base:Image he="572" wi="899" file="GDA0003327089700001152.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0495" num="n0476">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0496" num="n0477">在式IVa的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0497" num="n0478">在式IVa的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0498" num="n0479">在式IVa的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0499" num="n0480">在式IVa的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0500" num="n0481">在式IVa的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0501" num="n0482">在式IVa的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0502" num="n0483">在式IVa的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0503" num="n0484">在式IVa的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0504" num="n0485">式IVa化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0505" num="n0486">
        <base:Image he="1000" wi="885" file="GDA0003327089700001161.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0506" num="n0487">
        <base:Image he="1000" wi="706" file="GDA0003327089700001171.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0507" num="n0488">
        <base:Image he="1000" wi="680" file="GDA0003327089700001181.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0508" num="n0489">
        <base:Image he="1000" wi="636" file="GDA0003327089700001191.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0509" num="n0490">
        <base:Image he="1000" wi="660" file="GDA0003327089700001201.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0510" num="n0491">
        <base:Image he="909" wi="1000" file="GDA0003327089700001211.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0511" num="n0492">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式IV化合物是式IVb化合物：</base:Paragraphs>
      <base:Paragraphs id="p0512" num="n0493">
        <base:Image he="566" wi="900" file="GDA0003327089700001212.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0513" num="n0494">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0514" num="n0495">在式IVb的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0515" num="n0496">在式IVb的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0516" num="n0497">在式IVb的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0517" num="n0498">在式IVb的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0518" num="n0499">在式IVb的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0519" num="n0500">在式IVb的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0520" num="n0501">在式IVb的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0521" num="n0502">在式IVb的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0522" num="n0503">式IVb化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0523" num="n0504">
        <base:Image he="848" wi="1000" file="GDA0003327089700001221.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0524" num="n0505">
        <base:Image he="1000" wi="732" file="GDA0003327089700001231.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0525" num="n0506">
        <base:Image he="1000" wi="707" file="GDA0003327089700001241.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0526" num="n0507">
        <base:Image he="1000" wi="639" file="GDA0003327089700001251.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0527" num="n0508">
        <base:Image he="1000" wi="637" file="GDA0003327089700001261.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0528" num="n0509">
        <base:Image he="1000" wi="826" file="GDA0003327089700001271.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0529" num="n0510">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式IV化合物是式IVc化合物：</base:Paragraphs>
      <base:Paragraphs id="p0530" num="n0511">
        <base:Image he="598" wi="868" file="GDA0003327089700001281.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0531" num="n0512">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0532" num="n0513">在式IVc的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0533" num="n0514">在式IVc的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0534" num="n0515">在式IVc的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0535" num="n0516">在式IVc的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0536" num="n0517">在式IVc的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0537" num="n0518">在式IVc的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0538" num="n0519">在式IVc的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0539" num="n0520">在式IVc的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0540" num="n0521">在式IVc的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0541" num="n0522">式IVc化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0542" num="n0523">
        <base:Image he="502" wi="1000" file="GDA0003327089700001282.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0543" num="n0524">
        <base:Image he="1000" wi="720" file="GDA0003327089700001291.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0544" num="n0525">
        <base:Image he="1000" wi="679" file="GDA0003327089700001301.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0545" num="n0526">
        <base:Image he="1000" wi="653" file="GDA0003327089700001311.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0546" num="n0527">
        <base:Image he="1000" wi="660" file="GDA0003327089700001321.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0547" num="n0528">
        <base:Image he="1000" wi="660" file="GDA0003327089700001331.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0548">
        <base:Image he="304" wi="1000" file="GDA0003327089700001341.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0549" num="n0529">在一个实施方案中，在有需要的宿主中治疗或预防COVID-19疾病的式IV化合物是式IVd化合物：</base:Paragraphs>
      <base:Paragraphs id="p0550" num="n0530">
        <base:Image he="575" wi="898" file="GDA0003327089700001342.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0551" num="n0531">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0552" num="n0532">在式IVd的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0553" num="n0533">在式IVd的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0554" num="n0534">在式IVd的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0555" num="n0535">在式IVd的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0556" num="n0536">在式IVd的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0557" num="n0537">在式IVd的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0558" num="n0538">在式IVd的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0559" num="n0539">在式IVd的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0560" num="n0540">在式IVd的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0561" num="n0541">式IVd化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0562" num="n0542">
        <base:Image he="1000" wi="708" file="GDA0003327089700001351.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0563" num="n0543">
        <base:Image he="1000" wi="679" file="GDA0003327089700001361.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0564" num="n0544">
        <base:Image he="1000" wi="666" file="GDA0003327089700001371.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0565" num="n0545">
        <base:Image he="942" wi="1000" file="GDA0003327089700001381.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0566" num="n0546">在一个实施方案中，在有需要的宿主中治疗或预防COVID-19疾病的式IV化合物是式IVe化合物：</base:Paragraphs>
      <base:Paragraphs id="p0567" num="n0547">
        <base:Image he="549" wi="899" file="GDA0003327089700001382.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0568" num="n0548">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0569" num="n0549">在式IVe的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0570" num="n0550">在式IVe的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0571" num="n0551">在式IVe的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0572" num="n0552">在式IVe的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0573" num="n0553">在式IVe的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0574" num="n0554">在式IVe的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0575" num="n0555">在式IVe的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0576" num="n0556">在式IVe的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0577" num="n0557">在式IVe的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0578" num="n0558">式IVe化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0579" num="n0559">
        <base:Image he="843" wi="1000" file="GDA0003327089700001391.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0580" num="n0560">
        <base:Image he="1000" wi="732" file="GDA0003327089700001401.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0581" num="n0561">
        <base:Image he="1000" wi="679" file="GDA0003327089700001411.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0582" num="n0562">
        <base:Image he="1000" wi="663" file="GDA0003327089700001421.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0583">
        <base:Image he="315" wi="1000" file="GDA0003327089700001431.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0584" num="n0563">在一个实施方案中，在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19疾病的式IV化合物是式IVf化合物：</base:Paragraphs>
      <base:Paragraphs id="p0585" num="n0564">
        <base:Image he="576" wi="901" file="GDA0003327089700001432.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0586" num="n0565">或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p0587" num="n0566">在式IVf的一个实施方案中，R<base:Sup>1</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0588" num="n0567">在式IVf的一个实施方案中，R<base:Sup>1</base:Sup>是环丙基。</base:Paragraphs>
      <base:Paragraphs id="p0589" num="n0568">在式IVf的一个实施方案中，R<base:Sup>2</base:Sup>是苯基。</base:Paragraphs>
      <base:Paragraphs id="p0590" num="n0569">在式IVf的一个实施方案中，R<base:Sup>2</base:Sup>是萘基。</base:Paragraphs>
      <base:Paragraphs id="p0591" num="n0570">在式IVf的一个实施方案中，R<base:Sup>4a</base:Sup>是氢并且R<base:Sup>4b</base:Sup>是甲基。</base:Paragraphs>
      <base:Paragraphs id="p0592" num="n0571">在式IVf的一个实施方案中，R<base:Sup>5</base:Sup>是异丙基。</base:Paragraphs>
      <base:Paragraphs id="p0593" num="n0572">在式IVf的一个实施方案中，化合物是Sp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0594" num="n0573">在式IVf的一个实施方案中，化合物是Rp-异构体并且氨基磷酸酯是L-构型。</base:Paragraphs>
      <base:Paragraphs id="p0595" num="n0574">在式IVf的一个实施方案中，药学上可接受的盐是半硫酸盐。</base:Paragraphs>
      <base:Paragraphs id="p0596" num="n0575">式IVf化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0597" num="n0576">
        <base:Image he="1000" wi="712" file="GDA0003327089700001441.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0598" num="n0577">
        <base:Image he="1000" wi="679" file="GDA0003327089700001451.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0599" num="n0578">
        <base:Image he="1000" wi="666" file="GDA0003327089700001461.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0600" num="n0579">
        <base:Image he="1000" wi="794" file="GDA0003327089700001471.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0601" num="n0580">本发明还包括式V化合物在治疗或预防由本文所述的SARS-CoV-2病毒引起的COVID-19疾病中的用途：</base:Paragraphs>
      <base:Paragraphs id="p0602" num="n0581">
        <base:Image he="573" wi="900" file="GDA0003327089700001481.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0603" num="n0582">或其药学上可接受的盐，其中：</base:Paragraphs>
      <base:Paragraphs id="p0604" num="n0583">Y和Y’独立地选自Cl和F；和</base:Paragraphs>
      <base:Paragraphs id="p0605" num="n0584">R<base:Sup>1</base:Sup>、R<base:Sup>2</base:Sup>、R<base:Sup>3</base:Sup>、R<base:Sup>4a</base:Sup>、R<base:Sup>4b</base:Sup>和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0606" num="n0585">在式IV的一个实施方案中，Y’为F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0607" num="n0586">在式IV的一个实施方案中，Y’是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0608" num="n0587">在式IV的一个实施方案中，Y’为F，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0609" num="n0588">在式IV的一个实施方案中，Y’是F，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0610" num="n0589">在式IV的一个实施方案中，Y’是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0611" num="n0590">在式IV的一个实施方案中，Y’是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0612" num="n0591">在式IV的一个实施方案中，Y’是Cl，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0613" num="n0592">在式IV的一个实施方案中，Y’是Cl，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0614" num="n0593">在式IV的一个实施方案中，Y’是Cl，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0615" num="n0594">在式IV的一个实施方案中，Y’是Cl，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0616" num="n0595">在式IV的一个实施方案中，Y’是Cl，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0617" num="n0596">在式IV的一个实施方案中，Y’是Cl，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0618" num="n0597">在式IV的一个实施方案中，Y’是F，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0619" num="n0598">在式IV的一个实施方案中，Y’是F，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0620" num="n0599">在式IV的一个实施方案中，Y’为F，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0621" num="n0600">在式IV的一个实施方案中，Y’是F，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0622" num="n0601">式V化合物的非限制性实例包括</base:Paragraphs>
      <base:Paragraphs id="p0623" num="n0602">
        <base:Image he="602" wi="1000" file="GDA0003327089700001491.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0624" num="n0603">
        <base:Image he="1000" wi="662" file="GDA0003327089700001501.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0625" num="n0604">
        <base:Image he="1000" wi="662" file="GDA0003327089700001511.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0626" num="n0605">
        <base:Image he="1000" wi="662" file="GDA0003327089700001521.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0627" num="n0606">
        <base:Image he="1000" wi="662" file="GDA0003327089700001531.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0628" num="n0607">
        <base:Image he="1000" wi="662" file="GDA0003327089700001541.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0629" num="n0608">
        <base:Image he="1000" wi="661" file="GDA0003327089700001551.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0630" num="n0609">
        <base:Image he="1000" wi="828" file="GDA0003327089700001561.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0631" num="n0610">式V化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0632" num="n0611">
        <base:Image he="1000" wi="638" file="GDA0003327089700001571.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0633">
        <base:Image he="548" wi="904" file="GDA0003327089700001581.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0634" num="n0612">本发明还包括式VI化合物在有需要的宿主中治疗或预防COVID-19的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0635" num="n0613">
        <base:Image he="580" wi="868" file="GDA0003327089700001582.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0636" num="n0614">其中</base:Paragraphs>
      <base:Paragraphs id="p0637" num="n0615">R<base:Sup>6</base:Sup>选自氢，-C(O)R<base:Sup>6A</base:Sup>，-C(O)OR<base:Sup>6A</base:Sup>，C<base:Sub>1-6</base:Sub>烷基和-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>，在一个替代实施方案中，-C(O)NR<base:Sup>6B</base:Sup>R<base:Sup>6C</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0638" num="n0616">R<base:Sup>6A</base:Sup>选自氢，C<base:Sub>1-6</base:Sub>烷基，C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基(例如-CHCl<base:Sub>2</base:Sub>,-CCl<base:Sub>3</base:Sub>,-CH<base:Sub>2</base:Sub>Cl,-CF<base:Sub>3</base:Sub>,-CHF<base:Sub>2</base:Sub>,-CH<base:Sub>2</base:Sub>F)，芳基和芳基(C<base:Sub>1-6</base:Sub>烷基)-，其中芳基任选地被选自烷氧基，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的取代基取代，在一个可选的实施方案中，R<base:Sup>6A</base:Sup>选自C<base:Sub>1-20</base:Sub>烷基和C<base:Sub>2-20</base:Sub>烯基；</base:Paragraphs>
      <base:Paragraphs id="p0639" num="n0617">R<base:Sup>6B</base:Sup>和R<base:Sup>6C</base:Sup>独立地选自氢，C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基，其中C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基可以任选地被选自烷氧基(包括但不限于甲氧基和乙氧基)，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的至少一个取代基取代；</base:Paragraphs>
      <base:Paragraphs id="p0640" num="n0618">R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>，H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0641" num="n0619">R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基，-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0642" num="n0620">Y选自F和Cl；</base:Paragraphs>
      <base:Paragraphs id="p0643" num="n0621">Z选自甲基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素(包括Cl和F)，在一个替代实施方案中，Z是C<base:Sub>1-4</base:Sub>烷基；和</base:Paragraphs>
      <base:Paragraphs id="p0644" num="n0622">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0645" num="n0623">R<base:Sup>6</base:Sup>的非限制性例子包括</base:Paragraphs>
      <base:Paragraphs id="p0646" num="n0624">
        <base:Image he="876" wi="1000" file="GDA0003327089700001591.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0647" num="n0625">在式VI的一个实施方案中，Z为CH<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0648" num="n0626">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0649" num="n0627">在式VI的一个实施方案中，Z为CH<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0650" num="n0628">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0651" num="n0629">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0652" num="n0630">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0653" num="n0631">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0654" num="n0632">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0655" num="n0633">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0656" num="n0634">在式VI的一个实施方案中，Z是CF<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0657" num="n0635">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0658" num="n0636">在式VI的一个实施方案中，Z是CF<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0659" num="n0637">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0660" num="n0638">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0661" num="n0639">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0662" num="n0640">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0663" num="n0641">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0664" num="n0642">在式VI的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0665" num="n0643">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0666" num="n0644">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0667" num="n0645">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0668" num="n0646">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0669" num="n0647">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0670" num="n0648">在式VI的一个实施方案中，Z为Cl，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0671" num="n0649">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0672" num="n0650">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0673" num="n0651">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0674" num="n0652">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0675" num="n0653">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0676" num="n0654">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0677" num="n0655">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>F，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0678" num="n0656">在式VI的一个实施例中，Z为CH<base:Sub>2</base:Sub>F，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0679" num="n0657">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，并且R 7是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0680" num="n0658">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0681" num="n0659">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0682" num="n0660">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0683" num="n0661">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0684" num="n0662">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0685" num="n0663">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0686" num="n0664">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0687" num="n0665">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0688" num="n0666">在式VI的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0689" num="n0667">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0690" num="n0668">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0691" num="n0669">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0692" num="n0670">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0693" num="n0671">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0694" num="n0672">在式VI的一个实施方案中，Z为CCH，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0695" num="n0673">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0696" num="n0674">在式VI的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0697" num="n0675">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0698" num="n0676">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0699" num="n0677">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0700" num="n0678">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0701" num="n0679">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0702" num="n0680">在式VI的一个实施方案中，Z为F，Y为F，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0703" num="n0681">在式VI的一个实施方案中，Z为CH<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0704" num="n0682">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0705" num="n0683">在式VI的一个实施方案中，Z为CH<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0706" num="n0684">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0707" num="n0685">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0708" num="n0686">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0709" num="n0687">在式VI的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0710" num="n0688">在式VI的一个实施方案中，Z为CH<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0711" num="n0689">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0712" num="n0690">在式VI的一个实施方案中，Z是CF<base:Sub>3</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0713" num="n0691">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0714" num="n0692">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0715" num="n0693">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0716" num="n0694">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0717" num="n0695">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0718" num="n0696">在式VI的一个实施方案中，Z为CF<base:Sub>3</base:Sub>，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0719" num="n0697">在式VI的一个实施方案中，Z为Cl，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0720" num="n0698">在式VI的一个实施方案中，Z是Cl，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0721" num="n0699">在式VI的一个实施方案中，Z为Cl，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0722" num="n0700">在式VI的一个实施方案中，Z是Cl，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0723" num="n0701">在式VI的一个实施方案中，Z是Cl，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0724" num="n0702">在式VI的一个实施方案中，Z为Cl，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0725" num="n0703">在式VI的一个实施方案中，Z为Cl，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0726" num="n0704">在式VI的一个实施方案中，Z为Cl，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0727" num="n0705">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>F，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0728" num="n0706">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0729" num="n0707">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>F，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0730" num="n0708">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0731" num="n0709">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>F，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0732" num="n0710">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0733" num="n0711">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0734" num="n0712">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0735" num="n0713">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，并且R 7是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0736" num="n0714">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>CH，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0737" num="n0715">在式VI的一个实施方案中，Z为CH<base:Sub>2</base:Sub>CH，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0738" num="n0716">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>CH，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0739" num="n0717">在式VI的一个实施方案中，Z是CH<base:Sub>2</base:Sub>CH，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0740" num="n0718">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0741" num="n0719">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0742" num="n0720">在式VI的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是Cl，R<base:Sup>1</base:Sup>是环丙基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是甲基，并且R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0743" num="n0721">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0744" num="n0722">在式VI的一个实施方案中，Z是CCH，Y是Cl，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>7</base:Sup>是H。</base:Paragraphs>
      <base:Paragraphs id="p0745" num="n0723">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0746" num="n0724">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)R<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0747" num="n0725">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，且R<base:Sup>7</base:Sup>为NHC(O)OR<base:Sup>6A</base:Sup>。</base:Paragraphs>
      <base:Paragraphs id="p0748" num="n0726">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为甲基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0749" num="n0727">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0750" num="n0728">在式VI的一个实施方案中，Z为CCH，Y为Cl，R<base:Sup>1</base:Sup>为环丙基，R<base:Sup>2</base:Sup>为芳基，R<base:Sup>3</base:Sup>为氢，R<base:Sup>4a</base:Sup>为氢，R<base:Sup>4a</base:Sup>为甲基，且R<base:Sup>5</base:Sup>为C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</base:Paragraphs>
      <base:Paragraphs id="p0751" num="n0729">式VI化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0752" num="n0730">
        <base:Image he="686" wi="1000" file="GDA0003327089700001691.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0753" num="n0731">
        <base:Image he="1000" wi="692" file="GDA0003327089700001701.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0754" num="n0732">
        <base:Image he="1000" wi="709" file="GDA0003327089700001711.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0755" num="n0733">
        <base:Image he="1000" wi="691" file="GDA0003327089700001721.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0756" num="n0734">
        <base:Image he="1000" wi="685" file="GDA0003327089700001731.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0757" num="n0735">
        <base:Image he="1000" wi="917" file="GDA0003327089700001741.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0758" num="n0736">式VI化合物的其他非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0759" num="n0737">
        <base:Image he="285" wi="1000" file="GDA0003327089700001742.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0760" num="n0738">
        <base:Image he="1000" wi="681" file="GDA0003327089700001751.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0761" num="n0739">
        <base:Image he="1000" wi="678" file="GDA0003327089700001761.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0762">
        <base:Image he="314" wi="1000" file="GDA0003327089700001771.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0763" num="n0740">本发明还包括式VII化合物在有需要的宿主中治疗或预防COVID-19的用途，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0764" num="n0741">
        <base:Image he="392" wi="694" file="GDA0003327089700001772.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0765" num="n0742">其中</base:Paragraphs>
      <base:Paragraphs id="p0766" num="n0743">B选自</base:Paragraphs>
      <base:Paragraphs id="p0767" num="n0744">
        <base:Image he="193" wi="1000" file="GDA0003327089700001773.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0768" num="n0745">R<base:Sup>6</base:Sup>选自氢，-C(O)R<base:Sup>6A</base:Sup>，-C(O)OR<base:Sup>6A</base:Sup>，C<base:Sub>1-6</base:Sub>烷基和-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>，在一个替代实施方案中，-C(O)NR<base:Sup>6B</base:Sup>R<base:Sup>6C</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0769" num="n0746">R<base:Sup>6A</base:Sup>选自氢，C<base:Sub>1-6</base:Sub>烷基，C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基(例如-CHCl<base:Sub>2</base:Sub>,-CCl<base:Sub>3</base:Sub>,-CH<base:Sub>2</base:Sub>Cl,-CF<base:Sub>3</base:Sub>,-CHF<base:Sub>2</base:Sub>,-CH<base:Sub>2</base:Sub>F)，芳基和芳基(C<base:Sub>1-6</base:Sub>烷基)-，其中芳基任选地被选自烷氧基，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的取代基取代，在一个可选的实施方案中，R<base:Sup>6A</base:Sup>选自C<base:Sub>1-20</base:Sub>烷基和C<base:Sub>2-20</base:Sub>烯基；</base:Paragraphs>
      <base:Paragraphs id="p0770" num="n0747">R<base:Sup>6B</base:Sup>和R<base:Sup>6C</base:Sup>独立地选自氢，C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基，其中C<base:Sub>1-20</base:Sub>烷基，C<base:Sub>2-20</base:Sub>烯基，芳基，芳基(C<base:Sub>1-6</base:Sub>烷基)-，杂芳基和杂芳基烷基可以任选地被选自烷氧基(包括但不限于甲氧基和乙氧基)，羟基，硝基，溴，氯，氟，叠氮基和卤代烷基的至少一个取代基取代；</base:Paragraphs>
      <base:Paragraphs id="p0771" num="n0748">R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>，H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0772" num="n0749">R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢，C<base:Sub>1-6</base:Sub>烷基，-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0773" num="n0750">Y选自F和Cl；</base:Paragraphs>
      <base:Paragraphs id="p0774" num="n0751">Z选自甲基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F，CHF<base:Sub>2</base:Sub>，CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>，CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F，CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>，CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>，和CH<base:Sub>2</base:Sub>Cl)，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基，C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素(包括Cl和F)，在一个替代实施方案中，Z是C<base:Sub>1-4</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0775" num="n0752">R<base:Sup>40</base:Sup>选自H，C<base:Sub>1-3</base:Sub>烷氧基，C<base:Sub>1-3</base:Sub>烷基，N<base:Sub>3</base:Sub>，CN和卤素(包括Cl和F)；</base:Paragraphs>
      <base:Paragraphs id="p0776" num="n0753">R<base:Sup>41</base:Sup>选自H，C<base:Sub>1-3</base:Sub>烷基(包括甲基)和卤素(包括Cl，F和Br)；</base:Paragraphs>
      <base:Paragraphs id="p0777" num="n0754">R<base:Sup>42a</base:Sup>和R<base:Sup>42b</base:Sup>选自C<base:Sub>1-3</base:Sub>烷基(包括甲基)，NH<base:Sub>2</base:Sub>，H，-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>和-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；和</base:Paragraphs>
      <base:Paragraphs id="p0778" num="n0755">R<base:Sup>1</base:Sup>，R<base:Sup>2</base:Sup>，R<base:Sup>3</base:Sup>，R<base:Sup>4a</base:Sup>，R<base:Sup>4b</base:Sup>，和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p0779" num="n0756">B的非限制性例子包括：</base:Paragraphs>
      <base:Paragraphs id="p0780" num="n0757">
        <base:Image he="494" wi="1000" file="GDA0003327089700001781.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0781" num="n0758">在一个实施方案中，本发明还包括式VIIa、式VIIb、式VIIc和式VIId的化合物：</base:Paragraphs>
      <base:Paragraphs id="p0782" num="n0759">
        <base:Image he="1000" wi="356" file="GDA0003327089700001791.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0783" num="n0760">在式VII的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；并且B是<base:Image he="301" wi="323" file="GDA0003327089700001801.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0784" num="n0761">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0785" num="n0762">在式VIIa的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；并且B是<base:Image he="223" wi="448" file="GDA0003327089700001802.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0786" num="n0763">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0787" num="n0764">在式VIIb的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；并且B是<base:Image he="270" wi="434" file="GDA0003327089700001803.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0788" num="n0765">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0789" num="n0766">在式VIIc的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；并且B是<base:Image he="273" wi="381" file="GDA0003327089700001811.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0790" num="n0767">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0791" num="n0768">在式VIId的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="364" wi="290" file="GDA0003327089700001812.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0792" num="n0769">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0793" num="n0770">在式VII的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="302" wi="322" file="GDA0003327089700001813.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0794" num="n0771">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0795" num="n0772">在式VIIa的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="211" wi="436" file="GDA0003327089700001821.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0796" num="n0773">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0797" num="n0774">在式VIIb的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="268" wi="441" file="GDA0003327089700001822.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0798" num="n0775">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0799" num="n0776">在式VIIc的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="274" wi="383" file="GDA0003327089700001823.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0800" num="n0777">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0801" num="n0778">在式VIId的一个实施方案中，Z是CH<base:Sub>3</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="361" wi="286" file="GDA0003327089700001831.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0802" num="n0779">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0803" num="n0780">在式VII的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="302" wi="328" file="GDA0003327089700001832.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0804" num="n0781">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0805" num="n0782">在式VIIa的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="216" wi="437" file="GDA0003327089700001833.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0806" num="n0783">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0807" num="n0784">在式VIIb的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="270" wi="440" file="GDA0003327089700001841.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0808" num="n0785">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0809" num="n0786">在式VIIc的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="273" wi="379" file="GDA0003327089700001842.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0810" num="n0787">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0811" num="n0788">在式VIId的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="361" wi="288" file="GDA0003327089700001843.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0812" num="n0789">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0813" num="n0790">在式VII的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="297" wi="328" file="GDA0003327089700001851.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0814" num="n0791">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0815" num="n0792">在式VIIa的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="214" wi="436" file="GDA0003327089700001852.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0816" num="n0793">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0817" num="n0794">在式VIIb的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="267" wi="439" file="GDA0003327089700001853.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0818" num="n0795">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0819" num="n0796">在式VIIc的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="273" wi="382" file="GDA0003327089700001861.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0820" num="n0797">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0821" num="n0798">在式VIId的一个实施方案中，Z是Cl，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="366" wi="286" file="GDA0003327089700001862.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0822" num="n0799">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0823" num="n0800">在式VII的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="304" wi="333" file="GDA0003327089700001863.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0824" num="n0801">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0825" num="n0802">在式VIIa的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="228" wi="540" file="GDA0003327089700001871.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0826" num="n0803">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0827" num="n0804">在式VIIb的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="267" wi="434" file="GDA0003327089700001872.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0828" num="n0805">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0829" num="n0806">在式VIIc的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="268" wi="383" file="GDA0003327089700001873.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0830" num="n0807">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0831" num="n0808">在式VIId的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="361" wi="290" file="GDA0003327089700001881.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0832" num="n0809">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0833" num="n0810">在式VII的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="308" wi="326" file="GDA0003327089700001882.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0834" num="n0811">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0835" num="n0812">在式VIIa的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="220" wi="439" file="GDA0003327089700001883.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0836" num="n0813">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0837" num="n0814">在式VIIb的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="267" wi="439" file="GDA0003327089700001891.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0838" num="n0815">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0839" num="n0816">在式VIIc的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="274" wi="384" file="GDA0003327089700001892.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0840" num="n0817">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0841" num="n0818">在式VIId的一个实施方案中，Z是CH<base:Sub>2</base:Sub>F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="362" wi="290" file="GDA0003327089700001893.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0842" num="n0819">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0843" num="n0820">在式VII的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="304" wi="328" file="GDA0003327089700001901.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0844" num="n0821">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0845" num="n0822">在式VIIa的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="216" wi="440" file="GDA0003327089700001902.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0846" num="n0823">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0847" num="n0824">在式VIIb的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="270" wi="440" file="GDA0003327089700001903.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0848" num="n0825">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0849" num="n0826">在式VIIc的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="273" wi="384" file="GDA0003327089700001911.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0850" num="n0827">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0851" num="n0828">在式VIId的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="360" wi="287" file="GDA0003327089700001912.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0852" num="n0829">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0853" num="n0830">在式VII的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="304" wi="328" file="GDA0003327089700001913.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0854" num="n0831">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0855" num="n0832">在式VIIa的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="218" wi="443" file="GDA0003327089700001921.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0856" num="n0833">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0857" num="n0834">在式VIIb的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="268" wi="441" file="GDA0003327089700001922.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0858" num="n0835">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0859" num="n0836">在式VIIc的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="271" wi="381" file="GDA0003327089700001923.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0860" num="n0837">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0861" num="n0838">在式VIId的一个实施方案中，Z是CHCH<base:Sub>2</base:Sub>，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="362" wi="290" file="GDA0003327089700001931.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0862" num="n0839">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0863" num="n0840">在式VII的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="302" wi="323" file="GDA0003327089700001932.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0864" num="n0841">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0865" num="n0842">在式VIIa的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="220" wi="434" file="GDA0003327089700001933.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0866" num="n0843">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0867" num="n0844">在式VIIb的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="266" wi="439" file="GDA0003327089700001941.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0868" num="n0845">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或氢。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0869" num="n0846">在式VIIc的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="273" wi="380" file="GDA0003327089700001942.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0870" num="n0847">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0871" num="n0848">在式VIId的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="360" wi="290" file="GDA0003327089700001951.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0872" num="n0849">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0873" num="n0850">在式VII的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="304" wi="323" file="GDA0003327089700001952.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0874" num="n0851">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0875" num="n0852">在式VIIa的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="214" wi="441" file="GDA0003327089700001953.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0876" num="n0853">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0877" num="n0854">在式VIIb的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="271" wi="443" file="GDA0003327089700001954.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0878" num="n0855">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0879" num="n0856">在式VIIc的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="271" wi="386" file="GDA0003327089700001961.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0880" num="n0857">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0881" num="n0858">在式VIId的一个实施方案中，Z是CCH，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="364" wi="287" file="GDA0003327089700001962.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0882" num="n0859">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0883" num="n0860">在式VII的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="303" wi="331" file="GDA0003327089700001971.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0884" num="n0861">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0885" num="n0862">在式VIIa的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="216" wi="439" file="GDA0003327089700001972.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0886" num="n0863">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0887" num="n0864">在式VIIb的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="270" wi="441" file="GDA0003327089700001973.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0888" num="n0865">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0889" num="n0866">在式VIIc的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="273" wi="377" file="GDA0003327089700001981.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0890" num="n0867">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0891" num="n0868">在式VIId的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氢；B是<base:Image he="361" wi="289" file="GDA0003327089700001982.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0892" num="n0869">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0893" num="n0870">在式VII的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="306" wi="327" file="GDA0003327089700001983.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0894" num="n0871">在进一步的实施方案中，R<base:Sup>1</base:Sup>是C<base:Sub>1-6</base:Sub>烷基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>1</base:Sup>是甲基并且R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0895" num="n0872">在式VIIa的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="219" wi="438" file="GDA0003327089700001991.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0896" num="n0873">在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为甲基且R<base:Sup>42a</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基且R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是甲基并且R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0897" num="n0874">在式VIIb的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="266" wi="436" file="GDA0003327089700001992.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0898" num="n0875">在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基。在进一步的实施方案中，R<base:Sup>41</base:Sup>是H，R<base:Sup>42a</base:Sup>是H，并且R<base:Sup>42b</base:Sup>是甲基。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>为-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0899" num="n0876">在式VIIc的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="270" wi="382" file="GDA0003327089700001993.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0900" num="n0877">在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为NH<base:Sub>2</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为H，R<base:Sup>42a</base:Sup>为-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为H。在进一步的实施方案中，R<base:Sup>41</base:Sup>为C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是NH<base:Sub>2</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，并且R<base:Sup>42b</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H。在进一步的实施方案中，R<base:Sup>41</base:Sup>是C<base:Sub>1-6</base:Sub>烷基或H，R<base:Sup>42a</base:Sup>是-NHCH<base:Sub>3</base:Sub>，且R<base:Sup>42b</base:Sup>为NH<base:Sub>2</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0901" num="n0878">在式VIId的一个实施方案中，Z是F，Y是F，R<base:Sup>1</base:Sup>是甲基，R<base:Sup>2</base:Sup>是芳基，R<base:Sup>3</base:Sup>是氢，R<base:Sup>4a</base:Sup>是氢，R<base:Sup>4a</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基，R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基，R<base:Sup>6</base:Sup>是氢，R<base:Sup>40</base:Sup>是氰基或硝基；B是<base:Image he="360" wi="289" file="GDA0003327089700002001.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0902" num="n0879">在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是卤素并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。在进一步的实施方案中，R<base:Sup>41</base:Sup>是Br并且R<base:Sup>42a</base:Sup>是-C(O)NHCH<base:Sub>3</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p0903" num="n0880">式VII化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0904" num="n0881">
        <base:Image he="803" wi="1000" file="GDA0003327089700002002.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0905" num="n0882">
        <base:Image he="1000" wi="718" file="GDA0003327089700002011.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0906" num="n0883">
        <base:Image he="1000" wi="611" file="GDA0003327089700002021.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0907" num="n0884">
        <base:Image he="1000" wi="787" file="GDA0003327089700002031.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0908" num="n0885">
        <base:Image he="1000" wi="676" file="GDA0003327089700002041.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0909" num="n0886">
        <base:Image he="1000" wi="710" file="GDA0003327089700002051.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0910" num="n0887">
        <base:Image he="1000" wi="667" file="GDA0003327089700002061.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0911">
        <base:Image he="297" wi="1000" file="GDA0003327089700002071.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0912" num="n0888">本发明还包括式VIII、式IX或式X的化合物的用途，其中R<base:Sup>10</base:Sup>是单磷酸酯、二磷酸酯、三磷酸酯或R<base:Sup>10A</base:Sup>，其中R<base:Sup>10A</base:Sup>是稳定的磷酸酯前药，其在体内代谢成单磷酸酯、二磷酸酯或三磷酸酯，以治疗或预防有需要的宿主的COVID-19疾病，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p0913" num="n0889">
        <base:Image he="751" wi="1000" file="GDA0003327089700002072.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0914" num="n0890">其中</base:Paragraphs>
      <base:Paragraphs id="p0915" num="n0891">R<base:Sup>10</base:Sup>选自<base:Image he="198" wi="935" file="GDA0003327089700002073.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />并且R<base:Sup>10A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p0916" num="n0892">R<base:Sup>10A</base:Sup>是一种稳定的磷酸酯前药，可在体内代谢为单磷酸酯、二磷酸酯或三磷酸酯；</base:Paragraphs>
      <base:Paragraphs id="p0917" num="n0893">R<base:Sup>11</base:Sup>选自氢和R<base:Sup>1</base:Sup>；和</base:Paragraphs>
      <base:Paragraphs id="p0918" num="n0894">R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0919" num="n0895">本发明还包括式XI和式XII的化合物：</base:Paragraphs>
      <base:Paragraphs id="p0920" num="n0896">
        <base:Image he="255" wi="1000" file="GDA0003327089700002081.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0921" num="n0897">或其药学上可接受的盐；</base:Paragraphs>
      <base:Paragraphs id="p0922" num="n0898">其中</base:Paragraphs>
      <base:Paragraphs id="p0923" num="n0899">R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>是氧保护基团并且R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>中的至少一个是-C(O)OC<base:Sub>1-6</base:Sub>烷基，例如-C(O)OtBu，或-C(O)O-苄基，其中烷基和苄基可以任选地被选自烷氧基、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代。</base:Paragraphs>
      <base:Paragraphs id="p0924" num="n0900">在一个实施方案中，R<base:Sup>12a</base:Sup>是-C(O)OC<base:Sub>1-6</base:Sub>烷基或-C(O)O-苄基并且R<base:Sup>12b</base:Sup>是氧保护基团，其当连接到氧时是酯、醚或甲硅烷基醚部分。在进一步的实施方案中，R<base:Sup>12b</base:Sup>是-C(O)OC<base:Sub>1-6</base:Sub>烷基或-C(O)O-苄基并且R<base:Sup>12a</base:Sup>是氧保护基团，其当连接到氧时是酯、醚或甲硅烷基醚部分。在一个实施方案中，R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>都是-C(O)OC<base:Sub>1-6</base:Sub>烷基，例如-C(O)OtBu。在一个实施例中，R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>都是-C(O)O-苄基。</base:Paragraphs>
      <base:Paragraphs id="p0925" num="n0901">在一个实施例中，式XII的化合物是式XIIA：</base:Paragraphs>
      <base:Paragraphs id="p0926" num="n0902">
        <base:Image he="279" wi="424" file="GDA0003327089700002082.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0927" num="n0903">在一个实施例中，式XII的化合物是式XIIB：</base:Paragraphs>
      <base:Paragraphs id="p0928" num="n0904">
        <base:Image he="282" wi="422" file="GDA0003327089700002083.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0929" num="n0905">例如，连接到氧上的保护基团可以是酯部分，例如苯甲酸乙酸酯。在一个实施例中，当与氧连接时，氧保护基团是甲硅烷基醚部分(例如(三甲基甲硅烷基(TMS)、三异丙基甲硅烷基(TIPS)、叔丁基二甲基甲硅烷基(TBDMS或TBS)或叔丁基二苯基甲硅烷基(TBDPS)。在一个实施方案中，当与氧连接时，氧保护基团是醚部分，例如甲醚、甲氧基甲醚或苄基醚。这些保护基团可以根据通过引用并入的Theodora W.Green,Protective Groups inOrganic Synthesis,Third Edition,John Wiley&amp;Sons(1999)中描述的方法之一进行设置，用于保护羟基。例如，当与氧相连的氧保护基团是酯部分时，式XI或式XII的化合物可以根据第149-178页的正文中描述的条件制备，并且当氧保护基团与氧相连时为甲硅烷基醚部分时，式XI或式XII化合物可根据第113-147页正文中所述的条件制备。在一个实施方案中，保护基团是叔丁基二甲基甲硅烷基(TBS)基团。使用第128页正文和Ogilvie等人.Can.J.Chem.1979,57,2230.中描述的条件，TBS基团选择性地设置在伯醇上而不是仲醇上。这些条件包括在25℃下在DMF中使用TBSCl、DMAP和NEt3。</base:Paragraphs>
      <base:Paragraphs id="p0930" num="n0906">连接到氧上的额外保护基团的非限制性实例还包括溴苯甲酸酯、对甲氧基苄氧基甲基醚(MPBM)、邻硝基苄氧基甲基醚(NBOM)、对硝基苄氧基甲基醚、叔丁氧基甲基醚、2,2,2-三氯乙氧基甲基醚、3-溴四氢吡喃基醚、四氢吡喃基醚、四氢噻喃基醚、1-甲氧基环己基醚、1,4-二恶烷-2-基醚、四氢呋喃基醚、四氢噻喃基醚、取代的苯基醚、2-甲基吡啶醚、4-甲基吡啶醚、1,3-苯并二硫戊环-2-基醚、对氯苯氧基乙酸酯、3-苯基丙酸酯、对苯基苯甲酸酯、烷基对硝基苯基羰基、烷基苄基羰基、烷基对甲氧基苄基羰基、烷基邻硝基苄基羰基，和烷基对硝基苄基羰基。</base:Paragraphs>
      <base:Paragraphs id="p0931" num="n0907">R<base:Sup>12a</base:Sup>和R<base:Sup>12b</base:Sup>的非限制性例子包括：</base:Paragraphs>
      <base:Paragraphs id="p0932" num="n0908">
        <base:Image he="346" wi="1000" file="GDA0003327089700002091.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0933" num="n0909">
        <base:Image he="532" wi="1000" file="GDA0003327089700002101.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0934" num="n0910">式XI和XII化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p0935" num="n0911">
        <base:Image he="759" wi="1000" file="GDA0003327089700002102.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0936" num="n0912">
        <base:Image he="1000" wi="547" file="GDA0003327089700002111.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0937">
        <base:Image he="445" wi="1000" file="GDA0003327089700002121.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0938" num="n0913">在一些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式IX、式X或式XIII的化合物，例如化合物1A、化合物1B、化合物2A、化合物2B、化合物3A、化合物3B、化合物4A或化合物4B以至少90％不含相反的磷对映异构体的形式使用，并且可以至少98％、99％或至100％不含相反的磷对映异构体。</base:Paragraphs>
      <base:Paragraphs id="p0939" num="n0914">化合物1(((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯)先前描述于美国专利号9,828,41；10,000,523；10,005,811；10,239,911；10,815,266；10,870,672；10,870,673；10,875,885；和，10,874,687；以及美国申请US2019-0201433和US2020-0222442；以及PCT申请WO2016/144918；WO2018/048937；WO2019/200005；以及转让给AteaPharmaceuticals的WO2020/117966。化合物1的合成描述于以下实施例1中。</base:Paragraphs>
      <base:Paragraphs id="p0940" num="n0915">化合物2先前描述于美国专利10,519,186；10,906,928；10,894,804；以及10,874,687和PCT申请WO2018/144640；WO2019/200005；以及转让给Atea Pharmaceuticals的WO2020/117966。通过抑制RNA依赖性RNA聚合酶(RdRp)(Good,S.S.et al.PLoS ONE 15(1),e0227104(2020))，化合物2A已证明对丙型肝炎病毒(HCV)临床分离株具有有效的体外活性(Good,S.S.et al.PLoS ONE 15(1),e0227104(2020))。化合物2A已在1b期研究(Berliba,E.et al.Antimicrob.Agents Chemther.63,e011201-19(2020))和2期临床试验(Mungar,Q.et al.EASL abstract(2020))中进行了评估。在后一项研究中，化合物2A在HCV感染的受试者中安全且良好耐受长达12周，并取得了很高的有效率。</base:Paragraphs>
      <base:Paragraphs id="p0941" num="n0916">化合物2(((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲基氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙基酯的半硫酸盐)的合成在以下实施例1中描述。</base:Paragraphs>
      <base:Paragraphs id="p0942" num="n0917">在一个实施方案中，化合物2以其药学上可接受的组合物或固体剂型提供。</base:Paragraphs>
      <base:Paragraphs id="p0943" num="n0918">用于制备化合物2的非限制性说明性方法包括</base:Paragraphs>
      <base:Paragraphs id="p0944" num="n0919">(i)第一步，在烧瓶或容器中，将化合物1溶于有机溶剂，例如丙酮、乙酸乙酯、甲醇、乙腈或醚等；</base:Paragraphs>
      <base:Paragraphs id="p0945" num="n0920">(ii)在第二个烧瓶或容器中加入与步骤(i)中的有机溶剂相同或不同的第二有机溶剂，任选地将第二溶剂冷却至0-10摄氏度，并滴加H<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>至第二有机溶剂，产生H<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>/有机溶剂混合物；并且其中溶剂例如可以是甲醇；</base:Paragraphs>
      <base:Paragraphs id="p0946" num="n0921">(iii)在环境温度或略微升高或降低的温度(例如23-35摄氏度)下将来自步骤(ii)的0.5/1.0摩尔比的H<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>/溶剂混合物逐滴加入步骤(i)的化合物1的溶液中)；</base:Paragraphs>
      <base:Paragraphs id="p0947" num="n0922">(iv)搅拌步骤(iii)的反应直到形成化合物2的沉淀，例如在环境温度或稍升高或降低的温度下；</base:Paragraphs>
      <base:Paragraphs id="p0948" num="n0923">(v)任选地过滤从步骤(iv)得到的沉淀物并用有机溶剂洗涤；和</base:Paragraphs>
      <base:Paragraphs id="p0949" num="n0924">(vi)任选地在真空中干燥所得化合物2，任选地在升高的温度下，例如55、56、57、58、59或60℃。</base:Paragraphs>
      <base:Paragraphs id="p0950" num="n0925">在一个实施例中，步骤(iii)的溶剂是醇，例如甲醇、乙醇或异丙醇。在一个实施方案中，步骤(iii)的溶剂是烷基酯，例如乙酸乙酯。</base:Paragraphs>
      <base:Paragraphs id="p0951" num="n0926">方案1提供了式I化合物的代谢途径，其涉及氨基磷酸酯(化合物1)的初始去酯化以形成代谢物1-1，其自发分解为代谢物1-2。代谢物1-2接下来转化为N<base:Sup>6</base:Sup>-甲基-2,6-二氨基嘌呤-5'-单磷酸衍生物(代谢物1-3)，后者又被代谢为游离的5'-羟基-N<base:Sup>6</base:Sup>-甲基-2，6-二氨基嘌呤核苷(代谢物1-8)和((2R,3R,4R,5R)-5-(2-氨基-6-氧代-1,6-二氢-9H-嘌呤-9-基)-4-氟-3-羟基-4-甲基四氢呋喃-2-基)甲基磷酸二氢酯作为5'-单磷酸酯(代谢物1-4)。代谢物1-4被合成代谢为相应的二磷酸酯(代谢物1-5)，然后是活性三磷酸酯衍生物(代谢物1-6)。5'-三磷酸酯可进一步代谢生成2-氨基-9-((2R,3R,4R,5R)-3-氟-4-羟基-5-(羟甲基)-3-甲基四氢呋喃-2-基)-1,9-二氢-6H-嘌呤-6-酮(1-7)。代谢物1-7在血浆中是可测量的，因此是活性三磷酸酯(1-6)(其在血浆中是不可测量的)的替代物。</base:Paragraphs>
      <base:Paragraphs id="p0952" num="n0927">
        <base:Image he="548" wi="1000" file="GDA0003327089700002141.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0953">
        <base:Image he="253" wi="1000" file="GDA0003327089700002151.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0954" num="n0928">定义</base:Paragraphs>
      <base:Paragraphs id="p0955" num="n0929">“患者”或“宿主”或“受试者”是需要治疗或预防由SARS-CoV-2病毒引起的COVID-19的人类或非人类动物。通常，宿主是人类。“患者”或“宿主”或“受试者”还指例如哺乳动物、灵长类动物(例如人)、牛、绵羊、山羊、马、狗、猫、兔、大鼠、小鼠、鸟、蝙蝠之类。</base:Paragraphs>
      <base:Paragraphs id="p0956" num="n0930">术语“预防性”或“预防性”在使用时是指施用活性化合物以预防、降低COVID-19发生或再次发生的可能性，或最大限度地减少与感染相关的新感染，如果没有这种治疗该感染就会发生。本发明包括治疗和预防性或预防性治疗。在一个实施例中，将活性化合物施用于已经暴露于COVID-19并因此有感染COVID-19风险的宿主。在另一个可供选择的实施方案中，提供了一种预防传播的方法，该方法包括向人类施用有效量的本文所述的化合物之一达足够长的时间，在暴露于可能被感染的人群之前，包括在旅行或公共活动或会议期间，包括例如，在可传染情况发生前最多3、5、7、10、12、14天或更长时间。</base:Paragraphs>
      <base:Paragraphs id="p0957" num="n0931">术语“共同施用”、“共同给药”或“组合”用于描述根据本发明的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII或其药学上可接受的盐与至少一种其他抗病毒活性剂组合。共同给药的时间最好由治疗患者的医学专家确定。有时希望这些药剂同时给药。或者，可以在不同时间向患者施予用于联合治疗的被选药物。当然，当存在不止一种病毒或其他感染或其他病症时，本发明的化合物可以根据需要与其他药物联合治疗其他感染或病症。</base:Paragraphs>
      <base:Paragraphs id="p0958" num="n0932">“药学上可接受的盐”是所公开化合物的衍生物，其中母体化合物被修饰成其无机和有机、酸或碱加成盐而没有过度毒性。本发明化合物的盐可以通过常规化学方法由具有碱性或酸性部分的母体化合物合成。通常，此类盐可以通过将这些化合物的游离酸形式与化学计量量的适当碱(例如Na、Ca、Mg或K的氢氧化物、碳酸盐、碳酸氢盐等)反应，或通过使游离碱形式与化学计量量的适当酸反应来制备这些化合物。此类反应通常在水或有机溶剂中或在两者的混合物中进行。通常，在可行的情况下，典型的非水介质如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈。本发明化合物的盐可以任选地以溶剂化物的形式提供。</base:Paragraphs>
      <base:Paragraphs id="p0959" num="n0933">药学上可接受的盐的实例包括但不限于，矿物或有机酸盐的碱性残基如胺的；碱金属或有机盐的酸性残基如羧酸；之类。药学上可接受的盐包括常规盐和母体化合物的季铵盐形成，例如由无过度毒性的无机或有机酸。例如，酸式盐包括衍生自无机酸如盐酸、氢溴酸、硫酸、氨基磺酸、磷酸、硝酸等的那些；以及由有机酸制备的盐，例如乙酸、丙酸、琥珀酸、乙醇酸、硬脂酸、乳酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、扑酸(pamoic)、马来酸、羟基马来酸、苯乙酸、谷氨酸、苯甲酸、水杨酸、甲磺酸、苯磺酸、苯磺酸、磺胺酸、2-乙酰氧基苯甲酸、富马酸、甲苯磺酸、甲磺酸、乙烷二磺酸、草酸、羟乙磺酸、HOOC-(CH<base:Sub>2</base:Sub>)n-COOH其中n为0-4等，或使用产生相同抗衡离子的不同酸。另外的合适的盐的列表可以在例如Remington'sPharmaceutical Sciences,17th ed.,Mack Publishing Company,Easton,Pa.,p.1418(1985)中找到。</base:Paragraphs>
      <base:Paragraphs id="p0960" num="n0934">化合物可以以任何摩尔比的盐提供，以提供所需的结果。例如，可以为化合物提供小于摩尔当量的抗衡离子，例如半硫酸盐的形式。或者，可以为化合物提供超过摩尔当量的抗衡离子，例如二硫酸盐的形式。化合物与抗衡离子的摩尔比的非限制性实例包括1:0.25、1:0.5、1:1和1:2。</base:Paragraphs>
      <base:Paragraphs id="p0961" num="n0935">“烷基”是直链或支链的饱和脂肪族烃基。在某些实施方案中，烷基是C<base:Sub>1</base:Sub>-C<base:Sub>2</base:Sub>、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>、C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>、C<base:Sub>1</base:Sub>-C<base:Sub>5</base:Sub>或C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>(即，烷基链可以是1、2、3、4、5或6个碳长度)。如本文所用的指定范围表示具有被描述为独立种类的范围的每个成员的长度的烷基。例如，本文所用的C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基表示具有1、2、3、4、5或6个碳原子的烷基，并且旨在表示这些中的每一个都被描述为独立的种类，而C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基被描述为本文所用的“烷基”表示具有1、2、3或4个碳原子的烷基，并且旨在表示这些中的每一个被描述为独立的种类。烷基的实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、叔戊基、新戊基、正己基、2-甲基戊烷、3-甲基戊烷、2,2-二甲基丁烷和2,3-二甲基丁烷。</base:Paragraphs>
      <base:Paragraphs id="p0962" num="n0936">“环烷基”是饱和的单环烃环系。环烷基的非限制性实例包括环丙基、环丁基、环戊基和环己基。</base:Paragraphs>
      <base:Paragraphs id="p0963" num="n0937">“烯基”是指一种非芳族烃基，其在相邻碳原子之间包含至少一个双键并且具有与本文另外描述的烷基相似的结构。例如，烯基可具有至多4个碳原子(即，C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基)。合适的烯基的实例包括但不限于乙烯基或乙烯基(-CH＝CH<base:Sub>2</base:Sub>)、烯丙基(-CH<base:Sub>2</base:Sub>CH＝CH<base:Sub>2</base:Sub>)、1-丁烯基(-C＝CH-CH<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>)和2-丁烯基(-CH<base:Sub>2</base:Sub>CH＝CHCH<base:Sub>2</base:Sub>)。</base:Paragraphs>
      <base:Paragraphs id="p0964" num="n0938">术语“炔基”是指在相邻碳原子之间含有至少一个三键的非芳族烃基和与本文另外描述的烷基相似的结构。例如，炔基可具有2至4个碳原子(即C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基)。炔基的实例包括但不限于乙炔基和丙炔基。</base:Paragraphs>
      <base:Paragraphs id="p0965" num="n0939">“芳基”表示在一个或多个芳环中仅包含碳的芳基。在一个实施方案中，芳基包含1至3个单独或稠合的环并且为6至约14或18个环原子，没有杂原子作为环成员。芳基包括例如苯基和萘基，包括1-萘基和2-萘基。在一个实施例中，芳基是侧接的。侧环的实例是被苯基取代的苯基。在一个实施方案中，芳基任选地如上所述被取代。在一个实施方案中，芳基包括例如二氢吲哚、二氢苯并呋喃、异吲哚啉-1-酮和吲哚啉-2-酮。</base:Paragraphs>
      <base:Paragraphs id="p0966" num="n0940">“芳基(烷基)-”是被如本文所述的芳基取代的如本文所述的烷基。例如，芳基(CH<base:Sub>2</base:Sub>)-是苄基。芳基(烷基)-的实例包括苄基、2-苯基(烷基)、3-苯基(烷基)和萘基(烷基)。</base:Paragraphs>
      <base:Paragraphs id="p0967" num="n0941">“杂芳基”是指稳定的单环、双环或多环芳环，其包含1至3个，或在一些实施例中包含1、2或3个选自N、O、S、B和P(并且通常选自N、O和S)的杂原子，其中剩余的环原子为碳，或含有至少一个5、6或7元芳环的稳定双环或三环系统，该环含有1至3个，或在一些实施方案中为1至2个选自N、O、S、B或P的杂原子，并剩余的环原子是碳。在一个实施方案中，唯一的杂原子是氮。在一个实施方案中，唯一的杂原子是氧。在一个实施方案中，唯一的杂原子是硫。单环杂芳基通常具有5或6个环原子。当杂芳基中S和O原子的总数超过1时，这些杂原子彼此不相邻。杂芳基的实例包括但不限于吡啶基(包括例如2-羟基吡啶基)、咪唑基、咪唑并吡啶基、嘧啶基(包括例如4-羟基嘧啶基)、吡唑基、三唑基、吡嗪基、呋喃基、噻吩基、异恶唑基、噻唑基、恶二唑基、恶唑基、异噻唑基、吡咯基、喹啉基、异喹啉基、四氢异喹啉基、吲哚基、苯并咪唑基、苯并呋喃基、噌啉基、吲唑基、吲嗪基、酞嗪基、哒嗪基、三嗪基、异吲哚基、蝶啶基、嘌呤基、恶二唑基、三唑基、噻二唑基、噻二唑基、呋呫基、苯并呋呫基、苯并噻吩基、苯并噻唑基、苯并恶唑基、喹唑啉基、喹喔啉基、萘啶基、四氢呋喃基和呋喃并吡啶基。</base:Paragraphs>
      <base:Paragraphs id="p0968" num="n0942">术语“杂烷基”是指如本文中所定义的烷基、烯基、炔基或卤代烷基部分，其中CH<base:Sub>2</base:Sub>基团被杂原子替代或碳原子被杂原子取代，例如胺、羰基、羧基、氧代、硫代、磷酸酯、膦酸酯，氮、磷、硅或硼。在一个实施方案中，唯一的杂原子是氮。在一个实施方案中，唯一的杂原子是氧。在一个实施方案中，唯一的杂原子是硫。在一个实施方案中，“杂烷基”用于表示具有1-6个碳原子的杂脂族基团(环状、无环、取代、未取代、分支或未分支)。</base:Paragraphs>
      <base:Paragraphs id="p0969" num="n0943">术语氨基磷酸酯在整个说明书中用于描述核苷呋喃糖环5'位置的部分并形成核苷化合物的前药形式，其中磷原子通过5'-O-键连接，其中磷还与至少一个氮共价结合，形成P-N键。在一些实施方案中，磷与天然或合成氨基酸(其可以是酯的形式)的氨基部分共价连接。</base:Paragraphs>
      <base:Paragraphs id="p0970" num="n0944">用于本发明的氨基磷酸酯基团包括例如具有以下结构的那些：</base:Paragraphs>
      <base:Paragraphs id="p0971">
        <base:Image he="974" wi="1000" file="GDA0003327089700002191.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0972" num="n0945">用于本发明的其他氨基磷酸酯包括具有以下结构的那些：</base:Paragraphs>
      <base:Paragraphs id="p0973" num="n0946">
        <base:Image he="358" wi="326" file="GDA0003327089700002192.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0974" num="n0947">其中：</base:Paragraphs>
      <base:Paragraphs id="p0975" num="n0948">R<base:Sup>P1</base:Sup>是任选取代的直链、支链或环状烷基，或任选取代的芳基、杂芳基或杂环基或其连接的组合；和</base:Paragraphs>
      <base:Paragraphs id="p0976" num="n0949">R<base:Sup>P2</base:Sup>为-NR<base:Sup>N1</base:Sup>R<base:Sup>N2</base:Sup>基团或B’基团；</base:Paragraphs>
      <base:Paragraphs id="p0977" num="n0950">其中：</base:Paragraphs>
      <base:Paragraphs id="p0978" num="n0951">R<base:Sup>N1</base:Sup>和R<base:Sup>N2</base:Sup>各自独立地为H、C<base:Sub>1-8</base:Sub>烷基、(C<base:Sub>3</base:Sub>-C<base:Sub>7</base:Sub>环烷基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>杂环)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-或(杂芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-；其可以任选地被取代；或者</base:Paragraphs>
      <base:Paragraphs id="p0979" num="n0952">R<base:Sup>N1</base:Sup>和R<base:Sup>N2</base:Sup>连同所连接的氮原子，连接形成3至7元杂环；</base:Paragraphs>
      <base:Paragraphs id="p0980" num="n0953">B’是<base:Image he="341" wi="592" file="GDA0003327089700002201.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0981" num="n0954">其中：</base:Paragraphs>
      <base:Paragraphs id="p0982" num="n0955">R<base:Sup>13</base:Sup>是氢、(C<base:Sub>1</base:Sub>-C<base:Sub>8</base:Sub>)烷基、(C<base:Sub>2</base:Sub>-C<base:Sub>8</base:Sub>)烯基、(C<base:Sub>2</base:Sub>-C<base:Sub>8</base:Sub>)炔基、(C<base:Sub>3</base:Sub>-C<base:Sub>8</base:Sub>环烷基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>杂环)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(杂芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-或氨基酸的侧链，例如通常选自丙氨酸、β-丙氨酸、精氨酸、天冬酰胺、天冬氨酸、半胱氨酸、胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、苯丙氨酸、组氨酸、异亮氨酸、赖氨酸、亮氨酸、甲硫氨酸、脯氨酸、丝氨酸、苏氨酸、缬氨酸、色氨酸或酪氨酸的氨基酸(如本文另外描述的)的侧链(通常R<base:Sup>13</base:Sup>是氢、甲基、异丙基或异丁基)；</base:Paragraphs>
      <base:Paragraphs id="p0983" num="n0956">R<base:Sup>14</base:Sup>是氢、(C<base:Sub>1</base:Sub>-C<base:Sub>8</base:Sub>)烷基、(C<base:Sub>2</base:Sub>-C<base:Sub>8</base:Sub>)烯基、(C<base:Sub>2</base:Sub>-C<base:Sub>8</base:Sub>)炔基、(C<base:Sub>3</base:Sub>-C<base:Sub>8</base:Sub>环烷基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>杂环)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(杂芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-或氨基酸的侧链，例如通常选自丙氨酸、β-丙氨酸、精氨酸、天冬酰胺、天冬氨酸、半胱氨酸、胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、苯丙氨酸、组氨酸、异亮氨酸、赖氨酸、亮氨酸、甲硫氨酸、脯氨酸、丝氨酸、苏氨酸、缬氨酸、色氨酸或酪氨酸的氨基酸(如本文另外描述的)的侧链(通常R<base:Sup>14</base:Sup>是氢、甲基、异丙基或异丁基)；</base:Paragraphs>
      <base:Paragraphs id="p0984" num="n0957">R<base:Sup>15</base:Sup>为氢或C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>烷基；或者</base:Paragraphs>
      <base:Paragraphs id="p0985" num="n0958">R<base:Sup>13</base:Sup>和R<base:Sup>14</base:Sup>可以形成(C<base:Sub>3</base:Sub>-C<base:Sub>7</base:Sub>)环烷基或(C<base:Sub>3</base:Sub>-C<base:Sub>7</base:Sub>)杂环基团；或者</base:Paragraphs>
      <base:Paragraphs id="p0986" num="n0959">R<base:Sup>13</base:Sup>和R<base:Sup>14</base:Sup>或R<base:Sup>16</base:Sup>可以形成(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>)杂环基团；和</base:Paragraphs>
      <base:Paragraphs id="p0987" num="n0960">R<base:Sup>16</base:Sup>是氢、(C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>)烷基、(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>)烯基、(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>)炔基、(C<base:Sub>3</base:Sub>-C<base:Sub>8</base:Sub>环烷基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基、(芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-、(C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>杂环)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-，(杂芳基)C<base:Sub>0</base:Sub>-C<base:Sub>4</base:Sub>烷基-。</base:Paragraphs>
      <base:Paragraphs id="p0988" num="n0961">优选的R<base:Sup>P1</base:Sup>基团包括任选取代的苯基、萘基和单环杂芳基，尤其是那些增强化合物在患者细胞中的生物利用度并且表现出降低毒性、增强治疗指数和增强药代动力学(化合物代谢和排泄更慢)的基团(特别是亲脂基团)。</base:Paragraphs>
      <base:Paragraphs id="p0989" num="n0962">稳定的磷酸酯前药</base:Paragraphs>
      <base:Paragraphs id="p0990" num="n0963">稳定的磷酸酯前药是可以体内递送单磷酸酯、二磷酸酯或三磷酸酯的部分。例如，McGuigan在美国专利Nos.∶8,933,053；8,759,318；8,658,616；8,263,575；8,119,779；7,951,787和7,115,590中公开了氨基磷酸酯。Alios在US 8,895,723和8,871,737(通过引用并入本文)中公开了硫代氨基磷酸酯。Alios还在美国专利No.8,772,474(通过参考引入本文)中公开了环核苷酸。Idenix在WO 2013/177219(通过引用并入本文)中公开了环状氨基磷酸酯和氨基磷酸酯/SATE衍生物。Idenix也在WO 2013/039920(通过引用并入本文)中公开了取代的羰氧基甲基氨基磷酸酯化合物。Hostetler公开了脂质磷酸酯前药，参见例如US7,517,858。Hostetler还公开了膦酸酯前药的共轭物，参见例如US 8,889,658；8,846,643；8,710,030；8,309,565；8,008,308；和7,790,703。Emory University在WO 2014/124430中公开了核苷酸鞘氨基醇和脂质衍生物。RFS Pharma在WO 2010/091386中公开了嘌呤核苷单磷酸酯前药。Cocrystal Pharma Inc.也在美国专利No.∶9,173,893(通过引用并入本文)中公开了嘌呤核苷单磷酸酯前药。HepDirect<base:Sup>TM</base:Sup>技术公开在论文"Design,Synthesis,andCharacterization of a Series of Cytochrome P(450)3A-Activated Prodrugs(HepDirect Prodrugs)Useful for Targeting Phosph(on)ate-Based Drugs to theLiver,"(J.Am.Chem.Soc.126,5154-5163(2004)中。另外的磷酸酯前药包括，但不限于磷酸酯、3’,5’-环状磷酸酯(包括CycloSAL)、SATE衍生物(S-酰基-2-硫代酯)和DTE(二硫代二乙基)前药。关于公开非限制性实例的参考文献综述，参见：A.Ray和K.Hostetler,“Application of kinase bypass strategies to nucleoside antivirals,”AntiviralResearch(2011)277-291；M.Sofia,“Nucleotide prodrugs for HCV therapy,”AntiviralChemistry and Chemotherapy 2011；22-23-49；和S.Peyrottes et al.,“SATEPronucleotide Approaches:An Overview,”Mini Reviews in Medicinal Chemistry2004,4,395。在一个实施方案中，在任一篇这些专利申请或文献中所述的5’-前药都可以用于本发明化合物的R<base:Sup>10A</base:Sup>位。</base:Paragraphs>
      <base:Paragraphs id="p0991" num="n0964">在一个替代实施方案中，稳定的磷酸酯前药包括但不限于美国专利第9,173,893号和美国专利第8,609,627号中描述的那些，通过引用并入本文，包括制备方法。例如，5'-前药可以由以下基团表示：</base:Paragraphs>
      <base:Paragraphs id="p0992" num="n0965">
        <base:Image he="199" wi="303" file="GDA0003327089700002221.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p0993" num="n0966">其中</base:Paragraphs>
      <base:Paragraphs id="p0994" num="n0967">Z是O或S；</base:Paragraphs>
      <base:Paragraphs id="p0995" num="n0968">R<base:Sup>17</base:Sup>和R<base:Sup>18</base:Sup>在体内给药时能够提供核苷单磷酸酯、二磷酸酯或三磷酸酯。代表性的R<base:Sup>12</base:Sup>和R<base:Sup>13</base:Sup>独立地选自：</base:Paragraphs>
      <base:Paragraphs id="p0996" num="n0969">(a)OR<base:Sup>19</base:Sup>，其中R<base:Sup>19</base:Sup>选自H、Li、Na、K、苯基和吡啶基并且其中苯基和吡啶基任选地被一到三个独立地选自(CH<base:Sub>2</base:Sub>)<base:Sub>0-6</base:Sub>CO<base:Sub>2</base:Sub>R<base:Sup>20</base:Sup>和(CH<base:Sub>2</base:Sub>)<base:Sub>0-6</base:Sub>CON(R<base:Sup>20</base:Sup>)<base:Sub>2</base:Sub>的取代基取代；</base:Paragraphs>
      <base:Paragraphs id="p0997" num="n0970">R<base:Sup>20</base:Sup>独立为H、C<base:Sub>1-20</base:Sub>烷基、衍生自脂肪醇(如油醇、二十八醇、三十烷醇、亚油醇等)的碳链，或被低级烷基取代的C<base:Sub>1-20</base:Sub>烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基、环烷基烷基、环杂烷基、芳基(如苯基)、杂芳基(如吡啶基)、取代的芳基或取代的杂芳基；其中取代基是C<base:Sub>1-5</base:Sub>烷基，或被低级烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基或环烷基取代的C<base:Sub>1-5</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p0998" num="n0971">(b)<base:Image he="342" wi="480" file="GDA0003327089700002222.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" /></base:Paragraphs>
      <base:Paragraphs id="p0999" num="n0972">(c)D-氨基酸或L-氨基酸的酯：</base:Paragraphs>
      <base:Paragraphs id="p1000" num="n0973">
        <base:Image he="240" wi="393" file="GDA0003327089700002231.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1001" num="n0974">其中</base:Paragraphs>
      <base:Paragraphs id="p1002" num="n0975">R<base:Sup>21</base:Sup>限于出现在天然L-氨基酸中的那些侧链，并且</base:Paragraphs>
      <base:Paragraphs id="p1003" num="n0976">R<base:Sup>22</base:Sup>为H、C<base:Sub>1-20</base:Sub>烷基、衍生自脂肪醇(如油醇、二十八醇、三十烷醇、亚油醇等)的碳链，或被低级烷基取代的C<base:Sub>1-20</base:Sub>烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基、环烷基烷基、环杂烷基、芳基(如苯基)、杂芳基(如吡啶基)、取代芳基或取代杂芳基；其中取代基是C<base:Sub>1-5</base:Sub>烷基，或被低级烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基或环烷基取代的C<base:Sub>1-5</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p1004" num="n0977">(d)R<base:Sup>17</base:Sup>和R<base:Sup>18</base:Sup>可以一起形成环：</base:Paragraphs>
      <base:Paragraphs id="p1005" num="n0978">
        <base:Image he="560" wi="297" file="GDA0003327089700002232.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1006" num="n0979">其中</base:Paragraphs>
      <base:Paragraphs id="p1007" num="n0980">R<base:Sup>23</base:Sup>为H、C<base:Sub>1-20</base:Sub>烷基、C<base:Sub>1-20</base:Sub>烯基、衍生自脂肪醇(如油醇、二十八醇、三十烷醇、亚油醇等)的碳链，或被低级烷基取代的C<base:Sub>1-20</base:Sub>烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基、环烷基烷基、环杂烷基、芳基(如苯基)、杂芳基(如吡啶基)、取代芳基或取代杂芳基；其中取代基是C<base:Sub>1-5</base:Sub>烷基，或被低级烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基或环烷基取代的C<base:Sub>1-5</base:Sub>烷基；</base:Paragraphs>
      <base:Paragraphs id="p1008" num="n0981">(e)R<base:Sup>17</base:Sup>和R<base:Sup>18</base:Sup>可以一起形成环，选自</base:Paragraphs>
      <base:Paragraphs id="p1009" num="n0982">
        <base:Image he="417" wi="1000" file="GDA0003327089700002241.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1010" num="n0983">其中</base:Paragraphs>
      <base:Paragraphs id="p1011" num="n0984">R<base:Sup>24</base:Sup>选自H、C<base:Sub>1-20</base:Sub>烷基、C<base:Sub>1-20</base:Sub>烯基、衍生自脂肪酸(如油酸、亚油酸等)的碳链，以及被低级烷基取代的C<base:Sub>1-20</base:Sub>烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基、环烷基烷基、环杂烷基、芳基(如苯基)、杂芳基(如吡啶基)、取代的芳基或取代的杂芳基；其中取代基是C<base:Sub>1-5</base:Sub>烷基，或被低级烷基、烷氧基、二(低级烷基)-氨基、氟、C<base:Sub>3-10</base:Sub>环烷基或环烷基取代的C<base:Sub>1-5</base:Sub>烷基；和</base:Paragraphs>
      <base:Paragraphs id="p1012" num="n0985">R<base:Sup>25</base:Sup>是O或NH。</base:Paragraphs>
      <base:Paragraphs id="p1013" num="n0986">在一个替代实施方案中，3',5'-前药可以表示为：</base:Paragraphs>
      <base:Paragraphs id="p1014" num="n0987">
        <base:Image he="806" wi="1000" file="GDA0003327089700002242.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1015" num="n0988">其中：</base:Paragraphs>
      <base:Paragraphs id="p1016" num="n0989">当磷中心存在手性时，它可以全部或部分为R<base:Sub>p</base:Sub>或S<base:Sub>p</base:Sub>或它们的任何混合物，并且可以是对映体富集的；</base:Paragraphs>
      <base:Paragraphs id="p1017" num="n0990">R<base:Sup>26</base:Sup>选自OR<base:Sup>19</base:Sup>、<base:Image he="343" wi="957" file="GDA0003327089700002251.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />或衍生自脂肪醇(例如但不限于亚油基-O-和油基-O-)；</base:Paragraphs>
      <base:Paragraphs id="p1018" num="n0991">R<base:Sup>11</base:Sup>选自R<base:Sup>1</base:Sup>和氢；和</base:Paragraphs>
      <base:Paragraphs id="p1019" num="n0992">R<base:Sup>1</base:Sup>、R<base:Sup>21</base:Sup>、R<base:Sup>22</base:Sup>和R<base:Sup>19</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p1020" num="n0993">同位素取代</base:Paragraphs>
      <base:Paragraphs id="p1021" num="n0994">本发明包括有效量的式I(包括例如化合物1、1A或1B)、式II(包括例如化合物3、3A或3B)、式III(包括例如、式IIIa、式IIIb、式IIIc、式IIId、式IIIe或式IIIf)、式IV的化合物(包括例如式IVa、式IVb、式IVc、式IVd、式IVe，或式IVf)、式V、式VI、式VII、式VIII、式IX、式X的化合物或其药学上可接受的盐，其中所述化合物具有高于同位素天然丰度的量的所需原子同位素取代，即，富集。同位素是原子序数相同但质量数不同的原子，即质子数相同但中子数不同的原子。作为一般示例而非限制，氢的同位素，例如，氘(<base:Sup>2</base:Sup>H)和氚(<base:Sup>3</base:Sup>H)可用于所述结构中的任何地方。可选或另外地，可以使用碳的同位素，例如<base:Sup>13</base:Sup>C和<base:Sup>14</base:Sup>C。同位素取代的一个例子是在分子的一个或多个位置用氘代替氢以提高药物的性能。氘可结合在代谢过程中键断裂的位置(α-氘动力学同位素效应)或键断裂位点旁边或附近(β-氘动力学同位素效应)。Achillion Pharmaceuticals,Inc.(WO/2014/169278和WO/2014/169280)描述了核苷酸的氘化以改善其药代动力学或药效学，包括在分子的5位。</base:Paragraphs>
      <base:Paragraphs id="p1022" num="n0995">用同位素如氘取代可提供某些治疗优势，因为代谢稳定性更高，例如增加体内半衰期或减少剂量需求。在代谢分解位点用氘代替氢可以降低该键处的代谢速率或消除该键的代谢。在化合物的任何可能存在氢原子的位置，氢原子可以是氢的任何同位素，包括氕(<base:Sup>1</base:Sup>H)、氘(<base:Sup>2</base:Sup>H)和氚(<base:Sup>3</base:Sup>H)。因此，除非上下文另有明确规定，否则本文提及的化合物包括所有潜在的同位素形式。</base:Paragraphs>
      <base:Paragraphs id="p1023" num="n0996">术语“同位素标记的”类似物是指“氘代类似物”、“<base:Sup>13</base:Sup>C-标记的类似物”或“氘代/<base:Sup>13</base:Sup>C-标记的类似物”。术语“氘代类似物”是指本文所述的化合物，其中H-同位素，例如氢/氕(<base:Sup>1</base:Sup>H)被H-同位素，例如氘(<base:Sup>2</base:Sup>H)取代。氘代可以是部分的或完全的。部分氘代是指至少一个氢被至少一个氘取代。</base:Paragraphs>
      <base:Paragraphs id="p1024" num="n0997">在某些实施方案中，同位素在任何感兴趣的位置90、95或99％或更多的同位素富集。在一些实施例中，在所需位置90、95或99％的氘富集。除非另有说明，所选位置的氘代率至少为80％。核苷的氘代可发生在任何可提供所需结果的可置换氢处。</base:Paragraphs>
      <base:Paragraphs id="p1025" num="n0998">在一个实施方案中，式XIII的化合物或其药学上可接受的盐，任选地在药学载体中，用于在有需要的宿主中治疗或预防由SARS-CoV-2引起的COVID-19疾病，如本文所述：</base:Paragraphs>
      <base:Paragraphs id="p1026" num="n0999">
        <base:Image he="574" wi="867" file="GDA0003327089700002261.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1027" num="n1000">其中</base:Paragraphs>
      <base:Paragraphs id="p1028" num="n1001">R<base:Sup>6</base:Sup>选自氢、-C(O)R<base:Sup>6A</base:Sup>、-C(O)OR<base:Sup>6A</base:Sup>、C<base:Sub>1-6</base:Sub>烷基和-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p1029" num="n1002">R<base:Sup>6</base:Sup>选自氢、-C(O)R<base:Sup>6A</base:Sup>、-C(O)OR<base:Sup>6A</base:Sup>、C<base:Sub>1-6</base:Sub>烷基和-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>，在一个替代实施方案中，-C(O)NR<base:Sup>6B</base:Sup>R<base:Sup>6C</base:Sup>；</base:Paragraphs>
      <base:Paragraphs id="p1030" num="n1003">R<base:Sup>6A</base:Sup>选自氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基(例如-CHCl<base:Sub>2</base:Sub>、-CCl<base:Sub>3</base:Sub>、-CH<base:Sub>2</base:Sub>Cl、-CF<base:Sub>3</base:Sub>、-CHF<base:Sub>2</base:Sub>、-CH<base:Sub>2</base:Sub>F)、芳基和芳基(C<base:Sub>1-6</base:Sub>烷基)-，其中芳基任选地被选自烷氧基、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代，在一个替代实施方案中，R<base:Sup>6A</base:Sup>选自C<base:Sub>1-20</base:Sub>烷基和C<base:Sub>2-20</base:Sub>烯基；</base:Paragraphs>
      <base:Paragraphs id="p1031" num="n1004">R<base:Sup>6B</base:Sup>和R<base:Sup>6C</base:Sup>独立地选自氢、C<base:Sub>1-20</base:Sub>烷基、C<base:Sub>2-20</base:Sub>烯基、芳基、芳基烷基、杂芳基和杂芳基烷基，其中C<base:Sub>1-20</base:Sub>烷基、C<base:Sub>2-20</base:Sub>烯基、芳基、芳基烷基、杂芳基和杂芳基烷基可以任选地被至少一个选自烷氧基(包括但不限于甲氧基和乙氧基)、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代；</base:Paragraphs>
      <base:Paragraphs id="p1032" num="n1005">R<base:Sup>30</base:Sup>是CH<base:Sub>3</base:Sub>、CD<base:Sub>3</base:Sub>、CHD<base:Sub>2</base:Sub>或CH<base:Sub>2</base:Sub>D；</base:Paragraphs>
      <base:Paragraphs id="p1033" num="n1006">R<base:Sup>31</base:Sup>是NH<base:Sub>2</base:Sub>或D或在一个替代实施方案中，CD<base:Sub>3</base:Sub>；</base:Paragraphs>
      <base:Paragraphs id="p1034" num="n1007">R<base:Sup>32</base:Sup>是CH<base:Sub>3</base:Sub>、CD<base:Sub>3</base:Sub>、CHD<base:Sub>2</base:Sub>或CH<base:Sub>2</base:Sub>D；和</base:Paragraphs>
      <base:Paragraphs id="p1035" num="n1008">Y选自F和Cl；和</base:Paragraphs>
      <base:Paragraphs id="p1036" num="n1009">R<base:Sup>1</base:Sup>、R<base:Sup>2</base:Sup>、R<base:Sup>3</base:Sup>、R<base:Sup>4a</base:Sup>、R<base:Sup>4b</base:Sup>和R<base:Sup>5</base:Sup>如本文所定义。</base:Paragraphs>
      <base:Paragraphs id="p1037" num="n1010">例如，式XIII化合物的非限制性实例包括：</base:Paragraphs>
      <base:Paragraphs id="p1038" num="n1011">
        <base:Image he="1000" wi="658" file="GDA0003327089700002271.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1039" num="n1012">
        <base:Image he="1000" wi="411" file="GDA0003327089700002281.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1040" num="n1013">
        <base:Image he="1000" wi="503" file="GDA0003327089700002291.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1041" num="n1014">式XIII化合物的其他实例包括：</base:Paragraphs>
      <base:Paragraphs id="p1042" num="n1015">
        <base:Image he="482" wi="956" file="GDA0003327089700002292.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1043" num="n1016">
        <base:Image he="1000" wi="393" file="GDA0003327089700002301.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1044" num="n1017">
        <base:Image he="1000" wi="395" file="GDA0003327089700002311.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1045">
        <base:Image he="453" wi="1000" file="GDA0003327089700002321.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1046" num="n1018">治疗或预防方法</base:Paragraphs>
      <base:Paragraphs id="p1047" num="n1019">如本文所用，治疗是指以有效量施用式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐于宿主(例如人类)，宿主感染或可能感染SARS-CoV-2病毒。在一个实施方案中，治疗方法包括施用有效量的化合物1A或化合物3A或其药学上可接受的盐，例如化合物2A或化合物4A。在一个实施方案中，治疗方法包括施用有效量的化合物1B或化合物3B或其药学上可接受的盐，例如化合物2B或化合物4B。</base:Paragraphs>
      <base:Paragraphs id="p1048" num="n1020">本发明还包括预防或预防性治疗。在一个实施方案中，将式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐给药至曾接触过SARS-CoV-2病毒并因此有感染风险或再次感染SARS-CoV-2病毒风险的宿主。例如，可以对尚未接触或感染SARS-CoV-2，但易感或有接触或感染COVID-19风险的受试者进行预防性治疗。在一个实施方案中，向处于感染或再感染风险的宿主施用式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，直至不再存在暴露风险。</base:Paragraphs>
      <base:Paragraphs id="p1049" num="n1021">在另一个可选的实施方案中，提供了一种预防传播的方法，该方法包括在暴露于可能被感染的人群之前向人类施用有效量的本文所述的化合物之一达足够长的时间，包括在旅行或公共活动或会议期间，包括例如，在可传染情况发生前最多3、5、7、10、12、14天或更长时间，因为该人被感染或者是为了防止在可传染情况下被感染者感染。</base:Paragraphs>
      <base:Paragraphs id="p1050" num="n1022">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐在感染后以有效量施用至少两周、三周、一个月、两个月、三个月、四个月、五个月或六个月或更长时间。</base:Paragraphs>
      <base:Paragraphs id="p1051" num="n1023">本发明涉及一种治疗COVID-19的方法，包括抗药性和多重抗药性形式的病毒的以及病毒感染的相关疾病状态、病症或并发症，包括肺炎，例如2019新型冠状病毒感染的肺炎(NCIP)、急性肺损伤(ALI)和急性呼吸窘迫综合征(ARDS)。其他非限制性并发症包括低氧性呼吸衰竭、急性呼吸衰竭(ARF)、急性肝损伤、急性心脏损伤、急性肾损伤、感染性休克、弥散性血管内凝血、血栓、多系统炎症综合征、慢性疲劳、横纹肌溶解和细胞因子风暴。</base:Paragraphs>
      <base:Paragraphs id="p1052" num="n1024">该方法还包括向有需要的宿主，通常是人，施用有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，任选地与至少一种额外的生物活性剂组合，例如，额外的抗病毒剂，进一步任选地与药学上可接受的载体添加剂和/或赋形剂组合。</base:Paragraphs>
      <base:Paragraphs id="p1053" num="n1025">在一个实施方案中，将式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐给药至有需要的患者导致进行性呼吸功能不全(PRI)的发生率降低，如使用下面描述的6级呼吸支持方法维持令人满意的氧合(SpO2≥93％)所需的呼吸支持方法增加大于或等于1级或甚至2级或更多。</base:Paragraphs>
      <base:Paragraphs id="p1054" num="n1026">增加呼吸支持水平的等级包括：</base:Paragraphs>
      <base:Paragraphs id="p1055" num="n1027">1级：室内空气(SpO<base:Sub>2</base:Sub>≥93％)下正常的氧合，无需补充O<base:Sub>2</base:Sub></base:Paragraphs>
      <base:Paragraphs id="p1056" num="n1028">2级：室内空气(SpO2≥93)下持续的低氧血症，需要通过鼻导管或面罩(最高2L/min)补充低水平的O<base:Sub>2</base:Sub>以维持SpO<base:Sub>2</base:Sub>≥93</base:Paragraphs>
      <base:Paragraphs id="p1057" num="n1029">3级：需要通过鼻导管或面罩(最高2L/min)提供更高水平的被动补充O<base:Sub>2</base:Sub>以维持SpO<base:Sub>2</base:Sub>≥93</base:Paragraphs>
      <base:Paragraphs id="p1058" num="n1030">4级：需要通过正压装置进行氧合作用，例如持续气道正压通气(CPAP)或双水平气道正压通气(BiPAP)或其他无创正压呼吸支持方法，以维持令人满意的氧合和/或通气</base:Paragraphs>
      <base:Paragraphs id="p1059" num="n1031">5级：需要有创呼吸支持(插管机械通气或ECMO)</base:Paragraphs>
      <base:Paragraphs id="p1060" num="n1032">6级：死亡</base:Paragraphs>
      <base:Paragraphs id="p1061" num="n1033">在一个实施例中，PRI的降低是从5级增加到3级、从5级增加到2级或从5级增加到1级。在一个实施方案中，PRI的降低是从4级增加到2级或4级到1级。在一个实施方案中，PRI的降低是从3级增加到1级。</base:Paragraphs>
      <base:Paragraphs id="p1062" num="n1034">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用到至少3、4、5或更多天减少临床恢复的中位时间(NIAID临床状态量表中的状态6、7或8，使用经过改编的国家过敏和传染病研究所(NIAID)临床状态序数量表)。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用导致改善，通过临床状态的适应顺序量表进行衡量。</base:Paragraphs>
      <base:Paragraphs id="p1063" num="n1035">从最严重的疾病到逐渐减轻的疾病，整体临床状态的适应顺序量表的阶段定义如下：</base:Paragraphs>
      <base:Paragraphs id="p1064" num="n1036">1.死亡</base:Paragraphs>
      <base:Paragraphs id="p1065" num="n1037">2.住院，有创机械通气或ECMO</base:Paragraphs>
      <base:Paragraphs id="p1066" num="n1038">3.住院，使用无创通气或高流量氧气设备</base:Paragraphs>
      <base:Paragraphs id="p1067" num="n1039">4.住院，需要补充氧气</base:Paragraphs>
      <base:Paragraphs id="p1068" num="n1040">5.住院，不需要补充氧气—需要持续的医疗护理(与COVID-19相关或其他)</base:Paragraphs>
      <base:Paragraphs id="p1069" num="n1041">6.住院，不需要补充氧气；不再需要对COVID-19进行密切的医疗护理</base:Paragraphs>
      <base:Paragraphs id="p1070" num="n1042">7.未住院，但活动受限且因COVID-19表现需要密切门诊护理</base:Paragraphs>
      <base:Paragraphs id="p1071" num="n1043">8.无需住院，活动不受限制，无需持续密切医疗护理</base:Paragraphs>
      <base:Paragraphs id="p1072" num="n1044">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用到至少5天，至少6天，至少7天、至少8天、至少9天或至少10天减少了临床恢复的中位时间(NIAID临床状态量表中的状态6、7或8，使用经过改编的美国国家过敏和传染病研究所(NIAID)临床状态序数量表)。</base:Paragraphs>
      <base:Paragraphs id="p1073" num="n1045">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用减少了感染SARS-CoV-2病毒的患者的住院时间。</base:Paragraphs>
      <base:Paragraphs id="p1074" num="n1046">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用减少了达到在感染了SARS-CoV-2病毒的患者的鼻子和/或喉咙中持续检测不到SARS-CoV-2病毒的时间。</base:Paragraphs>
      <base:Paragraphs id="p1075" num="n1047">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用减少了呼吸衰竭或死亡。</base:Paragraphs>
      <base:Paragraphs id="p1076" num="n1048">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的施用减少了在至少约5、6、7、8、9、10、11、12、13或14天的治疗后，医院人群中SARS-CoV-2呈阳性的患者比例。</base:Paragraphs>
      <base:Paragraphs id="p1077" num="n1049">在另一个实施方案中，通过向宿主施用有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐来提供在有需要的宿主(通常是人)中治疗或预防SARS-CoV-2感染的方法，其中SARS-CoV-2感染是由病毒变体引起的，该变体在野生型上发生了自然或药物诱导的突变。</base:Paragraphs>
      <base:Paragraphs id="p1078" num="n1050">在一些实施方案中，SARS-CoV-2变体在选自包膜(E)蛋白、膜(M)蛋白、刺突(S)蛋白、nsp1、nsp2、nsp3、nsp4、nsp5、nsp6、nsp7、nsp8、nsp9、nsp10、nsp12、nsp13、nsp14、nsp15、nsp16、ORF1ab、ORF<base:Sub>3</base:Sub>a、ORF6、ORF7a、ORF7b、ORF8和ORF10的病毒蛋白中具有天然突变或药物诱导突变。在一些实施方案中，SARS-CoV-2变体具有导致对一种或多种抗病毒药物的获得性抗性的突变。</base:Paragraphs>
      <base:Paragraphs id="p1079" num="n1051">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸H69和V70的缺失。</base:Paragraphs>
      <base:Paragraphs id="p1080" num="n1052">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸D614G的缺失。</base:Paragraphs>
      <base:Paragraphs id="p1081" num="n1053">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸Y144的缺失。</base:Paragraphs>
      <base:Paragraphs id="p1082" num="n1054">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换N501Y。</base:Paragraphs>
      <base:Paragraphs id="p1083" num="n1055">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换A570D。</base:Paragraphs>
      <base:Paragraphs id="p1084" num="n1056">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换P681H。</base:Paragraphs>
      <base:Paragraphs id="p1085" num="n1057">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换T716I。</base:Paragraphs>
      <base:Paragraphs id="p1086" num="n1058">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换S982A。</base:Paragraphs>
      <base:Paragraphs id="p1087" num="n1059">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换D1118H。</base:Paragraphs>
      <base:Paragraphs id="p1088" num="n1060">在一些实施方案中，SARS-CoV-2变体在ORF8的蛋白质产物中具有过早终止密码子突变Q27stop。</base:Paragraphs>
      <base:Paragraphs id="p1089" num="n1061">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换K417N。</base:Paragraphs>
      <base:Paragraphs id="p1090" num="n1062">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换E484K。</base:Paragraphs>
      <base:Paragraphs id="p1091" num="n1063">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换K417N。</base:Paragraphs>
      <base:Paragraphs id="p1092" num="n1064">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换D215G。</base:Paragraphs>
      <base:Paragraphs id="p1093" num="n1065">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换A701V。</base:Paragraphs>
      <base:Paragraphs id="p1094" num="n1066">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换L18F。</base:Paragraphs>
      <base:Paragraphs id="p1095" num="n1067">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换R246I。</base:Paragraphs>
      <base:Paragraphs id="p1096" num="n1068">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸242-244处的缺失</base:Paragraphs>
      <base:Paragraphs id="p1097" num="n1069">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换Y453F。</base:Paragraphs>
      <base:Paragraphs id="p1098" num="n1070">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换I692V。</base:Paragraphs>
      <base:Paragraphs id="p1099" num="n1071">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换M1229I。</base:Paragraphs>
      <base:Paragraphs id="p1100" num="n1072">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换N439K。</base:Paragraphs>
      <base:Paragraphs id="p1101" num="n1073">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换A222V。</base:Paragraphs>
      <base:Paragraphs id="p1102" num="n1074">在一些实施方案中，SARS-CoV-2变体具有刺突蛋白氨基酸置换S477N。</base:Paragraphs>
      <base:Paragraphs id="p1103" num="n1075">在一些实施例中，SARS-CoV-2变体具有刺突蛋白氨基酸置换A376T。</base:Paragraphs>
      <base:Paragraphs id="p1104" num="n1076">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换P323L。</base:Paragraphs>
      <base:Paragraphs id="p1105" num="n1077">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换Y455I。</base:Paragraphs>
      <base:Paragraphs id="p1106" num="n1078">在一些实施方案中，SARS-CoV-2变体具有Orf8蛋白氨基酸置换R52I。</base:Paragraphs>
      <base:Paragraphs id="p1107" num="n1079">在一些实施方案中，SARS-CoV-2变体具有ORF8蛋白氨基酸置换Y73C。</base:Paragraphs>
      <base:Paragraphs id="p1108" num="n1080">在一些实施方案中，SARS-CoV-2变体具有核苷(N)蛋白氨基酸置换D3L。</base:Paragraphs>
      <base:Paragraphs id="p1109" num="n1081">在一些实施方案中，SARS-CoV-2变体具有核苷(N)蛋白氨基酸置换S235F。</base:Paragraphs>
      <base:Paragraphs id="p1110" num="n1082">在一些实施方案中，SARS-CoV-2变体具有ORF1ab蛋白氨基酸置换T1001I。</base:Paragraphs>
      <base:Paragraphs id="p1111" num="n1083">在一些实施方案中，SARS-CoV-2变体具有ORF1ab蛋白氨基酸置换A1708D。</base:Paragraphs>
      <base:Paragraphs id="p1112" num="n1084">在一些实施方案中，SARS-CoV-2变体具有ORF1ab蛋白氨基酸置换I2230T。</base:Paragraphs>
      <base:Paragraphs id="p1113" num="n1085">在一些实施方案中，SARS-CoV-2变体具有ORF1ab蛋白氨基酸SGF3675-3677缺失。</base:Paragraphs>
      <base:Paragraphs id="p1114" num="n1086">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换S861X，其中X是任何氨基酸。</base:Paragraphs>
      <base:Paragraphs id="p1115" num="n1087">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换F480V。</base:Paragraphs>
      <base:Paragraphs id="p1116" num="n1088">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换V557L。</base:Paragraphs>
      <base:Paragraphs id="p1117" num="n1089">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换D484Y。</base:Paragraphs>
      <base:Paragraphs id="p1118" num="n1090">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换F480X，其中X＝任何氨基酸。</base:Paragraphs>
      <base:Paragraphs id="p1119" num="n1091">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换V557X，其中X＝任何氨基酸。</base:Paragraphs>
      <base:Paragraphs id="p1120" num="n1092">在一些实施方案中，SARS-CoV-2变体具有nsp12蛋白氨基酸置换D484X，其中X＝任何氨基酸。</base:Paragraphs>
      <base:Paragraphs id="p1121" num="n1093">在一些实施方案中，SARS-CoV-2变体包括刺突蛋白氨基酸69-70的缺失、刺突蛋白氨基酸Y144的缺失、刺突蛋白氨基酸置换N501Y、刺突蛋白氨基酸置换A570D、刺突蛋白氨基酸置换D614G、刺突蛋白氨基酸置换P681H、刺突蛋白氨基酸置换T716I、刺突蛋白氨基酸置换S982A、刺突蛋白氨基酸置换D1118H和ORF8的蛋白质产物过早终止密码子突变(Q27stop)。</base:Paragraphs>
      <base:Paragraphs id="p1122" num="n1094">在一些实施方案中，SARS-CoV-2变体包括刺突蛋白中的N501Y、K417N、E484K、D80A、D215G、L18F和R246I的刺突蛋白氨基酸置换，以及刺突蛋白中氨基酸242-244处的氨基酸缺失。</base:Paragraphs>
      <base:Paragraphs id="p1123" num="n1095">在一些实施方案中，所述SARS-CoV-2变体选自SARS-CoV-2进化枝O、S、L、V、G、GH或GR，如Alm等人"Geographical and temporal distribution of SARS-CoV-2clades inthe WHO European Region,January to June 2020".Euro Surveillance:BulletinEuropean Sur les Maladies Transmissibles＝European Communicable DiseaseBulletin.25(32)所述。</base:Paragraphs>
      <base:Paragraphs id="p1124" num="n1096">在一些实施方案中，SARS-CoV-2变体选自SARS-CoV-2进化枝G614、S84、V251、I378或D392，如Guan等人，A genetic barcode of SARS-CoV-2for monitoring globaldistribution of different clades during the COVID-19pandemic.Int J InfectDis.2020Nov；100:216–223所述。</base:Paragraphs>
      <base:Paragraphs id="p1125" num="n1097">在一些实施方案中，SARS-CoV-2变体选自SARS-CoV-2进化枝19A、19B、20A或20C，如Nextstrain：Genomic epidemiology of novel coronavirus-Global sub-sampling.Available from:https://nextstrain.org/ncov所述。</base:Paragraphs>
      <base:Paragraphs id="p1126" num="n1098">在一些实施例中，所述SARS-CoV-2变体选自SARS-CoV-2谱系A、B、B.1、B.1.1或B.1.177，如Rambaut等人，Phylogenetic Assignment of Named Global OutbreakLINeages(pangolin).San Francisco:GitHub.Available from:https://github.com/cov-lineages/pangolin；Rambaut等人，A dynamic nomenclature proposal for SARS-CoV-2lineages to assist genomic epidemiology.Nat Microbiol.2020Nov；5(11):1403-1407；Rambaut et al.SARS-CoV-2lineages.Available from:https://cov-lineages.org/所述。</base:Paragraphs>
      <base:Paragraphs id="p1127" num="n1099">在一些实施方案中，SARS-CoV-2变体是“簇5”变体，其包括刺突蛋白氨基酸置换D614G。</base:Paragraphs>
      <base:Paragraphs id="p1128" num="n1100">在一些实施方案中，SARS-CoV-2变体是VUI202012/01(Variant UnderInvestigation，2020年，12月，变体01)(也称为B.1.1.7谱系和20B/501Y.V1)，其由多个刺突蛋白变化确定，包括刺突蛋白氨基酸69-70的缺失、刺突蛋白氨基酸Y144的缺失、刺突蛋白氨基酸置换N501Y、刺突蛋白氨基酸置换A570D、刺突蛋白氨基酸置换D614G、刺突蛋白氨基酸置换P681H、刺突蛋白氨基酸置换T716I、刺突蛋白氨基酸置换S982A、刺突蛋白氨基酸置换D1118H，以及ORF8蛋白产物中的提前终止密码子突变(Q27stop)。</base:Paragraphs>
      <base:Paragraphs id="p1129" num="n1101">在一些实施方案中，SARS-CoV-2变体是B.1.351谱系变体(也称为501.V2、20C/501Y.V2)，其在刺突蛋白中的受体结合域(RBD)中包括几个突变：N501Y、K417N和E484K，使病毒更容易附着在人体细胞上，以及刺突蛋白中的氨基酸置换D80A，刺突蛋白中的氨基酸置换D215G，刺突蛋白中的氨基酸置换A701V，刺突蛋白中的氨基酸置换L18F，刺突蛋白中的氨基酸置换R246I，以及刺突蛋白的氨基酸242-244处的氨基酸缺失。</base:Paragraphs>
      <base:Paragraphs id="p1130" num="n1102">在一些实施方案中，SARS-CoV-2变体是501Y.V2谱系变体(也称为501Y.V2、20C/20H/501Y.V2)，其还包括刺突蛋白突变N501Y、K417N和E484K。</base:Paragraphs>
      <base:Paragraphs id="p1131" num="n1103">在一些实施方案中，SARS-CoV-2变体是P.1谱系变体(也称为Brazil(ian)变体)，其在刺突蛋白突变中包括十个突变，包括N501Y和E484K。</base:Paragraphs>
      <base:Paragraphs id="p1132" num="n1104">在一些实施方案中，SARS-CoV-2变体是B.1.1.207谱系变体，其包括刺突蛋白中的P681H突变。</base:Paragraphs>
      <base:Paragraphs id="p1133" num="n1105">在一些实施方案中，SARS-CoV-2变体是丹麦貂变体，其包括刺突蛋白中H69和V70的氨基酸缺失，以及刺突蛋白中的氨基酸置换Y453F。</base:Paragraphs>
      <base:Paragraphs id="p1134" num="n1106">在一些实施方案中，SARS-CoV-2变体是丹麦貂簇5变体，其包括刺突蛋白中H69和V70的氨基酸缺失、刺突蛋白中的氨基酸置换Y453F、刺突蛋白中的氨基酸置换I692V，以及刺突蛋白中的氨基酸置换M1229I。</base:Paragraphs>
      <base:Paragraphs id="p1135" num="n1107">在一些实施方案中，SARS-CoV-2变体包括刺突蛋白中H69和V70的氨基酸缺失，以及刺突蛋白中的氨基酸置换N439K。</base:Paragraphs>
      <base:Paragraphs id="p1136" num="n1108">在一些实施方案中，SARS-CoV-2变体是Nexstrain簇20A.EU1变体，其在刺突蛋白中包括氨基酸置换A222V。</base:Paragraphs>
      <base:Paragraphs id="p1137" num="n1109">在一些实施方案中，SARS-CoV-2变体是Nexstrain簇20A.EU2变体，其包括刺突蛋白中的氨基酸置换S477N和核衣壳蛋白中的氨基酸置换A376T。</base:Paragraphs>
      <base:Paragraphs id="p1138" num="n1110">在一些实施方案中，SARS-CoV-2变体具有一个或多个选自以下的突变：ORF1ab蛋白产物中的氨基酸置换T1001I；ORF1a蛋白产物中的氨基酸置换A1708D；ORF1ab蛋白产物中的氨基酸置换I2230T；ORF1ab蛋白产物中3675-3677位氨基酸SGF的缺失；ORF3a的蛋白质产物中的氨基酸置换G251V；ORF8的蛋白质产物中的氨基酸置换S24L；ORF8的蛋白质产物中的氨基酸置换R52I；ORF8的蛋白质产物中的氨基酸置换Y73C；ORF8的蛋白质产物中的氨基酸置换L84S；nsp12结构域中的氨基酸置换P323L；nsp12结构域中的氨基酸置换Y455I；ORF3a的蛋白质产物中的氨基酸置换Q57H；nsp2中的氨基酸置换R27C；nsp2中的氨基酸置换V198I；nsp2中的氨基酸置换T85I；nsp2中的氨基酸置换P585S；nsp2中的氨基酸置换I559V；nsp4中的氨基酸置换M33I；nsp5中的氨基酸置换G15S；nsp6中的氨基酸置换L37F；nsp13中的氨基酸置换Y541C；nsp13中的氨基酸置换P504L；刺突蛋白中的氨基酸置换S477N；刺突蛋白中的氨基酸置换N439K；刺突蛋白中的氨基酸置换N501Y；刺突蛋白中的氨基酸置换Y453F；刺突蛋白中的氨基酸置换K417N；刺突蛋白中的氨基酸置换E484K；刺突蛋白中的氨基酸置换A222V；刺突蛋白中的氨基酸置换S98F；刺突蛋白中的氨基酸置换D80Y；刺突蛋白中的氨基酸置换A626S；刺突蛋白中的氨基酸置换V1122L；刺突蛋白中的氨基酸置换A570D；刺突蛋白中的氨基酸置换P681H；刺突蛋白中的氨基酸置换V1122L；刺突蛋白中的氨基酸置换T716I；刺突蛋白中的氨基酸置换S982A；刺突蛋白中的氨基酸置换D1118H；刺突蛋白中的氨基酸置换E583D；刺突蛋白中的氨基酸置换V483A；刺突蛋白中的氨基酸置换Q675R；刺突蛋白中的氨基酸置换A344S；刺突蛋白中的氨基酸置换T345S；刺突蛋白中的氨基酸置换R346K；刺突蛋白中的氨基酸置换A348S；刺突蛋白中的氨基酸置换A348T；刺突蛋白中的氨基酸置换N354K；刺突蛋白中的氨基酸置换S359N；刺突蛋白中的氨基酸置换V367F；刺突蛋白中的氨基酸置换V382L；刺突蛋白中的氨基酸置换P384L；刺突蛋白中的氨基酸置换P384S；刺突蛋白中的氨基酸置换T385S；刺突蛋白中的氨基酸置换V395I；刺突蛋白中的氨基酸置换R403K；刺突蛋白中的氨基酸置换D405V；刺突蛋白中的氨基酸置换Q414P；刺突蛋白中的氨基酸置换Q414E；刺突蛋白中的氨基酸置换I418V；刺突蛋白中的氨基酸置换L441I；刺突蛋白中的氨基酸置换R457K；刺突蛋白中的氨基酸置换K458Q；刺突蛋白中的氨基酸置换P463S；刺突蛋白中的氨基酸置换A475V；刺突蛋白中的氨基酸置换G476S；刺突蛋白中的氨基酸置换T478A；刺突蛋白中的氨基酸置换P479L；刺突蛋白中的氨基酸置换V483A；刺突蛋白中的氨基酸置换F490L；刺突蛋白中的氨基酸置换Q493L；刺突蛋白中的氨基酸置换A520S；刺突蛋白中的氨基酸置换L5F；刺突蛋白中的氨基酸置换P521R；刺突蛋白中的氨基酸置换A522S；刺突蛋白中的氨基酸置换A831V；刺突蛋白中的氨基酸置换D839Y；刺突蛋白中的氨基酸置换D839N；刺突蛋白中的氨基酸置换D839E；刺突蛋白中的氨基酸置换L8V；刺突蛋白中的氨基酸置换L8W；刺突蛋白中的氨基酸置换H49Y；刺突蛋白中氨基酸H69的缺失；刺突蛋白中氨基酸V70的缺失；刺突蛋白中氨基酸Y144的缺失；核衣壳蛋白中的氨基酸置换D3L；核衣壳蛋白中的氨基酸置换S253F；核衣壳蛋白中的氨基酸置换RG203KR；核衣壳蛋白中的氨基酸置换G214C；核衣壳蛋白中的氨基酸置换S194L；nsp14蛋白中的氨基酸置换F377L；nsp3中的氨基酸置换K1186R；或nsp3中的氨基酸置换A58T。</base:Paragraphs>
      <base:Paragraphs id="p1139" num="n1111">在一些实施方案中，SARS-CoV-2变体在包膜(E)蛋白中含有一种或多种以下突变：S68F；L73F；P71L；S55F；R69I；T9I；V24M；D72H；T30I；S68C；V75L；V58F；V75F；或L21F；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1140" num="n1112">在一些实施方案中，SARS-CoV-2变体在膜(M)蛋白中含有一种或多种以下突变：T175M；D3G；V23L；W31C；A2V；V70F；W75L；M109I；I52T；L46F；V70I；D3Y；K162N；H125Y；K15R；D209Y；R146H；R158C；L87F；A2S；A69S；S214I；T208I；L124F；或S4F；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1141" num="n1113">在一些实施方案中，SARS-CoV-2变体在核衣壳(N)蛋白中含有一种或多种以下突变：RG203KR；S194L；S197L；P13L；D103Y；S193I；S188L；I292T；S202N；D401Y；S190I；D22G；A208G；T205I；S183Y；S33I；D81Y；T393I；A119S；D377Y；S37P；T247I；A156S；D128Y；P199L；R195I；P207L；E62V；R209T；T362I；G18C；T24N；R185C；S180I；M234I；Q9H；P383L；A35S；P383S；D348H；K374N；R32H；S327L；G179C；G238C；A55S；S190G；H300Y；A119V；D144Y；L139F；P199S；P344S；P6L；R203K；P364L；R209I；S188P；A35V；K387N；P122L；R191C；R195K；T391I；A252S；Q418L；T271I；T325I；G18V；L161F；Q289H；R203S；P162L；D340N；K373N；P168Q；A211V；D3L；G212V；K370N；P151L；T334I；A359S；G34W；P67T；R203M；D144N；R191L；S232I；D402Y；P168S；S187L；T366I；A152S；A381T；N140T；T198I；A251V；A398V；A90S；D348Y；D377G；G204R；G243C；G34E；Q229H；R185L；T24I；T379I；A134V；N196I；P365S；Q384H；R276I；S235F；D216A；M210I；M322I；P20S；Q389H；R209缺失；或V246I；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1142" num="n1114">在一些实施方案中，SARS-CoV-2变体在nsp1蛋白中含有一个或多个以下突变：M85；D75E；G82缺失；V84缺失；P80缺失；H83缺失；V86缺失；H81缺失；E87缺失；L88缺失；K141缺失；A79缺失；V89缺失；V56I；R124C；D75G；A90缺失；Y118C；D139N；Y136缺失；G30D；R24C；D139Y；E37K；H45Y；H110Y；G52S；I71V；D156缺失；A76T；E37D；S135缺失；S166G；A138T；F157缺失；G49C；M85I；或D144A；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1143" num="n1115">在一些实施方案中，SARS-CoV-2变体在nsp10蛋白中含有一种或多种以下突变：D64E；P136S；A104V；A32V；T12I；T111I；P84S；T51I；I55V；T102I；或T51A；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1144" num="n1116">在一些实施方案中，SARS-CoV2变体在nsp12蛋白中含有一种或多种以下突变：P323L；T141I；A449V；S434F；M666I；H613Y；S647I；M380I；E922D；M629I；G774S；M601I；E436G；N491S；Q822H；A443V；T85I；A423V；M463I；T26I；A656T；M668I；T806I；T276M；T801N；V588L；K267N；V880I；K718R；L514F；F415S；T252N；Y38H；E744D；H752Q；I171V；S913L；A526V；A382V；G228C；P94L；E84K；K59N；P830S；T908I；P21S；D879Y；G108D；K780N；R279S；D258Y；T259I；K263N；D284Y；Q292H；T293I；N297S；V299F；D304Y；T319I；F321L；P328S；V330E；I333T；G337C；T344I；Y346H；L351P；V354L；Q357H；E370G；L372F；A400S；T402I；V405F；V410I；D418N；K426N；K430N；V435F；Q444H；D445G；A448V；R457C；P461T；C464F；I466V；V473F；K478N；D481G；D517G；D523N；A529V；P537S；S549N；A555V；C563F；M566I；A581T；G584V；A585T；G596S；T604I；S607I；D608G；V609I；M615V；W617L；M629V；I632V；L636F；L638F；A639V；T643I；T644M；L648F；V667I；A699S；N713S；H725；N734T；D736N；V737F；T739I；V742M；N743S；M756I；L758I；A771V；L775V；A777T；K780T；F793L；T801I；T803A；H810Y；G823C；D825Y；V827A；Y828H；V848L；T870I；K871R；N874D；Q875R；E876D；H882Y；H892Y；D901Y；M906I；N909D；T912N；P918S；E919D；A923T；F480V；V557L；D484Y；或S433G；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1145" num="n1117">在一些实施方案中，SARS-CoV-2变体在nsp13蛋白中包含一种或多种以下突变：Y541C；P504L；A18V；R392C；P47L；S485L；L297P；H290Y；T127I；L176F；V193I；V570L；D260Y；V49I；Q518H；S468L；A598V；D204Y；S74L；T588I；G206C；V226L；V348L；M576I；A302D；P53S；T481M；K524N；A338V；P419S；V479F；P77L；V169F；N124S；P78S；S80G；V496L；A4V；T413I；A296S；A368S；K460R；L297F；P172S；A302S；P402S；T530I；L428F；P504S；A368V；D458Y；P364S；S74P；T416A；A568V；M474I；S166L；S350L；D344N；E341D；I432T；L581F；S38L；T250I；Y253H；A509V；E244D；H164Y；S74A；T141I；V356F；E319D；E365D；G170S；L526F；R155C；或Y396C；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1146" num="n1118">在一些实施方案中，SARS-CoV-2变体在nsp14蛋白中含有一种或多种以下突变：A320V；F233L；T250I；V182L；A225V；R289C；A274S；P24L；I150T；S374A；H26Y；L177F；L157F；T16I；A482V；P297S；V120A；S255I；P203L；A23缺失；K311N；M72I；V290F；F431L；K349N；M58I；P140S；R205C；T193A；L409F；P443S；Y260C；D345G；E204D；R163C；R81K；T524I；T113I；T31I；L493F；A119V；D345Y；M501I；A360V；A371V；T206I；V287F；A360S；I74T；M315I；P142L；或Q343K；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1147" num="n1119">在一些实施方案中，SARS-CoV-2变体在nsp15蛋白中含有一种或多种以下突变：V320L；A217V；V22L；V172L；D219N；P205S；V127F；Q19H；M218缺失；A92V；D282G；I252V；T33I；G129S；L331F；A81V；V69L；S312F；T325I；A171V；R206S；D272Y；D87N；S288F；K109R；P270S；P65S；D267Y；D128Y；E215I；T144I；S261L；S287L；T112I；E260K；P205L；S161I；V66L；D39Y；或T114A；或其组合。</base:Paragraphs>
      <base:Paragraphs id="p1148" num="n1120">在一些实施方案中，SARS-CoV-2变体在nsp16蛋白中含有一个或多个以下突变：S33R；K160R；P134S；Q28K；T195I；V78G；T35I；G265V；K249N；A204S；K182N；R287I；A188S；A116V；T140I；L111F；M270T；R216N；A188V；A34V；D108N；L163F；L163H；M17I；T91M；A226S；G77R；L126F；N298L；R216S；T48I；Q238H；或R279K；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1149" num="n1121">在一些实施方案中，SARS-CoV-2变体在nsp2蛋白中含有一种或多种以下突变：T85IP585S；I559V；D268；G212D；V198I；H237R；F10L；G339S；T166I；R27C；L271F；S211F；P91S；G199E；T371I；A336V；I120F；S122F；A476V；S138L；V480A；T388I；T634I；P129S；R218C；I188T；T170I；P568L；E574A；I367V；H208Y；S99F；T429I；A306V；M405V；P129L；R222C；T44I；Q275H；R380C；A360V；A361V；G115C；L353F；H237Y；L462F；E261G；R4C；S263F；T573I；A318V；G262V；P624L；S430L；T422I；A357S；I100V；E272G；L400F；A192V；D464A；E172D；G262S；L501F；S369F；E172K；G465S；K219R；A411V；A522V；H194Y；S32L；F437L；P181S；P446L；G115V；H532Y；N92H；P13S；A159V；A184S；A306S；I273T；L274F；P13L；R370H；T223I；T590I；E453D；H145Y；K618N；S301F；T153M；V244I；V530I；A127V；L24F；P191L；Q182L；S196L；S248G；S378F；T139I；T434I；A205V；A375V；A411S；C51Y；F300L；M135T；P568S；Q496H；S348P；T412I；T528I；T547I；V447F；或V577I；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1150" num="n1122">在一些实施方案中，SARS-CoV-2变体在nsp3蛋白中含有一种或多种以下突变：A58T；T1198K；T428I；P153L；S1197R；D218E；S1424F；A1431V；S1285F；P74L；Q1884H；P1326L；L1221F；P141S；P1103S；S126L；Y916H；L557F；E391D；A1311V；S650F；P1103L；Y952H；P340S；A534V；P1787S；L1791F；N1587S；S371N；K1693N；G282V；P278S；T1335I；A1711V；K19R；A994D；K1325R；P822L；K412N；A465V；T1004I；T808I；G489D；S1699F；M1436V；S1265R；V1768G；A231V；M951I；K384N；T1288I；Q966H；R1614K；T1036I；T1306I；A1179V；P395L；N1785D；P679L；S166G；A1769V；T181I；L1718F；P822S；T1022I；A1381V；A602T；I1720V；K837N；T73I；A1033V；S1204；C1223Y；P389L；T398A；M1441I；M494I；T1303I；T181A；P1228L；R1135K；V267F；A1883V；A655V；S1296F；T686I；L198I；P1403S；L781F；T1046A；A1215V；E374D；I205缺失；V477F；E324K；I707V；P109L；P1558L；P74S；S1212L；S1807F；T819I；T864I；H1000Y；P340L；S697F；T1189I；A480V；D729Y；K1771R；S1717L；T749I；M829I；Q172R；T1482I；A1395V；I385T；M560I；S1206L；S1699P；T1269I；T779I；V1315I；V1795F；V325F；A1892V；A579V；E493G；H1274Y；S1467F；T1063I；T350I；V61F；A1736V；K1804N；R646W；T583I；T611I；V1243I；V190I；A41V；H290Y；H295Y；H342Y；L1244F；Q128H；V1673I；A1305V；A1526S；E948K；L72F；P125S；P402T；A1766V；D1214N；E1271D；G1440D；G283D；K1211N；K902N；K945N；L1839S；L312F；N1263S；P1292S；S1670F；S743A；T771I；V1936I；A1262V；A1321V；A358V；A41T；C55Y；G1273S；K463E；K497Q；P1044S；R30K；S1375F；S1682F；T133I；T1348I；465I；T1830I；T237I；V1248L；A225V；A496V；G1217R；I1816T；L956I；N1369T；N506S；P153S；P2L；T1275I；T1459I；V1234M；E595D；F90L；G1585S；H1307Y；I1409V；L1034V；L1328F；L292F；N1264；P1326T；S1197G；T1456I；T64I；T703I；T720I；T820I；V1229F；V234I；A1279V；A333V；A54S；D1121G；D1761N；E731D；I1672T；I789V；K1037R；K487N；L142F；N1177H；P1228S；P723S；Q180H；Q474R；Q940L；S370L；T1180I；T275I；T422I；T526I；T724I；V1434G；或V207L；或其组合。</base:Paragraphs>
      <base:Paragraphs id="p1151" num="n1123">在一些实施方案中，SARS-CoV-2变体在nsp4蛋白中含有一种或多种以下突变：F308Y；T295I；M33I；A307V；A457V；G309C；L360F；A231V；H313Y；K399E；V20F；S137L；S34F；A380V；H470Y；T204I；S336L；L264F；L438F；M33L；S209F；C296S；L475I；G79V；T327N；T350I；L206F；M324I；E230G；L436缺失；T237I；T492I；A260V；A446V；M458I；S395G；S481L；H36Y；T73I；L323F；L349F；S59F；T214I；或T60I；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1152" num="n1124">在一些实施方案中，SARS-CoV-2变体在nsp5蛋白中含有一种或多种以下突变：G15S；D248E；K90R；L89F；A266V；P108S；A70T；A129V；T45I；G71S；L75F；A191V；L220F；N274D；L67F；P241L；K236R；V157L；K61R；P184S；S62Y；T21I；L50F；P108L；S254F；T93I；A255V；A94V；P132S；A234V；A260V；R60C；P96L；V247F；或T199I；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1153" num="n1125">在一些实施方案中，SARS-CoV-2变体在nsp6蛋白中含有一种或多种以下突变：L37F；G277S；A46V；L75F；F37缺失；T10I；V149F；L260F；Q208H；M83I；A136V；V145I；N156D；M86I；Y153C；G188V；L230I；F34缺失；I189V；R233H；V114A；L33F；A287V；H11Y；A287T；A51V；G188S；I162T；M126V；M183I；N40Y；S104；F35L；M58L；或V84F；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1154" num="n1126">在一些实施方案中，SARS-CoV-2变体在nsp7蛋白中含有一种或多种以下突变：S25L；S26F；L71F；S15T；M75I；或N78S；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1155" num="n1127">在一些实施方案中，SARS-CoV-2变体在nsp8蛋白中含有一个或多个以下突变：M129I；I156V；T145I；R51C；T123I；L95F；T89I；P133S；S41F；K37N；T141M；V34F；R51L；A14T；A74V；I107V；A16V；P10S；A194V；D30G；A152V；或T187I；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1156" num="n1128">在一些实施方案中，SARS-CoV-2变体在nsp9蛋白中含有一个或多个以下突变：T77I；T109I；L42F；T34I；T19I；M101V；T62I；或T19K；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1157" num="n1129">在一些实施方案中，SARS-CoV-2变体在ORF10的蛋白质产物中含有一种或多种以下突变：L17P；A28V；P10S；I4L；S23F；R24C；*39Q；Q29终止；Y14C；R20I；或A8V；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1158" num="n1130">在一些实施方案中，SARS-CoV-2变体在ORF3a的蛋白质产物中含有一种或多种以下突变：Q57H；G251V；V13L；G196V；A54S；A99V；H93Y；T14I；L46F；Q185H；T175I；Q213K；L108F；K61N；Y264C；A72S；T151I；A23S；G224C；K67N；S171L；W69L；H78Y；K136E；L86F；W131C；L147F；S58N；Y91H；I63T；D155Y；G172C；P240L；Y189C；W131R；KN136NY；T223I；G100C；S195Y；V112F；W131L；G44V；D27H；G174C；K21N；S165F；L65F；T229I；T89I；S74F；A99S；G254R；H204N；K75N；F43L；L53F；Q38P；S26L；S40L；M260I；V256缺失；K16N；Q218R；S253P；V163L；W69C；A23V；L41F；L106F；V55F；V88A；A99D；E239D；L52F；T24I；A31T；D27Y；I186V；L73F；P104L；D22Y；F114V；L95F；P240S；P42L；T268M；或T32I；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1159" num="n1131">在一些实施方案中，SARS-CoV-2变体在ORF6的蛋白质产物中含有一种或多种以下突变：I33T；W27L；D53G；F22缺失；P57L；D61Y；D61L；K42N；D53Y；H3Y；I32T；或R20S；或其组合。</base:Paragraphs>
      <base:Paragraphs id="p1160" num="n1132">在一些实施方案中，SARS-CoV-2变体在ORF7a的蛋白质产物中含有一种或多种以下突变：S81L；A8T；L96F；A50V；V104F；Q62终止；S83L；E16D；T14I；T28I；V93F；G38V；H47Y；T39I；T120S；Q62缺失；Q62L；S37T；V104；P34S；P99L；T120I；V108L；H73Y；V24F；V29L；A13T；或L5F；或其组合。</base:Paragraphs>
      <base:Paragraphs id="p1161" num="n1133">在一些实施方案中，SARS-CoV-2变体在ORF7b的蛋白质产物中含有一种或多种以下突变：C41F；T40I；A43V；L11F；S31L；C41缺失；H42；H42L；S5L；L20F；L32F；E33终止；A15S；或F13缺失；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1162" num="n1134">在一些实施方案中，SARS-CoV-2变体在ORF8的蛋白质产物中含有一种或多种以下突变：E110终止；G66缺失；S69L；T11I；F104L；F120L；G8R；P38S；D119E；I10S；或I39V；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1163" num="n1135">在一些实施方案中，SARS-CoV-2变体在刺突蛋白中含有一种或多种以下突变：D614G；D936Y；P1263L；L5F；N439K；R21I；D839Y；L54F；A879S；L18F；F1121L；R847K；T478I；A829T；Q675H；S477N；H49Y；T29I；G769V；G1124V；V1176F；K1073N；P479S；S1252P；Y145缺失；E583D；R214L；A1020V；Q1208H；D215G；H146Y；S98F；T95I；G1219C；A846V；I197V；R102I；V367F；T572I；A1078S；A831V；P1162L；T73I；A845S；G1219V；H245Y；L8V；Q675R；S254F；V483A；Q677H；D138H；D80Y；M1237T；D1146H；E654D；H655Y；S50L；S939F；S943P；G485R；Q613H；T76I；V341I；M153I；S221L；T859I；W258L；L242F；P681L；V289I；A520S；V1104L；V1228L；L176F；M1237I；T307I；T716I；L141；M1229I；A1087S；P26S；P330S；P384L；R765L；S940F；T323I；V826L；E1202Q；L1203F；L611F；V615I；A262S；A522V；A688V；A706V；A892S；E554D；Q836H；T1027I；T22I；A222V；A27S；A626V；C1247F；K1191N；M731I；P26L；S1147L；S1252F；S255F；V1264L；V308L；D80A；I670L；P251L；P631S；*1274Q；A344S；A771S；A879T；D1084Y；D253G；H1101Y；L1200F；Q14H；Q239K；A623V；D215Y；E1150D；G476S；K77M；M177I；P812S；S704L；T51I；T547I；T791I；V1122L；Y145H；D574Y；G142D；G181V；I834T；N370S；P812L；S12F；T791P；V90F；W152L；A292S；A570V；A647S；A845V；D1163Y；G181R；L84I；L938F；P1143L；P809S；R78M；T1160I；V1133F；V213L；V615F；A831V；D839Y；D839N；D839E；S943P；P1263L；或V622F；及其组合。</base:Paragraphs>
      <base:Paragraphs id="p1164" num="n1136">药物组合物和剂型</base:Paragraphs>
      <base:Paragraphs id="p1165" num="n1137">式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐可以以有效量施用用于在有需要的宿主(通常是人类)中治疗由SARS-CoV-2病毒引起的2019冠状病毒病(COVID-19)。在一个实施方案中，化合物是化合物1A或化合物3A或其药学上可接受的盐，例如化合物2A或化合物4A。在一个实施方案中，化合物是化合物1B或化合物3B或其药学上可接受的盐，例如化合物2B或化合物4B。</base:Paragraphs>
      <base:Paragraphs id="p1166" num="n1138">该化合物或其盐可以作为纯化学品提供，但更通常作为药物组合物给药，该药物组合物包含对需要治疗COVID-19的宿主(通常是人类)有效量。因此，在一个实施方案中，本公开内容提供的药物组合物包含有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X、式X或式XIII的化合物或其药学上可接受的盐，以及至少一种药学上可接受的载体，用于治疗COVID-19。所述药物组合物可含有式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐作为唯一活性剂，或者，在替代实施例中，与至少一种另外的活性剂组合。</base:Paragraphs>
      <base:Paragraphs id="p1167" num="n1139">式I(包括但不限于化合物1、1A或1B)、式II(包括但不限于化合物3、3A或3B)、式III(包括，式IIIa、式IIIb、式IIIc、式IIId、式IIIe或式IIIf)、式IV(包括式IVa、式IVb、式IVc、式IVd、式IVe或式IVf)、式V、式VI、式VII、式VIII、式IX、式X或式XIII化合物或其药学上可接受的盐，可以与一种或多种药学上可接受的载体一起配制。有时选择口服剂型是因为易于给药和预期的患者顺应性。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以固体剂型提供，例如片剂或丸剂，它们是本领域公知的并在下面进一步描述。肠溶包衣口服片剂也可用于提高化合物口服给药途径的生物利用度。药物组合物(制剂)可以通过口服、肠胃外、静脉内、吸入、肌肉内、局部、经皮、口腔、皮下、栓剂或其他途径给药，包括鼻内喷雾递送途径。</base:Paragraphs>
      <base:Paragraphs id="p1168" num="n1140">在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐通过静脉内施用。在一个非限制性实施方案中，本发明的化合物以550mg/天的负荷剂量和275mg/天的维持剂量静脉内施用。在一个实施方案中，负荷剂量施用一次并且维持剂量每天施用两次，持续至少3、4、5、6、7、8、9、10、11或12天。在一个非限制性实施方案中，静脉内负荷剂量是550毫克/天化合物1(即，600毫克/天化合物1的半硫酸盐)，并且维持剂量是275毫克/天(即，300毫克/天的化合物1半硫酸盐))。</base:Paragraphs>
      <base:Paragraphs id="p1169" num="n1141">有效剂型将取决于所选特定药剂的生物利用度/药代动力学以及患者疾病的严重程度。式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐可以通过一种或多种形式施用，例如，片剂、胶囊剂、注射剂、静脉内制剂、悬浮液、液体、乳剂、植入物、颗粒、微球、乳膏剂、软膏剂、栓剂、可吸入剂型、透皮剂型、口腔、舌下、局部、凝胶、粘膜等形式。</base:Paragraphs>
      <base:Paragraphs id="p1170" num="n1142">静脉内和肌肉内制剂通常在无菌盐水中施用。本领域普通技术人员可以改进制剂以使其更易溶于水或另一种载体，例如，这可以通过微小的改进(盐制剂、酯化等)容易地实现。</base:Paragraphs>
      <base:Paragraphs id="p1171" num="n1143">这里考虑的药物组合物任选地包括载体，如下文进一步描述的。载体必须具有足够高的纯度和足够低的毒性，以使其适合施用于接受治疗的患者。载体可以是惰性的，也可以具有其自身的药学益处。与化合物结合使用的载体的量足以为每单位剂量的化合物提供实际量的用于给药的材料。代表性载体包括溶剂、稀释剂、pH调节剂、防腐剂、抗氧化剂、悬浮剂、润湿剂、粘度剂、张度剂、稳定剂及其组合。在一些实施例中，载体是水性载体。</base:Paragraphs>
      <base:Paragraphs id="p1172" num="n1144">可以将一种或多种粘合剂加入到药物组合物中以根据需要增加组合物的粘度。有用的粘合剂的实例包括但不限于透明质酸、透明质酸钠、卡波姆、聚丙烯酸、纤维素衍生物、聚卡波非(polycarbophil)、聚乙烯吡咯烷酮、明胶、糊精、多糖、聚丙烯酰胺、聚乙烯醇(包括部分水解的聚乙酸乙烯酯)、聚乙酸乙烯酯、其衍生物及其混合物。</base:Paragraphs>
      <base:Paragraphs id="p1173" num="n1145">用于给药的溶液、悬浮液或乳剂可以用有效量的缓冲剂进行缓冲，以维持适合所选给药的pH值。合适的缓冲剂是本领域技术人员熟知的。一些有用的缓冲液的例子是醋酸盐、硼酸盐、碳酸盐、柠檬酸盐和磷酸盐缓冲剂。</base:Paragraphs>
      <base:Paragraphs id="p1174" num="n1146">为了制备根据本发明的药物组合物，治疗有效量的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X，或式XIII的化合物或其药学上可接受的盐可与药学上可接受的载体根据常规药物配制技术混合以产生剂量。根据给药所需的制剂形式，例如口服或肠胃外，载体可以采用多种形式。</base:Paragraphs>
      <base:Paragraphs id="p1175" num="n1147">在制备口服剂型的药物组合物时，可以使用任何常用的药物介质。因此，对于液体口服制剂例如混悬剂、酏剂和溶液剂，可以使用合适的载体和添加剂，包括水、乙二醇、油、醇、调味剂、防腐剂、着色剂等。对于固体口服制剂如粉剂、片剂、胶囊和固体制剂如栓剂，合适的载体和添加剂包括淀粉、糖载体，如右旋糖、甘露醇、乳糖和相关载体、稀释剂、造粒剂、润滑剂、粘合剂可以使用崩解剂等。如果需要，片剂或胶囊可以通过标准技术进行肠溶包衣或缓释。这些剂型的使用可显著提高化合物在患者体内的生物利用度。</base:Paragraphs>
      <base:Paragraphs id="p1176" num="n1148">对于肠胃外制剂，载体通常包括无菌水或氯化钠水溶液，但也可包括其他成分，包括有助于分散的成分。当然，在使用无菌水并保持无菌的情况下，组合物和载体也必须灭菌。也可以制备可注射的悬浮液，在这种情况下可以使用合适的液体载体、悬浮剂等。</base:Paragraphs>
      <base:Paragraphs id="p1177" num="n1149">脂质体悬液(包括靶向病毒抗原的脂质体)也可以通过常规方法制备以生产药学上可接受的载体。这可能适合于递送根据本发明的核苷化合物的游离核苷、酰基/烷基核苷或磷酸酯前药形式。</base:Paragraphs>
      <base:Paragraphs id="p1178" num="n1150">本公开中提到的量和重量通常是指游离形式(即，非盐、水合物或溶剂化物形式)。本文所述的典型值代表游离形式的当量，即，如同将施用游离形式的量。如果施用盐，则需要根据盐和游离形式之间的分子量比来计算量。</base:Paragraphs>
      <base:Paragraphs id="p1179" num="n1151">式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐在根据本发明的药学上可接受的制剂中的量是实现治疗COVID-19、降低COVID-19可能性或抑制、减少和/或消除COVID-19或其继发效应(包括疾病状态、状况和/或继发于病毒的并发症)的所需结果的有效量。作为非限制性实施方案，药物剂型中本发明化合物的治疗有效量可以在例如每天约0.001mg/kg至约100mg/kg或更多的范围内。式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，例如在非限制性的实施方案中可以以每天约0.1mg/kg至约15mg/kg患者的量施用，这取决于药剂在患者体内的药代动力学。</base:Paragraphs>
      <base:Paragraphs id="p1180" num="n1152">除非另外特别指明，本文所述剂型中活性化合物的重量是关于化合物的游离形式或盐形式。例如，大约600mg的化合物2相当于大约550mg的化合物1。</base:Paragraphs>
      <base:Paragraphs id="p1181" num="n1153">在某些实施方案中，药物组合物的剂型在单位剂型中包含约1mg至约2000mg、约10mg至约1000mg、约100mg至约800mg、约200mg至约600mg、约300mg至约500mg，或约400mg至约450mg的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式的化合物X，或式XIII的化合物或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p1182" num="n1154">在某些实施方案中，该药物组合物是一种剂型，例如一种固体剂型，其在单位剂型中含有最多约10、约50、约100、约125、约150、约175、约200、约225、约250、约275、约300、约325、约350、约375、约400、约425、约450、约475、约500、约525、约550、约575、约600、约625、约650、约675、约700、约725、约750、约775、约800、约825、约850、约875、约900、约925、约950、约975、约1000mg、约1050mg、约1100mg、约1150mg、约1200mg、约1250mg、约1300mg、约1350mg、约1400mg、约1450mg、约1500mg、约1550mg、约1600mg、约1650mg、约1700mg或更多的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的。</base:Paragraphs>
      <base:Paragraphs id="p1183" num="n1155">在某些实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐，例如化合物1或化合物2以初始剂量(或负荷剂量)给药，随后以至少约300mg、至少约350mg、至少约400mg、至少约450mg、至少约500mg、至少约550毫克、至少约650mg或至少约750毫克的维持剂量给药，并且该剂量每天服用一次或两次。在一个实施方案中，负荷剂量是维持剂量的约1.5倍、约2倍、约2.5倍或3倍。在一个实施方案中，负荷剂量在第一次维持剂量之前施用一次、两次、三次、四次或更多次。</base:Paragraphs>
      <base:Paragraphs id="p1184" num="n1156">在一个实施方案中，该药物组合物是一种剂型，例如一种固体剂型，其在单位剂型中含有至少500mg、至少550mg、600mg、至少700mg、至少800mg、至少900mg、至少1000mg、至少1100mg、至少1200、至少1300mg、至少1400mg或至少1500mg的式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII或其药学上可接受的盐。</base:Paragraphs>
      <base:Paragraphs id="p1185" num="n1157">在某些实施方案中，药物组合物，例如固体剂型，含有至少约450mg、550mg、650mg、750mg或850mg的化合物1或化合物3。在一个实施方案中，药物组合物含有至少约500mg、至少约550mg或至少约600mg的化合物1或化合物3并且该组合物每天给药两次。在一个实施方案中，该药物组合物含有至少约550mg的化合物1并且该药物组合物每天给药两次。在一个实施方案中，所述药物组合物以至少约900mg、1000mg、1100mg、1100mg或1200mg化合物1的初始剂量(或负荷剂量)施用，随后施用至少约400mg、至少约450mg、至少约500mg、至少约550、至少约600mg或至少约650mg剂量的化合物1每天两次。在一个实施方案中，药物组合物以至少约1100mg化合物1的初始剂量(或负荷剂量)随后以至少约450mg、550mg、650mg、750mg或850mg的剂量施用化合物1每天两次。在一个实施方案中，药物组合物以至少约1100mg化合物1的初始剂量(或负荷剂量)给药，随后以至少约550mg化合物1的剂量每天两次给药。在一个实施方案中，维持剂量施用约4、5、6、7、8、9、10或更多天。在一个实施例中，化合物1是化合物1A。在一个实施例中，化合物1是化合物1B。</base:Paragraphs>
      <base:Paragraphs id="p1186" num="n1158">在一个实施方案中，有效量的式I化合物：</base:Paragraphs>
      <base:Paragraphs id="p1187" num="n1159">
        <base:Image he="478" wi="899" file="GDA0003327089700002561.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1188" num="n1160">或其药学上可接受的盐，任选地在药学上可接受的载体中，用于在有需要的人中治疗由SARS-CoV-2病毒引起的2019冠状病毒病(COVID-19)，其中所述化合物根据以下时间表施用：</base:Paragraphs>
      <base:Paragraphs id="p1189" num="n1161">(i)一天内单次负荷剂量1100毫克游离碱；接着是</base:Paragraphs>
      <base:Paragraphs id="p1190" num="n1162">(ii)每天550毫克游离碱的维持剂量。</base:Paragraphs>
      <base:Paragraphs id="p1191" num="n1163">在一个实施例中，有效量的下式化合物：</base:Paragraphs>
      <base:Paragraphs id="p1192" num="n1164">
        <base:Image he="479" wi="899" file="GDA0003327089700002562.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1193" num="n1165">或其药学上可接受的盐，任选地在药学上可接受的载体中，用于在有需要的人中治疗由SARS-CoV-2病毒引起的2019冠状病毒病(COVID-19)，其中所述化合物根据以下时间表施用：</base:Paragraphs>
      <base:Paragraphs id="p1194" num="n1166">(i)一天内单次负荷剂量1100毫克游离碱；接着是</base:Paragraphs>
      <base:Paragraphs id="p1195" num="n1167">(ii)每天550毫克游离碱的维持剂量。</base:Paragraphs>
      <base:Paragraphs id="p1196" num="n1168">在一个实施方案中，有效量的下式化合物：</base:Paragraphs>
      <base:Paragraphs id="p1197" num="n1169">
        <base:Image he="454" wi="957" file="GDA0003327089700002563.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1198" num="n1170">任选地在药学上可接受的载体中，施用用于治疗在有需要的人中由SARS-CoV-2病毒引起的2019冠状病毒病(COVID-19)，其中该化合物根据以下时间表施用：</base:Paragraphs>
      <base:Paragraphs id="p1199" num="n1171">(i)一天内单次负荷剂量1200毫克盐；接着</base:Paragraphs>
      <base:Paragraphs id="p1200" num="n1172">(ii)每天600毫克盐的维持剂量。</base:Paragraphs>
      <base:Paragraphs id="p1201" num="n1173">在某些实施方案中，药物组合物，例如固体剂型，含有至少约400mg、至少约500mg、600mg、700mg或800mg的化合物2或化合物4。在一个实施方案中，药物组合物含有至少约500mg、至少约600mg或至少约700mg的化合物2或化合物4，并且该组合物每天施用两次。在一个实施方案中，该药物组合物含有至少约600mg的化合物2并且该药物组合物一天施用两次。在一个实施方案中，所述药物组合物以至少约900mg、1000mg、1100mg、1200mg或1300mg化合物2的初始剂量(或负荷剂量)施用，随后施用至少约400mg的剂量、500mg、600mg、700mg或800mg化合物2一天一次、两次或三次。在一个实施方案中，所述药物组合物以至少约1000mg、1200mg或1400mg化合物2的初始剂量(或负荷剂量)施用，随后以至少约600mg化合物2的剂量每天两次施用。在一个实施方案中，所述药物组合物以至少约1200mg化合物2的初始剂量(或负荷剂量)随后以至少约400mg、500mg、600mg、700mg或800mg化合物2的剂量一天施用两次。在一个实施方案中，药物组合物以至少约1200mg化合物2的初始剂量(或负荷剂量)施用，随后以至少约600mg化合物2的剂量一天施用两次。在一个实施方案中，维持剂量施用约4、5、6、7、8、9、10或更多天。在一个实施例中，化合物2是化合物2A。在一个实施例中，化合物2是化合物1B。</base:Paragraphs>
      <base:Paragraphs id="p1202" num="n1174">在某些实施方案中，施用式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐至少五天、六天、七天、八天、九天、十天、两周、三周、一个月、至少两个月、至少三个月、至少四个月、至少五个月，至少六个月或更长时间。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐每天施用一次，两次、三次或更多次。在一个实施方案中，它每天口服施用两次。</base:Paragraphs>
      <base:Paragraphs id="p1203" num="n1175">出于本发明的目的，根据本发明的组合物的预防或预防有效量通常可以落入上述范围内，并且可以根据医疗保健提供者的最佳判断来确定。在一个实施方案中，本发明的化合物在病毒风险增加时季节性施用以预防感染，或者可以例如在旅行或暴露之前、期间和/或之后施用。</base:Paragraphs>
      <base:Paragraphs id="p1204" num="n1176">本领域的普通技术人员将认识到，治疗有效量将随着要治疗的感染或病症、其严重程度、要采用的治疗方案、所用药剂的药代动力学以及治疗的患者或受试者(动物或人)而变化。此类治疗量可由主治医师或专家确定。</base:Paragraphs>
      <base:Paragraphs id="p1205" num="n1177">固体剂型</base:Paragraphs>
      <base:Paragraphs id="p1206" num="n1178">本发明的一个方面是一种固体剂型，其包括有效量的式I(包括但不限于化合物1、1A、1B、2、2A或2B)、式II(包括但不限于化合物3)、式III(包括式IIIa、式IIIb、式IIIc、式IIId、式IIIe或式IIIf)、式IV(包括式IVa、式IVb、式IVc、式IVd、式IVe或式IVf)、式V、式VI、式VII、式VIII、式IX、式X或式XIII化合物或其药学上可接受的盐，任选地在药学上可接受的载体中。</base:Paragraphs>
      <base:Paragraphs id="p1207" num="n1179">在一个实施方案中，固体剂型包括式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐的喷雾干燥固体分散体，该组合物适于口服给药。在另一个实施方案中，固体剂型是式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII化合物或其药学上可接受的盐的颗粒层状固体分散体，该组合物适于口服给药。</base:Paragraphs>
      <base:Paragraphs id="p1208" num="n1180">在其他实施方案中，固体分散体还含有至少一种选自共聚维酮、泊洛沙姆和HPMC-AS的赋形剂。在一个实施例中，泊洛沙姆是泊洛沙姆407或包括泊洛沙姆407的泊洛沙姆的混合物。在一个实施方案中，HPMC-AS是HPMC-AS-L。</base:Paragraphs>
      <base:Paragraphs id="p1209" num="n1181">在其他实施方案中，由式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受盐制备的固体剂型还包含一种或多种以下赋形剂：磷酸甘油酯；磷脂酰胆碱；二棕榈酰磷脂酰胆碱(DPPC)；二油基磷脂酰乙醇胺(DOPE)；二油酰氧基丙基三乙基铵(DOTMA)；二油酰磷脂酰胆碱；胆固醇；胆固醇酯；二酰基甘油；二酰基甘油琥珀酸酯；二磷脂酰甘油(DPPG)；十六烷醇；脂肪醇如聚乙二醇(PEG)；聚氧乙烯-9-月桂基醚；表面活性脂肪酸，如棕榈酸或油酸；脂肪酸；脂肪酸单甘油酯；脂肪酸甘油二酯；脂肪酸酰胺；脱水山梨糖醇三油酸酯<base:Image he="77" wi="291" file="GDA0003327089700002591.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />甘胆酸盐；脱水山梨糖醇单月桂酸酯<base:Image he="80" wi="380" file="GDA0003327089700002592.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />聚山梨醇酯20<base:Image he="73" wi="359" file="GDA0003327089700002593.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />聚山梨醇酯60<base:Image he="74" wi="357" file="GDA0003327089700002594.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />聚山梨醇酯65<base:Image he="77" wi="359" file="GDA0003327089700002595.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />聚山梨醇酯80<base:Image he="77" wi="357" file="GDA0003327089700002596.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />聚山梨醇酯85<base:Image he="77" wi="360" file="GDA0003327089700002597.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />聚氧乙烯单硬脂酸酯；表面活性素；泊洛沙姆；脱水山梨糖醇脂肪酸酯如脱水山梨糖醇三油酸酯；卵磷脂；溶血卵磷脂；磷脂酰丝氨酸；磷脂酰肌醇；鞘磷脂；磷脂酰乙醇胺(脑磷脂)；心磷脂；磷脂酸；脑苷脂；双十六烷基磷酸酯；二棕榈酰磷脂酰甘油；硬脂胺；十二胺；十六烷基胺；乙酰棕榈酸酯；蓖麻油酸甘油酯；硬脂酸十六烷基酯；肉豆蔻酸异丙酯；泰洛沙泊；聚(乙二醇)5000-磷脂酰乙醇胺；聚(乙二醇)400-单硬脂酸酯；磷脂；具有高表面活性剂特性的合成和/或天然洗涤剂；脱氧胆酸盐；环糊精；离液盐；离子配对剂；葡萄糖、果糖、半乳糖、核糖、乳糖、蔗糖、麦芽糖、海藻糖、纤维二糖、甘露糖、木糖、阿拉伯糖、葡糖醛酸、半乳糖醛酸、甘露糖醛酸、葡糖胺、半乳糖胺和神经氨酸；支链淀粉、纤维素、微晶纤维素、硅化微晶纤维素、羟丙基甲基纤维素(HPMC)、羟纤维素(HC)、甲基纤维素(MC)、葡聚糖、环糊精、糖原、羟乙基淀粉、角叉菜胶、糖苷、直链淀粉、壳聚糖、N,O-羧甲基壳聚糖、藻胶和藻酸、淀粉、几丁质、菊粉、魔芋、葡甘露聚糖、脓毒杆菌、肝素、透明质酸、凝胶多糖和黄原胶、甘露糖醇、山梨糖醇、木糖醇、赤藓糖醇、麦芽糖醇和乳糖醇、普郎尼克聚合物、聚乙烯、聚碳酸酯(例如聚(1,3-二恶烷-2酮))、聚酐(例如，聚(癸二酸酐))、聚富马酸丙酯、聚酰胺(例如聚己内酰胺)、聚缩醛、聚醚、聚酯(例如，聚丙交酯、聚乙交酯、聚丙交酯-共-乙交酯、聚己内酯，聚羟基酸(例如，聚((β-羟基链烷酸酯)))、聚(原酸酯)、聚氰基丙烯酸酯、聚乙烯醇、聚氨酯、聚磷腈、聚丙烯酸酯、聚甲基丙烯酸酯、聚脲、聚苯乙烯和聚胺、聚赖氨酸、聚乙二醇赖氨酸-PEG共聚物和聚(乙烯亚胺)、聚(乙烯亚胺)-PEG共聚物、单辛酸甘油酯、丙二醇、维生素ETPGS(也称为d-α-生育酚聚乙二醇1000琥珀酸酯)、明胶、二氧化钛、聚乙烯吡咯烷酮(PVP)、羟丙基甲基纤维素(HPMC)、羟丙基纤维素(HPC)、甲基纤维素(MC)、环氧乙烷和环氧丙烷的嵌段共聚物(PEO/PPO)、聚乙二醇(PEG)、羧甲基纤维素钠(NaCMC)或羟丙基甲基纤维素醋酸琥珀酸纤维素(HPMCAS)。</base:Paragraphs>
      <base:Paragraphs id="p1210" num="n1182">在其他实施方案中，由式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受盐制备的固体剂型还包含一种或多种以下表面活性剂：聚乙二醇、聚丙二醇、癸基葡糖苷、月桂基葡糖苷、辛基葡糖苷、聚乙二醇辛基苯酚、Triton X-100、甘油烷基酯、月桂酸甘油酯、椰油酰胺MEA、椰油酰胺DEA、十二烷基二甲胺氧化物和泊洛沙姆。泊洛沙姆的实例包括泊洛沙姆188、237、338和407。这些泊洛沙姆可以商品名<base:Image he="65" wi="284" file="GDA0003327089700002601.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />(可从BASF,Mount Olive,NJ获得)并且分别对应于<base:Image he="62" wi="284" file="GDA0003327089700002602.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />F-68、F-87、F-108和F-127。泊洛沙姆188(对应于<base:Image he="61" wi="284" file="GDA0003327089700002603.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />F-68)是平均分子量为约7,000至约10,000Da，或约8,000至约9,000Da，或约8,400Da的嵌段共聚物。泊洛沙姆237(对应于<base:Image he="68" wi="279" file="GDA0003327089700002604.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />F-87)是平均分子量为约6,000至约9,000Da，或约6,500至约8,000Da，或约7,700Da的嵌段共聚物。泊洛沙姆338(对应于<base:Image he="69" wi="287" file="GDA0003327089700002605.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />F-108)是平均分子量为约12,000至约18,000Da，或约13,000至约15,000Da，或约14,600Da的嵌段共聚物。泊洛沙姆407(对应于<base:Image he="70" wi="284" file="GDA0003327089700002606.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />F-127)是一种聚氧乙烯-聚氧丙烯三嵌段共聚物，其比例在约E101 P56 E101与约E106 P70 E106之间，或约E101 P56E101或约E106 P70 E106之间，具有平均分子量约10,000至约15,000Da，或约12,000至约14,000Da，或约12,000至约13,000Da，或约12,600Da。</base:Paragraphs>
      <base:Paragraphs id="p1211" num="n1183">在其他实施方案中，由式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或药学其可接受的盐制备的固体剂型还包括以下表面活性剂中的一种或多种：聚乙酸乙烯酯、胆酸钠盐、磺基琥珀酸二辛酯钠、十六烷基三甲基溴化铵、皂苷、糖酯、Triton X系列、脱水山梨糖醇三油酸酯、脱水山梨糖醇单油酸酯、聚氧乙烯(20)脱水山梨糖醇单月桂酸酯、聚氧乙烯(20)脱水山梨糖醇单油酸酯、油基聚氧乙烯(2)醚、硬脂基聚氧乙烯(2)醚、月桂基聚氧乙烯(4)醚、氧乙烯和氧丙烯的嵌段共聚物、二甘醇二油酸酯、油酸四氢糠酯、油酸乙酯、异丙酯肉豆蔻酸酯、单油酸甘油酯、单硬脂酸甘油酯、单蓖麻油酸甘油酯、鲸蜡醇、硬脂醇、氯化十六烷基吡啶、苯扎氯铵、橄榄油、单月桂酸甘油酯、玉米油、棉籽油和葵花籽油。</base:Paragraphs>
      <base:Paragraphs id="p1212" num="n1184">在替代实施方案中，由式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐制备的固体剂型通过包括溶剂或干法造粒，任选随后压缩或压实、喷雾干燥、纳米悬浮处理、热熔挤出、挤出/滚圆、模塑、滚圆、分层(例如喷雾分层悬浮液或溶液)等的方法制备。这种技术的例子包括使用合适的冲头和模具直接压缩，例如其中冲头和模具安装到合适的压片机上；使用合适的造粒设备如高剪切造粒机湿法造粒，形成湿颗粒，然后干燥成颗粒；造粒，然后使用合适的冲头和模具压制，其中冲头和模具安装在合适的压片机上；将湿物质挤压成圆柱形挤压物，在重力和磨损下切成所需长度或断裂成长度；挤出/滚圆，其中挤出物被倒圆成球形颗粒并通过滚圆致密；使用常规锅或Wurster柱等技术将悬浮液或溶液喷涂到惰性核心上；使用安装在压缩单元上的合适模具进行注射或压缩成型；和类似方法。</base:Paragraphs>
      <base:Paragraphs id="p1213" num="n1185">示例性崩解剂包括海藻酸、羧甲基纤维素钙、羧甲基纤维素钠、交联羧甲基纤维素钠(交联羧甲基纤维素钠)、粉状纤维素、壳聚糖、交联羧甲基纤维素钠、交聚维酮、瓜尔胶、低取代羟丙基纤维素、甲基纤维素钠、微晶纤维素、海藻酸钠、乙醇酸淀粉钠、部分预胶化淀粉、预胶化淀粉、淀粉、羧甲基淀粉钠等，或它们的组合。</base:Paragraphs>
      <base:Paragraphs id="p1214" num="n1186">示例性润滑剂包括硬脂酸钙、硬脂酸镁、山嵛酸甘油酯、棕榈硬脂酸甘油酯、氢化蓖麻油、轻质矿物油、十二烷基硫酸钠、十二烷基硫酸镁、硬脂富马酸钠、硬脂酸、硬脂酸锌、二氧化硅、胶体二氧化硅、二甲基二氯硅烷处理与二氧化硅、滑石或其组合。</base:Paragraphs>
      <base:Paragraphs id="p1215" num="n1187">可对本文所述的剂型核心进行包衣以产生包衣片剂。核心的剂量可以用功能性或非功能性包衣，或功能性和非功能性包衣的组合包衣。“功能性包衣”包括改变整个组合物的释放特性的片剂包衣，例如持续释放或延迟释放包衣。“非功能性包衣”包括不是功能性包衣的包衣，例如装饰性包衣。由于包衣的初始溶解、水合作用、穿孔等，非功能包衣可能对活性剂的释放有一些影响，但不会被认为是与非包衣组合物的显著偏差。非功能性包衣还可掩盖包含活性药物成分的未包衣组合物的味道。包衣可包括光阻挡材料、光吸收材料或光阻挡材料和光吸收材料。</base:Paragraphs>
      <base:Paragraphs id="p1216" num="n1188">示例性的聚甲基丙烯酸酯包括丙烯酸酯和甲基丙烯酸酯的共聚物，例如，a.氨基甲基丙烯酸酯共聚物USP/NF，例如聚(甲基丙烯酸丁酯、(2-二甲基氨基乙基)甲基丙烯酸甲酯、甲基丙烯酸甲酯)1:2:1(例如EUDRAGIT E 100、EUDRAGIT EPO和EUDRAGIT E 12.5；CAS登记号24938-16-7)；b.聚(甲基丙烯酸，丙烯酸乙酯)1:1(例如，EUDRAGIT L30 D-55、EUDRAGIT L100-55、EASTACRYL 30D、KOLLICOAT MAE 30D和30DP；CAS号25212-88-8)；c.聚(甲基丙烯酸，甲基丙烯酸甲酯)1:1(例如，EUDRAGIT L 100、EUDRAGIT L 12.5和12.5P；也称为甲基丙烯酸共聚物，A型NF；CAS编号25806-15-1)；d.聚(甲基丙烯酸，甲基丙烯酸甲酯)1:2(例如，EUDRAGIT S 100、EUDRAGIT S 12.5和12.5P；CAS编号25086-15-1)；e.聚(丙烯酸甲酯、甲基丙烯酸甲酯、甲基丙烯酸)7:3:1(例如，Eudragit FS 30D；CAS No.26936-24-3)；f.聚(丙烯酸乙酯、甲基丙烯酸甲酯、甲基丙烯酸三甲铵基乙酯氯化物)1:2:0.2或1:2:0.1(例如EUDRAGITS RL 100、RL PO、RL 30D、RL 12.5、RS 100、RS PO、RS 30D，或RS 12.5；CAS号33434-24-1)；g.聚(丙烯酸乙酯、甲基丙烯酸甲酯)2:1(例如，EUDRAGIT NE 30D、Eudragit NE 40D、Eudragit NM 30D；CAS No.9010-88-2)；等等，或者其组合。</base:Paragraphs>
      <base:Paragraphs id="p1217" num="n1189">合适的烷基纤维素包括例如甲基纤维素、乙基纤维素等，或其组合。示例性的水基乙基纤维素包衣包括AQUACOAT，一种30％的分散体，进一步包含十二烷基硫酸钠和鲸蜡醇，可从FMC,Philadelphia,PA获得；SURELEASE 25％分散体进一步含有稳定剂或其他包衣成分(例如油酸铵、癸二酸二丁酯、胶体无水二氧化硅、中链甘油三酯等)，购自Colorcon,WestPoint,PA；乙基纤维素可以从Aqualon或Dow Chemical Co(Ethocel),Midland,MI获得。本领域技术人员将理解，其他纤维素聚合物，包括其他烷基纤维素聚合物，可以替代部分或全部乙基纤维素。</base:Paragraphs>
      <base:Paragraphs id="p1218" num="n1190">可用于制备功能性包衣的其他合适材料包括醋酸羟丙基甲基纤维素琥珀酸酯(HPMCAS)；邻苯二甲酸醋酸纤维素(CAP)；聚醋酸乙烯邻苯二甲酸酯；中性或合成蜡、脂肪醇(例如月桂醇、肉豆蔻醇、硬脂醇、鲸蜡醇醇或特别是十六十八醇)、脂肪酸，包括脂肪酸酯、脂肪酸甘油酯(甘油单酯、甘油二酯和甘油三酯)、氢化脂肪，烃类、普通蜡、硬脂酸、硬脂醇、具有烃主链的疏水性和亲水性材料，或它们的组合。合适的蜡包括蜂蜡、糖蜡、蓖麻蜡、巴西棕榈蜡、微晶蜡、小烛树蜡和蜡样物质，例如在室温下通常为固体且熔点为约30℃至约100℃的材料，或其组合。</base:Paragraphs>
      <base:Paragraphs id="p1219" num="n1191">在其他实施方案中，功能性包衣可包括可消化的，长链(例如，C<base:Sub>8</base:Sub>-C<base:Sub>50</base:Sub>，特别是C<base:Sub>12</base:Sub>-C<base:Sub>40</base:Sub>)，取代或未取代的烃类，例如脂肪酸、脂肪醇、脂肪酸的甘油酯、矿物油和植物油、蜡，或它们的组合。可以使用熔点在约25℃和约90℃之间的烃类。具体而言，可以使用长链烃材料、脂肪(脂肪族)醇。</base:Paragraphs>
      <base:Paragraphs id="p1220" num="n1192">包衣可任选地包含额外的药学上可接受的赋形剂，例如增塑剂、稳定剂、水溶性组分(例如，致孔剂)、抗粘剂(例如，滑石)、表面活性剂，等等，或其的组合。</base:Paragraphs>
      <base:Paragraphs id="p1221" num="n1193">功能性包衣可包括释放改性剂，其影响功能性包衣的释放特性。例如，释放调节剂可用作成孔剂或基质破坏剂。释放改性剂可以是有机的或无机的，并且包括可以在使用环境中从包衣中溶解、提取或浸出的材料。缓释剂可以包括一种或多种亲水性聚合物，包括纤维素醚和其他纤维素，例如羟丙基甲基纤维素、羟丙基纤维素、羟乙基纤维素、甲基纤维素、醋酸邻苯二甲酸纤维素或醋酸邻苯二甲酸羟丙基甲基纤维素；聚维酮；聚乙烯醇；丙烯酸聚合物，例如胃溶性Eudragit FS 30D、pH敏感的Eudragit L30D 55、L 100、S 100或L 100-55；或其组合。其他示例性的释放改性剂包括聚维酮；糖类(例如乳糖等)；金属硬脂酸盐；无机盐(例如磷酸氢钙、氯化钠等)；聚乙二醇(例如，聚乙二醇(PEG)1450等)；糖醇(例如山梨糖醇、甘露糖醇等)；碱金属烷基硫酸盐(例如，月桂基硫酸钠)；聚氧乙烯脱水山梨糖醇脂肪酸酯(例如聚山梨醇酯)；或其组合。示例性基质破坏剂包括水不溶性有机或无机材料。有机聚合物包括但不限于纤维素、纤维素醚如乙基纤维素、纤维素酯如乙酸纤维素、乙酸丁酸纤维素和乙酸丙酸纤维素；淀粉可以作为基质破坏剂。无机破坏剂的实例包括多种钙盐，例如磷酸一钙、二钙和三钙；二氧化硅和滑石粉。</base:Paragraphs>
      <base:Paragraphs id="p1222" num="n1194">包衣可任选地包含增塑剂以改进涂层的物理性能。例如，因为乙基纤维素具有相对高的玻璃化转变温度并且在正常包衣条件下不形成柔性膜，所以在将其用作包衣材料之前向乙基纤维素添加增塑剂可能是有利的。通常，包衣溶液中包含的增塑剂的量基于聚合物的浓度，例如，取决于聚合物，可以为约1％至约200％，但最通常为约1wt％至约100wt％的聚合物。然而，增塑剂的浓度可以通过常规实验确定。</base:Paragraphs>
      <base:Paragraphs id="p1223" num="n1195">用于乙基纤维素和其他纤维素的增塑剂的例子包括例如癸二酸二丁酯、邻苯二甲酸二乙酯、柠檬酸三乙酯、柠檬酸三丁酯、三醋精或它们的组合的增塑剂，尽管其他水不溶性增塑剂(例如乙酰化甘油单酯、邻苯二甲酸酯、蓖麻油等)都可以使用。</base:Paragraphs>
      <base:Paragraphs id="p1224" num="n1196">用于丙烯酸聚合物的增塑剂的实例包括柠檬酸酯，例如柠檬酸三乙酯NF、柠檬酸三丁酯、邻苯二甲酸二丁酯、1,2-丙二醇、聚乙二醇、丙二醇、邻苯二甲酸二乙酯、蓖麻油、三醋精或它们的组合，尽管它也可以使用其他增塑剂(例如乙酰化甘油单酯、邻苯二甲酸酯、蓖麻油等)。</base:Paragraphs>
      <base:Paragraphs id="p1225" num="n1197">可以使用合适的方法将包衣材料施加到剂型核心的表面。可以使用诸如简单或复杂凝聚、界面聚合、液体干燥、热和离子凝胶化、喷雾干燥、喷雾冷却、流化床包衣、锅包衣或静电沉积的方法。</base:Paragraphs>
      <base:Paragraphs id="p1226" num="n1198">在某些实施方案中，在剂型核心和外部包衣之间使用任选的中间包衣。这种中间包衣可用于保护活性剂或核心亚单元的其他组分免受外部包衣中使用的材料的影响或提供其他性能。示例性中间涂层通常包括水溶性成膜聚合物。此类中间包衣可包括成膜聚合物，例如羟乙基纤维素、羟丙基纤维素、明胶、羟丙基甲基纤维素、聚乙二醇、聚环氧乙烷等，或其组合；和增塑剂。增塑剂可用于降低脆性并增加拉伸强度和弹性。示例性增塑剂包括聚乙二醇丙二醇和甘油。</base:Paragraphs>
      <base:Paragraphs id="p1227" num="n1199">联合和交替疗法</base:Paragraphs>
      <base:Paragraphs id="p1228" num="n1200">本文所述的化合物或其药学上可接受的盐可以在当前COVID患者护理标准的基础上给药，或者与医疗保健提供者认为对患者有益的任何其他化合物或疗法组合或交替给药。组合和/或交替疗法可以是治疗性的、辅助性的或姑息性的。</base:Paragraphs>
      <base:Paragraphs id="p1229" num="n1201">据观察，COVID患者可能会经历不同的疾病阶段，护理标准可能因患者出现或进展到的疾病阶段而异。COVID值得注意的是免疫系统和凝血系统之间“串扰”的发展。随着疾病的进展，患者的免疫系统可能会产生过度反应，这可能会导致许多严重的后果，包括细胞因子风暴。通过免疫系统和凝血系统之间的交互作用，患者可以在身体的各个部位开始凝血，包括呼吸系统、大脑、心脏和其他器官。在COVID患者中观察到全身多个凝块，需要抗凝治疗。人们认为，如果不治疗和缓解疾病，这些凝块可能会造成长期甚至永久性的损害。</base:Paragraphs>
      <base:Paragraphs id="p1230" num="n1202">更具体地说，COVID-19被描述为经历三个一般性疾病阶段：第1阶段(早期感染)、第2阶段(肺阶段)和第3阶段(过度炎症阶段/细胞因子风暴)。</base:Paragraphs>
      <base:Paragraphs id="p1231" num="n1203">第1阶段的特征是非特异性的，通常是轻微的症状。病毒复制正在发生，适合立即开始使用本文所述的化合物进行治疗，并且可能与另一种抗病毒疗法组合或交替使用。也可以施用干扰素-β以增强对病毒的先天免疫反应。因此，在一个实施方案中，以有效量使用式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐与干扰素-β和/或另外的抗病毒药物组合或交替。在这个阶段或随着疾病的进展，有时也会服用锌补充剂和/或维生素C。</base:Paragraphs>
      <base:Paragraphs id="p1232" num="n1204">COVID-19的第2阶段是肺阶段，患者可能会出现急性低氧性呼吸衰竭。事实上，COVID-19的主要器官衰竭是低氧性呼吸衰竭。已经表明，通过类固醇(例如地塞米松)进行适度的免疫抑制对急性低氧性呼吸衰竭和/或机械通气患者有益。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以有效量用于与可以是糖皮质激素的皮质类固醇组合。非限制性实例是布地奈德(Entocort EC)、倍他米松(Celestone)、泼尼松(Prednisone Intensol)、泼尼松龙(Orapred，Prelone)、曲安西龙(Aristospan Intra-Articular，AristospanIntralesional，Kenalog)、甲基强的松龙(Medrol,Depo-Medrol,Solu-Medrol)、氢化可的松或地塞米松(地塞米松Intensol，DexPak 10天，DexPak 13天，DexPak 6天)。</base:Paragraphs>
      <base:Paragraphs id="p1233" num="n1205">NS5B抑制剂瑞德西韦(Remdesivir)用于COVID-19患者提供了混合结果。它只能在医院环境中给药，并且只能通过静脉注射给药，通常一天3次，这使得它不适用于轻度至中度COVID-19患者。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以以下形式给药：与瑞德西韦组合或交替使用，以增强整体抗病毒作用。</base:Paragraphs>
      <base:Paragraphs id="p1234" num="n1206">第3阶段是疾病的最后阶段，其特征是进行性弥散性血管内凝血(DIC)，这是一种在整个血流中形成小血块的病症。这个阶段还可能包括多器官衰竭(例如血管舒张性休克、心肌炎)。还观察到，许多患者对这种严重的COVID-19感染阶段产生“细胞因子风暴”的反应。DIC和细胞因子风暴之间似乎确实存在双向的协同关系。为了对抗DIC，患者经常服用抗凝剂，例如可以是间接凝血酶抑制剂或直接口服抗凝剂(“DOAC”)。非限制性实例是低分子量肝素、华法林、比伐卢定(Angiomax)、利伐沙班(Xarelto)、达比加群(Pradaxa)、阿哌沙班(Eliquis)或依度沙班(Lixiana)。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以以下形式给药：联合或交替使用抗凝治疗。在COVID患者的一些严重凝血病例中，可以使用TPA(组织纤溶酶原激活剂)。</base:Paragraphs>
      <base:Paragraphs id="p1235" num="n1207">据观察，高水平的细胞因子白细胞介素6(IL-6)是COVID-19患者呼吸衰竭和死亡的前兆。为了治疗这种可能构成细胞因子风暴的免疫反应激增，可以向患者施用靶向IL-6的单克隆抗体、药物抑制剂或蛋白质降解剂，例如与IL-6和介导降解的蛋白质结合的双特异性化合物。抗体的例子包括托珠单抗、sarilumab、司妥昔单抗、olokizumab和clazakizumab。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以以下形式给药：与托珠单抗或sarilumab组合或交替使用。用于治疗过度反应免疫系统的免疫抑制剂药物的其他非限制性例子包括Janus激酶抑制剂(托法替尼(Xeljanz))；钙调磷酸酶抑制剂(环孢素(Neoral、Sandimmune、SangCya))、他克莫司(Astagraf XL、Envarsus XR、Prograf))；mTOR抑制剂(西罗莫司(Rapamune)、依维莫司(Afinitor、Zortress))；和IMDH抑制剂(咪唑硫嘌呤(Azasan，Imuran)，来氟米特(Arava)，麦考酚酯(CellCept，Myfortic))。其他抗体和生物制剂包括阿巴西普(Orencia)、阿达木单抗(Humira)、阿那白滞素(Kineret)、赛妥珠单抗(Cimzia)、依那西普(Enbrel)、戈利木单抗(Simponi)、英夫利昔单抗(Remicade)、ixekizumab(Taltz)、那他珠单抗(Tysabri)、利妥昔单抗(Rituxan)、苏金单抗(Cosentyx)、托珠单抗(Actemra)、优特克单抗(Stelara)、维多珠单抗(Entyvio)、巴利昔单抗(Simulect)和达克珠单抗(Zinbryta)。</base:Paragraphs>
      <base:Paragraphs id="p1236" num="n1208">IL-1阻断IL-6和其他促炎性细胞因子的产生。COVID患者有时也接受抗IL-1治疗以减少过度炎症反应，例如静脉注射阿那白滞素。抗IL-1疗法通常可以是例如靶向单克隆抗体、药物抑制剂或蛋白质降解剂，例如结合IL-1以及介导降解的蛋白质的双特异性化合物。</base:Paragraphs>
      <base:Paragraphs id="p1237" num="n1209">COVID患者常会发展为病毒性肺炎，可导致细菌性肺炎。患有严重COVID-19的患者也可能受到败血症或“败血性休克”的影响。继发于COVID或败血症的细菌性肺炎的治疗包括使用抗生素，例如大环内酯类抗生素，包括阿奇霉素、克拉霉素、红霉素或罗红霉素。其他抗生素包括阿莫西林、强力霉素、头孢氨苄、环丙沙星、克林霉素、甲硝唑、磺胺甲恶唑、甲氧苄啶、阿莫西林、克拉维酸盐或左氧氟沙星。在一个实施方案中，因此施用式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐与抗生素组合或交替使用，例如阿奇霉素。其中一些抗生素如阿奇霉素具有独立的抗炎特性。此类药物既可用作COVID患者的抗炎药，又可对继发性细菌感染产生治疗作用。</base:Paragraphs>
      <base:Paragraphs id="p1238" num="n1210">治疗感染COVID-19的患者面临的一个独特挑战是，如果患者需要持续长达或超过5、10或甚至14天的机械通气，则需要相对长期的镇静。对于治疗过程中持续疼痛，可以依次加入镇痛药，对于持续焦虑，可以依次加入镇静剂。镇痛剂的非限制性实例包括对乙酰氨基酚、氯胺酮和PRN阿片类药物(氢吗啡酮、芬太尼和吗啡)。镇静剂的非限制性实例包括褪黑激素、具有镇静优势性质的非典型抗精神病药(奥氮平、喹硫平)、丙泊酚或右美托咪定、氟哌啶醇和苯巴比妥。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以以下形式给药：与镇痛药组合或交替使用，如对乙酰氨基酚、氯胺酮、氢吗啡酮、芬太尼或吗啡。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以以下形式给药：与镇静剂组合或交替使用，如褪黑激素、奥氮平、喹硫平、丙泊酚、右美托咪定、氟哌啶醇或苯巴比妥。</base:Paragraphs>
      <base:Paragraphs id="p1239" num="n1211">COVID-19的研究药物包括氯喹和羟氯喹。在一个实施方案中，式I、式II、式III、式IV、式V、式VI、式VII、式VIII、式IX、式X或式XIII的化合物或其药学上可接受的盐以以下形式给药：与氯喹或羟氯喹组合或交替使用。</base:Paragraphs>
      <base:Paragraphs id="p1240" num="n1212">也可以使用蛋白酶抑制剂，如洛匹那韦或利托那韦，之前已批准用于HIV治疗。</base:Paragraphs>
      <base:Paragraphs id="p1241" num="n1213">可用于治疗COVID患者的其他药物包括但不限于法匹拉韦、芬戈莫德(Gilenya)、甲基强的松龙、贝伐单抗(Avastin)、Actemra(托珠单抗)、乌米诺韦、氯沙坦和REGN3048的单克隆抗体组合和REGN3051或利巴韦林。这些药物或疫苗中的任何一种都可以与本文提供的活性化合物组合或交替使用以治疗对其敏感的病毒感染。</base:Paragraphs>
      <base:Paragraphs id="p1242" num="n1214">在一个实施方案中，本发明的化合物以有效量与抗冠状病毒疫苗疗法组合使用，包括但不限于mRNA-1273(Moderna,Inc.)、AZD-1222(AstraZeneca and University ofOxford)、BNT162(辉瑞和BioNTech)、CoronaVac(Sinovac)、NVX-CoV 2372(NovoVax)、SCB-2019(赛诺菲和GSK)、ZyCoV-D(Zydus Cadila)和CoVaxin(Bharat Biotech)。在另一个实施方案中，本发明的化合物以有效量与被动抗体疗法或恢复期血浆疗法组合使用。</base:Paragraphs>
      <base:Paragraphs id="p1243" num="n1215">SARS-CoV-2不断突变，许多突变会增加毒力和传播率。长期使用抗病毒药物治疗后，可能会出现耐药病毒变种。耐药性可能通过编码病毒复制中使用的酶的基因发生突变而发生。在某些情况下，通过将化合物与另一种，甚至可能是两种或三种其他抗病毒化合物组合或交替给药，可以延长、增强或恢复药物对RNA病毒感染的疗效，这些抗病毒化合物可诱导不同的突变或通过一种不同的途径，与主要药物的途径不同。</base:Paragraphs>
      <base:Paragraphs id="p1244" num="n1216">或者，药物的药代动力学、生物分布、半衰期或其他参数可以通过这种联合治疗(如果考虑协同，可以包括交替治疗)来改变。由于所公开的嘌呤核苷酸是聚合酶抑制剂，因此将化合物与例如以下物质组合施用宿主可能是有用的：</base:Paragraphs>
      <base:Paragraphs id="p1245" num="n1217">(1)蛋白酶抑制剂；</base:Paragraphs>
      <base:Paragraphs id="p1246" num="n1218">(2)另一种聚合酶抑制剂；</base:Paragraphs>
      <base:Paragraphs id="p1247" num="n1219">(3)变构聚合酶抑制剂；</base:Paragraphs>
      <base:Paragraphs id="p1248" num="n1220">(4)干扰素alfa-2a，可能被聚乙二醇化或以其他方式修饰，和/或利巴韦林；</base:Paragraphs>
      <base:Paragraphs id="p1249" num="n1221">(5)非基于底物的抑制剂；</base:Paragraphs>
      <base:Paragraphs id="p1250" num="n1222">(6)解旋酶抑制剂；</base:Paragraphs>
      <base:Paragraphs id="p1251" num="n1223">(7)反义寡脱氧核苷酸(S-ODN)；</base:Paragraphs>
      <base:Paragraphs id="p1252" num="n1224">(8)适体；</base:Paragraphs>
      <base:Paragraphs id="p1253" num="n1225">(9)核酸酶抗性核酶；</base:Paragraphs>
      <base:Paragraphs id="p1254" num="n1226">(10)iRNA，包括microRNA和SiRNA；</base:Paragraphs>
      <base:Paragraphs id="p1255" num="n1227">(11)该病毒的抗体、部分抗体或域抗体；或者</base:Paragraphs>
      <base:Paragraphs id="p1256" num="n1228">(12)诱导宿主抗体反应的病毒抗原或部分抗原。</base:Paragraphs>
      <base:Paragraphs id="p1257">实施例</base:Paragraphs>
      <base:Paragraphs id="p1258" num="n1229">通用方法</base:Paragraphs>
      <base:Paragraphs id="p1259" num="n1230">
        <base:Sup>1</base:Sup>H、<base:Sup>19</base:Sup>F和<base:Sup>31</base:Sup>P NMR谱在400MHz傅里叶变换Brücker谱仪上记录。除非另有说明，否则谱均为DMSO-d<base:Sub>6</base:Sub>。自旋多重度由符号s(单峰)、d(双重峰)、t(三重峰)、m(多重峰)和Br(宽峰)表示。耦合常数(J)以Hz为单位报告。反应通常在干燥的氮气气氛下，使用Sigma-Aldrich无水溶剂进行。所有常见的化学品均从商业来源购买。</base:Paragraphs>
      <base:Paragraphs id="p1260" num="n1231">实施例中使用以下缩写：</base:Paragraphs>
      <base:Paragraphs id="p1261" num="n1232">BID:一天两次</base:Paragraphs>
      <base:Paragraphs id="p1262" num="n1233">DCM:二氯甲烷</base:Paragraphs>
      <base:Paragraphs id="p1263" num="n1234">EtOAc:乙酸乙酯</base:Paragraphs>
      <base:Paragraphs id="p1264" num="n1235">EtOH:乙醇</base:Paragraphs>
      <base:Paragraphs id="p1265" num="n1236">GT:基因型</base:Paragraphs>
      <base:Paragraphs id="p1266" num="n1237">HPLC:高效液相色谱</base:Paragraphs>
      <base:Paragraphs id="p1267" num="n1238">LD:负荷剂量</base:Paragraphs>
      <base:Paragraphs id="p1268" num="n1239">NaOH:氢氧化钠</base:Paragraphs>
      <base:Paragraphs id="p1269" num="n1240">Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>:硫酸钠(无水)</base:Paragraphs>
      <base:Paragraphs id="p1270" num="n1241">MeOH:甲醇</base:Paragraphs>
      <base:Paragraphs id="p1271" num="n1242">Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>:硫酸钠</base:Paragraphs>
      <base:Paragraphs id="p1272" num="n1243">NH<base:Sub>4</base:Sub>Cl:氯化铵</base:Paragraphs>
      <base:Paragraphs id="p1273" num="n1244">PE:石油醚</base:Paragraphs>
      <base:Paragraphs id="p1274" num="n1245">硅胶(230至400目，Sorbent)</base:Paragraphs>
      <base:Paragraphs id="p1275" num="n1246">t-BuMgCl:叔丁基氯化镁</base:Paragraphs>
      <base:Paragraphs id="p1276" num="n1247">THF:四氢呋喃(THF)，无水</base:Paragraphs>
      <base:Paragraphs id="p1277" num="n1248">TP:三磷酸酯</base:Paragraphs>
      <base:Paragraphs id="p1278" num="n1249">实施例1.化合物1A和化合物2A的合成</base:Paragraphs>
      <base:Paragraphs id="p1279" num="n1250">A部分：(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-2-(羟甲基)-4-甲基四氢呋喃-3-醇(1-7)的合成</base:Paragraphs>
      <base:Paragraphs id="p1280" num="n1251">在步骤1中，将化合物1-1溶解在DCM中并将反应冷却至10℃，然后加入氯甲酸苄酯，然后加入NEt<base:Sub>3</base:Sub>。使反应冷却至室温并搅拌12-14小时。之后在适当的后处理和纯化条件下，分离化合物1-2。在步骤2中，在加入Morpho DAST之前，将化合物1-2溶解在乙腈中并冷却至-15至5℃。搅拌反应6小时。之后在适当的后处理和纯化条件下，分离化合物1-3。在步骤3中，将化合物1-3溶解在甲苯中并将反应冷却至0-10℃，之后加入还原铝。然后，在适当的后处理和纯化条件下，化合物1-4被分离成为在羟基位置具有(R)-立体化学的非对映异构体。在步骤4中，将化合物1-4溶解在乙腈中并冷却至-15至5℃，然后加入CBr4和PPh3。然后在适当的后处理和纯化条件下，分离化合物1-5。在步骤5中，将化合物1-5溶解在乙腈中并加入t-BuOH、t-BuOK和6-氯-9H-嘌呤-2-胺。将反应加热至40–50℃。然后在适当的后处理和纯化条件下，分离化合物1-6。在步骤6中，将化合物1-6溶解在MeOH中并加入MeNH<base:Sub>2</base:Sub>。将反应加热至20-30℃。在适当的后处理和纯化条件下，分离出化合物1-7。</base:Paragraphs>
      <base:Paragraphs id="p1281" num="n1252">B部分：(羟基(苯氧基)磷酰基)-L-丙氨酸异丙酯的二氢奎宁盐(1-12)的合成</base:Paragraphs>
      <base:Paragraphs id="p1282" num="n1253">
        <base:Image he="223" wi="1000" file="GDA0003327089700002731.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1283" num="n1254">将二氯磷酸苯酯(1-8，150g，1.0eq.)加入到1300mL乙酸异丙酯中。将溶液冷却至-10℃±5℃，然后加入苯甲醇(1-9，80.6g，1.05eq.)和Et<base:Sub>3</base:Sub>N(86.3g，1.2eq.)的溶液。在-10±5℃下搅拌混合物3小时。通过TLC监测反应终点。</base:Paragraphs>
      <base:Paragraphs id="p1284" num="n1255">在-10℃±5℃下加入L-丙氨酸异丙酯盐酸盐(1-10，125g，1.05eq.)和Et<base:Sub>3</base:Sub>N(152g，2.1eq.)。将反应混合物在-10±5℃搅拌2小时。通过TLC监测反应终点。</base:Paragraphs>
      <base:Paragraphs id="p1285" num="n1256">过滤反应混合物，滤饼用20mL乙酸异丙酯洗涤。滤液用1N HCl、水和碳酸氢钠水溶液洗涤。分离的有机层用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥，然后在40℃-50℃真空浓缩至干，得到240g粗产物1-11，为非对映体混合物(约1:1)。(淡黄色油；产率：89.6％mol/mol；HPLC纯度：83.4％面积；HPLC分析：86.2％w/w)。该产物含有大约6％-7％的残留苯甲醇。粗品1-4直接用于下一步。</base:Paragraphs>
      <base:Paragraphs id="p1286" num="n1257">将化合物1-11(135g，1.0eq.，86.2％分析)和奎宁(100g，1.0eq.)加入650mL异丙醇。加入5％Pd/C(19.2g，60％水，按照KF)后，在密闭系统中使用氢气袋在20℃-25℃下氢化8小时。反应完成后，混合物通过布氏漏斗过滤。真空浓缩滤液以除去溶剂。</base:Paragraphs>
      <base:Paragraphs id="p1287" num="n1258">向上述残留物中加入300mL TBME。在40℃-45℃下真空浓缩混合物以除去溶剂，然后用另外300mL MTBE重复该步骤。向其中加入600mL MTBE，将混合物在40℃-45℃下搅拌1小时，然后在0℃-5℃下再搅拌1小时。过滤混合物，滤饼用100mL MTBE洗涤。滤饼在45℃非真空下干燥16小时，得到152g(羟基(苯氧基)磷酰基)-L-丙氨酸异丙酯的二氢奎宁盐(1-12，白色固体；产率：69.5％mol/mol；HPLC纯度：97.91％)。</base:Paragraphs>
      <base:Paragraphs id="p1288" num="n1259">C部分：化合物1A的合成</base:Paragraphs>
      <base:Paragraphs id="p1289" num="n1260">(羟基(苯氧基)磷酰基)-L-丙氨酸异丙酯的二氢奎宁盐(1-12，5.9g，1.5eq.)、化合物1-7(2.0g，1.0eq)、DIPEA(0.83g，1.0eq)、和HATU(3.65g，1.5eq)加入到100mL二氯甲烷中。将混合物加热至40℃并搅拌18小时。通过TLC和HPLC监测反应。</base:Paragraphs>
      <base:Paragraphs id="p1290" num="n1261">反应完成后，将反应混合物冷却至室温，用1N盐酸(100mLx2)、水(100mLx2)和5％碳酸氢钠水溶液15mLx1洗涤。分离出的有机相用2g无水硫酸钠干燥，过滤并在40℃-45℃真空浓缩得到黄色油。</base:Paragraphs>
      <base:Paragraphs id="p1291" num="n1262">添加乙酸异丙酯(10mL)。搅拌后，真空浓缩混合物。然后，加入25mL乙酸异丙酯。将混合物加热至45℃以提供澄清溶液。室温搅拌2小时后，过滤固体沉淀，45℃非真空条件下干燥15小时，得到2.0g化合物1A粗品(收率：53.8％mol/mol；HPLC纯度：93.1％面积(含有3.7％的Rp-化合物1B)。</base:Paragraphs>
      <base:Paragraphs id="p1292" num="n1263">将粗化合物1A(2.0g)和15mL乙酸异丙酯的混合物加热至80℃-85℃以提供溶液。将溶液冷却至20℃-25℃并搅拌1小时。过滤沉淀的固体，用乙酸异丙酯(1mL)洗涤，在50℃非真空条件下干燥16小时，得到1.7g化合物1A(收率：45.7％mol/mol；HPLC纯度：98.99％)。<base:Sup>1</base:Sup>HNMR、<base:Sup>19</base:Sup>FNMR和<base:Sup>31</base:Sup>PNMR谱证实了化合物1A的结构。</base:Paragraphs>
      <base:Paragraphs id="p1293" num="n1264">D部分：半硫酸盐化合物2A的合成</base:Paragraphs>
      <base:Paragraphs id="p1294" num="n1265">将甲醇(151mL)装入250mL烧瓶并将溶液冷却至0-5℃。在10分钟内滴加H<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>的浓溶液。将化合物1A(151g)和丙酮(910mL)装入单独的烧瓶中，并在25-30℃下经2.5小时逐滴加入H<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>/MeOH溶液。沉淀出大量固体。将溶液在25-30℃搅拌12-15小时后，将混合物过滤，用甲醇/丙酮(25mL/150mL)洗涤，并在55-60℃真空干燥，得到化合物2A(121g，74％)。<base:Sup>1</base:Sup>HNMR:(400MHz,DMSO-d<base:Sub>6</base:Sub>):δ8.41(br,1H),7.97(s,1H),7.36(t,J＝8.0Hz,2H),7.22(d,J＝8.0Hz,2H),7.17(t,J＝8.0Hz,1H),6.73(s,2H),6.07(d,J＝8.0Hz,1H),6.00(dd,J＝12.0,8.0Hz,1H),5.81(br,1H),4.84-4.73(m,1H),4.44-4.28(m,3H),4.10(t,J＝8.0Hz,2H),3.85-3.74(m,1H),2.95(s,3H),1.21(s,J＝4.0Hz,3H),1.15-1.10(m,9H)</base:Paragraphs>
      <base:Paragraphs id="p1295" num="n1266">实施例2.本发明的选择化合物的合成</base:Paragraphs>
      <base:Paragraphs id="p1296" num="n1267">核磁共振谱在400MHz傅里叶变换Brücker谱仪上记录。该谱是从在CDCl<base:Sub>3</base:Sub>、CD<base:Sub>3</base:Sub>OD或DMSO-d<base:Sub>6</base:Sub>中以5mm直径管制备的样品获得的。自旋多重度由下述符号指示：s(单峰)、d(双重峰)、t(三重峰)、m(多重峰)和Br(宽峰)。耦合常数(J)以Hz报告。MS谱是在AgilentTechnologies 6120四极MS装置上使用电喷雾电离(ESI)获得的。反应通常在干燥的氮气气氛下，使用Sigma-Aldrich无水溶剂进行。所有常用化学品都购自市售来源。</base:Paragraphs>
      <base:Paragraphs id="p1297" num="n1268">合成2.((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基)-4-甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物5)</base:Paragraphs>
      <base:Paragraphs id="p1298" num="n1269">步骤1：N-(6-氯-9-((6aR,8R,9R,9aR)-2,2,4,4-四异丙基-9-((三甲基甲硅烷基)氧基)四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环(trioxadisilocin)-8-基)-9H-嘌呤-2-基)乙酰胺：中间体2-1(50.2g，92.25mmol)的DCM(500mL)中的溶液和吡啶(75ml)在0℃下加入TMSCl(30.1g，276.74mmol)并在0℃下搅拌0.5小时。向该溶液中加入乙酸酐(28.2g，276.74mmol)并将反应在0℃下搅拌0.5小时，然后在室温下搅拌1小时。向反应混合物中加入H<base:Sub>2</base:Sub>O和EtOAc。有机相用饱和盐水洗涤，用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，EA/PE＝0至10％)纯化，得到中间体2-2(53g，51％)，为黄色固体。</base:Paragraphs>
      <base:Paragraphs id="p1299" num="n1270">第2步：N-(6-氯-9-((6aR,8R,9R,9aS)-9-羟基-2,2,4,4-四异丙基四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)乙酰胺：在室温下向中间体2-2(53g,82.25mmol)的THF(530mL)中的溶液中加入对甲苯磺酸一水合物(5.9g,36.67mmol)。在室温下搅拌溶液1小时。然后，加入TEA(8.3g，82.25mmol)并将反应混合物浓缩。残余物通过柱层析(硅胶，EA/PE＝10％至20％)纯化，得到中间体2-3(47g，99.5％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1300" num="n1271">第3步：N-(6-氯-9-((6aR,8R,9aR)-2,2,4,4-四异丙基-9-氧代四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)乙酰胺：将三氧化铬(18.9g，189.36mmol)分散在DCM(280mL)中，并滴加吡啶(15.0g，189.36mmol)和乙酸酐(19.3g，189.36mmol)。反应混合物变黑。在室温下加入在DCM(380ml)中的中间体2-3(37g，63.12mmol)并反应搅拌0.5小时。添加EtOAc(1200mL)。过滤反应混合物并浓缩，与甲苯(200mL)共沸。残余物通过柱层析法(硅胶，EA/PE＝33％至100％)纯化，得到中间体2-4(34.8g，94％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1301" num="n1272">第4步：N-(6-氯-9-((6aR,8R,9S,9aR)-9-羟基-2,2,4,4-四异丙基-9-甲基四氢-6H-呋喃并[3,2-f)][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)乙酰胺：将镁粉(6.7g，278.66mmol)分散在无水乙醚(380mL)中，加入氘代甲基碘(9.2g，63.33mmol)，反应在室温下搅拌0.5小时，然后升至室温。滴加氘代甲基碘(27.5g,190.00mmol)，并搅拌反应1h，然后将温度降至10℃以下并加入中间体2-4(37g,63.33mmol)的DCM(380ml)溶液。搅拌反应1小时，然后用饱和NaHCO<base:Sub>3</base:Sub>淬灭并用EtOAc萃取。有机相用饱和盐水洗涤，用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。通过柱层析法(硅胶，EA/PE＝33％至50％)纯化残余物以提供呈固态形式的中间体2-5(22g，57.9％)。</base:Paragraphs>
      <base:Paragraphs id="p1302" num="n1273">步骤5：N-(6-氯-9-((2R,3S,4R,5R)-3,4-二羟基-5-(羟甲基)-3-甲基四氢呋喃-2-基)-9H-嘌呤-2-基)乙酰胺：向中间体2-5(22g，36.65mmol)的THF(150mL)溶液中加入四丁基氟化铵(23.12g，73.30mmol)的THF(70ml)溶液。将溶液在室温搅拌1小时并浓缩。通过柱层析法(硅胶，MeOH/DCM＝2％至5％)纯化残余物以提供呈固态中间体2-6(20g，&gt;100％)。</base:Paragraphs>
      <base:Paragraphs id="p1303" num="n1274">步骤6:(2R,3R,4S,5R)-5-(2-乙酰氨基-6-氯-9H-嘌呤-9-基)-2-(乙酰氧甲基)-4-羟基-4-甲基四氢呋喃-3-基乙酸酯：向中间体2-6(20g，55.90mmol)在无水DCM(400mL)和吡啶(8ml)中的溶液中加入乙酸酐(22.8g，223.62mmol)。将溶液在0℃搅拌过夜。然后，加入EtOAc并过滤悬浮液。溶液用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析纯化，得到呈固体状的中间体2-7(8.4g，3个步骤29.8％的产率)。</base:Paragraphs>
      <base:Paragraphs id="p1304" num="n1275">步骤7:(2R,3R,4R,5R)-5-(2-乙酰氨基-6-氯-9H-嘌呤-9-基)-2-(乙酰氧甲基)-4-氟-4-甲基四氢呋喃-3-基乙酸酯：在-65℃下向中间体2-7(5.4g，12.22mmol)的DCM(220mL)溶液中滴加DAST(5.9g，36.67mmol)并搅拌反应0.5小时。使反应升温至室温并搅拌1小时。反应用饱和碳酸氢钠淬灭并分离。有机相用饱和盐水洗涤，用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。通过柱层析色谱法(硅胶，EA/PE＝50％至100％)纯化残余物以提供呈固态中间体2-8(1.54g，30％)。</base:Paragraphs>
      <base:Paragraphs id="p1305" num="n1276">步骤8:(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-2-(羟甲基)-4-甲基四氢呋喃-3-醇：将中间体2-8(890mg，2.01mmol)的甲胺(18％在EtOH中)(36mL)溶液在密封容器中，室温下搅拌过夜并浓缩。之后加入另外的甲醇钠(325.0mg，6.02mmol)，在室温下将溶液再搅拌1小时。加入乙酸将pH调节至7并将溶液浓缩。通过柱层析法(硅胶，MeOH/DCM＝0至2％)纯化残余物以提供固体中间体2-9(400mg，64.5％)。<base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ8.057(s,1H),6.103(d,J＝18.4Hz,1H),4.047-4.015(m,2H),3.878-3.845(m,1H),3.030(s,3H).<base:Sup>19</base:Sup>F NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ164.351(s).MS(ESI)m/z C<base:Sub>12</base:Sub>H<base:Sub>14</base:Sub>D<base:Sub>3</base:Sub>FN<base:Sub>6</base:Sub>O<base:Sub>3</base:Sub>[M+H]<base:Sup>+</base:Sup>的理论值316.13；实测值316.4。</base:Paragraphs>
      <base:Paragraphs id="p1306" num="n1277">步骤9:((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基)-4-甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯：向中间体2-9(230mg，0.736mmol)和((R)-(全氟苯氧基)(苯氧基)磷酰基))-L-丙氨酸异丙酯(334mg,0.736mmol)在THF(4ml)中的溶液在-5℃下逐滴加入t-BuMgCl(1.7N在THF中)(912μL,1.55mmol)。溶液在0℃搅拌0.5小时。然后用饱和NH<base:Sub>4</base:Sub>Cl水溶液猝灭反应混合物。通过柱层析法(硅胶，MeOH/DCM＝0至3.3％)纯化残余物以提供固体形式的化合物5(130mg，30.5％)。<base:Sup>1</base:Sup>HNMR(400MHz,DMSO)δ7.81(s,1H),7.32-7.16(m,5H)，6.13-6.08(d,J＝18.8,8.0Hz,1H),4.87(s,1H)，4.50(m,3H)，4.19(m,1H),3.89(m,1H),3.02(s,1H),1.30-1.27(m,3H),1.17-1.13(m,9H).<base:Sup>19</base:Sup>F NMR(400MHz,DMSO)δ-163.42(s).MS(ESI)m/z C<base:Sub>24</base:Sub>H<base:Sub>30</base:Sub>D<base:Sub>3</base:Sub>FN<base:Sub>7</base:Sub>O<base:Sub>7</base:Sub>P[M+H]<base:Sup>+</base:Sup>的理论值585.22；实测值585.5。</base:Paragraphs>
      <base:Paragraphs id="p1307" num="n1278">合成3.((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-4-(氟甲基)-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物6)</base:Paragraphs>
      <base:Paragraphs id="p1308" num="n1279">步骤1:(6aR,8R,9R,9aS)-8-(2-氨基-6-氯-9H-嘌呤-9-基)-2,2,4,4-四异丙基四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-9-醇：在0±5℃向中间体3-1(81.8g，0.27mol)的吡啶(330mL)溶液中逐滴加入TPDSCl<base:Sub>2</base:Sub>(102.6g，0.32mol)。将溶液在0℃搅拌2小时并用水淬灭。然后，加入EtOAc，分离各相并用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥。将溶液浓缩并与甲苯共沸3次以除去吡啶。残余物经柱层析(DCM/MeOH＝200:1-100:1)纯化，得到油状中间体3-2(123.3g，83.6％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1309" num="n1280">步骤2：N-(6-氯-9-((6aR,8R,9R,9aR)-2,2,4,4-四异丙基-9-((三甲基甲硅烷基)氧基)四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)异丁酰胺：在0～5℃下向中间体3-2(122.6g 0.225mol)的DCM(1300mL)和吡啶(184mL)的溶液中逐滴加入TMSCl(48.7g，0.45mol)。将反应混合物在0℃搅拌10分钟。然后加入异丁酰氯(36g，0.337mol)并在0℃下再搅拌反应10分钟。加入水，分离各相并用CuSO<base:Sub>4</base:Sub>水溶液洗涤。有机相用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩以获得粗中间体3-3(151.7g)。</base:Paragraphs>
      <base:Paragraphs id="p1310" num="n1281">步骤3：N-(6-氯-9-((6aR,8R,9R,9aS)-9-羟基-2,2,4,4-四异丙基四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)异丁酰胺：向中间体3-3(151.7g,0.22mol)的THF(1500mL)溶液中加入对甲苯磺酸一水合物(29g，0.155mol)。混合物在室温下搅拌10分钟，然后加入三乙胺(35ml)猝灭。溶液经柱层析(DCM/MeOH＝200:1-100:1)浓缩并纯化得到中间体3-4(81g，2步收率58.5％)。</base:Paragraphs>
      <base:Paragraphs id="p1311" num="n1282">步骤4：N-(6-氯-9-((6aR,8R,9aR)-2,2,4,4-四异丙基-9-氧代四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)异丁酰胺：在0℃向中间体3-4(40g,0.065mol)的DCM(300mL)溶液中加入DMP(56g,0.13mol)。反应混合物在室温下搅拌过夜。然后，加入乙醚(2000mL)并过滤悬浮液。溶液依次用饱和NaHCO<base:Sub>3</base:Sub>水溶液、饱和Na<base:Sub>2</base:Sub>S<base:Sub>2</base:Sub>O<base:Sub>3</base:Sub>水溶液和盐水洗涤。有机相用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥，浓缩，与甲苯共沸，得到中间体3-5，直接用于下一步。</base:Paragraphs>
      <base:Paragraphs id="p1312" num="n1283">步骤5：N-(6-氯-9-((6aR,8R,9S,9aR)-9-羟基-2,2,4,4-四异丙基-9-((三甲基甲硅烷基)乙炔基)四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)异丁酰胺：在-15～-20℃向三甲基硅基乙炔(52g,0.529mol)的无水THF溶液中滴加正丁基锂(204ml，0.51mol)(350ml)。溶液在-15～-20℃搅拌30分钟。然后，将反应混合物冷却至-70℃并逐滴加入中间体3-5(54g，0.088mol)的无水DMF(200mL)溶液。溶液在-70℃搅拌20分钟。将所得溶液缓慢升温至0℃并通过加入饱和NH<base:Sub>4</base:Sub>Cl水溶液淬灭。加入EtOAc，分离有机相并用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(DCM/MeOH＝200:1-100:1)纯化，得到黄色固态中间体3-6(35.1g，2步产率56％)。</base:Paragraphs>
      <base:Paragraphs id="p1313" num="n1284">步骤6:N-(6-氯-9-((6aR,8R,9R,9aR)-9-氟-2,2,4,4-四异丙基-9-((三甲基甲硅烷基)乙炔基)四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-9H-嘌呤-2-基)异丁酰胺：在-70℃下向中间体3-6(2g，2.81mmol)的DCM(20mL)和吡啶(0.703g，8.85mmol)溶液中加入DAST(2.27g，14.05mmol)。将反应混合物缓慢升温至-30℃并在-30℃搅拌5分钟。然后，将溶液缓慢加入饱和NaHCO<base:Sub>3</base:Sub>水溶液中并加入DCM。分离有机相并用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。通过柱层析法(DCM/MeOH＝200:1-100:1)纯化残余物以提供白色固态中间体3-7(1.257g，62.85％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1314" num="n1285">步骤7:N-(9-((6aR,8R,9R,9aR)-9-乙炔基-9-氟-2,2,4,4-四异丙基四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-6-(甲氨基)-9H-嘌呤-2-基)异丁酰胺：在0℃下向中间体3-7(14g,19.65mmol)的甲醇(30mL)溶液中加入30％甲胺甲醇溶液(30ml)并将反应在室温下搅拌5分钟。然后在室温下浓缩溶液以除去甲胺。之后将所得溶液浓缩并通过柱层析法(DCM/MeOH＝200:1-100:1)纯化以提供白色固态中间体3-8(8.8g，70.4％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1315" num="n1286">步骤8:N-(9-((6aR,8R,9R,9aR)-9-氟-2,2,4,4-四异丙基-9-乙烯基四氢-6H-呋喃并[3,2-f][1,3,5,2,4]三氧杂二硅杂八环-8-基)-6-(甲氨基)-9H-嘌呤-2-基)异丁酰胺。向中间体3-8(8.8g，13.86mmol)在EtOAc(88mL)的溶液中加入Lindlar催化剂(3.52g)。然后，在室温下将溶液在氢气气氛(0.8MPa)下搅拌过夜。过滤反应混合物以除去催化剂，浓缩并通过柱层析法(DCM/MeOH＝200:1-100:1)纯化以提供固态中间体3-9(7.5g，85.2％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1316" num="n1287">步骤9:N-(9-((2R,3R,4R,5R)-3-氟-4-羟基-5-(羟甲基)-3-乙烯基四氢呋喃-2-基)-6-(甲氨基)-9H-嘌呤-2-基)异丁酰胺。在0℃下，向中间体3-9(7.5g，11.77mmol)的THF(40ml)溶液中加入TBAF(5.56g，17.65mmol)的THF(35ml)溶液。当TLC指示起始材料完全转化时，将溶液浓缩并通过柱层析法(DCM/MeOH＝200:1-10:1)纯化以提供固态中间体3-10(3.8g，82.6％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1317" num="n1288">步骤10:((2R,3R,4R,5R)-3-(苯甲酰氧基)-4-氟-5-(2-异丁酰胺基-6-(甲氨基)-9H-嘌呤-9-基)-4-乙烯基四氢呋喃-2-基)甲基苯甲酸酯。在0℃下，向化合物中间体3-10(3.7g，9.38mmol)的吡啶(19ml)溶液中加入BzCl(2.9g，20.64mmol)。将反应混合物在室温搅拌过夜。然后，反应混合物用甲醇淬灭并浓缩。通过柱层析法(DCM/MeOH＝200:1-100:1)纯化残余物以提供白色固态中间体3-11(4.68g，82.8％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1318" num="n1289">步骤11:((2R,3R,4R,5R)-3-(苯甲酰氧基)-4-((S)-1,2-二羟乙基)-4-氟-5-(2-异丁酰胺基-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-基)甲基苯甲酸酯。向中间体3-11(4.68g,7.77mmol)的THF(46.8ml)和H<base:Sub>2</base:Sub>O(9.36ml)溶液中加入NMO(1.82g,15.53mmol)和OsO<base:Sub>4</base:Sub>(0.65g,2.56mmol)。将反应混合物在室温搅拌过夜。然后，用饱和Na<base:Sub>2</base:Sub>S<base:Sub>2</base:Sub>O<base:Sub>3</base:Sub>水溶液猝灭反应混合物并加入EtOAc。分离有机相并用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(DCM/MeOH＝200:1-50:1)纯化，得到白色固态中间体3-12(4g，82％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1319" num="n1290">步骤12:((2R,3R,4R,5R)-3-(苯甲酰氧基)-4-氟-4-(羟甲基)-5-(2-异丁酰胺基-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-基)甲基苯甲酸酯。将中间体3-12(4g,6.28mmol)溶解在甲醇(40ml)、THF(11.7ml)和水(7ml)中。然后，将高碘酸钠(2g，9.42mmol)加入到溶液中并将反应混合物在室温下搅拌3小时。过滤反应混合物并用甲醇和THF洗涤。将NaBH<base:Sub>4</base:Sub>(0.382g，10.05mmol)分批加入所得溶液中并将反应搅拌10分钟。用冰水淬灭反应混合物并加入EtOAc。分离有机相并用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(DCM/MeOH＝200:1-50:1)纯化，得到白色固态中间体3-13(3.17g，83.2％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1320" num="n1291">步骤13:((2R,3R,4R,5R)-3-(苯甲酰氧基)-4-氟-4-(氟甲基)-5-(2-异丁酰胺基-6-(甲氨基)-9H-嘌呤-9-基)四氢呋喃-2-基)甲基苯甲酸酯。在-15～-20℃下，向中间体3-13(1000mg，1.65mmol)的DCM(10ml)和吡啶(650mg，8.24mmol)溶液中加入三氟甲磺酸酐(838mg，2.97mmol)。反应混合物在-15～-20℃搅拌10分钟。溶液用饱和NaHCO<base:Sub>3</base:Sub>水溶液淬灭并用CuSO<base:Sub>4</base:Sub>水溶液洗涤。然后，有机相用盐水洗涤，用无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。将粗产物溶解在乙腈(10ml)中并将TBAF(1M，8.25ml)的THF溶液加入到所得溶液中。将反应混合物搅拌5分钟并通过TLC监测。然后用EtOAc和水稀释反应。分离各相并用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。通过柱层析法(DCM/MeOH＝200:1-100:1)纯化残余物以提供白色固态中间体3-14(113mg，37.7％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1321" num="n1292">步骤14:(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-4-(氟甲基)-2-(羟甲基)四氢呋喃-3-醇。将中间体3-14(0.51g,0.84mmol)溶于20％甲胺甲醇溶液，在密闭钢制反应器中100℃搅拌过夜。将反应混合物浓缩并通过柱层析法(DCM/MeOH＝200:1-10:1)纯化以提供呈白色固态中间体3-15(241mg，87.6％产率)。<base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ7.94(s,1H),6.28(d,J＝20.0Hz,1H),4.84-4.56(m,1H),4.46(t,J＝24.0Hz,1H)，4.35-3.89(m,1H)，3.86(m,2H)，3.30(d,J＝20.0Hz,1H)，3.03(s,3H).<base:Sup>19</base:Sup>F NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ179.67(s)，80.15(s)。</base:Paragraphs>
      <base:Paragraphs id="p1322" num="n1293">步骤15:((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-4-(氟甲基)-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯。将中间体3-15(150mg，0.45mmol)溶解在乙腈(6mL)中，在室温下加入NMI(895.6mg，10.80mmol)。将溶液冷却至0℃，滴加(氯(苯氧基)磷酰基)-L-丙氨酸异丙酯(1247.7mg，4.05mmol)的乙腈(2mL)溶液。将反应混合物在0℃搅拌5分钟并通过TLC监测。然后，所得溶液用水猝灭并用EtOAc稀释。分离各相并用盐水洗涤，经无水Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(DCM/MeOH＝200:1-30:1)纯化，得到白色固态化合物6(111mg，40.8％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1323" num="n1294">
        <base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ7.78(s,1H),7.31-7.16(m,5H)，6.27(dd,J＝20.0,8.0Hz,1H),4.91-4.84(m,1H)，4.56(m,1H)，4.51(m,4H),4.50(m,1H),3.87(dd,J＝20.0,8.0Hz,1H),3.03(s,3H),1.27-1.13(m,9H).<base:Sup>19</base:Sup>F NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ179.09(s).<base:Sup>31</base:Sup>P NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ3.86,3.79(d).MS(ESI)m/z C<base:Sub>24</base:Sub>H<base:Sub>32</base:Sub>F<base:Sub>2</base:Sub>N<base:Sub>7</base:Sub>O<base:Sub>7</base:Sub>P[M+H]<base:Sup>+</base:Sup>理论值600.2；实测值600.2。</base:Paragraphs>
      <base:Paragraphs id="p1324" num="n1295">合成4.((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-乙炔基-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物7)</base:Paragraphs>
      <base:Paragraphs id="p1325" num="n1296">步骤1：在0℃下向中间体4-1(30mg，0.09mmol)的无水THF(2mL)溶液中滴加叔丁基氯化镁(1M在THF中)(112μL，0.11mmol)。将溶液在0℃下搅拌15分钟并在室温下搅拌45分钟。然后，将反应混合物冷却至0℃，并逐滴加入((R,S)-(五氟苯氧基)-苯氧基-磷酰基)-L-丙氨酸异丙酯(51mg，0.11mmol)的无水THF(1mL)溶液。将所得溶液缓慢升温至室温并搅拌15小时。然后用EtOAc(10mL)和饱和NH<base:Sub>4</base:Sub>Cl水溶液(8mL)稀释反应混合物。分离各相并用EtOAc(2×5mL)反萃取水层。合并的有机物用饱和NH<base:Sub>4</base:Sub>Cl水溶液(10mL)和盐水(10mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至10％)和反相柱层析法(C-18二氧化硅，H<base:Sub>2</base:Sub>O/MeOH 0至100％)纯化。得到化合物7(9mg，16％)，为白色固体。<base:Sup>1</base:Sup>H NMR(300MHz,CD<base:Sub>3</base:Sub>OD)δ7.81,7.79(s+s,1H),7.36-7.14(m,5H),6.26(d,J＝17.4Hz,0.1H),6.24(d,J＝17.4Hz,0.9H),4.93-4.89(和H<base:Sub>2</base:Sub>O重叠,m,1H),4.80-4.78(m,1H),4.53-4.49(m,2H),4.21-4.18(m,1H),3.95-3.84(m,1H),3.23-3.20(m,1H),3.04(bs,1H),1.31-1.14(m,9H).<base:Sup>31</base:Sup>P NMR(121MHz,CD<base:Sub>3</base:Sub>OD)δ4.06(s),3.97(s).MS(ESI)m/z C<base:Sub>25</base:Sub>H<base:Sub>32</base:Sub>FN<base:Sub>7</base:Sub>O<base:Sub>7</base:Sub>P[M+H]<base:Sup>+</base:Sup>理论值592.2；实测值592.2。</base:Paragraphs>
      <base:Paragraphs id="p1326" num="n1297">合成5.((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基)-4-乙烯基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物8)</base:Paragraphs>
      <base:Paragraphs id="p1327" num="n1298">步骤1:(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-2-(羟甲基)-4-乙烯基四氢呋喃-3-醇(3)。</base:Paragraphs>
      <base:Paragraphs id="p1328" num="n1299">向中间体4-1(255mg，0.79mmol)的EtOH(4mL)中的中加入钯(BaSO45％)(60mg)和喹啉(2滴)。将溶液置于H<base:Sub>2</base:Sub>气氛并在室温下搅拌1小时。然后，将混合物在硅藻土上过滤并浓缩。通过柱层析法(硅胶，DCM/MeOH 0至10％)纯化残余物。获得呈白色固态的中间体5-1(177mg，70％)。<base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ7.98(s,1H),6.12(d,J＝18.6Hz,1H),5.52-5.35(m,2H),5.25-5.19(m,1H),4.86-4.70(m,1H,和H<base:Sub>2</base:Sub>O重叠),4.13-3.86(m,3H),3.03(br.s,3H).MS(ESI)m/zC<base:Sub>13</base:Sub>H<base:Sub>18</base:Sub>FN<base:Sub>6</base:Sub>O<base:Sub>3</base:Sub>[M+H]<base:Sup>+</base:Sup>理论值325.1；实测值325.2。</base:Paragraphs>
      <base:Paragraphs id="p1329" num="n1300">步骤2:(2S)-异丙基2-(((((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-乙烯基-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)氨基)丙酸酯。在0℃下向中间体5-1(150mg，0.47mmol)的无水THF(10mL)溶液中逐滴加入叔丁基氯化镁(1M在THF中)(560μL，0.55mmol)。将溶液在0℃下搅拌15分钟并在室温下搅拌45分钟。然后，将反应混合物冷却至0℃，滴加((R,S)-(五氟苯氧基)-苯氧基-磷酰基)-L-丙氨酸异丙酯(250mg，0.55mmol)的无水THF(5mL)溶液。将所得溶液缓慢升温至室温并搅拌15小时。然后用EtOAc(50mL)和饱和NH<base:Sub>4</base:Sub>Cl水溶液(40mL)稀释反应混合物。分离各相并用EtOAc(2×25mL)反向萃取水层。合并有机物用饱和NH<base:Sub>4</base:Sub>Cl水溶液(50mL)和盐水(50mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至10％)和反相柱层析法(C-18二氧化硅，H<base:Sub>2</base:Sub>O/MeOH 0至100％)纯化。得到化合物8(45mg，16％)，为白色固体。<base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ7.81(s,1H),7.36-7.14(m,5H),6.12(d,J＝19.1Hz,1H),5.54-5.547(m,2H),5.28-5.23(m,1H),4.91-4.81(m,1H,和H<base:Sub>2</base:Sub>O重叠),4.58-4.47(m,2H),4.28-4.22(m,1H),3.95-3.85(m,1H),3.05(br.s,3H),1.32-1.13(m,9H).<base:Sup>31</base:Sup>P NMR(162MHz,CD<base:Sub>3</base:Sub>OD)δ3.86(s).MS(ESI)m/zC<base:Sub>25</base:Sub>H<base:Sub>34</base:Sub>FN<base:Sub>7</base:Sub>O<base:Sub>7</base:Sub>P[M+H]<base:Sup>+</base:Sup>理论值594.2；实测值594.2。</base:Paragraphs>
      <base:Paragraphs id="p1330" num="n1301">合成6.((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-(羟甲基)四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物9)</base:Paragraphs>
      <base:Paragraphs id="p1331" num="n1302">步骤1:(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-2-(((叔丁基二苯基甲硅烷基)氧基)甲基)-4-氟-4-乙烯基四氢呋喃-3-醇(5)。在0℃下向中间体5-1(185mg，0.57mmol)的无水DMF(7mL)溶液中加入咪唑(232mg，3.40mmol)和TDPSCl(445μL，1.70mmol)。将溶液在0℃下搅拌1h。然后用EtOAc(50mL)和饱和NH<base:Sub>4</base:Sub>Cl水溶液(40mL)稀释反应混合物。分离各相，有机层用饱和NH<base:Sub>4</base:Sub>Cl水溶液(4×30mL)洗涤，用Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至5％)纯化，得到中间体6-1(352mg，84％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1332" num="n1303">步骤2:(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-2-(((叔丁基二苯基甲硅烷基)氧基)甲基)-4-氟-4-(羟甲基)四氢呋喃-3-醇(6)。向中间体6-1(200mg，0.36mmol)在二恶烷(5ml)的溶液中加入N-甲基吗啉-N-氧化物(220mg，1.87mmol)和OsO<base:Sub>4</base:Sub>(4％的H<base:Sub>2</base:Sub>O)(210μL)。将溶液在室温下避光搅拌15小时。然后，混合物用EtOAc(25mL)稀释并用硅藻土过滤。溶液用盐水(20mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。将残余物溶解在DCM(5mL)中并加入NaIO<base:Sub>4</base:Sub>(吸附在二氧化硅上)(2.3g)。所得浆液在室温下研磨15小时。然后，将二氧化硅过滤并用DCM彻底洗涤。浓缩合并的滤液。将残余物溶解在EtOH(5mL)中，并在0℃下加入NaBH<base:Sub>4</base:Sub>(225mg，6.0mmol)。将溶液在0℃下搅拌3小时，然后用饱和NH<base:Sub>4</base:Sub>Cl水溶液(15mL)淬灭。混合物用EtOAc(2×20mL)萃取。合并有机物用盐水(10mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至5％)纯化，得到中间体6-2(143mg，70％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1333" num="n1304">步骤3:9-((2R,3R,4R,5R)-5-(((叔丁基二苯基甲硅烷基)氧基)甲基)-3-氟-4-((四氢-2H-吡喃-2-基)氧基)-3-(((四氢-2H-吡喃-2-基)氧基)甲基)四氢呋喃-2-基)-N<base:Sup>6</base:Sup>-甲基-9H-嘌呤-2,6-二胺(7)。向中间体6-2(130mg,0.23mmol)的无水DCM(10mL)溶液中加入3,4-二氢-2H-吡喃(360μL,4.0mmol)和樟脑磺酸(100mg,0.43mmol)。将溶液在室温搅拌2小时并用DCM(20mL)稀释。添加饱和NaHCO<base:Sub>3</base:Sub>水溶液(20mL)并分离各相。有机物用盐水(20mL)洗涤，用Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，PE/EtOAc 0至40％)纯化，得到中间体6-3(137mg，81％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1334" num="n1305">步骤4:((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-((四氢-2H-吡喃-2-基)氧基)-4-(((四氢-2H-吡喃-2-基)氧基)甲基)四氢呋喃-2-基)甲醇(8)。向中间体6-3(130mg，0.18mmol)的无水THF(5mL)溶液中加入TBAF(1M在THF中)(360μL，0.36mmol)。将溶液在室温搅拌1小时并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至5％)纯化，得到中间体6-4(81mg，92％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1335" num="n1306">步骤5:(2S)-异丙基2-(((((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-(羟甲基)四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)氨基)丙酸酯(9)。在0℃下向中间体6-4(50mg，0.10mmol)的无水THF(3mL)溶液中滴加叔丁基氯化镁(1M在THF中)(130μL，0.13mmol)。将溶液在0℃搅拌15分钟并在室温搅拌45分钟。然后，将反应混合物冷却至0℃，逐滴加入(R,S)-(五氟苯氧基)-苯氧基-磷酰基)-L-丙氨酸异丙酯(52mg，0.11mmol)的无水THF(1mL)溶液。将所得溶液缓慢升温至室温并搅拌15小时。然后用EtOAc(10mL)和饱和NH<base:Sub>4</base:Sub>Cl水溶液(8mL)稀释反应混合物。分离各相并用EtOAc(2×5mL)反萃取水层。合并有机物用饱和NH<base:Sub>4</base:Sub>Cl水溶液(10mL)和盐水(10mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。将残余物溶解在HCl(1.25M在i-PrOH中)(2mL)中。将溶液在室温搅拌2小时并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至10％)和反相柱层析法(C-18二氧化硅，H<base:Sub>2</base:Sub>O/MeOH 0至100％)纯化。获得呈白色固体的化合物9(29mg，49％)。<base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ7.80(s,1H),7.36-7.13(m,5H),6.17(d,J＝18.3Hz,1H),4.92-4.73(m,2H,overlapped with H<base:Sub>2</base:Sub>O),4.55-4.49(m,2H),4.26-4.18(m,1H),3.93-3.80(m,2H),3.57-3.43(m,1H),3.03(br.s,3H),1.28(d,J＝7.3Hz,3H),1.15(t,J＝6.6Hz,6H).<base:Sup>31</base:Sup>P NMR(162MHz,CD<base:Sub>3</base:Sub>OD)δ3.90(s).MS(ESI)m/zC<base:Sub>24</base:Sub>H<base:Sub>34</base:Sub>FN<base:Sub>7</base:Sub>O<base:Sub>8</base:Sub>P[M+H]<base:Sup>+</base:Sup>理论值598.2；实测值598.2。</base:Paragraphs>
      <base:Paragraphs id="p1336" num="n1307">合成7.((((2R,3R,4R,5R)-5-(2-氨基-6-(环丙基氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-(羟甲基)四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物10)</base:Paragraphs>
      <base:Paragraphs id="p1337" num="n1308">步骤1:(2R,3R,4R,5R)-5-(2-氨基-6-(环丙基氨基)-9H-嘌呤-9-基)-4-氟-2-(羟甲基)-4-乙烯基四氢呋喃-3-醇(11)。向中间体7-1(232mg，0.67mmol)的EtOH(4mL)溶液中加入钯(BaSO4 5％)(50mg)和喹啉(2滴)。将溶液置于H<base:Sub>2</base:Sub>气氛下并在室温下搅拌1小时。然后，将混合物在硅藻土上过滤并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至10％)纯化，得到中间体7-2(170mg，73％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1338" num="n1309">步骤2:(2R,3R,4R,5R)-5-(2-氨基-6-(环丙基氨基)-9H-嘌呤-9-基)-2-(((叔丁基二苯基甲硅烷基)氧基)甲基)-4-氟-4-乙烯基四氢呋喃-3-醇(12)。在0℃下向中间体7-2(168mg,0.48mmol)的无水DMF(5mL)溶液中加入咪唑(200mg,2.91mmol)和TDPSCl(375μL，1.46mmol)。将溶液在0℃下搅拌1h。然后用EtOAc(40mL)和饱和NH<base:Sub>4</base:Sub>Cl水溶液(30mL)稀释反应混合物。分离各相，有机层用饱和NH<base:Sub>4</base:Sub>Cl水溶液(4×20mL)洗涤，用Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至5％)纯化，得到中间体7-3(254mg，89％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1339" num="n1310">步骤3:(2R,3R,4R,5R)-5-(2-氨基-6-(环丙基氨基)-9H-嘌呤-9-基)-2-(((叔丁基二苯基甲硅烷基)氧基)甲基)-4-氟-4-(羟甲基)四氢呋喃-3-醇(13)。向中间体7-3(250mg，0.42mmol)的二恶烷(6mL)溶液中加入N-甲基吗啉-N-氧化物(257mg，2.19mmol)和OsO<base:Sub>4</base:Sub>(4％的H<base:Sub>2</base:Sub>O)(245μL)。将溶液在室温下在黑暗中搅拌15小时。然后，混合物用EtOAc(30mL)稀释并在硅藻土上过滤。溶液用盐水(20mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。将残余物溶解在DCM(6mL)中并加入NaIO4(吸附在二氧化硅上)(2.7g)上。所得浆液在室温下研磨15小时。然后，将二氧化硅过滤并用DCM彻底洗涤。浓缩合并的滤液。将残余物溶解在EtOH(6mL)中，并在0℃下加入NaBH<base:Sub>4</base:Sub>(263mg,7.0mmol)。将溶液在0℃下搅拌3小时，然后用饱和NH<base:Sub>4</base:Sub>Cl水溶液(20mL)淬灭。混合物用EtOAc(2×25mL)萃取。合并有机物用盐水(10mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至5％)纯化，得到中间体7-4(159mg，64％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1340" num="n1311">步骤4:9-((2R,3R,4R,5R)-5-(((叔丁基二苯基甲硅烷基)氧基)甲基)-3-氟-4-((四氢-2H-吡喃-2-基)氧基)-3-(((四氢-2H-吡喃-2-基)氧基)甲基)四氢呋喃-2-基)-N<base:Sup>6</base:Sup>-环丙基-9H-嘌呤-2,6-二胺(14)。向中间体7-4(150mg，0.25mmol)的无水DCM(10mL)溶液中加入3,4-二氢-2H-吡喃(360μL，4.0mmol)和樟脑磺酸(100mg，0.43mmol))。将溶液在室温搅拌2小时并用DCM(20mL)稀释。添加饱和NaHCO<base:Sub>3</base:Sub>水溶液(20mL)并分离各相。有机物用盐水(20mL)洗涤，用Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。残余物通过柱层析法(硅胶，PE/EtOAc 0至40％)纯化，得到中间体7-5(146mg，76％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1341" num="n1312">步骤5:((2R,3R,4R,5R)-5-(2-氨基-6-(环丙基氨基)-9H-嘌呤-9-基)-4-氟-3-((四氢-2H-吡喃-2-基)氧基)-4-(((四氢-2H-吡喃-2-基)氧基)甲基)四氢呋喃-2-基)甲醇(15)。向中间体7-5(140mg，0.18mmol)在无水THF(5mL)中的溶液中加入TBAF(1M在THF中)(360μL，0.36mmol)。将溶液在室温搅拌1小时并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH0至5％)纯化，得到中间体7-6(86mg，90％)，为白色固体。</base:Paragraphs>
      <base:Paragraphs id="p1342" num="n1313">步骤6:(2S)-异丙基2-(((((2R,3R,4R,5R)-5-(2-氨基-6-(甲基氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-(羟甲基)四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)氨基)丙酸酯(16)。在0℃下向中间体7-6(51mg，0.10mmol)在无水THF(3mL)中的溶液中滴加叔丁基氯化镁(1M在THF中)(130μL，0.13mmol)。将溶液在0℃搅拌15分钟并在室温搅拌45分钟。然后，将反应混合物冷却至0℃，逐滴加入((R,S)-(五氟苯氧基)-苯氧基-磷酰基)-L-丙氨酸异丙酯(52mg，0.11mmol)的无水THF(1mL)溶液。将所得溶液缓慢升温至室温并搅拌15小时。然后用EtOAc(10mL)和饱和NH<base:Sub>4</base:Sub>Cl水溶液(8mL)稀释反应混合物。分离各相并用EtOAc(2×5mL)反萃取水层。合并有机物用饱和NH<base:Sub>4</base:Sub>Cl水溶液(10mL)和盐水(10mL)洗涤，经Na<base:Sub>2</base:Sub>SO<base:Sub>4</base:Sub>干燥并浓缩。将残余物溶解在HCl(1.25M在i-PrOH中)(2mL)中。将溶液在室温搅拌2小时并浓缩。残余物通过柱层析法(硅胶，DCM/MeOH 0至10％)和反相柱层析法(C-18二氧化硅，H<base:Sub>2</base:Sub>O/MeOH 0至100％)纯化。得到化合物10(25mg，41％)，为白色固体。<base:Sup>1</base:Sup>H NMR(400MHz,CD<base:Sub>3</base:Sub>OD)δ7.81(s,1H),7.33-7.14(m,5H),6.19(d,J＝18.3Hz,1H),4.93-4.81(m,2H,和H<base:Sub>2</base:Sub>O重叠),4.53-4.50(m,2H),4.24-4.20(m,1H),3.92-3.80(m,2H),3.55-3.44(m,1H),2.91-2.88(br.m,1H),1.27(d,J＝7.2Hz,3H),1.15(t,J＝7.0Hz,6H),0.86-0.81(m,2H),0.61-0.57(m,2H).<base:Sup>31</base:Sup>P NMR(162MHz,CD<base:Sub>3</base:Sub>OD)δ3.85(s).MS(ESI)m/z C<base:Sub>26</base:Sub>H<base:Sub>36</base:Sub>FN<base:Sub>7</base:Sub>O<base:Sub>8</base:Sub>P[M+H]<base:Sup>+</base:Sup>理论值624.2；实测值624.3。</base:Paragraphs>
      <base:Paragraphs id="p1343" num="n1314">合成8.((R)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲基氨基)-9H-嘌呤-9-基)-4-氟-3-羟基-4-(三氟甲基)四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯(化合物11B)</base:Paragraphs>
      <base:Paragraphs id="p1344" num="n1315">步骤1:向三颈圆底烧瓶中加入无水四氢呋喃(100mL)和LDA(25mL，50mmol)。搅拌混合物并冷却至-75℃。然后向该混合物中缓慢加入中间体8-1(8.7g，50mmol)，同时保持批料温度低于-74℃。将混合物在-76℃搅拌60分钟，缓慢加入新蒸馏的D-甘油醛(6.5g，50mmol)的无水THF(20mL)溶液，同时保持批次温度低于-74℃。添加后，将混合物搅拌约60分钟并添加100g 20％的NH<base:Sub>4</base:Sub>Cl溶液。将混合物缓慢升温至环境温度并转移至分液漏斗。分离水相并用二氯甲烷萃取。合并有机相，用MgSO<base:Sub>4</base:Sub>干燥，过滤，浓缩，得到粗中间体8-2，残余物通过柱色谱纯化，得到黄色油状产物(7.3g，50％产率)。<base:Sup>1</base:Sup>H NMR(CDCl<base:Sub>3</base:Sub>,400MHz):δ(ppm)1.33-1.43(m,9H),4.06-4.42(m,6H)；<base:Sup>19</base:Sup>F NMR(CDCl<base:Sub>3</base:Sub>,376.5MHz)δ(ppm)-73.83(s,1F),-73.00(t,3F).</base:Paragraphs>
      <base:Paragraphs id="p1345" num="n1316">步骤2:将中间体8-2(3.0g，10mmol)、20克EtOH和2克12％硫酸的混合物在78℃下回流5小时。将混合物冷却至环境温度并加入1g三乙胺以中和酸。将混合物浓缩至干燥。将残余物与20g甲苯混合并将混合物再次浓缩至干燥。将残余物溶解在15g乙腈中。在室温下向该溶液中加入催化量的4-二甲胺基吡啶(DMAP)和4-氯苯甲酰氯(5g，36mmol)。将混合物在冰水浴中冷却，然后加入三乙胺(7.3g，72mmol)。混合物在室温下搅拌过夜。通过加入水(60mL)淬灭反应并且在减压下浓缩所得溶液。残余物用乙酸乙酯(100mL)稀释，用水和盐水洗涤(各2×50mL)。减压浓缩有机层，残余物通过柱色谱纯化，得到中间体8-3，为浅黄色固体(2.5g，50％产率)。<base:Sup>1</base:Sup>H NMR(CDCl<base:Sub>3</base:Sub>,400MHz)δ(ppm)4.60-4.68(m,1H),4.75-4.84(m,1H),4.92-5.00(m,1H),6,06-6.16(m,1H),7.40-7.53(m,4H),7.91-7.98(m,4H)；<base:Sup>19</base:Sup>F NMR(CDCl<base:Sub>3</base:Sub>,376.5MHz)δ(ppm)-78.63(s,1F),-74.74(t,3F).</base:Paragraphs>
      <base:Paragraphs id="p1346" num="n1317">步骤3:将中间体8-3(5g，10mmol)装入干燥的圆底烧瓶中并将固体溶解在无水THF(50mL)中。将溶液冷却至-20℃。然后通过加料漏斗加入三叔丁氧基铝锂溶液(1.0M在THF中)(17mL，17mmol)20分钟，并将所得混合物在-20℃搅拌1小时加入乙酸乙酯(12mL)并使混合物缓慢升温至0℃。然后加入饱和氯化铵水溶液(4.5mL)并将混合物真空浓缩并用EtOAc(100mL)稀释。加入HCl水溶液(3N，30mL)以溶解固体。相分离后，有机层用盐水(100mL)洗涤，硫酸钠干燥，减压浓缩，得到固体。通过柱色谱纯化残余固体以提供呈白色固体状的中间体8-4(3.5g，70％产率)。<base:Sup>1</base:Sup>H NMR(CDCl<base:Sub>3</base:Sub>,400MHz)δ(ppm)4.65-4.74(m,3H),5.57-6.17(m,2H),7.31-7.47(m,4H),7.91-8.01(m,4H)；<base:Sup>19</base:Sup>F NMR(CDCl<base:Sub>3</base:Sub>,376.5MHz)δ(ppm)-79.25(d,1F),-75.14(d,1F),-74.88(d,1F),-72.20(d,1F).</base:Paragraphs>
      <base:Paragraphs id="p1347" num="n1318">步骤4:在氮气-20℃下将中间体8-4(1.5g，3mmol)溶解在二氯甲烷(18ml)中并加入PPh3(1.5g，4.5mmol)。将反应混合物搅拌15分钟并分批加入CBr4(2.4g，4.5mmol)。将反应在-20℃和-15℃之间搅拌1.5小时。通过硅胶柱层析法纯化(无需后处理和浓缩)反应混合物，得到中间体8-5(1.18g，70％得率)。<base:Sup>1</base:Sup>H NMR(CDCl<base:Sub>3</base:Sub>,400MHz)δ(ppm)4.58-4.85(m,3H),5.75-5.78(m,0.5H),6.41-6.70(m,1.4H),7.38-7.47(m,4H),7.94-8.04(m,4H)；<base:Sup>19</base:Sup>F NMR(CDCl<base:Sub>3</base:Sub>,376.5MHz)δ(ppm)-79.27(d,1F),-75.23(d,1F),-72.81(d,1F),-70.46(d,1F).</base:Paragraphs>
      <base:Paragraphs id="p1348" num="n1319">步骤5:在搅拌下，在三颈圆底烧瓶中加入6-氯-2-丁腈(1.1g，6.5mmol)，然后加入无水tBuOH(45mL)。在室温下向上述搅拌的溶液中分批加入叔丁醇钾(1.5g，7mmol)。30分钟后，在室温下加入中间体8-5(1.1g，2mol)在无水乙腈(4mL)中的溶液。将混合物缓慢加热至50℃并搅拌22小时。加入饱和氯化铵水溶液(4.5mL)，溶液用乙酸乙酯(60mL)稀释，用水和盐水洗涤(各2×30mL)。在减压下浓缩有机层并且通过柱层析法纯化残余物以提供中间体8-6(0.5g，40％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1349" num="n1320">步骤6:在5mL烧瓶中装入甲胺(3mL，30％的甲醇溶液)并在10±5℃下搅拌。在20±5℃下分批加入中间体6(325mg，0.5mmol)并将反应搅拌1小时得到澄清溶液。将反应再搅拌6-8小时，此时TLC表明中间体少于溶液的1％。反应器装入固体NaOH(0.2g)，搅拌30分钟并浓缩。所得残余物通过柱层析法(DCM:MeOH＝50:1至20:1)纯化以提供中间体7(120mg，65％产率)。</base:Paragraphs>
      <base:Paragraphs id="p1350" num="n1321">步骤7:中间体8-7(110mg,0.3mmol)和(S)-2-[((S)-(2,3,4,5,6-五氟苯氧基)(苯氧基)磷酰基)-氨基]丙酸异丙酯(150mg，0.33mmol)悬浮在THF(2mL)中并在氮气下搅拌。然后将悬浮液冷却至低于-15℃的温度并缓慢加入1.7M的t-BuMgCl溶液(0.5mL，0.85mol)，同时维持-15至-10℃的温度。将反应再搅拌16小时，此时TLC表明中间体少于溶液的5％。室温下向悬浮液中加入饱和氯化铵水溶液(4.5mL)，溶液用乙酸乙酯(60mL)稀释，用水和盐水(各2×30mL)洗涤。在减压下浓缩有机层并且通过柱层析法(DCM:MeOH＝150:1至50:1)纯化残余物以提供化合物11B(100mg，53％产率)。<base:Sup>1</base:Sup>H NMR(CDCl<base:Sub>3</base:Sub>,400MHz)δ(ppm)1.71-1.18(m,6H),1.29-1.32(m,3H),3.05(s,3H),3.87-3.91(m,1H),4.11-4.12(bs,1H),4.37-4.40(m,2H),4.70-4.77(m,1H),4.87-4.95(m,1H),6.45-6.49(d,1H),7.20-7.38(m,5H),7.73(d,1H)；<base:Sup>19</base:Sup>FNMR(CDCl<base:Sub>3</base:Sub>,376.5MHz)δ(ppm)-178.22(s,1F),-76.37(d,3F).</base:Paragraphs>
      <base:Paragraphs id="p1351" num="n1322">合成9.((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲基氨基)-9H-嘌呤-9-基)-4,4-二氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯</base:Paragraphs>
      <base:Paragraphs id="p1352" num="n1323">
        <base:Image he="504" wi="992" file="GDA0003327089700002961.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1353" num="n1324">((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲基氨基)-9H-嘌呤-9-基)-4,4-二氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯可以如Hertel etal.J.Org.Chem.1988,53,2406描述的方法和实施例1合成。下面描述了一个非限制性示例：</base:Paragraphs>
      <base:Paragraphs id="p1354" num="n1325">使用Reformatskii条件，在活化锌的存在下，将2-溴-2,2-二氟乙酸乙酯耦合至(R)-2,2-二甲基-1,3-二氧戊环-4-甲醛I，得到(3R)-3-(2,2-二甲基-1,3-二氧戊环-4-基)-2,2-二氟-3-羟基丙酸乙酯，然后如Hertel等人所述，对其进行水解去除异丙基和内酯开环。用CBz基团保护后，(2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氟-2-(羟甲基)四氢呋喃-3-醇可以使用与实施例1，A部分，步骤3-6中所述相同的程序合成。</base:Paragraphs>
      <base:Paragraphs id="p1355" num="n1326">如实施例1部分C中所述，(2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氟-2-(羟甲基)四氢呋喃-3-醇之后偶联至(羟基(苯氧基)磷酰基)-L-丙氨酸异丙酯(1-12)的二氢奎宁盐，得到((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯：</base:Paragraphs>
      <base:Paragraphs id="p1356" num="n1327">
        <base:Image he="742" wi="1000" file="GDA0003327089700002981.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1357" num="n1328">合成10.((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氯-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯</base:Paragraphs>
      <base:Paragraphs id="p1358" num="n1329">
        <base:Image he="497" wi="991" file="GDA0003327089700002982.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1359" num="n1330">((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氯-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯可以如Pinho etal.J.Org.Chem.2017,27,3468描述的方法和实施例1方法合成。下面描述了一个非限制性示例：</base:Paragraphs>
      <base:Paragraphs id="p1360" num="n1331">2,2,2-三氯乙酸异丙酯在Turbo Grignard存在下与(R)-2,2-二甲基-1,3-二氧戊环-4-甲醛偶联，得到(3R)-3-(2,2-二甲基-1,3-二氧戊环-4-基)-2,2-二氯-3-羟基丙酸乙酯，然后如Pinho等人所述在乙酸条件下进行处理和内酯关环。用CBz基团保护后，(2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氟-2-(羟甲基)四氢呋喃-3-醇可以使用与实施例1，部分A，步骤3-6中所述相同的程序合成。</base:Paragraphs>
      <base:Paragraphs id="p1361" num="n1332">如实施例1，部分C中所述，(2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氯-2-(羟甲基)四氢呋喃-3-醇之后偶联至(羟基(苯氧基)磷酰基)-L-丙氨酸异丙酯(1-12)的二氢奎宁盐，得到((S)-(((2R,3R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4,4-二氯-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯:</base:Paragraphs>
      <base:Paragraphs id="p1362" num="n1333">
        <base:Image he="429" wi="1000" file="GDA0003327089700003001.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1363" num="n1334">合成11.((S)-(((2R,3R,4S,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氯-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯</base:Paragraphs>
      <base:Paragraphs id="p1364" num="n1335">
        <base:Image he="501" wi="991" file="GDA0003327089700003002.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1365" num="n1336">(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氯-4-氟-2-(羟甲基)四氢呋喃-3-醇可以采用美国专利US 20150175648描述的方法和实施例1的方法合成.下面描述了一个非限制性示例：</base:Paragraphs>
      <base:Paragraphs id="p1366" num="n1337">
        <base:Image he="306" wi="1000" file="GDA0003327089700003003.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1367" num="n1338">(3S,4R)-3-羟基-4-(羟甲基)环戊烷-1-酮首先被CBz-保护，得到苄基(((1R,2S)-2-((((苄氧基)羰基)氧基)-4-氧代环戊基)甲基)碳酸酯，然后使用NFSI(N-氟苯磺酰亚胺)处理得到苄基(((1R,2R,3S)-2-(((苄氧基)羰基)氧基)-3-氟-4-氧代环戊基)甲基)碳酸酯，中间体然后使用NCS(N-氯代琥珀酰亚胺)处理以获得苄基(((1R,2R,3S)-2-((((苄氧基)羰基)氧基)-3-氟-4-氧代环戊基)甲基)碳酸酯，如美国专利'648中所述。</base:Paragraphs>
      <base:Paragraphs id="p1368" num="n1339">(2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氯-4-氟-2-(羟甲基)四氢呋喃-3-醇之后偶联至(羟基(苯氧基)磷酰基)-L-丙氨酸异丙酯(1-12)的二氢奎宁盐，如实施例1，部分C中所述，以提供((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲氨基)-9H-嘌呤-9-基)-4-氯-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯:</base:Paragraphs>
      <base:Paragraphs id="p1369" num="n1340">
        <base:Image he="423" wi="1000" file="GDA0003327089700003021.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1370" num="n1341">在一个实施方案中，氟化反应提供了“α-氟”和“β-氟”内酯衍生物的混合物，并且通过本领域技术人员已知的常规方法例，如柱色谱或结晶来分离所述化合物以分离这两种非对映体。在该实施方案中，两种非对映异构体都被推进以提供“α-氟”和“β-氟”最终产物：</base:Paragraphs>
      <base:Paragraphs id="p1371" num="n1342">
        <base:Image he="989" wi="992" file="GDA0003327089700003022.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1372" num="n1343">在另一个实施方案中，氟化反应是用N-氟-邻-苯二磺酰亚胺(NFOBS)或选择性氟试剂进行的。</base:Paragraphs>
      <base:Paragraphs id="p1373" num="n1344">实施例3.化合物1A在Huh7细胞中对抗冠状病毒的活性</base:Paragraphs>
      <base:Paragraphs id="p1374" num="n1345">在Huh7细胞中测试了化合物1A对抗人冠状病毒alpha-229E和beta-OC43的活性。</base:Paragraphs>
      <base:Paragraphs id="p1375" num="n1346">
        <base:Image he="603" wi="956" file="GDA0003327089700003031.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1376" num="n1347">Huh7细胞孵育过夜后，以在每孔中产生80-100％汇合单层的浓度接种在96孔板中。将化合物1A溶解在DMSO中至10mg/mL，并在测试培养基(含有5％胎牛血清和50μL庆大霉素的改良Eagle培养基)中制备8个半对数系列稀释液，最高浓度为50μg/mL。96孔板上的5个测试孔中加入100μL的每种浓度，并且3个测试孔在测试培养基中用测试病毒感染(≤100CCID50/孔)。将等量的测试培养基加入剩余的测试孔中以评估对未感染细胞的毒性。6个孔被感染以用作未处理的病毒对照。仅培养基添加到6个孔中作为细胞对照。将板在37℃湿润的5％CO<base:Sub>2</base:Sub>气氛中孵育，直到在显微镜下观察到细胞病变效应(CPE)。</base:Paragraphs>
      <base:Paragraphs id="p1377" num="n1348">为了获得CPE终点，将孔用0.011％中性红色染料染色约2小时。虹吸去除染料并用磷酸盐缓冲盐水冲洗孔一次以除去残留的未掺入的染料。搅拌下加入200μL 50:50Sorensen柠檬酸盐缓冲液/乙醇&gt;30分钟，然后在分光光度计上测量540nm处的吸光度。</base:Paragraphs>
      <base:Paragraphs id="p1378" num="n1349">为了获得病毒产量降低(VYR)终点，将来自每个化合物浓度的3个重复孔的上清液合并，并使用标准终点稀释CCID<base:Sub>50</base:Sub>测定法测量病毒滴度，并使用Reed Muench(1948)方程(Reed,LJ和Muench,H.Am.J.Hygiene 27:493-497(1948))计算滴度。使用回归分析确定将病毒产量降低1log10所需的化合物浓度(EC<base:Sub>90</base:Sub>)。</base:Paragraphs>
      <base:Paragraphs id="p1379" num="n1350">如表1所示，化合物1A能有效对抗α-229E冠状病毒和β-OC43冠状病毒。在病毒产量降低试验中，化合物1A对α-229E的EC<base:Sub>90</base:Sub>值为0.71μM，对β-OC43的EC<base:Sub>90</base:Sub>值为0.29μM。此外，化合物1A对α和β冠状病毒均表现出高CC<base:Sub>50</base:Sub>值和选择性指数(SI)。例如，对于β冠状病毒，当使用病毒产量降低测定法测量时，化合物1A的选择性指数大于170，而在中性红测定法测量时，CC<base:Sub>50</base:Sub>值大于50μM。</base:Paragraphs>
      <base:Paragraphs id="p1380" num="n1351">表1.化合物1A对冠状病毒Alpha-229E和Beta-OC43的活性</base:Paragraphs>
      <base:Paragraphs id="p1381" num="n1352">
        <base:Image he="310" wi="1000" file="GDA0003327089700003041.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1382" num="n1353">目视和中性红SI:CC<base:Sub>50</base:Sub>/EC<base:Sub>50</base:Sub></base:Paragraphs>
      <base:Paragraphs id="p1383" num="n1354">VYR S1:CC<base:Sub>50</base:Sub>/<base:Sub>EC90</base:Sub></base:Paragraphs>
      <base:Paragraphs id="p1384" num="n1355">NT:未测定</base:Paragraphs>
      <base:Paragraphs id="p1385" num="n1356">实施例4.化合物1A和1B在BHK-21和MES-21细胞中对抗冠状病毒的活性</base:Paragraphs>
      <base:Paragraphs id="p1386" num="n1357">在BHK-21细胞(表2A和表2B)和MES-1细胞(表3A和表3B)中测试了化合物1A和化合物1B对抗人冠状病毒的活性。测定EC<base:Sub>50</base:Sub>和CC<base:Sub>50</base:Sub>并与索非布韦进行比较。</base:Paragraphs>
      <base:Paragraphs id="p1387" num="n1358">化合物对抗冠状病毒的活性是基于抑制病毒诱导的细胞致病性，剧烈感染的感染复数(m.o.i.)为0.01。在37℃下孵育3天后，通过Pauwels等人(J.Virol.Methods 1988,20,309-321)所述的MTT方法确定细胞活力。</base:Paragraphs>
      <base:Paragraphs id="p1388" num="n1359">为了确定细胞毒性，将细胞以1x10<base:Sup>6</base:Sup>细胞/mL的初始密度接种在含有Earles’s盐(MEM-E)、L-谷氨酰胺、1mM丙酮酸钠和25mg/L卡那霉素，补充10％胎牛血清的最低必需培养基的96孔板中。然后在不存在或存在测试化合物的系列稀释液的情况下，将细胞培养物在37℃湿润的5％CO<base:Sub>2</base:Sub>气氛中培养。用MTT法测定细胞活力。</base:Paragraphs>
      <base:Paragraphs id="p1389" num="n1360">表2A.选择化合物在BHK-21细胞中对HCoV的活性</base:Paragraphs>
      <base:Paragraphs id="p1390" num="n1361">
        <base:TableDetails num="0001">
          <base:Table>
            <base:Title />
            <tbl:tgroup cols="3">
              <tbl:colspec colname="c001" colwidth="31%" />
              <tbl:colspec colname="c002" colwidth="34%" />
              <tbl:colspec colname="c003" colwidth="34%" />
              <tbl:tbody>
                <tbl:row>
                  <tbl:entry morerows="1">化合物</tbl:entry>
                  <tbl:entry morerows="1"><![CDATA[CC<sub>50</sub>[uM]<sup>a</sup>]]></tbl:entry>
                  <tbl:entry morerows="1"><![CDATA[EC<sub>50</sub>[uM]<sup>b</sup>]]></tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1" />
                  <tbl:entry morerows="1">&gt;100</tbl:entry>
                  <tbl:entry morerows="1">1.6</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1" />
                  <tbl:entry morerows="1">&gt;100</tbl:entry>
                  <tbl:entry morerows="1">2.5</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1" />
                  <tbl:entry morerows="1">&gt;100</tbl:entry>
                  <tbl:entry morerows="1">&gt;100</tbl:entry>
                </tbl:row>
              </tbl:tbody>
            </tbl:tgroup>
          </base:Table>
        </base:TableDetails>
      </base:Paragraphs>
      <base:Paragraphs id="p1391" num="n1362">
        <base:Sup>a</base:Sup>将模拟感染的BHK细胞的活力降低50％需要的化合物浓度(μM)，在孵育3天后通过MTT方法测定</base:Paragraphs>
      <base:Paragraphs id="p1392" num="n1363">
        <base:Sup>b</base:Sup>保持BHK细胞免受病毒诱导的细胞致病性达到50％的保护作用需要的化合物浓度(μM)，在感染后第3天通过MTT方法确定</base:Paragraphs>
      <base:Paragraphs id="p1393" num="n1364">表2B.选择化合物在BHK-21细胞中对抗HCoV的活性</base:Paragraphs>
      <base:Paragraphs id="p1394" num="n1365">
        <base:Image he="64" wi="1000" file="GDA0003327089700003051.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1395" num="n1366">
        <base:Image he="962" wi="1000" file="GDA0003327089700003061.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1396" num="n1367">
        <base:Sup>a</base:Sup>将模拟感染的BHK细胞的活力降低50％需要的化合物浓度(μM)，在孵育3天后通过MTT方法测定</base:Paragraphs>
      <base:Paragraphs id="p1397" num="n1368">
        <base:Sup>b</base:Sup>使BHK细胞免受病毒诱导的细胞致病性达到50％的保护作用需要的化合物浓度(μM)，在感染后第3天通过MTT方法确定</base:Paragraphs>
      <base:Paragraphs id="p1398" num="n1369">表3A.选定化合物在MES-1细胞中对抗HCoV的活性</base:Paragraphs>
      <base:Paragraphs id="p1399" num="n1370">
        <base:Image he="128" wi="1000" file="GDA0003327089700003062.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1400" num="n1371">
        <base:Image he="1000" wi="983" file="GDA0003327089700003071.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1401" num="n1372">
        <base:Sup>c</base:Sup>将模拟感染MES-1细胞的活力降低50％需要的化合物浓度(μM)，在孵育3天后通过MTT方法测定</base:Paragraphs>
      <base:Paragraphs id="p1402" num="n1373">
        <base:Sup>d</base:Sup>使MES-1细胞免受病毒诱导的细胞致病性达到50％的保护作用需要的化合物浓度(μM)，在感染后第3天通过MTT方法确定</base:Paragraphs>
      <base:Paragraphs id="p1403" num="n1374">表3B.选定化合物在MES-1细胞中对抗HCoV的活性</base:Paragraphs>
      <base:Paragraphs id="p1404" num="n1375">
        <base:Image he="136" wi="1000" file="GDA0003327089700003072.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1405" num="n1376">
        <base:Image he="1000" wi="929" file="GDA0003327089700003081.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1406" num="n1377">
        <base:Sup>c</base:Sup>将模拟感染MES-1细胞的活力降低50％需要的化合物浓度(μM)，在孵育3天后通过MTT方法测定</base:Paragraphs>
      <base:Paragraphs id="p1407" num="n1378">
        <base:Sup>d</base:Sup>使MES-1细胞免受病毒诱导的细胞致病性达到50％的保护作用需要的化合物浓度(μM)，在感染后第3天通过MTT方法确定</base:Paragraphs>
      <base:Paragraphs id="p1408" num="n1379">实施例5.化合物1A对抗SARS-CoV和SARS-CoV-2的活性</base:Paragraphs>
      <base:Paragraphs id="p1409" num="n1380">化合物1A在Huh7细胞中针对SARS-CoV和在分化的正常人支气管上皮(dNHBE，也称为HAE(人气道上皮))细胞中针对SARS-CoV-2进行了测试，结果在表4中提供。CC<base:Sub>50</base:Sub>是使用中性红试验确定，EC<base:Sub>90</base:Sub>和SI使用病毒产量减少试验确定。EC<base:Sub>90</base:Sub>以μg/mL和μM提供。化合物1A对SARS-CoV的EC<base:Sub>90</base:Sub>为0.34μM，对SARS-CoV-2的EC<base:Sub>90</base:Sub>为0.64μM。</base:Paragraphs>
      <base:Paragraphs id="p1410" num="n1381">表4.化合物1A对抗SARS-CoV和SARS-CoV-2的活性</base:Paragraphs>
      <base:Paragraphs id="p1411" num="n1382">
        <base:Image he="492" wi="1000" file="GDA0003327089700003091.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1412" num="n1383">
        <base:Sup>1</base:Sup>CC<base:Sub>50</base:Sub>是通过目视检查细胞来估计的</base:Paragraphs>
      <base:Paragraphs id="p1413" num="n1384">
        <base:Sup>2</base:Sup>值表示两次重复EC<base:Sub>90</base:Sub>测定，0.33和0.41μg/mL</base:Paragraphs>
      <base:Paragraphs id="p1414" num="n1385">在中性红(NR)试验中，在感染了SARS-CoV(Urbani)的Huh-7细胞中评估了化合物1A的活性以评估细胞毒性，然后使用病毒产量降低(VYR)试验进行测试以评估抗病毒活性。</base:Paragraphs>
      <base:Paragraphs id="p1415" num="n1386">中性红测定：将化合物1A以10mg/mL的浓度溶解在100％DMSO中，并在测试培养基(补充有5％FBS和50μg/mL庆大霉素的最低必需培养基)中使用8个半对数稀释进行系列稀释。起始(高)测试浓度为50μg/mL。将每个稀释液添加到96孔板的5个测试孔中，其中含有80-100％覆盖度的Huh7或RD细胞(仅限hCoV beta OC43)。每个稀释度的三个测试孔用病毒感染，两个测试孔保持未感染作为毒性对照。六个未处理的测试孔被感染作为病毒对照，而六个未处理的测试孔未被感染用作细胞对照。病毒被稀释到每毫升特定的50％细胞培养感染剂量(CCID<base:Sub>50</base:Sub>)，以实现最低可能的感染复数(MOI)，在5-7天内产生&gt;80％的毒性。MOI为0.03CCID<base:Sub>50</base:Sub>/细胞。板在37±2℃、5％CO<base:Sub>2</base:Sub>下孵育。</base:Paragraphs>
      <base:Paragraphs id="p1416" num="n1387">在感染后(p.i.)第7天，将板用中性红色染料染色约2小时(±15分钟)。去除上清染料，用PBS冲洗孔，并在50:50的Sorensen柠檬酸盐缓冲液/乙醇中提取掺入的染料&gt;30分钟，并在分光光度计上在540nm处读取光密度。将光密度转化为细胞对照的百分比，并计算在没有病毒的情况下引起50％细胞死亡所需的化合物1A浓度(CC<base:Sub>50</base:Sub>)。选择性指数(SI)是CC<base:Sub>50</base:Sub>除以EC<base:Sub>50</base:Sub>。</base:Paragraphs>
      <base:Paragraphs id="p1417" num="n1388">病毒产量降低试验：将Vero76细胞接种在96孔板中并过夜(37℃)生长至80％汇合。在感染后第3天收集来自每个化合物浓度的上清液样品(合并3个测试孔)，并使用标准终点稀释CCID<base:Sub>50</base:Sub>测定法测试病毒滴度，并使用Reed-Muench(1948)方程(Reed,LJ和Muench,H.Am.J.Hygiene 27:493-497(1948))计算滴度。通过回归分析计算将病毒产量降低1log10所需的化合物浓度(EC<base:Sub>90</base:Sub>)。</base:Paragraphs>
      <base:Paragraphs id="p1418" num="n1389">接下来使用分化的正常人支气管上皮(dNHBE；HAE(人气道上皮)细胞，由MatTekCorporation(Ashland,MA)定制)评估化合物1A的抗病毒活性。</base:Paragraphs>
      <base:Paragraphs id="p1419" num="n1390">细胞培养：dNHBE细胞在6毫米网孔盘上生长，并以带有12孔或24孔transwell插入物的试剂盒形式提供。在运输过程中，组织被固定在一片琼脂糖上，收到后将其移除。估计一个插入物由大约1.2x10<base:Sup>6</base:Sup>个细胞组成。细胞插入物试剂盒(EpiAirwayTM AIR-100，AIR-112)来自单个供体，#9831，一名23岁、健康、不吸烟的白人男性。细胞在形成层方面具有独特的特性，其顶端仅暴露在空气中并形成粘蛋白层。到达后，根据制造商的说明书将细胞transwell插入物立即转移到6孔板的各个孔中，并将1mL的MatTek专有培养基(AIR-100-MM)添加到基底侧，而顶端暴露在潮湿的5％CO<base:Sub>2</base:Sub>环境中。实验开始前，细胞在37℃培养1天。24小时平衡期后，细胞顶端分泌的粘蛋白层使用400μL预热的30mM HEPES缓冲盐溶液3X洗涤去除。在洗涤步骤之后补充培养基。</base:Paragraphs>
      <base:Paragraphs id="p1420" num="n1391">病毒：病毒在感染前在AIR-100-MM培养基中稀释，产生每个细胞大约0.0015CCID<base:Sub>50</base:Sub>的感染复数(MOI)。</base:Paragraphs>
      <base:Paragraphs id="p1421" num="n1392">实验设计：将每种化合物处理(120μL)和病毒(120μL)应用于顶侧。同时，将化合物处理(1mL)应用于基底侧，孵育2小时。作为病毒对照，一些细胞用安慰剂(仅细胞培养基)处理。感染2小时后，去除顶端培养基，并用新鲜化合物或培养基(1mL)替换基底侧。细胞保持在气液界面。在第5天，通过目测评估安慰剂处理的插入物的细胞毒性(CC<base:Sub>50</base:Sub>值)，从所有插入物中取出培养基并从基底侧丢弃。通过添加400μL在37℃下预热的培养基收获释放到dNHBE细胞顶端隔室中的病毒。将内容物孵育30分钟，充分混合，收集，彻底涡旋并铺板在Vero 76细胞上进行VYR滴定。重复孔用于病毒对照和细胞对照。</base:Paragraphs>
      <base:Paragraphs id="p1422" num="n1393">每个处理的细胞培养物的病毒滴度测定：将Vero76细胞接种在96孔板中并过夜(37℃)生长至汇合。含有病毒的样品在感染培养基中以10倍的增量稀释，每种稀释度的200μL转移到96孔微量滴定板的各个孔中。每个稀释度使用四个微孔来确定50％的病毒终点。孵育5天后，如果与未感染的对照相比观察到任何细胞病变效应(CPE)，则每个孔的病毒评分为阳性，并在第6天和第7天确认计数为终点。能够感染50％培养细胞的病毒剂量(CCID<base:Sub>50</base:Sub>每0.1mL)通过Reed-Muench方法(1948)(Reed,LJ and Muench,H.Am.J.Hygiene 27:493-497(1948))来计算，和90％有效浓度(EC<base:Sub>90</base:Sub>(将病毒产量降低1log10的浓度)通过回归分析确定。报告第5天的值。未处理、未感染的细胞用作细胞对照。</base:Paragraphs>
      <base:Paragraphs id="p1423" num="n1394">实施例6.化合物1A和其他口服抗病毒药物对各种人类冠状病毒的体外活性</base:Paragraphs>
      <base:Paragraphs id="p1424" num="n1395">在各种细胞系中进行化合物1A和其他口服抗病毒药物对抗各种人类冠状病毒(表5)的测试。数据表明化合物1A对抗多种CoVs的有效体外活性，针对HCoV-229E、HCoV-OC43、SARS-CoV-1和SARS-CoV-2的EC<base:Sub>90</base:Sub>值范围分别为0.34至1.2μM，而对抗MERS-CoV的活性较低(平均EC<base:Sub>90</base:Sub>＝36μM)。</base:Paragraphs>
      <base:Paragraphs id="p1425" num="n1396">表5.化合物1A和其他口服抗病毒药物对抗人类冠状病毒的活性</base:Paragraphs>
      <base:Paragraphs id="p1426" num="n1397">
        <base:Image he="60" wi="1000" file="GDA0003327089700003111.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1427" num="n1398">
        <base:Image he="879" wi="1000" file="GDA0003327089700003121.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1428" num="n1399">
        <base:Sup>a</base:Sup>2次实验(1.6和2.0μM)的平均值</base:Paragraphs>
      <base:Paragraphs id="p1429" num="n1400">
        <base:Sup>b</base:Sup>通过染料染色确定的EC<base:Sub>50</base:Sub>(病毒产量减少实质上高估了细胞毒性化合物的抗病毒效力)</base:Paragraphs>
      <base:Paragraphs id="p1430" num="n1401">
        <base:Sup>c</base:Sup>CC<base:Sub>50</base:Sub>/EC<base:Sub>50</base:Sub></base:Paragraphs>
      <base:Paragraphs id="p1431" num="n1402">
        <base:Sup>d</base:Sup>未测定(该病毒在该细胞系中没有细胞病变效应)</base:Paragraphs>
      <base:Paragraphs id="p1432" num="n1403">
        <base:Sup>e</base:Sup>通过目检查细胞单层评估细胞毒性</base:Paragraphs>
      <base:Paragraphs id="p1433" num="n1404">
        <base:Sup>f</base:Sup>两次重复(0.57和0.70μM)的平均值</base:Paragraphs>
      <base:Paragraphs id="p1434" num="n1405">
        <base:Sup>g</base:Sup>两次重复(0.52和0.42μM)的平均值</base:Paragraphs>
      <base:Paragraphs id="p1435" num="n1406">
        <base:Sup>h</base:Sup>两次重复(4.7和3.1μM)的平均值</base:Paragraphs>
      <base:Paragraphs id="p1436" num="n1407">BHK-21，幼仓鼠肾细胞系</base:Paragraphs>
      <base:Paragraphs id="p1437" num="n1408">Huh-7，人肝细胞癌细胞系(已确定从化合物1A形成三磷酸酯的能力)</base:Paragraphs>
      <base:Paragraphs id="p1438" num="n1409">RD，人横纹肌肉瘤细胞系(未知从化合物1A形成三磷酸酯的能力)HAE，人气道上皮细胞培养物(已确定从化合物1A形成三磷酸酯的能力)(已确定从化合物1A形成三磷酸酯的能力)</base:Paragraphs>
      <base:Paragraphs id="p1439" num="n1410">在初步筛选中，将被季节性人类alpha冠状病毒HCoV-229E急性感染的BHK-21细胞暴露于化合物1A的系列稀释液中。经过3天的孵育，从两个独立的实验中获得对病毒诱导的细胞病变效应(CPE)的50％抑制所需的化合物1A的有效浓度(EC<base:Sub>50</base:Sub>)平均为1.8μM。相比之下，2'-氟-2'-甲基尿苷核苷酸前药索非布韦在高达100μM的浓度下不抑制HCoV-229E复制(表5)。两种药物均未检测到毒性。然后在基于Huh-7细胞的测定中评估了化合物1A对抗HCoV-229E、HCoV-OC43(另一种季节性人类冠状病毒株)、MERS-CoV和SARS-CoV-1的体外效力。这种人肝癌细胞系的选择是基于其在细胞内将化合物1A激活为其三磷酸酯代谢物的能力，这与Good,S.S.等人报道(Good,S.S.et al.PLoS One 15(1),e0227104(2020))的MRC-5细胞不同，在MRC-5细胞中，化合物1A缺乏针对HCoV-229E的活性(EC<base:Sub>50</base:Sub>&gt;100μM)。在Huh-7细胞暴露于病毒和测试化合物系列稀释物后，通过两种不同的方法评估抗病毒活性，测试方法是：1)5天(229E和OC43)或7天(MERS和SARS)孵育后通过中性红色染料染色测定病毒诱导的CPE，和2)将传染性病毒分泌到培养基中减少90％需要的有效浓度(EC<base:Sub>90</base:Sub>)，经过3天的孵化，使用标准终点稀释CCID<base:Sub>50</base:Sub>测定来确定病毒产量减少(VYR)。在不存在病毒的情况下，通过化合物处理的重复的中性红染色，测量半数最大细胞毒性(CC<base:Sub>50</base:Sub>)。尽管在感染了HCoV-OC43或SARS-CoV-1的Huh-7细胞中获得了稳健的VYR终点，但未观察到CPE，并且未通过这些病毒获得使用中性红染色的EC50值。分别测定化合物1A对HCoV-229E、HCoV-OC43和SARS-CoV-1的EC<base:Sub>90</base:Sub>值的范围为0.34至1.2μM，而针对MERS-CoV的值平均为37μM(表5)。化合物1A在浓度高达86μM(测试的最高浓度)时未检测到细胞毒性。</base:Paragraphs>
      <base:Paragraphs id="p1440" num="n1411">氯喹和羟氯喹似乎对HCoV-229E和HCoV-OC43非常有效，根据使用VYR测量获得EC<base:Sub>90</base:Sub>值&lt;0.05μM(表5)。使用中性红测定获得的这两种药物的各自EC50值(8.1和7.4μM)显著更高，仅比相应的CC<base:Sub>50</base:Sub>值低2.6至3.6倍，表明效力相当低且选择性指数较差。这些差异说明仅使用VYR测量来评估细胞毒性化合物的抗病毒活性存在固有误差。当细胞被有毒药物中毒并走向死亡时，它们支持病毒复制和繁殖的能力以及自身健康可能会大大减弱。在通过染色检测到细胞死亡时，病毒产量减少的测量可能反映了抗病毒活性和细胞毒性的组合，从而高估了抗病毒效力。</base:Paragraphs>
      <base:Paragraphs id="p1441" num="n1412">与Wang,M.等人(Cell Research 2020,30,269)发表的数据相反，Huh-7细胞不允许SARS-CoV-2复制。使用人气道上皮(HAE)细胞制剂开发了一种检测方法，这是一种高度相关的肺体外模型，已被确立为比SARS-CoV-2复制的细胞系更具代表性的系统(Jomsdottir,HR,Virol.J.13,24(2016))。这些原代细胞形成极化单层，其顶端暴露在空气中并产生粘蛋白层，与人类呼吸道的生理学一致(Jomsdottir,H.R.,Virol.J.13,24(2016))。来自两个单独的HAE测定(分别为0.5和&gt;86μM)的化合物1A对抗SARS-CoV-2的平均EC<base:Sub>90</base:Sub>和CC<base:Sub>50</base:Sub>值与HCoV-OC43和SARS-CoV-1获得的值范围相同(表5)。</base:Paragraphs>
      <base:Paragraphs id="p1442" num="n1413">在第二HAE测定中，化合物1A的活性与N<base:Sup>4</base:Sup>-羟基胞苷平行测试，最近报道了针对SARS-CoV-2的体外和体内活性(Sheahan,TP等人Sci.Transl.Med.12,eabb5883(2020))。在同一实验中，N<base:Sup>4</base:Sup>-羟基胞苷对SARS-CoV-2的效力(EC<base:Sub>90</base:Sub>＝3.9μM)比化合物1A的效力低8倍。</base:Paragraphs>
      <base:Paragraphs id="p1443" num="n1414">观察到MERS-CoV和其他CoV之间化合物1A活性的存在30倍的差异。核苷酸和核苷酸类似物的选择是在CoV RdRp活性位点实现的，nsp12基因产物由其辅助因子nsp7和nsp8的持续合成激活(Subissi,L.,Proc.Natl.Acad.Sci.USA 111(37)3900-9(2014))。保守氨基酸基序A和C参与磷酸二酯键的形成，而基序F和B分别参与核苷酸通道和活性位点的结合。在这些必要基序中，MERS-CoV和其他CoV之间没有明显的结构差异。由于化合物1A和索非布韦之间有类似的核糖修饰，索非布韦选择性缺乏活性不太可能归因于nsp14携带的CoV核酸外切酶的切除(Ferron,F.,Proc.Natl.Acad.Sci.USA 115(2)162-171(2018))。</base:Paragraphs>
      <base:Paragraphs id="p1444" num="n1415">细胞、抗病毒药物和病毒</base:Paragraphs>
      <base:Paragraphs id="p1445" num="n1416">BHK-21(幼仓鼠肾)细胞、Huh-7(人肝癌)细胞、RD(人横纹肌肉瘤)细胞和季节性人冠状病毒(HCoV-229E和HCoV-OC43)获自美国典型培养物保藏中心，马纳萨斯，弗吉尼亚州。MERS-CoV(EMC)、SARS-CoV-1(Urbani)和SARS-CoV-2(USA-WA1/2020)由佐治亚州亚特兰大市疾病控制与预防中心提供。HAE细胞制剂(EpiAirwayTM AIR-100或AIR-112)购自马萨诸塞州亚什兰的MatTek Corporation。化合物1A和N<base:Sup>4</base:Sup>-羟基胞苷分别由中国上海TopharmanShanghai Co.,Ltd.和法国Montpellier Oxeltis为Atea Pharmaceuticals制备。氯喹和羟氯喹购自Mason-Chem,Palo Alto,CA，以及sofosbuvir购自Pharma Sys,Inc.,Cary,NC。</base:Paragraphs>
      <base:Paragraphs id="p1446" num="n1417">抗病毒检测</base:Paragraphs>
      <base:Paragraphs id="p1447" num="n1418">BHK-21细胞：将测试化合物以100mM溶解在DMSO中，然后在含有1mM丙酮酸钠和25μg/mL卡那霉素的Earle’s盐(MEM-E)最低必需培养基中稀释，并补充10％FBS(生长培养基)至100、20、4和0.8μM的最终浓度(每个有两个24孔重复板)。BHK-21细胞在96孔板中生长至汇合后，将生长培养基更换为新鲜的维持培养基(含有1％灭活FBS代替10％FBS的生长培养基)，其中含有多次稀释的测试化合物和0.01的感染复数(MOI)的HCoV-229E。在连续稀释的化合物存在下未感染的细胞用于评估化合物的细胞毒性。在37℃湿润的5％CO<base:Sub>2</base:Sub>环境中培养3天后，通过MTT方法测定细胞活力(Pauwels,R et al.J.Virol.Methods 20(4):309-321(1988))。防止50％的病毒诱导的细胞病变效应(CPE)需要的测试化合物有效浓度(EC<base:Sub>50</base:Sub>)和在没有病毒的情况下引起50％细胞死亡需要的测试化合物有效浓度(CC<base:Sub>50</base:Sub>)通过回归分析计算。</base:Paragraphs>
      <base:Paragraphs id="p1448" num="n1419">Huh-7和RD细胞：使用中性红测定法评估测试化合物对人类冠状病毒alpha(229E)、beta(OC43)、MERS(EMC)和SARS(Urbani)的抗病毒活性，以确定对病毒诱导的和化合物诱导的CPE，并使用病毒产量降低(VYR)测定作为对病毒诱导的CPE抑制的第二个独立测定。</base:Paragraphs>
      <base:Paragraphs id="p1449" num="n1420">中性红测定：将测试化合物以10mg/mL的浓度溶解在DMSO中，并在测试培养基(补充有5％FBS和50μg/mL庆大霉素的最低必需培养基)中使用8个半对数稀释进行系列稀释，以便获得最高50μg/mL的测试浓度。将每个稀释液添加到96孔板的5个测试孔中，其中含有80-100％汇合的Huh-7或RD细胞(仅OC43)。每个稀释度的三个测试孔用病毒感染，两个测试孔保持未感染作为毒性对照。六个未处理的测试孔被感染作为病毒对照，而六个未处理的测试孔未感染以用作病毒对照。对于229E、OC43、MERS和SARS，病毒被稀释到MOI分别为每细胞0.003、0.002、0.001和0.03CCID50。将测试板在37±2℃下在含有5％CO<base:Sub>2</base:Sub>的潮湿气氛中孵育。</base:Paragraphs>
      <base:Paragraphs id="p1450" num="n1421">在感染后第5天(229E和OC43)或第7天(MERS和SARS)，当未处理的病毒对照孔达到最大CPE时，将平板用中性红色染料染色约2小时(±15分钟)。去除上清液染料，用PBS冲洗孔，并在50:50的Sorensen柠檬酸盐缓冲液/乙醇中提取掺入的染料&gt;30分钟，并在分光光度计上在540nm处读取光密度。将光密度转换为对照的百分比，并计算防止病毒诱导的CPE50％(EC<base:Sub>50</base:Sub>)和在没有病毒的情况下导致50％细胞死亡(CC<base:Sub>50</base:Sub>)所需的测试化合物浓度。</base:Paragraphs>
      <base:Paragraphs id="p1451" num="n1422">病毒产量降低试验：将Vero 76细胞接种在96孔板中并过夜(37℃)生长至汇合。在感染后第3天收集来自每个化合物浓度的上清液样品(合并3个孔)，并使用标准终点稀释CCID<base:Sub>50</base:Sub>测定和使用Reed-Muench方程(1948)(Reed,LJ and Muench,H.Am.J.Hygiene 27:493-497(1948))，并且通过回归分析确定将病毒产量降低90％所需的化合物浓度(EC<base:Sub>90</base:Sub>)。</base:Paragraphs>
      <base:Paragraphs id="p1452" num="n1423">HAE细胞的制备</base:Paragraphs>
      <base:Paragraphs id="p1453" num="n1424">使用定制的人气道上皮(HAE)细胞评估了测试化合物对抗SARS-CoV-2(USA-WA1/2020)的抗病毒活性。</base:Paragraphs>
      <base:Paragraphs id="p1454" num="n1425">细胞培养：HAE细胞在6毫米网孔盘上生长，并以带有12孔或24孔transwell插入物的试剂盒形式提供。在运输过程中，组织被固定在一张琼脂糖上，收到后将其取出。估计一个插入物由大约1.2x10<base:Sup>6</base:Sup>个细胞组成。细胞插入物试剂盒(EpiAirway<base:Sup>TM</base:Sup> AIR-100、AIR-112)来自单个供体，#9831，一名23岁、健康、不吸烟的白人男性。细胞在形成极化单层，其顶端仅暴露在空气中并形成粘蛋白层。到达后，根据制造商的说明将细胞transwell插入物立即转移到6孔板的各个孔中，并将1mL的MatTek专有培养基(AIR-100-MM)添加到基底侧，而顶端暴露在潮湿的5％CO<base:Sub>2</base:Sub>环境中。实验开始前，细胞在37℃培养1天。24小时平衡期后，细胞顶端分泌的粘蛋白层使用400μL预热的30mM HEPES缓冲盐溶液3X洗涤去除。在洗涤步骤之后补充培养基。</base:Paragraphs>
      <base:Paragraphs id="p1455" num="n1426">病毒：病毒在感染前在AIR-100-MM培养基中稀释以产生当添加到培养物中时的感染复数(MOI)每细胞大约0.0015CCID50。</base:Paragraphs>
      <base:Paragraphs id="p1456" num="n1427">实验设计：将每种化合物处理(120μL)和病毒(120μL)应用于顶侧。同时，将化合物处理(1mL)应用于基底侧，孵育2小时。作为病毒对照，一些细胞用安慰剂(仅细胞培养基)处理。感染2小时后，去除顶端培养基，并用新鲜化合物或培养基(1mL)替换基底侧。细胞保持在气液界面。在第5天，通过目测评估未感染的、化合物处理的插入物的细胞毒性(CC<base:Sub>50</base:Sub>值)。从所有插入物中取出培养基并从基底侧丢弃。通过添加400μL在37℃下预热的培养基收集释放到HAE细胞顶端隔室中的病毒。将内容物孵育30分钟，充分混合，收集，彻底涡旋并铺板在Vero 76细胞上进行VYR滴定。单独的孔用于病毒对照，重复孔用于未处理的细胞对照。如上所述方法测定来自每个处理培养物的病毒滴度。</base:Paragraphs>
      <base:Paragraphs id="p1457" num="n1428">实施例7.人鼻和支气管细胞中的化合物1A三磷酸酯水平</base:Paragraphs>
      <base:Paragraphs id="p1458" num="n1429">将化合物1A(10μM)与人鼻和支气管上皮细胞一式三份孵育8小时。在对单个测试物品的8小时暴露结束时，去除培养基并用Hepes缓冲盐水溶液(HBSS)洗涤细胞层。去除HBSS，然后加入不含测试物的新鲜细胞培养基。在取出试验品后0、15、24、48和72小时，除去细胞外培养基，用HBSS冲洗细胞层。将细胞从平板上刮下并悬浮在含有内标AT 9005的60％冷甲醇水溶液中，并储存在约-20℃。然后离心进行LC/MS/MS分析化合物1A、化合物1-6的相应三磷酸酯代谢物的形成(方案1)。表6提供了每个时间点的三磷酸酯代谢物化合物1-6的平均细胞内浓度。图1是化合物1-6在每个暴露后时间点在支气管细胞和鼻细胞中的浓度图。鼻细胞的半衰期(t1/2)为38小时，支气管细胞为39小时。支气管细胞中的三磷酸酯水平高于鼻细胞，但两者都形成了显著水平的三磷酸酯。两种细胞的半衰期都超过1.5天，并且在高达100μM时未观察到毒性。</base:Paragraphs>
      <base:Paragraphs id="p1459" num="n1430">表6.支气管和鼻细胞中三磷酸酯浓度的细胞内浓度</base:Paragraphs>
      <base:Paragraphs id="p1460" num="n1431">
        <base:Image he="629" wi="1000" file="GDA0003327089700003181.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1461" num="n1432">
        <base:Sup>1</base:Sup>使用平均体积1320微米<base:Sup>3</base:Sup>对于肺泡I型和II型上皮细胞计算(Crapo,J.D.etal.1982Am.Rev.Respir.Dis.126(2):332-7.doi:10.1164/arrd.1982.126.2.332.)</base:Paragraphs>
      <base:Paragraphs id="p1462" num="n1433">图2和图3分别是在每个时间点支气管和鼻细胞中三磷酸酯水平的条形图。图2和3比较了由化合物1A形成的三磷酸酯水平与由ALS-8112(如下所示)和4'-Me取代的前药(((S)-(((2R,3R,4R,5R)-5-(2-氨基-6-(甲胺基)-9H-嘌呤-9-基)-4-氟-3-羟基-2,4-二甲基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸异丙酯，如下左图所示)形成的三磷酸酯水平。ALS-8112是一种临床有效的抗RSV药物，在RSV感染的HAE细胞中的体外EC<base:Sub>90</base:Sub>为1.3–2.7μM(Deval,J.等人，2015PLoS Pathog 11(6):e1004995)。</base:Paragraphs>
      <base:Paragraphs id="p1463" num="n1434">
        <base:Image he="379" wi="542" file="GDA0003327089700003191.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1464" num="n1435">如图2和3所示，与ALS-8112或4'-Me取代的前药相比，化合物1A在人支气管和鼻细胞中形成的三磷酸酯明显更多。在与浓度为10μM的每种药物孵育8小时结束时，来自化合物1A的三磷酸酯与ALS-8112和4'-Me取代的前药的比例在支气管细胞中分别为2和84，在鼻细胞中分别为1和14。冲洗后15小时，来自化合物1A的三磷酸酯与ALS-8112和4'-Me取代的前药的比率在支气管细胞中分别为5和54，在鼻细胞中分别为3和8。</base:Paragraphs>
      <base:Paragraphs id="p1465" num="n1436">实施例8.口服施用化合物2A后非人灵长类动物组织中的三磷酸酯水平</base:Paragraphs>
      <base:Paragraphs id="p1466" num="n1437">对非人灵长类动物施用为期三天的化合物2A口服给药方案以达到稳态水平。灵长类动物施用一次60mg/kg剂量，然后施用五次30mg/kg剂量每12小时(剂量从100mg负荷剂量+550mg每天两次(BID)的临床给药方案异速调整)。</base:Paragraphs>
      <base:Paragraphs id="p1467" num="n1438">测定代谢物化合物1A、化合物1-2和三磷酸酯替代物化合物1-7的血浆PK。在倒数第二次给药之前和之后的0.5、1、2、4、6、8和12小时(在最后一次给药之前)，从3只猴子获得血样并与EDTA混合。然后通过离心制备血浆并通过LC-MS/MS分析化合物1A、化合物1-2和化合物1-7的浓度。(三磷酸酯化合物1-6在细胞中产生并且不会离开。因此在血浆中无法测量。但是，5'-OH代谢物化合物1-7(参见方案1)从细胞中输出，因此可在血浆中测量，并可作为细胞内活性代谢物化合物1-6的替代物。)代谢物的血浆PK数据在表7中给出。</base:Paragraphs>
      <base:Paragraphs id="p1468" num="n1439">表7.化合物2A给药后代谢物1A、1-2和1-7的血浆PK数据</base:Paragraphs>
      <base:Paragraphs id="p1469" num="n1440">
        <base:Image he="368" wi="1000" file="GDA0003327089700003201.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1470" num="n1441">图4、5和6分别是化合物1A、化合物1-2和化合物1-7的平均血浆分布图，在非人灵长类动物中继续施用口服剂量的化合物2A(30mg/kg BID 3天)。化合物1-2(中间前药)和化合物1-7(细胞内TP水平的替代物)的血浆谷浓度(0和12小时时间点的平均值)分别为0.20和0.11μM。曲线显示化合物1A快速转化为化合物1-2和化合物1-7(三磷酸酯化合物1-6的替代物)。</base:Paragraphs>
      <base:Paragraphs id="p1471" num="n1442">在最后一次给药后12、24和48小时(每个时间点3只雄性)测定三磷酸酯化合物1-6、化合物1A和其他代谢物的肺、肾和肝组织水平，如图7A和图7B所示。如上所述，给三只雄性非幼稚食蟹猴施用60mg/kg负荷剂量，然后施用五次30mg/kg剂量每12小时。在最后一次给药后的12、24和48小时，在每个时间点从三只麻醉动物收集血浆、肺、肾和肝组织样本，并立即在液氮中速冻。使用Polytron将大约0.5g的每个组织样品均质化到5倍体积(5mL/g)70％甲醇：30％268mM EDTA中，调节至pH 7.8，并在试管中含有适当的内标，浸入到干冰：乙醇浴中。通过LC-MS/MS分析匀浆中的化合物1A、化合物1-2、化合物1-6和化合物1-7的浓度。</base:Paragraphs>
      <base:Paragraphs id="p1472" num="n1443">肺、肾和肝非人灵长类动物组织中活性代谢物三磷酸酯化合物1-6的谷值(12小时)水平分别为0.14μM、0.13μM和0.09μM。在12小时稳态谷值水平时，肺中的三磷酸酯物质浓度是肝脏的1.6倍。表8提供了在每个时间点肺、肾和肝组织中三磷酸酯代谢物化合物1-6的平均细胞内浓度。如图7A所示，化合物1-6在肺、肾和肝中的半衰期分别为9.4小时、8.0小时和4.3小时。化合物1-6的半衰期通过将ln(2)除以k确定，k是化合物1-6浓度下降的速率常数，从线性回归分析后的ln(组织浓度)对时间曲线的斜率获得。</base:Paragraphs>
      <base:Paragraphs id="p1473" num="n1444">表8.肺、肾和肝细胞中化合物2A三磷酸酯浓度的细胞内浓度</base:Paragraphs>
      <base:Paragraphs id="p1474" num="n1445">
        <base:Image he="531" wi="1000" file="GDA0003327089700003211.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1475" num="n1446">
        <base:Sup>1</base:Sup>分别使用0.75和0.9mL/g肺和肝脏的非间质体积以及0.83mL/g肾脏的假定体积计算(Mandikian,D.et al.2018AAPS Journal 20(6):107.doi.org/10.1208/s12248-018-0264-z.)</base:Paragraphs>
      <base:Paragraphs id="p1476" num="n1447">实施例9.基于化合物1-6在非人灵长类动物中的组织水平预测三磷酸酯化合物1-6的人肺和肾浓度</base:Paragraphs>
      <base:Paragraphs id="p1477" num="n1448">如(Good,S.S.et al.2020PLoS ONE 15(1):e0227104)中所述，测定了使用10μM化合物1A孵育的人和猴肝细胞中三磷酸酯化合物1-6的水平。图8是比较两个物种中的水平的图，并且如图所示，通过AUC<base:Sub>0-24</base:Sub>值评估，人肝细胞中的三磷酸酯化合物1-6浓度是非人灵长类(猴)肝细胞中的7倍。数据也见表9。使用3.4x10-9mL(14)的肝细胞体积计算细胞内浓度，化合物1-6在人肝细胞中的8小时峰值为26±1μM，而猴肝细胞中最高浓度在4小时时为3.1±0.1μM。</base:Paragraphs>
      <base:Paragraphs id="p1478" num="n1449">表9.猴和人肝细胞内三磷酸酯浓度的细胞内浓度</base:Paragraphs>
      <base:Paragraphs id="p1479" num="n1450">
        <base:Image he="526" wi="1000" file="GDA0003327089700003221.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1480" num="n1451">
        <base:Sup>1</base:Sup>使用肝细胞体积3.4x10<base:Sup>-9</base:Sup>mL计算(Lodish,H.et al.2000Molecular CellBiology(fifth edition),W.H.Freeman and Co..New York.P.10。</base:Paragraphs>
      <base:Paragraphs id="p1481" num="n1452">基于人与猴三磷酸酯化合物1-6的浓度的比率(7.0)，确定了预测的人组织中水平，通过在原代肝细胞中的体外形式测定三磷酸酯化合物1-6的浓度。猴中三磷酸酯化合物1-6的实际组织水平和人类中预测的组织水平显示在表10中。1100mg LD(负荷剂量)+550mgBID(每天两次)的临床给药方案预计可实现肺细胞内三磷酸酯化合物1-6的谷水平(12小时)高于化合物2A在HAE细胞培养物中对抗SARS-CoV-2复制的体外EC<base:Sub>90</base:Sub>。预计该给药方案中的三磷酸酯水平将始终高于化合物2A对抗SARS-CoV-2的体外EC<base:Sub>90</base:Sub>。预测是保守的(至少对于肺而言)，因为以BID剂量，与非人灵长类动物肺组织(9.4小时)相比，人支气管/鼻细胞中的ling三磷酸酯半衰期(38小时)预测人类具有更高的稳态水平，但这并未考虑到预测中。</base:Paragraphs>
      <base:Paragraphs id="p1482" num="n1453">表10.化合物1-6的实际(猴子)和预测(人类)组织水平</base:Paragraphs>
      <base:Paragraphs id="p1483" num="n1454">
        <base:Image he="216" wi="1000" file="GDA0003327089700003231.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1484" num="n1455">实施例10.人肺组织中三磷酸酯化合物1-6的细胞内浓度的模拟</base:Paragraphs>
      <base:Paragraphs id="p1485" num="n1456">化合物1-7(三磷酸酯化合物1-6的替代物，因为无法在血浆中测量化合物1-6)的血浆浓度曲线，从接受600mg QD剂量的化合物2A(相当于553mg化合物1A游离碱)持续7天的受试者(N＝18)获得，作为AT-01B-001研究的一部分(如Berliba,e.etal.2019Antimicrob.Agents Chemother.63(12):e01201-19的图1和表3中所述)。使用Monolix Suite 2019Suite 2019(Lixosoft,Antony,France)对这些曲线进行群体药代动力学(PPK)分析。然后使用获得的PPK参数以及相关的方差和协方差矩阵，使用MonolixSuite的Simulx模块模拟化合物1-7在各种给药方案下的血浆PK曲线。</base:Paragraphs>
      <base:Paragraphs id="p1486" num="n1457">假设1)化合物1-7的肺三磷酸酯水平是其核苷代谢物化合物1-7的血浆水平的1.6倍，基于在猴子中获得的化合物1-6的肺-肝浓度的比率；2)在HAE细胞制剂中，化合物1A对SARS-CoV-2的体外平均EC<base:Sub>90</base:Sub>约为0.55uM。在这些假设下，模拟的肺化合物1-6水平在施用1100mg负荷剂量后不久将超过体外EC<base:Sub>90</base:Sub>，并在剩余天数保持550BID维持剂量后保持高于EC<base:Sub>90</base:Sub>。在5天的过程中模拟的肺部化合物1-6浓度显示在图9中。</base:Paragraphs>
      <base:Paragraphs id="p1487" num="n1458">还进行了额外的模拟。使用来自每天给予550mg化合物2A剂量的受试者的血浆化合物1-7的公开数据(描述于Berliba,e.et al.2019Antimicrob.Agents Chemother.63(12):e01201-19)基于在猴子中观察到的肺-肝化合物1-6浓度比也适用于人类的假设，放大了1.6倍，模拟化合物2A 550mg BID给药方案5天(图10)的人肺化合物1-6水平的动力学。对于该给药方案，人肺中活性三磷酸酯化合物1-6的预期稳态峰值和谷值水平分别为1.5和0.9μM。第二种方法使用相同的模拟血浆化合物1-7数据预测人肺化合物1-6浓度，但通过因子1.2校正血浆值，这是平均稳态12小时肺化合物1-6在猴子中的浓度与血浆中化合物1-7的浓度的比率。该预测为人肺三磷酸酯浓度的峰值和谷值分别提供了1.1和0.7μM的估计值。</base:Paragraphs>
      <base:Paragraphs id="p1488" num="n1459">根据这两种方法，从首次给药后几小时内到给药期结束，化合物1-6的预测人肺水平超过了在HAE细胞中对抗SARS-CoV-2复制观察到的EC<base:Sub>90</base:Sub>值。</base:Paragraphs>
      <base:Paragraphs id="p1489" num="n1460">图10显示了使用两种方法在人肺中模拟的化合物1-6浓度。实线代表，在化合物1-6肺-肝浓度比率1.6校正后，活性三磷酸酯化合物1-6代谢物的预测肺浓度。虚线代表，在化合物1-6肺与化合物1-7血浆比率1.2校正之后，活性三磷酸酯化合物1-6代谢物的预测肺浓度。水平线代表化合物1A在体外HAE细胞中对抗SARS-CoV-2的EC<base:Sub>90</base:Sub>(0.47μM)。</base:Paragraphs>
      <base:Paragraphs id="p1490" num="n1461">实施例11.选择化合物对SARS-CoV-2的体外活性</base:Paragraphs>
      <base:Paragraphs id="p1491" num="n1462">在SARS-CoV-2试验中测试了本发明的选定化合物。如实施例6中所述，使用人气道上皮(HAE；dNHBE)细胞进行测定。瑞德西韦是阳性对照并且将化合物与索非布韦进行比较。使用每种化合物的4个系列稀释(10、2.5、0.625和0.156μg/mL)。索非布韦仅以10ug/mL的浓度重复测试，化合物1A以1和0.1ug/mL的浓度进行单线态测试，以及瑞德西韦以最高浓度1ug/mL以4个连续对数稀释的单线态测试。结果显示在表11中。在2'-位具有氘取代的化合物5表现出0.31μM的EC<base:Sub>90</base:Sub>和具有2'-CH<base:Sub>2</base:Sub>F取代的化合物6表现出1.8μM的EC<base:Sub>90</base:Sub>。没有一种化合物显示出目测毒性。</base:Paragraphs>
      <base:Paragraphs id="p1492" num="n1463">表11.选定化合物对SARS-CoV-2的活性</base:Paragraphs>
      <base:Paragraphs id="p1493" num="n1464">
        <base:Image he="1000" wi="865" file="GDA0003327089700003251.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1494" num="n1465">
        <base:Image he="1000" wi="664" file="GDA0003327089700003261.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1495" num="n1466">
        <base:Image he="637" wi="1000" file="GDA0003327089700003271.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1496" num="n1467">表11B.其他选定化合物对SARS-CoV-2的活性</base:Paragraphs>
      <base:Paragraphs id="p1497" num="n1468">
        <base:Image he="622" wi="1000" file="GDA0003327089700003272.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1498" num="n1469">
        <base:Image he="645" wi="1000" file="GDA0003327089700003281.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1499" num="n1470">实施例12.化合物2A的制剂描述和制备</base:Paragraphs>
      <base:Paragraphs id="p1500" num="n1471">化合物2A片剂(50mg和100mg)的代表性非限制性批次制剂列于表12中。这些片剂是使用直接压制工艺由普通混合工艺生产。基于原样(as-is)测定，根据微晶纤维素百分比的调整来调节活性药物成分(API)。API和赋形剂(微晶纤维素、乳糖一水合物和交联羧甲基纤维素钠)过筛，放入V型混合器(PK Blendmaster，0.5L碗)中，25rpm混合5分钟。然后将硬脂酸镁过筛、加入并将混合物继续混合2分钟。将普通混合物分开用于生产50mg和100mg片剂。然后使用单冲研究压片机(Korsch XP1)和重力送粉器以10片/分钟的速度压制润滑的混合物。50mg片剂使用6mm圆形标准凹面工具和3.5kN力生产。100mg片剂使用8mm圆形标准凹形工具和3.9-4.2kN力生产。</base:Paragraphs>
      <base:Paragraphs id="p1501" num="n1472">表12. 50mg和100mg化合物2片剂的制剂</base:Paragraphs>
      <base:Paragraphs id="p1502" num="n1473">
        <base:Image he="59" wi="1000" file="GDA0003327089700003282.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1503" num="n1474">
        <base:Image he="577" wi="1000" file="GDA0003327089700003291.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </base:Paragraphs>
      <base:Paragraphs id="p1504" num="n1475">基于原样测定，根据微晶纤维素百分比的调整来调节化合物2A。化合物2A和赋形剂(微晶纤维素、乳糖一水合物和交联羧甲基纤维素钠)过筛，放入V型混合器(PKBlendmaster，0.5L碗)中，25rpm混合5分钟。然后将硬脂酸镁过筛、加入并将混合物继续混合2分钟。将普通混合物分开用于生产50mg和100mg片剂。然后使用单冲研究压片机(KorschXP1)和重力送粉器以10片/分钟的速度压制润滑的混合物。50mg片剂使用6mm圆形标准凹面工具和3.5kN力生产。100mg片剂使用8mm圆形标准凹形工具和3.9-4.2kN力生产。50mg和100mg片剂的参数见表13。</base:Paragraphs>
      <base:Paragraphs id="p1505" num="n1476">表13. 50mg和100mg化合物2A片剂的参数</base:Paragraphs>
      <base:Paragraphs id="p1506" num="n1477">
        <base:TableDetails num="0002">
          <base:Table>
            <base:Title />
            <tbl:tgroup cols="3">
              <tbl:colspec colname="c001" colwidth="38%" />
              <tbl:colspec colname="c002" colwidth="30%" />
              <tbl:colspec colname="c003" colwidth="30%" />
              <tbl:tbody>
                <tbl:row>
                  <tbl:entry morerows="1" />
                  <tbl:entry morerows="1">50mg片</tbl:entry>
                  <tbl:entry morerows="1">100mg片</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1">平均重量(n＝10)</tbl:entry>
                  <tbl:entry morerows="1">100±5mg</tbl:entry>
                  <tbl:entry morerows="1">200±10mg</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1">单个重量</tbl:entry>
                  <tbl:entry morerows="1">100±10mg</tbl:entry>
                  <tbl:entry morerows="1">200±20mg</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1">硬度</tbl:entry>
                  <tbl:entry morerows="1">5.3kp</tbl:entry>
                  <tbl:entry morerows="1">8.3kp</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1">崩解</tbl:entry>
                  <tbl:entry morerows="1">&lt;15分钟</tbl:entry>
                  <tbl:entry morerows="1">&lt;15分钟</tbl:entry>
                </tbl:row>
                <tbl:row>
                  <tbl:entry morerows="1">脆碎度</tbl:entry>
                  <tbl:entry morerows="1">NMT 0.5％</tbl:entry>
                  <tbl:entry morerows="1">NMT 0.5％</tbl:entry>
                </tbl:row>
              </tbl:tbody>
            </tbl:tgroup>
          </base:Table>
        </base:TableDetails>
      </base:Paragraphs>
      <base:Paragraphs id="p1507" num="n1478">如上所述生产的50mg和100mg片剂在以下三种条件下进行了6个月的稳定性研究：5℃(冷藏)、25℃/60％RH(环境)和40℃/75％RH(加速)。在所有三种测试条件下，50mg和100mg片剂在化学上都是稳定的。</base:Paragraphs>
      <base:Paragraphs id="p1508" num="n1479">在冷藏条件(5℃)下，50mg和100mg片剂均保持白色固体，从T＝0到T＝6个月外观没有变化。在整个6个月的研究中，没有报告50毫克片剂或100毫克片剂的杂质含量超过0.05％。两种片剂在6个月后的含水量也低于3.0％w/w。当片剂经受环境条件(25℃/60％RH)时，报告了类似的结果；两种片剂在整个6个月内均未报告大于0.05％的杂质，并且在6个月时水含量不超过3.0％w/w。当片剂经受加速条件(40℃/75％RH)时，50mg和100mg片剂的外观与白色圆形片剂没有变化。3个月后报告了1种杂质，但杂质仅为0.09％。6个月后报告了第二种杂质，但50mg和100mg片剂的总杂质百分比仅为0.21％。50mg片剂的含水量在6个月时为3.4％w/w，100mg片剂的含水量为3.2％w/w。</base:Paragraphs>
      <base:Paragraphs id="p1509" num="n1480">在另一项研究中，测量了50mg和100mg化合物2A片剂在环境条件(25℃/60％RH)下9个月的稳定性。在9个月的过程中，50mg和100mg片剂的外观与白色圆形片剂没有变化。9个月后50mg片剂中的杂质小于0.10％，100mg片剂中的杂质小于0.05％。50mg片剂和100mg片剂在9个月后的含水量分别仅为2.7％w/w和2.6％w/w。</base:Paragraphs>
      <base:Paragraphs id="p1510" num="n1481">已经参考本发明的实施例描述了本说明书。鉴于此处的教导，本领域的普通技术人员将能够出于期望的目的修改本发明，并且此类变化被认为在本发明的范围内。</base:Paragraphs>
    </business:InventionMode>
  </business:Description>
  <business:Drawings lang="zh" sourceDB="national office">
    <base:Figure id="f0001" num="0001" figureLabels="图1">
      <base:Image id="if0001" he="662" wi="1000" file="HDA0003246408250000011.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0002" num="0002" figureLabels="图2">
      <base:Image id="if0002" he="609" wi="1000" file="HDA0003246408250000012.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0003" num="0003" figureLabels="图3">
      <base:Image id="if0003" he="605" wi="1000" file="HDA0003246408250000021.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0004" num="0004" figureLabels="图4">
      <base:Image id="if0004" he="635" wi="1000" file="HDA0003246408250000022.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0005" num="0005" figureLabels="图5">
      <base:Image id="if0005" he="629" wi="1000" file="HDA0003246408250000031.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0006" num="0006" figureLabels="图6">
      <base:Image id="if0006" he="625" wi="1000" file="HDA0003246408250000032.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0007" num="0007" figureLabels="图7A">
      <base:Image id="if0007" he="631" wi="1000" file="HDA0003246408250000041.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0008" num="0008" figureLabels="图7B">
      <base:Image id="if0008" he="693" wi="1000" file="HDA0003246408250000042.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0009" num="0009" figureLabels="图8">
      <base:Image id="if0009" he="725" wi="1000" file="HDA0003246408250000051.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0010" num="0010" figureLabels="图9">
      <base:Image id="if0010" he="688" wi="1000" file="HDA0003246408250000052.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0011" num="0011" figureLabels="图10">
      <base:Image id="if0011" he="711" wi="1000" file="HDA0003246408250000061.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
    <base:Figure id="f0012" num="0012" figureLabels="图11">
      <base:Image id="if0012" he="480" wi="907" file="HDA0003246408250000062.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
    </base:Figure>
  </business:Drawings>
  <business:Claims lang="zh" dataFormat="original" sourceDB="national office" creator="03">
    <business:Claim id="cl0001" num="0001">
      <business:ClaimText>1.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式I化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0001" he="564" wi="897" file="FDA0003246408230000011.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中：</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基和C<base:Sub>3-7</base:Sub>环烷基；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0002" num="0002">
      <business:ClaimText>2.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式II化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0002" he="568" wi="834" file="FDA0003246408230000012.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中：</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0003" num="0003">
      <business:ClaimText>3.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式III或式IV化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0003" he="1000" wi="760" file="FDA0003246408230000021.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中：</business:ClaimText>
      <business:ClaimText>X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基、和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0004" num="0004">
      <business:ClaimText>4.如权利要求3所述的方法，其中所述化合物选自式IIIa、式IIIb、式IIIc、式IIId、式IIIe和式IIIf：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0004" he="1000" wi="493" file="FDA0003246408230000031.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0005" he="1000" wi="518" file="FDA0003246408230000041.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0005" num="0005">
      <business:ClaimText>5.如权利要求3所述的方法，其中所述化合物选自式IVa、式IVb、式IVc、式IVd、式IVe和式IVf：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0006" he="567" wi="898" file="FDA0003246408230000042.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0007" he="1000" wi="305" file="FDA0003246408230000051.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0008" he="76" wi="203" file="FDA0003246408230000061.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0006" num="0006">
      <business:ClaimText>6.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式V化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0009" he="572" wi="899" file="FDA0003246408230000062.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中：</business:ClaimText>
      <business:ClaimText>Y和Y’独立地选自F和Cl；</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0007" num="0007">
      <business:ClaimText>7.如权利要求6所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0010" he="471" wi="898" file="FDA0003246408230000063.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0011" he="1000" wi="600" file="FDA0003246408230000071.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0008" num="0008">
      <business:ClaimText>8.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式VI化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0012" he="594" wi="865" file="FDA0003246408230000072.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6</base:Sup>选自氢、-C(O)R<base:Sup>6A</base:Sup>、-C(O)OR<base:Sup>6A</base:Sup>、C<base:Sub>1-6</base:Sub>烷基、-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6A</base:Sup>选自氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基、芳基、芳基(C<base:Sub>1-6</base:Sub>烷基)-其中芳基任选地被选自烷氧基、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代；</business:ClaimText>
      <business:ClaimText>R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>、H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、-C(O)R<base:Sup>6A</base:Sup>、和-C(O)OR<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>Y选自F和Cl；和</business:ClaimText>
      <business:ClaimText>Z选自甲基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0009" num="0009">
      <business:ClaimText>9.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式VII化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0013" he="390" wi="692" file="FDA0003246408230000081.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中</business:ClaimText>
      <business:ClaimText>B选自</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0014" he="172" wi="1000" file="FDA0003246408230000082.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0015" he="367" wi="269" file="FDA0003246408230000091.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基和C<base:Sub>3-7</base:Sub>环烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6</base:Sup>选自氢、-C(O)R<base:Sup>6A</base:Sup>、-C(O)OR<base:Sup>6A</base:Sup>、C<base:Sub>1-6</base:Sub>烷基、-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>，和-C(O)NR<base:Sup>6B</base:Sup>R<base:Sup>6C</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6A</base:Sup>选自氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基、C<base:Sub>1-20</base:Sub>烷基和C<base:Sub>2-20</base:Sub>烯基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6B</base:Sup>和R<base:Sup>6C</base:Sup>独立地选自氢、C<base:Sub>1-20</base:Sub>烷基、C<base:Sub>2-20</base:Sub>烯基、芳基、芳基烷基、杂芳基和杂芳基烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>、H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>Y选自F和Cl；</business:ClaimText>
      <business:ClaimText>Z选自甲基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素；</business:ClaimText>
      <business:ClaimText>R<base:Sup>40</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷氧基、C<base:Sub>1-3</base:Sub>烷基、N<base:Sub>3</base:Sub>、CN和卤素；</business:ClaimText>
      <business:ClaimText>R<base:Sup>41</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷基和卤素；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>42a</base:Sup>和R<base:Sup>42b</base:Sup>选自C<base:Sub>1-3</base:Sub>烷基、NH<base:Sub>2</base:Sub>、H、-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>和-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0010" num="0010">
      <business:ClaimText>10.如权利要求9所述的方法，其中B选自</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0016" he="194" wi="1000" file="FDA0003246408230000092.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0017" he="340" wi="1000" file="FDA0003246408230000101.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0011" num="0011">
      <business:ClaimText>11.如权利要求1-10中任一项所述的方法，其中R<base:Sup>2</base:Sup>是芳基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0012" num="0012">
      <business:ClaimText>12.如权利要求11所述的方法，其中R<base:Sup>2</base:Sup>是苯基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0013" num="0013">
      <business:ClaimText>13.如权利要求1-12中任一项所述的方法，其中R<base:Sup>3</base:Sup>是氢。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0014" num="0014">
      <business:ClaimText>14.如权利要求1-12中任一项所述的方法，其中R<base:Sup>3</base:Sup>是甲基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0015" num="0015">
      <business:ClaimText>15.如权利要求1-13中任一项所述的方法，其中R<base:Sup>4a</base:Sup>是甲基并且R<base:Sup>4b</base:Sup>是氢。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0016" num="0016">
      <business:ClaimText>16.如权利要求1-13中任一项所述的方法，其中R<base:Sup>4a</base:Sup>是甲基并且R<base:Sup>4b</base:Sup>是甲基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0017" num="0017">
      <business:ClaimText>17.如权利要求1-16中任一项所述的方法，其中R<base:Sup>5</base:Sup>是C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0018" num="0018">
      <business:ClaimText>18.如权利要求17所述的方法，其中R<base:Sup>5</base:Sup>选自甲基、乙基和异丙基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0019" num="0019">
      <business:ClaimText>19.如权利要求18所述的方法，其中R<base:Sup>5</base:Sup>是异丙基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0020" num="0020">
      <business:ClaimText>20.如权利要求1-10中任一项所述的方法，</business:ClaimText>
      <business:ClaimText>其中：</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>是苯基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>是氢；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>是甲基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4b</base:Sup>是氢；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是异丙基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0021" num="0021">
      <business:ClaimText>21.如权利要求1-10中任一项所述的方法，</business:ClaimText>
      <business:ClaimText>其中：</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>是苯基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>是氢；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>是甲基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4b</base:Sup>是氢；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是异丙基；和</business:ClaimText>
      <business:ClaimText>氨基磷酸酯呈S<base:Sub>p</base:Sub>构型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0022" num="0022">
      <business:ClaimText>22.如权利要求1-10中任一项所述的方法，</business:ClaimText>
      <business:ClaimText>其中：</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>是苯基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>是氢；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>是甲基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4b</base:Sup>是氢；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是异丙基；和</business:ClaimText>
      <business:ClaimText>氨基磷酸酯处于R<base:Sub>p</base:Sub>构型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0023" num="0023">
      <business:ClaimText>23.如权利要求1所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0018" he="479" wi="954" file="FDA0003246408230000121.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0024" num="0024">
      <business:ClaimText>24.如权利要求23所述的方法，其中所述化合物选自下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0019" he="989" wi="952" file="FDA0003246408230000122.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0025" num="0025">
      <business:ClaimText>25.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0020" he="480" wi="952" file="FDA0003246408230000123.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0026" num="0026">
      <business:ClaimText>26.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0021" he="482" wi="953" file="FDA0003246408230000131.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0027" num="0027">
      <business:ClaimText>27.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0022" he="478" wi="955" file="FDA0003246408230000132.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0028" num="0028">
      <business:ClaimText>28.如权利要求23所述的方法，其中所述化合物选自下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0023" he="479" wi="952" file="FDA0003246408230000133.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0024" he="984" wi="952" file="FDA0003246408230000141.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0029" num="0029">
      <business:ClaimText>29.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0025" he="496" wi="982" file="FDA0003246408230000142.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0030" num="0030">
      <business:ClaimText>30.如权利要求23所述的方法，其中所述化合物选自下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0026" he="480" wi="953" file="FDA0003246408230000143.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0027" he="488" wi="984" file="FDA0003246408230000151.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0031" num="0031">
      <business:ClaimText>31.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0028" he="493" wi="980" file="FDA0003246408230000152.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0032" num="0032">
      <business:ClaimText>32.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0029" he="488" wi="982" file="FDA0003246408230000153.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0033" num="0033">
      <business:ClaimText>33.如权利要求23所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0030" he="493" wi="985" file="FDA0003246408230000154.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0034" num="0034">
      <business:ClaimText>34.如权利要求23所述的方法，其中所述化合物选自下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0031" he="1000" wi="644" file="FDA0003246408230000161.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0035" num="0035">
      <business:ClaimText>35.如权利要求4所述的方法，其中所述化合物选自：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0032" he="1000" wi="968" file="FDA0003246408230000162.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0033" he="1000" wi="515" file="FDA0003246408230000171.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0036" num="0036">
      <business:ClaimText>36.如权利要求7所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0034" he="476" wi="954" file="FDA0003246408230000181.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0037" num="0037">
      <business:ClaimText>37.如权利要求36所述的方法，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0035" he="485" wi="954" file="FDA0003246408230000182.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0038" num="0038">
      <business:ClaimText>38.一种在有需要的宿主中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用有效量的式VIII、式IX或式X化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0036" he="678" wi="1000" file="FDA0003246408230000183.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0037" he="77" wi="152" file="FDA0003246408230000191.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中</business:ClaimText>
      <business:ClaimText>R<base:Sup>10</base:Sup>选自<base:Image id="icf0038" he="189" wi="1000" file="FDA0003246408230000192.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="yes" />和R<base:Sup>10A</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>10A</base:Sup>是稳定的磷酸酯前药，其在体内代谢为单磷酸酯、二磷酸酯或三磷酸酯；</business:ClaimText>
      <business:ClaimText>R<base:Sup>11</base:Sup>选自氢和R<base:Sup>1</base:Sup>；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0039" num="0039">
      <business:ClaimText>39.如权利要求38所述的方法，其中所述化合物选自：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0039" he="433" wi="1000" file="FDA0003246408230000201.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0040" num="0040">
      <business:ClaimText>40.如权利要求38所述的方法，其中化合物具有下式</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0040" he="365" wi="633" file="FDA0003246408230000202.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>其中</business:ClaimText>
      <business:ClaimText>R<base:Sup>10a</base:Sup>是稳定的磷酸酯前药，其在体内代谢为单磷酸酯、二磷酸酯或三磷酸酯。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0041" num="0041">
      <business:ClaimText>41.如权利要求1-40中任一项所述的方法，其中所述药学上可接受的载体是适合于口服给药的剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0042" num="0042">
      <business:ClaimText>42.如权利要求41所述的方法，其中所述剂型是固体剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0043" num="0043">
      <business:ClaimText>43.如权利要求42所述的方法，其中所述固体剂型是片剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0044" num="0044">
      <business:ClaimText>44.如权利要求42所述的方法，其中所述固体剂型是胶囊剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0045" num="0045">
      <business:ClaimText>45.如权利要求41所述的方法，其中所述剂型是液体剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0046" num="0046">
      <business:ClaimText>46.权利要求45的方法，其中所述液体剂型是溶液或混悬液。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0047" num="0047">
      <business:ClaimText>47.如权利要求1-40中任一项所述的方法，其中所述药学上可接受的载体为适合静脉内给药的剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0048" num="0048">
      <business:ClaimText>48.如权利要求1-40中任一项所述的方法，其中所述药学上可接受的载体为适合肠胃外给药的剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0049" num="0049">
      <business:ClaimText>49.如权利要求1-48中任一项所述的方法，其中所述化合物被施用至少一周。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0050" num="0050">
      <business:ClaimText>50.如权利要求1-48中任一项所述的方法，其中该化合物被施用至少两周。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0051" num="0051">
      <business:ClaimText>51.如权利要求1-48中任一项所述的方法，其中该化合物被施用至少一个月。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0052" num="0052">
      <business:ClaimText>52.如权利要求1-48中任一项所述的方法，其中该化合物被施用至少六周。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0053" num="0053">
      <business:ClaimText>53.如权利要求1-48中任一项所述的方法，其中该化合物被给药至少两个月。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0054" num="0054">
      <business:ClaimText>54.如权利要求1-53中任一项所述的方法，其中所述化合物每天施用一次。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0055" num="0055">
      <business:ClaimText>55.如权利要求1-53中任一项所述的方法，其中所述化合物每天施用两次。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0056" num="0056">
      <business:ClaimText>56.如权利要求1-53中任一项所述的方法，其中所述化合物每天施用3次。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0057" num="0057">
      <business:ClaimText>57.如权利要求1-56中任一项所述的方法，其中施用至少约500mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0058" num="0058">
      <business:ClaimText>58.如权利要求1-56中任一项所述的方法，其中施用至少约600mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0059" num="0059">
      <business:ClaimText>59.如权利要求1-56中任一项所述的方法，其中施用至少约700mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0060" num="0060">
      <business:ClaimText>60.如权利要求1-56中任一项所述的方法，其中施用至少约800mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0061" num="0061">
      <business:ClaimText>61.如权利要求1-56中任一项所述的方法，其中施用至少约1000mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0062" num="0062">
      <business:ClaimText>62.如权利要求1-56中任一项所述的方法，其中施用至少1200mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0063" num="0063">
      <business:ClaimText>63.如权利要求1-56中任一项所述的方法，其中施用至少约1500mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0064" num="0064">
      <business:ClaimText>64.如权利要求1-56中任一项所述的方法，其中每天一次施用至少约550mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0065" num="0065">
      <business:ClaimText>65.根据权利要求1-56中任一项所述的方法，其中每天两次施用至少约550mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0066" num="0066">
      <business:ClaimText>66.如权利要求1-56中任一项所述的方法，其中每天一次施用至少约600mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0067" num="0067">
      <business:ClaimText>67.如权利要求1-56中任一项所述的方法，其中每天两次施用至少约600mg的所述化合物。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0068" num="0068">
      <business:ClaimText>68.如权利要求1-67中任一项所述的方法，其中所述宿主是人。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0069" num="0069">
      <business:ClaimText>69.一种在有需要的人中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用下式化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0041" he="443" wi="986" file="FDA0003246408230000231.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中所述化合物以约550mg的口服剂量每天两次施用。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0070" num="0070">
      <business:ClaimText>70.一种在有需要的人中治疗或预防由SARS-CoV-2病毒引起的COVID-19的方法，包括施用下式化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0042" he="443" wi="987" file="FDA0003246408230000241.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>任选地在药学上可接受的载体中，其中所述化合物以约600mg的口服剂量每天两次施用。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0071" num="0071">
      <business:ClaimText>71.如权利要求69或70所述的方法，其中所述口服剂量是片剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0072" num="0072">
      <business:ClaimText>72.如权利要求69或70所述的方法，其中所述口服剂量是胶囊剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0073" num="0073">
      <business:ClaimText>73.如权利要求69-72中任一项所述的方法，其中该化合物被施用至少一周。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0074" num="0074">
      <business:ClaimText>74.如权利要求69-72中任一项所述的方法，其中该化合物被施用至少两周。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0075" num="0075">
      <business:ClaimText>75.如权利要求69-72中任一项所述的方法，其中该化合物被施用至少一个月。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0076" num="0076">
      <business:ClaimText>76.如权利要求1-75中任一项所述的方法，其中所述SARS-CoV-2病毒已发生自然或药物诱导的突变。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0077" num="0077">
      <business:ClaimText>77.如权利要求76所述的方法，其中所述天然或药物诱导的突变是在选自包膜(E)蛋白、膜(M)蛋白和刺突(S)蛋白的病毒蛋白中。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0078" num="0078">
      <business:ClaimText>78.如权利要求77所述的方法，其中所述突变在刺突(S)蛋白中。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0079" num="0079">
      <business:ClaimText>79.如权利要求76所述的方法，其中所述天然或药物诱导的突变在选自nsp1、nsp2、nsp3、nsp4、nsp5、nsp6、nsp7、nsp8、nsp9、nsp10、nsp12、nsp13、nsp14、nsp15和nsp16的病毒蛋白中。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0080" num="0080">
      <business:ClaimText>80.如权利要求76所述的方法，其中所述天然或药物诱导的突变在选自ORF1ab、ORF3a、ORF6、ORF7a、ORF7b、ORF8和ORF10的病毒蛋白中。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0081" num="0081">
      <business:ClaimText>81.式I或式II的化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0043" he="1000" wi="775" file="FDA0003246408230000251.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其以有效量用于在有需要的宿主中治疗或预防2019冠状病毒病(COVID-19)，其中：</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0082" num="0082">
      <business:ClaimText>82.如权利要求81所述的化合物，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0044" he="480" wi="954" file="FDA0003246408230000261.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0083" num="0083">
      <business:ClaimText>83.如权利要求81所述的化合物，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0045" he="480" wi="952" file="FDA0003246408230000262.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0084" num="0084">
      <business:ClaimText>84.如权利要求82所述的化合物，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0046" he="481" wi="954" file="FDA0003246408230000271.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0085" num="0085">
      <business:ClaimText>85.如权利要求82所述的化合物，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0047" he="490" wi="981" file="FDA0003246408230000272.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0086" num="0086">
      <business:ClaimText>86.如权利要求85所述的化合物，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0048" he="493" wi="982" file="FDA0003246408230000273.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0087" num="0087">
      <business:ClaimText>87.如权利要求86所述的化合物，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0049" he="488" wi="982" file="FDA0003246408230000274.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0088" num="0088">
      <business:ClaimText>88.式III或式IV的化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0050" he="1000" wi="718" file="FDA0003246408230000281.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其以有效量用于在有需要的宿主中治疗或预防2019冠状病毒病(COVID-19)，其中：</business:ClaimText>
      <business:ClaimText>X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F、CHF<base:Sub>2</base:Sub>、CF<base:Sub>3</base:Sub>、CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>、CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>、CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F、CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>、CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>和CH<base:Sub>2</base:Sub>Cl)、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0089" num="0089">
      <business:ClaimText>89.权利要求88所述的化合物，其中所述化合物具有式IIIa、式IIIb、式IIIc、式IIId或式IIIe：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0051" he="1000" wi="353" file="FDA0003246408230000291.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0052" he="1000" wi="668" file="FDA0003246408230000301.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0090" num="0090">
      <business:ClaimText>90.如权利要求88所述的化合物，其中所述化合物具有式IVa、式IVb、式IVc、式IVd或式VIe：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0053" he="1000" wi="781" file="FDA0003246408230000302.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0054" he="1000" wi="383" file="FDA0003246408230000311.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0091" num="0091">
      <business:ClaimText>91.式V、式VI或式VII的化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0055" he="1000" wi="567" file="FDA0003246408230000321.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，其中</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6</base:Sup>选自氢、-C(O)R<base:Sup>6A</base:Sup>、-C(O)OR<base:Sup>6A</base:Sup>、C<base:Sub>1-6</base:Sub>烷基、-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6A</base:Sup>选自氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基、芳基、芳基(C<base:Sub>1-6</base:Sub>烷基)-其中芳基任选地被选自烷氧基、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代；</business:ClaimText>
      <business:ClaimText>R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>、H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>Y和Y’独立地选自F和Cl；</business:ClaimText>
      <business:ClaimText>Z选自甲基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素；</business:ClaimText>
      <business:ClaimText>B选自</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0056" he="351" wi="1000" file="FDA0003246408230000331.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>R<base:Sup>40</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷氧基、C<base:Sub>1-3</base:Sub>烷基、N<base:Sub>3</base:Sub>、CN和卤素；</business:ClaimText>
      <business:ClaimText>R<base:Sup>41</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷基和卤素；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>42a</base:Sup>和R<base:Sup>42b</base:Sup>选自C<base:Sub>1-3</base:Sub>烷基、NH<base:Sub>2</base:Sub>、H、-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>和-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0092" num="0092">
      <business:ClaimText>92.如权利要求81-91所述的化合物，其中所述药学上可接受的载体为适于口服给药的剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0093" num="0093">
      <business:ClaimText>93.如权利要求92所述的化合物，其中所述剂型是固体剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0094" num="0094">
      <business:ClaimText>94.如权利要求93所述的化合物，其中所述固体剂型是片剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0095" num="0095">
      <business:ClaimText>95.如权利要求93所述的化合物，其中所述固体剂型是胶囊剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0096" num="0096">
      <business:ClaimText>96.如权利要求92所述的化合物，其中所述剂型是液体剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0097" num="0097">
      <business:ClaimText>97.如权利要求96所述的化合物，其中所述液体剂型是溶液或混悬液。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0098" num="0098">
      <business:ClaimText>98.式I、式II、式III或式IV化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0057" he="1000" wi="355" file="FDA0003246408230000341.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，用于制造在有需要的宿主中治疗或预防2019冠状病毒病(COVID-19)的药物的用途，</business:ClaimText>
      <business:ClaimText>其中</business:ClaimText>
      <business:ClaimText>X选自C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基(包括C<base:Sub>1-3</base:Sub>氟烷基和C<base:Sub>1-3</base:Sub>氯烷基，例如CH<base:Sub>2</base:Sub>F、CHF<base:Sub>2</base:Sub>、CF<base:Sub>3</base:Sub>、CH<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>、CH<base:Sub>2</base:Sub>CHF<base:Sub>2</base:Sub>、CH<base:Sub>2</base:Sub>CH<base:Sub>2</base:Sub>F、CF<base:Sub>2</base:Sub>CH<base:Sub>3</base:Sub>、CF<base:Sub>2</base:Sub>CF<base:Sub>3</base:Sub>和CH<base:Sub>2</base:Sub>Cl)、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基和C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、和C<base:Sub>3-7</base:Sub>环烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>是氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0099" num="0099">
      <business:ClaimText>99.如权利要求98所述的用途，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0058" he="479" wi="954" file="FDA0003246408230000351.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0100" num="0100">
      <business:ClaimText>100.如权利要求99所述的用途，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0059" he="483" wi="952" file="FDA0003246408230000352.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0101" num="0101">
      <business:ClaimText>101.权利要求100的用途，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0060" he="485" wi="954" file="FDA0003246408230000361.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0102" num="0102">
      <business:ClaimText>102.如权利要求99所述的用途，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0061" he="488" wi="982" file="FDA0003246408230000371.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0103" num="0103">
      <business:ClaimText>103.如权利要求102所述的用途，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0062" he="494" wi="983" file="FDA0003246408230000372.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0104" num="0104">
      <business:ClaimText>104.如权利要求103所述的用途，其中所述化合物具有下式：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0063" he="487" wi="976" file="FDA0003246408230000373.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0105" num="0105">
      <business:ClaimText>105.式V、式VI或式VII化合物：</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0064" he="571" wi="901" file="FDA0003246408230000374.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0065" he="996" wi="866" file="FDA0003246408230000381.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>或其药学上可接受的盐，任选地在药学上可接受的载体中，用于制造在有需要的宿主中治疗或预防2019冠状病毒病(COVID-19)的药物的用途，</business:ClaimText>
      <business:ClaimText>其中</business:ClaimText>
      <business:ClaimText>R<base:Sup>1</base:Sup>选自C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基、C<base:Sub>3</base:Sub>-C<base:Sub>6</base:Sub>环烷基和-C(O)C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>2</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>3</base:Sup>为氢或C<base:Sub>1-6</base:Sub>烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>4a</base:Sup>和R<base:Sup>4b</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基和C<base:Sub>3-7</base:Sub>环烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>5</base:Sup>为氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1-6</base:Sub>卤代烷基、C<base:Sub>3-7</base:Sub>环烷基、芳基(C<base:Sub>1</base:Sub>-C<base:Sub>4</base:Sub>烷基)-、芳基、杂芳基或杂烷基；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6</base:Sup>选自氢、-C(O)R<base:Sup>6A</base:Sup>、-C(O)OR<base:Sup>6A</base:Sup>、C<base:Sub>1-6</base:Sub>烷基、-CH<base:Sub>2</base:Sub>-O-R<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>6A</base:Sup>选自氢、C<base:Sub>1-6</base:Sub>烷基、C<base:Sub>1</base:Sub>-C<base:Sub>6</base:Sub>卤代烷基、芳基、芳基(C<base:Sub>1-6</base:Sub>烷基)-其中芳基任选地被选自烷氧基、羟基、硝基、溴、氯、氟、叠氮基和卤代烷基的取代基取代；</business:ClaimText>
      <business:ClaimText>R<base:Sup>7</base:Sup>是NH<base:Sub>2</base:Sub>、H或-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>；</business:ClaimText>
      <business:ClaimText>R<base:Sup>8</base:Sup>和R<base:Sup>9</base:Sup>独立地选自氢、C<base:Sub>1-6</base:Sub>烷基、-C(O)R<base:Sup>6A</base:Sup>和-C(O)OR<base:Sup>6A</base:Sup>；</business:ClaimText>
      <business:ClaimText>Y选自F和Cl；</business:ClaimText>
      <business:ClaimText>Z选自甲基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>卤代烷基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>烯基、C<base:Sub>2</base:Sub>-C<base:Sub>4</base:Sub>炔基、C<base:Sub>1</base:Sub>-C<base:Sub>3</base:Sub>羟烷基和卤素；</business:ClaimText>
      <business:ClaimText>B选自</business:ClaimText>
      <business:ClaimText>
        <base:Image id="icf0066" he="352" wi="1000" file="FDA0003246408230000391.JPG" imgContent="drawing" imgFormat="JPEG" orientation="portrait" inline="no" />
      </business:ClaimText>
      <business:ClaimText>R<base:Sup>40</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷氧基、C<base:Sub>1-3</base:Sub>烷基、N<base:Sub>3</base:Sub>、CN和卤素；</business:ClaimText>
      <business:ClaimText>R<base:Sup>41</base:Sup>选自H、C<base:Sub>1-3</base:Sub>烷基和卤素；和</business:ClaimText>
      <business:ClaimText>R<base:Sup>42a</base:Sup>和R<base:Sup>42b</base:Sup>选自C<base:Sub>1-3</base:Sub>烷基、NH<base:Sub>2</base:Sub>、H、-NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>和-C(O)NR<base:Sup>8</base:Sup>R<base:Sup>9</base:Sup>。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0106" num="0106">
      <business:ClaimText>106.如权利要求98-105中任一项所述的用途，其中所述药学上可接受的载体是适合于口服施用的剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0107" num="0107">
      <business:ClaimText>107.权利要求106的用途，其中所述剂型是固体剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0108" num="0108">
      <business:ClaimText>108.权利要求107的用途，其中所述固体剂型是片剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0109" num="0109">
      <business:ClaimText>109.权利要求107的用途，其中所述固体剂型是胶囊剂。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0110" num="0110">
      <business:ClaimText>110.权利要求106的用途，其中所述剂型是液体剂型。</business:ClaimText>
    </business:Claim>
    <business:Claim id="cl0111" num="0111">
      <business:ClaimText>111.权利要求110的用途，其中所述液体剂型是溶液或混悬液。</business:ClaimText>
    </business:Claim>
  </business:Claims>
</business:PatentDocumentAndRelated>